

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAPLUS enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	NOV 23	Addition of SCAN format to selected STN databases
NEWS	11	NOV 23	Annual Reload of IFI Databases
NEWS	12	DEC 01	FRFULL Content and Search Enhancements
NEWS	13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS	14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS	15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS	16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information
NEWS EXPRESS	MAY 26 09	CURRENT WINDOWS VERSION IS V8.4, AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.	
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges

and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 10:53:21 ON 08 DEC 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 10:53:45 ON 08 DEC 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 DEC 2009 HIGHEST RN 1196143-67-5  
DICTIONARY FILE UPDATES: 7 DEC 2009 HIGHEST RN 1196143-67-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10537630 RCE.str



chain nodes :  
10 11 12 13 16 20 21 23 25  
ring nodes :  
1 2 3 4 5 6 7 8 9  
chain bonds :

```

7-10 10-11 10-25 11-12 11-13 13-16 20-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
10-25 11-12 11-13 13-16 20-21
exact bonds :
5-7 6-9 7-8 7-10 8-9 10-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

```

G1:H,Cb,Ak

G2:O,S,SO2,[\*1]

G3:Cb,Cy,Hy

G4:O,S

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 16:CLASS 20:CLASS 21:CLASS 23:CLASS 24:Atom
25:CLASS

```

L1 STRUCTURE UPLOADED

=> d L`

L1 HAS NO ANSWERS


'L` ' IS NOT A VALID STRUCTURE FORMAT KEYWORD

ENTER STRUCTURE FORMAT (SIM), NOS:end

=> d L1

L1 HAS NO ANSWERS

L1 STR



G1 H,Cb,Ak

G2 O,S,SO2,[\*1]

G3 Cb,Cy,Hy

G4 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 SSS full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 10:54:18 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 24827 TO ITERATE

100.0% PROCESSED 24827 ITERATIONS

3606 ANSWERS

SEARCH TIME: 00.00.03

L2

3606 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

185.88

186.10

FILE 'CAPLUS' ENTERED AT 10:54:26 ON 08 DEC 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Dec 2009 VOL 151 ISS 24

FILE LAST UPDATED: 7 Dec 2009 (20091207/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L2 SSS full

L3

166 L2

=> s L3 AND (PY<2003 OR AY<2003 OR PRY<2003)

23001768 PY<2003

4531275 AY<2003

4001513 PRY<2003

L4


111 L3 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> d ibib abs hitstr 1-



YOU HAVE REQUESTED DATA FROM 111 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2008:1383574 CAPLUS Full-text  
DOCUMENT NUMBER: 149:555086  
TITLE: Oxidation of carbonyl compounds with organohypervalent  
iodine reagents  
AUTHOR(S): Moriarty, Robert M.; Prakash, Om  
CORPORATE SOURCE: The University of Illinois at Chicago, Chicago, IL,  
USA  
SOURCE: Organic Reactions (Hoboken, NJ, United States) ( 1999), 54, No pp. given  
CODEN: ORHNBA  
URL: <http://www3.interscience.wiley.com/cgi-bin/mrwhome/107610747/HOME>  
PUBLISHER: John Wiley & Sons, Inc.  
DOCUMENT TYPE: Journal; General Review; (online computer file)  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 149:555086  
AB A review of the article Oxidation of carbonyl compds. with organohypervalent  
iodine reagents.  
IT 24467-92-3  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(Oxidation of Carbonyl Compds. with Organohypervalent Iodine Reagents)  
RN 24467-92-3 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



L4 ANSWER 2 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2006:950685 CAPLUS Full-text  
DOCUMENT NUMBER: 145:336078  
TITLE: Sulfonyl-substituted bicyclic compounds as modulators  
of PPAR, and their preparation, pharmaceutical  
compositions and use for treatment of various diseases  
INVENTOR(S): Noble, Stewart A.; Oshiro, Guy; Malecha, James W.;  
Zhao, Cunxiang; Duron, Sergio G.; Lindstrom, Andrew  
K.; Shiau, Andrew K.; Lou, Boliang; Govek, Steven P.;  
Thomas, David J.  
PATENT ASSIGNEE(S): Kalypsys, Inc., USA  
SOURCE: U.S. Pat. Appl. Publ., 72pp., Cont.-in-part of U.S.  
Ser. No. 258,463.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20060205736	A1	20060914	US 2006-435082	20060516 <--

US 7517884	B2	20090414		
US 20060167012	A1	20060727	US 2005-258463	20051025
US 7494999	B2	20090224		
ZA 2007002918	A	20080827	ZA 2007-2918	20070410
US 20090029971	A1	20090129	US 2008-204459	20080904
US 20090264417	A1	20091022	US 2008-204489	20080904
US 20090227599	A1	20090910	US 2009-396513	20090303
PRIORITY APPLN. INFO.:			US 1998-79813P	P 19980330 <--
			US 2004-623252P	P 20041029
			US 2005-258463	A2 20051025
			US 2005-679813P	P 20050511
			US 2006-435082	A3 20060516

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 145:336078

GI



AB Compds. of formula I that are useful as modulators of peroxisome proliferator activated receptors, pharmaceutical compns. comprising the same, and methods of treating disease using the same are disclosed. Compds. of formula I wherein A is (un)saturated (hetero)hydrocarbon chain forming a 5- to 7-membered ring; T is CO<sub>2</sub>H, CONH<sub>2</sub>, or tetrazole; G<sub>1</sub> is (CR<sub>1</sub>R<sub>2</sub>)<sub>n</sub>, Z(CR<sub>1</sub>R<sub>2</sub>)<sub>n</sub>, (CR<sub>1</sub>R<sub>2</sub>)<sub>n</sub>Z, or (CR<sub>1</sub>R<sub>2</sub>)<sub>r</sub>Z(CR<sub>1</sub>R<sub>2</sub>)<sub>s</sub>; Z is O, S, or NH and derivs.; r and s are independently 0 or 1; R<sub>1</sub> and R<sub>2</sub> are independently H, halo, (un)substituted lower (hetero)alkyl, (un)substituted lower alkoxy, lower perhaloalkyl, or together may form (un)substituted cycloalkyl; X<sub>1</sub>-X<sub>3</sub> are independently H, (un)substituted lower alkyl, (un)substituted cycloalkyl, halo, perhaloalkyl, OH, (un)substituted lower alkoxy, NO<sub>2</sub>, CN, or NH<sub>2</sub>; G<sub>2</sub> is (un)substituted (un)saturated (hetero)cycloalkyl; G<sub>3</sub> is a single bond, double bond, (CR<sub>3</sub>R<sub>4</sub>)<sub>m</sub>, CO, or (CR<sub>3</sub>R<sub>4</sub>)<sub>m</sub>CR<sub>3</sub>=CR<sub>4</sub>; n and m are independently 0, 1 or 2; R<sub>3</sub> and R<sub>4</sub> are independently H, (un)substituted lower alkyl(oxy), lower perhaloalkyl, (un)substituted aryl, CN, or NO<sub>2</sub>; G<sub>4</sub> is H, (un)substituted (hetero)aryl, (un)substituted cyclo(hetero)alkyl, (un)substituted cyclo(hetero)aryl, (un)substituted cycloalkenyl, or N=(CR<sub>5</sub>R<sub>6</sub>); R<sub>5</sub> and R<sub>6</sub> are independently H, (un)substituted alkyl, (un)substituted (hetero)aryl, (un)substituted cyclo(hetero)alkyl, or (un)substituted cycloalkenyl; and their

pharmaceutically acceptable salts, esters, or prodrugs thereof are claimed. Example compound II was prepared by amidation of 5-(chlorosulfonyl)benzothien-3-ylacetic acid with 1-(2-fluoro-4-trifluoromethylphenyl)piperazine. All the invention compds. were evaluated for their PPAR- $\alpha$ , PPAR- $\gamma$ , and PPAR- $\delta$  binding affinity. From the assay, it was determined that example compound II have EC50 values <5  $\mu$ M for PPAR- $\alpha$ , PPAR- $\gamma$ , and PPAR- $\delta$ .


IT 888325-76-6P 888325-77-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of sulfonyl-substituted bicyclic compds. as PPAR receptor modulators useful in treatment of diseases)


RN 888325-76-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-5-[[4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]sulfonyl]- (CA INDEX NAME)



RN 888325-77-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[4-(3,4-dichlorophenyl)-1-piperazinyl]sulfonyl]-2,3-dihydro-6-methoxy- (CA INDEX NAME)




IT 91284-09-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of sulfonyl-substituted bicyclic compds. as PPAR receptor modulators useful in treatment of diseases)

RN 91284-09-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT:

48

THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:878169 CAPLUS Full-text

DOCUMENT NUMBER: 141:366218

TITLE: Preparation of substituted (hetero)aromatic compounds that modulate PPAR activity

INVENTOR(S): Bratton, Larry D.; Cheng, Xue-Min; Erasga, Noe; Filzen, Gary F.; Geyer, Andrew G.; Lee, Chitase; Trivedi, Bharat K.; Unangst, Paul C.

PATENT ASSIGNEE(S): Warner Lambert Company LLC, USA

SOURCE: U.S. Pat. Appl. Publ., 90 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040209936	A1	20041021	US 2004-774260	20040206
US 7244763	B2	20070717		
US 20030225158	A1	20031204	US 2003-347749	20030122 <--
US 6875780	B2	20050405		
CA 2522118	A1	20041028	CA 2004-2522118	20040405
WO 2004091604	A1	20041028	WO 2004-IB1178	20040405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1620086	A1	20060201	EP 2004-725756	20040405
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009486	A	20060502	BR 2004-9486	20040405
JP 2006524220	T	20061026	JP 2006-506486	20040405
NL 1025961	A1	20041026	NL 2004-1025961	20040416
NL 1025961	C2	20050215		

PRIORITY APPLN. INFO.:  
US 2003-463641P P 20030417  
US 2002-370508P P 20020405 <--  
US 2002-386026P P 20020605 <--  
WO 2004-IB1178 W 20040405

OTHER SOURCE(S): CASREACT 141:366218; MARPAT 141:366218

GI



AB Title compds. I [X0-2 = absent, O, S, amino, etc.; Ar1-2 = (hetero)aryl, etc.; V1 = absent, (un)saturated hydrocarbon chain, etc.; T = (un)saturated, (un)substituted hydrocarbon, etc.; R1-3 = H, alkyl, alkoxy, etc.; R7-8 = H, alkyl, halo, etc.; n = 0-5; q = 0-10; p = 0-10] are prepared For instance, [7-[(4-(4-Chlorophenyl)-4-oxobutyl)sulfanyl]indan-4-yloxy]acetic acid is prepared in 5 steps from 4-hydroxyindan-1-one, Me bromoacetate and 4-chloro-1-(4-chlorophenyl)butan-1-one. Compds. of the invention exhibit IC50 < 9,344 nM for PPAR $\beta$  and IC50 of < 15,000 nM for PPAR $\alpha$ . I are useful for the treatment of dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia.


IT 779187-48-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted (hetero)aromatic compds. that modulate ppar activity for the treatment of, e.g., dyslipidemia)

RN 779187-48-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methoxy]- (CA INDEX NAME)




IT 779202-60-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted (hetero)aromatic compds. that modulate ppar activity for the treatment of, e.g., dyslipidemia)

RN 779202-60-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methoxy]-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)  
 REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:565052 CAPLUS Full-text  
 DOCUMENT NUMBER: 141:123483  
 TITLE: Preparation of indaneacetic acid derivatives and their use as pharmaceutical agents  
 INVENTOR(S): Cantin, Louis-David; Choi, Soongyu; Clark, Roger B.; Hentemann, Martin F.; Ma, Xin; Rudolph, Joachim; Liang, Sidney X.; Akuche, Christiana; Lavoie, Rico C.; Chen, Libing; Majumdar, Dyuti; Wickens, Philip L.  
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA  
 SOURCE: PCT Int. Appl., 230 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058174	A2	20040715	WO 2003-US40842	20031219 <--
WO 2004058174	A3	20041202		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2510793	A1	20040715	CA 2003-2510793	20031219 <--
AU 2003299790	A1	20040722	AU 2003-299790	20031219 <--
EP 1578715	A2	20050928	EP 2003-800063	20031219 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006516251	T	20060629	JP 2004-563903	20031219 <--
US 20060084680	A1	20060420	US 2005-537630	20050603 <--
PRIORITY APPLN. INFO.:			US 2002-435310P	P 20021220 <--
			WO 2003-US40842	W 20031219


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 141:123483

GI



I



II

AB The title compds. [I; R1, R2 = H, alkyl, cycloalkyl; L = (CH2)mX, Y(CH2)nX, etc.; X = O, S, SO, SO2, Y = O, S, SO, SO2, (un)substituted NH; m = 1-3; n = 2-4; Ar = (un)substituted Ph, 5-6 membered heteroaryl containing up to three N atoms] which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases, were prepared and formulated. Thus, coupling Et {(1S)-5-[3-(4-bromo-2-methoxyphenoxy)propoxy]-2,3-dihydro-1H-inden-1-yl}acetate (preparation given) with 3-thiopheneboronic acid in the presence of PdCl2(dppf).CH2Cl2, NaHCO3 in DME/H2O followed by treatment of the resulting ester with LiOH afforded (1S)-II.

IT 496061-78-0P


RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indaneacetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 496061-78-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT	724466-23-3P	724466-34-6P	724466-36-8P
	724466-39-1P	724466-43-7P	724466-46-0P
	724466-49-3P	724466-53-9P	724466-68-5P
	724466-71-1P	724466-74-4P	724466-77-7P
	724466-79-9P	724466-81-3P	724467-23-6P
	724467-24-7P	724467-25-8P	724467-26-9P
	724467-27-0P	724467-29-2P	724467-31-6P
	724467-33-8P	724467-35-6P	724467-37-5P
	724467-39-4P	724467-41-8P	724467-43-0P
	724467-50-9P	724467-98-5P	724468-16-0P
	724468-19-3P	724468-23-9P	724468-31-9P
	724468-32-0P	724468-33-1P	724468-38-6P
	724468-39-7P	724468-49-0P	724468-41-1P
	724468-56-8P	724468-57-9P	724468-66-0P


724468-67-1P	724468-78-4P	724468-79-5P
724468-81-3P	724468-82-0P	724468-87-5P
724468-88-6P	724468-92-2P	724468-93-3P
724468-94-1P	724469-17-4P	724469-18-5P
724469-20-9P	724469-81-2P	724469-82-3P
724470-36-4P	724470-37-5P	724470-38-6P
724470-39-7P	724470-54-6P	724470-62-6P
724470-64-3P	724470-70-6P	724471-02-7P
724478-25-5P	724478-28-8P	724478-29-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of indaneacetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 724466-23-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-(4-ethyl-2-thiazolyl)-2-propylphenoxy]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-34-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(1-methyl-1H-indol-5-yl)oxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724466-36-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(4-methyl-1H-indol-5-yl)oxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 724466-39-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(4-propyl-1H-indol-5-yl)oxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-43-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(1-methyl-4-propyl-1H-indol-5-yl)oxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-46-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(3-methyl-6-benzofuranyl)oxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-49-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(3-methyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-53-9 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[3-[[2,3-dihydro-3-hydroxy-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-68-6 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-, ethyl ester (CA INDEX NAME)



RN 724466-71-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(trifluoromethyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-74-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(3-thienyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-77-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(3-thienyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-79-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(6-methyl-2-pyridinyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-81-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(phenylamino)propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-23-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(4-cyano-2-propylphenoxy)propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-24-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(aminothioxomethyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-25-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(4-cyano-2-methoxyphenoxy)propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-26-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(aminothioxomethyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-27-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-thiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-29-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(2-benzothiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-31-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(6,7-dihydro-5H-pyrano[2,3-d]thiazol-2-yl)-2-propylphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-33-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-35-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(1-methylethoxy)-2-thiazolyl]phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-37-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(2-thiazolyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724467-39-4 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[4-[3-[(1S)-1-(2-ethoxy-2-oxoethyl)-2,3-

dihydro-1H-inden-5-yl]oxy]propoxy]-3-methoxyphenyl]-4-(hydroxymethyl)-,  
ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-41-8 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[4-[3-[(1S)-1-(2-ethoxy-2-oxoethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]-3-methoxyphenyl]-4-methyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-43-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(2-benzothiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-50-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-oxazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-98-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-methoxy-2-propylphenoxy)propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-16-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-, methyl ester, (4R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 724468-19-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(6-ethyl-2-methyl-3-pyridinyl)oxy]propoxy]-2,3-dihydro-, methyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724468-23-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[(2,6-dimethyl-3-pyridinyl)oxy]ethoxy]-2,3-dihydro-, methyl ester, (1S)- (CA INDEX NAME)



dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-31-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(5-cyano-2-pyridinyl)oxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-32-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(aminothioxomethyl)-2-pyridinyl]oxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-33-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4,5-dimethyl-2-thiazolyl)-2-pyridinyl]oxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-38-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(5-cyano-2-pyridinyl)amino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-39-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(5-cyano-2-pyridinyl)propylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-40-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(aminothioxomethyl)-2-pyridinyl]propylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-41-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4,5-dimethyl-2-thiazolyl)-2-pyridinyl]propylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-56-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(5-bromo-2-pyrimidinyl)amino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-57-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(5-bromo-2-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-66-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[4-(1,3-benzodioxol-5-yl)-2-pyrimidinyl]amino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724468-67-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[4-(1,3-benzodioxol-5-yl)-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-78-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[6-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-79-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[6-(4-methoxyphenyl)-5-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-81-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[6-chloro-3-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-82-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[6-(4-methoxyphenyl)-3-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-87-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[6-chloro-5-cyano-3-fluoro-2-pyridinyl]methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-88-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-cyano-3-fluoro-6-(4-methoxyphenyl)-2-pyridinyl]methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-92-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[6-(4-ethylphenyl)-3-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-93-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[6-(4-ethylphenyl)-3-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-94-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[6-(4-ethylphenyl)-3-(trifluoromethyl)-2-pyridinyl]methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-17-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(2-chloro-5-methyl-4-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-18-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-20-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(3-methoxyphenoxy)-5-methyl-4-pyrimidinyl)methylamino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-81-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(2-chloro-5-methyl-4-pyrimidinyl)amino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-82-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(2-chloro-5-methyl-4-pyrimidinyl)propylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724470-36-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(2,5-dichloro-4-pyrimidinyl)amino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 724470-37-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(2,5-dichloro-4-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-38-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-(4-methoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-39-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2,5-bis(4-methoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-54-6 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[[1-(2-chloro-5-methyl-4-pyrimidinyl)-4-piperidinyl]oxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-62-6 CAPLUS

CN 1H-Indene-1-acetic acid, 4-[[1-(2-chloro-5-methyl-4-pyrimidinyl)-4-piperidinyl]oxy]-2,3-dihydro-, ethyl ester (CA INDEX NAME)




RN 724470-64-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(6-chloro-2-pyridinyl)ethoxy]-2,3-dihydro-, ethyl ester (CA INDEX NAME)

ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-70-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(4-methoxyphenyl)-3-methyl-2-pyridinyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724471-02-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[3-[4-(6,7-dihydro-5H-pyrano[3,2-d]thiazol-2-yl)-2-propylphenoxy]propyl]thio]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724478-25-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724478-28-8 CAPLUS

CN 1H-indene-1-acetic acid, 2,3-dihydro-5-[3-[2-hydroxy-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724478-29-9 CAPLUS

CN 1H-indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propoxy-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT	724466-17-5P	724466-24-4P	724466-25-5P
	724466-26-6P	724466-27-7P	724466-28-8P
	724466-29-9P	724466-30-2P	724466-31-3P
	724466-32-4P	724466-35-7P	724466-37-9P
	724466-40-4P	724466-44-8P	724466-47-1P
	724466-50-6P	724466-54-0P	724466-55-1P
	724466-56-2P	724466-57-3P	724466-58-4P
	724466-59-5P	724466-60-8P	724466-61-9P
	724466-62-0P	724466-63-1P	724466-64-2P
	724466-65-3P	724466-66-4P	724466-69-7P
	724466-72-2P	724466-75-5P	724466-78-8P
	724466-80-2P	724466-82-4P	724466-83-5P
	724466-84-6P	724466-86-8P	724466-87-9P

724466-86-0P	724466-89-1P	724466-90-4P
724466-91-5P	724466-92-6P	724466-93-7P
724466-94-8P	724466-95-9P	724466-96-0P
724466-97-1P	724466-98-2P	724466-99-3P
724467-00-9P	724467-01-0P	724467-02-1P
724467-03-2P	724467-04-3P	724467-05-4P
724467-06-5P	724467-07-6P	724467-08-7P
724467-09-8P	724467-10-1P	724467-11-2P
724467-12-3P	724467-13-4P	724467-14-5P
724467-15-6P	724467-16-7P	724467-17-6P
724467-18-9P	724467-19-0P	724467-20-3P
724467-21-4P	724467-22-5P	724467-23-1P
724467-30-5P	724467-32-7P	724467-34-9P
724467-36-1P	724467-38-3P	724467-40-7P
724467-42-9P	724467-48-5P	724467-51-0P
724467-52-1P	724467-53-2P	724467-54-3P
724467-55-4P	724467-56-5P	724467-57-6P
724467-58-7P	724467-59-6P	724467-60-1P
724467-61-2P	724467-62-3P	724467-63-4P
724467-64-5P	724467-65-6P	724467-66-7P
724467-67-8P	724467-68-9P	724467-69-0P
724467-70-3P	724467-71-4P	724467-72-5P
724467-73-6P	724467-74-7P	724467-75-8P
724467-76-9P	724467-77-0P	724467-78-1P
724467-79-2P	724467-80-5P	724467-81-6P
724467-82-7P	724467-83-8P	724467-84-9P
724467-85-0P	724467-86-1P	724467-87-2P
724467-98-3P	724467-89-4P	724467-90-7P
724467-91-8P	724467-92-9P	724467-93-0P
724467-94-1P	724467-95-2P	724467-96-3P
724467-97-4P	724467-99-6P	724468-00-2P
724468-01-3P	724468-02-4P	724468-04-6P
724468-05-7P	724468-06-8P	724468-07-9P
724468-09-1P	724468-10-4P	724468-11-5P
724468-12-6P	724468-13-7P	724468-14-8P
724468-15-9P	724468-17-1P	724468-18-2P
724468-20-6P	724468-24-0P	724468-25-1P
724468-26-2P	724468-27-3P	724468-28-4P
724468-29-5P	724468-34-2P	724468-42-2P
724468-43-3P	724468-44-4P	724468-45-5P
724468-46-6P	724468-48-8P	724468-49-9P
724468-50-2P	724468-51-3P	724468-52-4P
724468-53-5P	724468-54-6P	724468-55-7P
724468-58-0P	724468-59-1P	724468-60-4P
724468-61-5P	724468-62-6P	724468-63-7P
724468-64-8P	724468-68-2P	724468-69-3P
724468-70-6P	724468-71-7P	724468-72-8P
724468-73-9P	724468-74-0P	724468-75-1P
724468-80-8P	724468-83-1P	724468-89-7P
724468-95-5P	724468-96-6P	724468-97-7P
724468-98-8P	724468-99-9P	724469-00-5P
724469-01-6P	724469-02-7P	724469-03-8P
724469-04-9P	724469-05-0P	724469-06-1P
724469-07-2P	724469-09-4P	724469-11-8P
724469-12-9P	724469-13-0P	724469-19-6P
724469-21-0P	724469-22-1P	724469-23-2P
724469-24-3P	724469-25-4P	724469-26-5P
724469-27-6P	724469-29-7P	724469-29-8P
724469-30-1P	724469-31-2P	724469-32-3P
724469-33-4P	724469-34-5P	724469-35-6P

724469-36-7P 724469-37-8P 724469-38-9P  
 724469-39-0P 724469-40-3P 724469-41-4P  
 724469-42-5P 724469-43-6P 724469-44-7P  
 724469-45-8P 724469-46-9P 724469-47-0P  
 724469-48-1P 724469-49-2P 724469-50-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of indaneacetic acid derivs. for treating diabetes, obesity,  
 hyperlipidemia, and atherosclerotic diseases)

RN 724466-17-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[[7-propyl-3-(trifluoromethyl)-  
 1,2-benzisoxazol-6-yl]oxy]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-24-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-(4-ethyl-2-thiazolyl)-2-  
 propylphenoxy]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-25-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(1H-indol-5-yloxy)ethoxy]-,  
 (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-26-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[(2-methyl-1H-indol-5-yl)oxy]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-27-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(1H-indol-6-yloxy)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-28-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(1H-indol-4-yloxy)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-29-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[(3-methyl-6-benzofuranyl)oxy]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-30-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[(2-methyl-5-benzothiazolyl)oxy]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-31-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(6-quinolinyl)oxy]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-32-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(7-quinolinyl)oxy]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 724466-35-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(1-methyl-1H-indol-5-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-37-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(4-methyl-1H-indol-5-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-40-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(4-propyl-1H-indol-5-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-44-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(1-methyl-4-propyl-1H-indol-5-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-47-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(3-methyl-6-benzofuranyl)oxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-50-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(3-methyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-54-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2,3-dihydro-3-hydroxy-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-55-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(1H-indol-5-yloxy)propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-56-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(2-methyl-1H-indol-5-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-57-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[4-(2-propen-1-yl)-1H-indol-5-yl]oxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-58-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(1H-indol-6-yloxy)propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-59-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(1H-indol-4-yloxy)propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-60-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(6-benzoxazolyl)oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-61-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(1,2-benzisoxazol-6-yloxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-62-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(3-methyl-1,2-benzisoxazol-6-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-63-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(3,7-dimethyl-1,2-benzisoxazol-6-yl)oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-64-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-65-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5,6,7,8-tetrahydro-1-naphthalenyl]oxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-66-4 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(5,6,7,8-tetrahydro-5-oxo-1-naphthalenyl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-69-7 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]- (CA INDEX NAME)



RN 724466-72-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(trifluoromethyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-75-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(3-thienyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-78-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(3-thienyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-80-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(6-methyl-2-pyridinyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-82-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(phenylamino)propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-83-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-(3-phenoxypropoxy)-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-84-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(2-propylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-86-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-methylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-87-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(2,4-dimethylphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724466-88-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(2-methoxy-4-methylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 724466-89-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(2-ethoxy-4-methylphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-90-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(2-bromo-4-methylphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-91-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-methyl-2-[(1-norobutyl)amino]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-92-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-(5-isoxazolyl)-4-methylphenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-93-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(4-ethylphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-94-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(4-ethyl-2-methoxyphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-95-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(1-methylethyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-96-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(trifluoromethyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-97-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(4-cyanophenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-98-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(4-cyano-2-propylphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-99-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(4-cyano-2-methoxyphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-00-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-methoxyphenoxy)propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-01-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-phenoxy-2-propylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-02-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(4-ethoxyphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-03-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(trifluoromethoxy)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724467-04-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(4-bromo-2-methoxyphenoxy)propoxy]-2,3-

dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-05-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(1H-1,2,4-triazol-1-yl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-06-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[2-(acetamino)-4-(1H-1,2,3-triazol-1-yl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-07-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[2-chloro-4-(1H-1,2,4-triazol-4-yl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-08-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methyl-4-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-09-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-[4,5-dihydro-4-hydroxy-4-(trifluoromethyl)-2-thiazolyl]phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-10-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(3-furanyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-11-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(2-thienyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(4-methyl-2-thienyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

COc1cc(OC2=CC=C(C=C2)C3=CC(=CC=C3)S4C(=CC(=CC=C4)C5=CC=C(C=C5)S6C(=CC(=CC=C6)C7=CC=C(C=C7)C8=CC=C(C=C8)S9C(=CC(=CC=C9)C10=CC=C(C=C10)C11=CC=C(C=C11)C12=CC=C(C=C12)C13=CC=C(C=C13)C14=CC=C(C=C14)C15=CC=C(C=C15)C16=CC=C(C=C16)C17=CC=C(C=C17)C18=CC=C(C=C18)C19=CC=C(C=C19)C20=CC=C(C=C20)C21=CC=C(C=C21)C22=CC=C(C=C22)C23=CC=C(C=C23)C24=CC=C(C=C24)C25=CC=C(C=C25)C26=CC=C(C=C26)C27=CC=C(C=C27)C28=CC=C(C=C28)C29=CC=C(C=C29)C30=CC=C(C=C30)C31=CC=C(C=C31)C32=CC=C(C=C32)C33=CC=C(C=C33)C34=CC=C(C=C34)C35=CC=C(C=C35)C36=CC=C(C=C36)C37=CC=C(C=C37)C38=CC=C(C=C38)C39=CC=C(C=C39)C40=CC=C(C=C40)C41=CC=C(C=C41)C42=CC=C(C=C42)C43=CC=C(C=C43)C44=CC=C(C=C44)C45=CC=C(C=C45)C46=CC=C(C=C46)C47=CC=C(C=C47)C48=CC=C(C=C48)C49=CC=C(C=C49)C50=CC=C(C=C50)C51=CC=C(C=C51)C52=CC=C(C=C52)C53=CC=C(C=C53)C54=CC=C(C=C54)C55=CC=C(C=C55)C56=CC=C(C=C56)C57=CC=C(C=C57)C58=CC=C(C=C58)C59=CC=C(C=C59)C60=CC=C(C=C60)C61=CC=C(C=C61)C62=CC=C(C=C62)C63=CC=C(C=C63)C64=CC=C(C=C64)C65=CC=C(C=C65)C66=CC=C(C=C66)C67=CC=C(C=C67)C68=CC=C(C=C68)C69=CC=C(C=C69)C70=CC=C(C=C70)C71=CC=C(C=C71)C72=CC=C(C=C72)C73=CC=C(C=C73)C74=CC=C(C=C74)C75=CC=C(C=C75)C76=CC=C(C=C76)C77=CC=C(C=C77)C78=CC=C(C=C78)C79=CC=C(C=C79)C80=CC=C(C=C80)C81=CC=C(C=C81)C82=CC=C(C=C82)C83=CC=C(C=C83)C84=CC=C(C=C84)C85=CC=C(C=C85)C86=CC=C(C=C86)C87=CC=C(C=C87)C88=CC=C(C=C88)C89=CC=C(C=C89)C90=CC=C(C=C90)C91=CC=C(C=C91)C92=CC=C(C=C92)C93=CC=C(C=C93)C94=CC=C(C=C94)C95=CC=C(C=C95)C96=CC=C(C=C96)C97=CC=C(C=C97)C98=CC=C(C=C98)C99=CC=C(C=C99)C100=CC=C(C=C100)C101=CC=C(C=C101)C102=CC=C(C=C102)C103=CC=C(C=C103)C104=CC=C(C=C104)C105=CC=C(C=C105)C106=CC=C(C=C106)C107=CC=C(C=C107)C108=CC=C(C=C108)C109=CC=C(C=C109)C110=CC=C(C=C110)C111=CC=C(C=C111)C112=CC=C(C=C112)C113=CC=C(C=C113)C114=CC=C(C=C114)C115=CC=C(C=C115)C116=CC=C(C=C116)C117=CC=C(C=C117)C118=CC=C(C=C118)C119=CC=C(C=C119)C120=CC=C(C=C120)C121=CC=C(C=C121)C122=CC=C(C=C122)C123=CC=C(C=C123)C124=CC=C(C=C124)C125=CC=C(C=C125)C126=CC=C(C=C126)C127=CC=C(C=C127)C128=CC=C(C=C128)C129=CC=C(C=C129)C130=CC=C(C=C130)C131=CC=C(C=C131)C132=CC=C(C=C132)C133=CC=C(C=C133)C134=CC=C(C=C134)C135=CC=C(C=C135)C136=CC=C(C=C136)C137=CC=C(C=C137)C138=CC=C(C=C138)C139=CC=C(C=C139)C140=CC=C(C=C140)C141=CC=C(C=C141)C142=CC=C(C=C142)C143=CC=C(C=C143)C144=CC=C(C=C144)C145=CC=C(C=C145)C146=CC=C(C=C146)C147=CC=C(C=C147)C148=CC=C(C=C148)C149=CC=C(C=C149)C150=CC=C(C=C150)C151=CC=C(C=C151)C152=CC=C(C=C152)C153=CC=C(C=C153)C154=CC=C(C=C154)C155=CC=C(C=C155)C156=CC=C(C=C156)C157=CC=C(C=C157)C158=CC=C(C=C158)C159=CC=C(C=C159)C160=CC=C(C=C160)C161=CC=C(C=C161)C162=CC=C(C=C162)C163=CC=C(C=C163)C164=CC=C(C=C164)C165=CC=C(C=C165)C166=CC=C(C=C166)C167=CC=C(C=C167)C168=CC=C(C=C168)C169=CC=C(C=C169)C170=CC=C(C=C170)C171=CC=C(C=C171)C172=CC=C(C=C172)C173=CC=C(C=C173)C174=CC=C(C=C174)C175=CC=C(C=C175)C176=CC=C(C=C176)C177=CC=C(C=C177)C178=CC=C(C=C178)C179=CC=C(C=C179)C180=CC=C(C=C180)C181=CC=C(C=C181)C182=CC=C(C=C182)C183=CC=C(C=C183)C184=CC=C(C=C184)C185=CC=C(C=C185)C186=CC=C(C=C186)C187=CC=C(C=C187)C188=CC=C(C=C188)C189=CC=C(C=C189)C190=CC=C(C=C190)C191=CC=C(C=C191)C192=CC=C(C=C192)C193=CC=C(C=C193)C194=CC=C(C=C194)C195=CC=C(C=C195)C196=CC=C(C=C196)C197=CC=C(C=C197)C198=CC=C(C=C198)C199=CC=C(C=C199)C200=CC=C(C=C200)C201=CC=C(C=C201)C202=CC=C(C=C202)C203=CC=C(C=C203)C204=CC=C(C=C204)C205=CC=C(C=C205)C206=CC=C(C=C206)C207=CC=C(C=C207)C208=CC=C(C=C208)C209=CC=C(C=C209)C210=CC=C(C=C210)C211=CC=C(C=C211)C212=CC=C(C=C212)C213=CC=C(C=C213)C214=CC=C(C=C214)C215=CC=C(C=C215)C216=CC=C(C=C216)C217=CC=C(C=C217)C218=CC=C(C=C218)C219=CC=C(C=C219)C220=CC=C(C=C220)C221=CC=C(C=C221)C222=CC=C(C=C222)C223=CC=C(C=C223)C224=CC=C(C=C224)C225=CC=C(C=C225)C226=CC=C(C=C226)C227=CC=C(C=C227)C228=CC=C(C=C228)C229=CC=C(C=C229)C230=CC=C(C=C230)C231=CC=C(C=C231)C232=CC=C(C=C232)C233=CC=C(C=C233)C234=CC=C(C=C234)C235=CC=C(C=C235)C236=CC=C(C=C236)C237=CC=C(C=C237)C238=CC=C(C=C238)C239=CC=C(C=C239)C240=CC=C(C=C240)C241=CC=C(C=C241)C242=CC=C(C=C242)C243=CC=C(C=C243)C244=CC=C(C=C244)C245=CC=C(C=C245)C246=CC=C(C=C246)C247=CC=C(C=C247)C248=CC=C(C=C248)C249=CC=C(C=C249)C250=CC=C(C=C250)C251=CC=C(C=C251)C252=CC=C(C=C252)C253=CC=C(C=C253)C254=CC=C(C=C254)C255=CC=C(C=C255)C256=CC=C(C=C256)C257=CC=C(C=C257)C258=CC=C(C=C258)C259=CC=C(C=C259)C260=CC=C(C=C260)C261=CC=C(C=C261)C262=CC=C(C=C262)C263=CC=C(C=C263)C264=CC=C(C=C264)C265=CC=C(C=C265)C266=CC=C(C=C266)C267=CC=C(C=C267)C268=CC=C(C=C268)C269=CC=C(C=C269)C270=CC=C(C=C270)C271=CC=C(C=C271)C272=CC=C(C=C272)C273=CC=C(C=C273)C274=CC=C(C=C274)C275=CC=C(C=C275)C276=CC=C(C=C276)C277=CC=C(C=C277)C278=CC=C(C=C278)C279=CC=C(C=C279)C280=CC=C(C=C280)C281=CC=C(C=C281)C282=CC=C(C=C282)C283=CC=C(C=C283)C284=CC=C(C=C284)C285=CC=C(C=C285)C286=CC=C(C=C286)C287=CC=C(C=C287)C288=CC=C(C=C288)C289=CC=C(C=C289)C290=CC=C(C=C290)C291=CC=C(C=C291)C292=CC=C(C=C292)C293=CC=C(C=C293)C294=CC=C(C=C294)C295=CC=C(C=C295)C296=CC=C(C=C296)C297=CC=C(C=C297)C298=CC=C(C=C298)C299=CC=C(C=C299)C300=CC=C(C=C300)C301=CC=C(C=C301)C302=CC=C(C=C302)C303=CC=C(C=C303)C304=CC=C(C=C304)C305=CC=C(C=C305)C306=CC=C(C=C306)C307=CC=C(C=C307)C308=CC=C(C=C308)C309=CC=C(C=C309)C310=CC=C(C=C310)C311=CC=C(C=C311)C312=CC=C(C=C312)C313=CC=C(C=C313)C314=CC=C(C=C314)C315=CC=C(C=C315)C316=CC=C(C=C316)C317=CC=C(C=C317)C318=CC=C(C=C318)C319=CC=C(C=C319)C320=CC=C(C=C320)C321=CC=C(C=C321)C322=CC=C(C=C322)C323=CC=C(C=C323)C324=CC=C(C=C324)C325=CC=C(C=C325)C326=CC=C(C=C326)C327=CC=C(C=C327)C328=CC=C(C=C328)C329=CC=C(C=C329)C330=CC=C(C=C330)C331=CC=C(C=C331)

CN 1H-Indene-1-acetic acid, 5-[3-([1,1'-biphenyl]-4-yloxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


O=C(O)C[C@H]1Cc2ccc(OCCCCOc3ccc(cc3)Ph)cc2S1

CN 1H-Indene-1-acetic acid, 5-[3-[(3,4'-dimethoxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

COc1ccc(cc1)C2=CC=C(C=C2)Oc3ccc(OC)c(OCCCCOC4=CC=C5C(=C4)C[C@H](C5)C(=O)O)C3

CN 1H-Indene-1-acetic acid, 5-[3-[(4'-fluoro-3-methoxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-16-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(3-pyridinyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-17-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(3-pyridinyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-18-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(4-methoxy-3-pyridinyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724467-19-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-[5-(trifluoromethyl)-2-



pyridinyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-20-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(5-pyrimidinyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-21-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(2,4-dimethoxy-5-pyrimidinyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-22-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(1H-indol-6-yl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-28-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-thiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-30-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(2-benzothiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-32-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(6,7-dihydro-5H-pyrano[2,3-d]thiazol-2-yl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-34-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-36-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-[4-(1-methylethoxy)-2-thiazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-38-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(2-thiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-40-7 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[4-[3-[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]-3-methoxyphenyl]-4-(hydroxymethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-42-9 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[4-[3-[[1S]-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]-3-methoxyphenyl]-4-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-48-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(2-benzothiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-51-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-oxazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-52-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(2-thiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-53-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(4-methyl-2-thiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-54-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-thiazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-55-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-oxazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-56-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-oxazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-57-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-[4-(1,1-dimethylethyl)-2-thiazolyl]-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-58-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-[4-(1,1-dimethylethyl)-2-oxazolyl]phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-59-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-[4-(1,1-dimethylethyl)-2-oxazolyl]-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724467-60-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-[4-(trifluoromethyl)-

2-thiazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-61-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-[4-(trifluoromethyl)-2-thiazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-62-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-[4-(trifluoromethyl)-2-oxazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-63-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-[4-(trifluoromethyl)-2-oxazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-64-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4,5-dimethyl-2-thiazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-65-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4,5-dimethyl-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-66-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(5,6-dihydro-4H-cyclopentathiazol-2-yl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724467-67-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(5,6-dihydro-4H-cyclopentathiazol-2-yl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 724467-68-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(5,6-dihydro-4H-cyclopentathiazol-2-yl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-69-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-70-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-71-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(4,5,6,7-tetrahydro-2-benzoxazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-72-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(4,5,6,7-tetrahydro-2-benzoxazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-73-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[2-ethoxy-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-74-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propoxy-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-75-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(4,5,6,7-tetrahydro-2-benzoxazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-76-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(6,7-dihydro-5H-pyrano[2,3-d]thiazol-2-yl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-77-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(4,5,6,7-tetrahydro-5,5-dimethyl-7-oxo-2-benzothiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-78-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(4-methoxy-2-thiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-79-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(4-methoxy-2-thiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-80-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethoxy-2-thiazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724467-81-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethoxy-2-thiazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-82-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethoxy-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-83-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-[4-(1-methylethoxy)-2-thiazolyl]-2-propylphenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-84-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethoxy-5-methyl-2-thiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-85-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethoxy-5-methyl-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-86-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethoxy-5-ethyl-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-87-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(5-acetyl-4-methyl-2-thiazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-88-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(5-acetyl-4-methyl-2-thiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-89-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(5-acetyl-4-methyl-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-90-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(5-acetyl-4-methyl-2-oxazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-91-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(5-acetyl-4-methyl-2-oxazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-92-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(5-acetyl-4-methyl-2-oxazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-93-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-[5-[(dimethylamino)carbonyl]-4-methyl-2-thiazolyl]-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-94-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-[5-[(dimethylamino)carbonyl]-4-methyl-2-thiazolyl]-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724467-95-2 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[4-[3-[[1S]-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]phenyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 724467-96-3 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[4-[3-[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]-3-propylphenyl]-4-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-97-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-[5-hydroxy-4-(trifluoromethyl)-2-oxazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724467-99-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-methoxy-2-propylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-00-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(3-methylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-01-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(3-methoxyphenoxy)propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-02-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-([1,1'-biphenyl]-3-yloxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-04-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(2,3-dimethoxyphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-05-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(acetylamino)-3-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-06-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(3,4-dimethoxyphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-07-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(3,4,5-trimethoxyphenoxy)propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-09-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[3-[2-methyl-4-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]phenoxy]propoxy]-, methyl ester, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-10-4 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[3-[2-methyl-4-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]phenoxy]propoxy]-, ( $\alpha$ S,1S)-

Absolute stereochemistry.




CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-, (aS,1S)- (CA INDEX NAME)

Absolute stereochemistry.




CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[3-[(3-methyl-6-benzofuranyl)oxy]propoxy]-, ( $\alpha$ S,1S)- (CA INDEX NAME)

Absolute stereochemistry.



CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[3-[4-(trifluoromethyl)phenoxy]propoxy]-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-14-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(4-ethylphenoxy)propoxy]-2,3-dihydro- $\alpha$ -methyl-, (aS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-15-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[3-[2-propyl-4-(trifluoromethyl)phenoxy]propoxy]-, (aS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-17-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-, (aR,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 724468-18-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-, (aR,1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-20-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(6-ethyl-2-methyl-3-pyridinyl)oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-24-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[(2,6-dimethyl-3-pyridinyl)oxy]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-25-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(3-pyridinyloxy)ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724468-26-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[(6-methyl-3-

pyridinyl)oxy]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-27-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[(2-methyl-3-pyridinyl)oxy]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-28-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[(5-chloro-3-pyridinyl)oxy]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-29-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[2-[[1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-34-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4,5-dimethyl-2-thiazolyl)-2-pyridinyl]oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-42-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4,5-dimethyl-2-thiazolyl)-2-pyridinyl]oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-43-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4-ethyl-2-thiazolyl)-2-pyridinyl]oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.





CN 1H-Indene-1-acetic acid, 5-[3-[[5-(5-acetyl-4-methyl-2-thiazolyl)-2-pyridinyl]oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

CC1=C(C)N=C(C1c2ccsc2-c3ccc(OCCCOCC4C=CC=C(C=C4)S[C@H](C4=CC=CC=C4)C(=O)O)cc3)c5ccccc5

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-(4,5,6,7-tetrahydro-2-benzothiazolyl)-2-pyridinyl]oxy]propoxy]-, (1S)- (CA INDEX NAME)


O=C(O)[C@H]1Cc2ccccc2S1COCCOc3nc(NC(=S)C4=CC=CC=C4C5=CCCCC5)nc3

CN 1H-Indene-1-acetic acid, 5-[3-[15-(4-ethoxy-2-thiazolyl)-2-pyridinyl]oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

CCOC1=NC=C(C2=CC=CC=C2OCC3=CC=CC=C3CC4CCCC4C(=O)O)S1

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4-ethyl-2-thiazolyl)-2-pyridinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-49-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(5-acetyl-4-methyl-2-thiazolyl)-2-pyridinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-50-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4,5-dimethyl-2-thiazolyl)-2-pyridinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-51-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4-ethyl-2-thiazolyl)-2-pyridinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-52-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(5-acetyl-4-methyl-2-thiazolyl)-2-pyridinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-53-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4,5-dimethyl-2-thiazolyl)-2-pyridinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-54-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4-ethyl-2-thiazolyl)-2-pyridinyl]propylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-55-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(5-acetyl-4-methyl-2-thiazolyl)-2-pyridinyl]propylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-58-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4-ethylphenyl)-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-59-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(1,3-benzodioxol-5-yl)-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-60-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4-fluorophenyl)-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-61-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-(4-methoxyphenyl)-2-pyrimidinyl]methylamino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-62-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-[4-(1,1-dimethylethyl)phenyl]-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-63-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[5-(3-thienyl)-2-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-64-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(5-benzo[b]thien-2-yl-2-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-68-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[4-(1,3-benzodioxol-5-yl)-2-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-69-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-70-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[propyl[4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-71-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[4-(1,3-benzodioxol-5-yl)-2-pyrimidinyl]propylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-72-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[4-(4-ethylphenyl)-5-(trifluoromethyl)-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-73-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[4-(4-methoxyphenyl)-5-(trifluoromethyl)-2-pyrimidinyl]methylamino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-74-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[4-(4-chlorophenyl)-5-(trifluoromethyl)-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-75-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[4-(1,3-benzodioxol-5-yl)-5-(trifluoromethyl)-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-80-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[6-(4-methoxyphenyl)-5-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724468-83-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[6-(4-methoxyphenyl)-3-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 724468-89-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-cyano-3-fluoro-6-(4-methoxyphenyl)-2-pyridinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-95-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[6-(4-ethylphenyl)-3-(trifluoromethyl)-2-pyridinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-96-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[6-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-97-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[6-(3,4-dimethoxyphenyl)-3-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-98-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[6-(1,3-benzodioxol-5-yl)-3-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-99-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[6-(4-fluorophenyl)-3-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-00-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[6-(4-methylphenyl)-3-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-01-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[6-phenyl-3-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-02-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[[6-(4-ethylphenyl)-3-(trifluoromethyl)-2-pyridinyl]amino]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-03-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[[6-(4-ethylphenyl)-3-(trifluoromethyl)-2-pyridinyl]methylamino]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-04-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[6-(3-fluoro-4-methoxyphenyl)-5-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-05-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[6-(3,4-dimethoxyphenyl)-5-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-06-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[6-(1,3-benzodioxol-5-yl)-5-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-07-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[6-(4-fluorophenyl)-5-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-09-4 CAPLUS

CN 1H-indene-1-acetic acid, 2,3-dihydro-5-[3-[[6-(4-methylphenyl)-5-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-11-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[6-phenyl-5-(trifluoromethyl)-2-pyridinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-12-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-cyano-6-(4-ethylphenyl)-3-fluoro-2-pyridinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-13-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-cyano-6-(4-ethylphenyl)-4-methyl-2-pyridinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-19-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-21-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[2-(4-methylphenyl)-4-pyrimidinyl]aminolpropoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-22-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-23-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-fluorophenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-24-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 724469-25-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-26-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-27-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(3,4-dimethoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-28-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-(dimethoxyphenyl)pyrimidin-4-yl)methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-29-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-(acetylphenyl)pyrimidin-4-yl)methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-30-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-5-methyl-4-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-31-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-32-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[5-methyl-2-(4-methylphenyl)-4-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-33-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-34-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(3-fluoro-4-methylphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-35-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(3-ethoxyphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-36-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(3,4-dimethoxyphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-37-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(3,4-dimethylphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-38-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[5-methyl-2-[4-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-39-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethoxyphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-40-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-acetylphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-41-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl(5-methyl-2-phenyl-4-pyrimidinyl)amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-42-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl(5-methyl-2-(3-methylphenyl)-4-pyrimidinyl)amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-43-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(3-chlorophenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-44-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724469-45-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro- $\alpha$ -methyl-,

( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-46-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-47-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 724469-48-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-49-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-fluoro-2-(4-methoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-50-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-fluoro-2-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT	724469-51-6P	724469-52-7P	724469-53-8P
	724469-54-9P	724469-55-0P	724469-56-1P
	724469-57-2P	724469-58-3P	724469-59-4P
	724469-60-7P	724469-61-8P	724469-62-9P
	724469-63-0P	724469-64-1P	724469-65-2P
	724469-66-3P	724469-67-4P	724469-68-5P
	724469-69-6P	724469-70-9P	724469-71-0P
	724469-72-1P	724469-73-2P	724469-74-3P
	724469-75-4P	724469-76-5P	724469-77-6P
	724469-78-7P	724469-79-8P	724469-80-1P
	724469-83-4P	724469-84-5P	724469-85-6P
	724469-86-7P	724469-87-8P	724469-88-9P
	724469-90-3P	724469-92-5P	724469-94-7P
	724469-96-9P	724469-97-0P	724469-98-1P
	724470-00-2P	724470-02-4P	724470-04-6P
	724470-05-7P	724470-07-9P	724470-09-1P
	724470-11-5P	724470-13-7P	724470-15-9P
	724470-17-1P	724470-19-3P	724470-21-7P
	724470-23-9P	724470-25-1P	724470-27-3P
	724470-29-5P	724470-40-0P	724470-41-1P
	724470-42-2P	724470-43-3P	724470-44-4P
	724470-45-5P	724470-46-6P	724470-47-7P
	724470-48-8P	724470-49-9P	724470-50-2P
	724470-51-3P	724470-52-4P	724470-55-7P
	724470-56-8P	724470-57-9P	724470-58-0P
	724470-59-1P	724470-60-4P	724470-61-5P
	724470-63-7P	724470-65-9P	724470-66-0P
	724470-71-7P	724470-72-8P	724470-73-9P
	724470-74-0P	724470-75-1P	724470-76-2P
	724470-77-3P	724470-78-4P	724470-79-5P
	724470-80-8P	724470-81-9P	724470-82-0P
	724470-83-1P	724470-84-2P	724470-85-3P
	724470-86-4P	724470-91-1P	724470-92-2P
	724470-93-3P	724470-94-4P	724470-95-5P
	724470-96-6P	724471-03-8P	724471-04-9P
	724471-05-0P	724471-06-1P	724471-07-2P
	724471-08-3P	724471-09-4P	724471-10-7P
	724471-11-8P	724478-26-6P	724478-27-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of indaneacetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 724469-51-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-fluoro-2-[4-(1-methylethyl)phenyl]]phenyl]]-4-

pyrimidinyl)methylaminolpropoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-52-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-acetylphenyl)-5-fluoro-4-pyrimidinyl)methylaminolpropoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-53-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-chlorophenyl)-5-fluoro-4-pyrimidinyl)methylaminolpropoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-54-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(5-fluoro-2-phenyl-4-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-55-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-fluoro-2-[4-(trifluoromethoxy)phenyl]-4-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-56-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethoxyphenyl)-5-fluoro-4-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-57-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-fluoro-2-(4-methylphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-58-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-fluoro-2-(4-fluorophenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-59-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-fluoro-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-60-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-5-fluoro-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-61-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-ethyl-2-(4-fluorophenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-62-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-ethyl-2-(4-ethylphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-63-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-5-ethyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-64-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-65-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[6-methyl-2-[4-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-66-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethoxyphenyl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-67-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-cyclohexylphenyl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724469-68-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-butylphenyl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 724469-69-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[6-methyl-2-(4-methylphenyl)-4-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-70-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-[4-(1,1-dimethylethyl)phenyl]-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-71-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-acetylphenyl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-72-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-73-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-fluorophenyl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-74-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(2-fluorophenyl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-75-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(2-chloro-4-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-76-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[5-methyl-2-(3-thienyl)-4-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-77-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methoxyphenoxy)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-78-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-fluorophenoxy)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-79-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(2-benzofuranyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-80-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(2-benzofuranyl)-5-fluoro-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-83-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]propylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-84-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[6-phenyl-4-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-85-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methylphenyl)-4-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-86-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-87-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-methyl-2-(4-methylphenyl)-4-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-88-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-90-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-5-methyl-4-pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-92-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-methyl-2-(3-thienyl)-4-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-94-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-fluorophenyl)-5-methyl-4-pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-96-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-methyl-2-(3-methylphenyl)-4-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724469-97-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(3-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724469-98-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 724470-00-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-methyl-2-(4-methylphenyl)-4-pyrimidinyl]propylamino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-02-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]propylamino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-04-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-5-methyl-4-pyrimidinyl]propylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-05-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-methyl-2-(3-thienyl)-4-pyrimidinyl]propylamino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-07-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-fluorophenyl)-5-methyl-4-pyrimidinyl]propylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-09-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-methyl-2-(3-methylphenyl)-4-pyrimidinyl]propylamino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-11-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methylphenyl)-4-pyrimidinyl]propylamino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-13-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-4-pyrimidinyl]propylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-15-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-4-pyrimidinyl]propylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-17-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methoxyphenyl)-4-pyrimidinyl]propylamino]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-19-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(cyclopropylmethyl)[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724470-21-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[(ethyl[2-(4-ethylphenyl)-5-methyl-4-

pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-23-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[ethyl[5-methyl-2-(4-methylphenyl)-4-pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-25-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-5-methyl-4-pyrimidinyl]ethylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724470-27-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[acetyl[2-(4-ethylphenyl)-5-methyl-4-

pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-29-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[acetyl[2-(1,3-benzodioxol-5-yl)-5-methyl-4-pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-40-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-(4-methoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724470-41-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2,5-bis(4-methoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

pyrimidinyl)methylaminolpropoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-42-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2,5-bis(4-acetylphenyl)-4-pyrimidinyl)methylaminolpropoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-43-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2,5-bis[4-(trifluoromethyl)phenyl]-4-pyrimidinyl)methylaminolpropoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-44-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2,5-bis(4-fluorophenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724470-45-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-(4-ethylphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 724470-46-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-[4-(trifluoromethoxy)phenyl]pyrimidin-4-yl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-47-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4-acetylphenyl)-2-chloro-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-48-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-49-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-(1,3-benzodioxol-5-yl)-2-chloro-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-50-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-(4-fluorophenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-51-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-(4-methylphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-52-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-(3,4-difluorophenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-55-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[1-[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]-4-piperidinyl]oxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-56-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[1-[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]-2-pyrrolidinyl]methoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-57-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[1-[2-(4-fluorophenyl)-5-methyl-4-pyrimidinyl]-4-piperidinyl]oxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-58-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[[1-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-pyrimidinyl]oxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-59-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[[1-[2-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]oxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-60-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[1-[2-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]-4-piperidinyl]oxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-61-5 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[[1-[2-(1,3-benzodioxol-5-yl)-5-methyl-4-pyrimidinyl]-4-piperidinyl]oxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-63-7 CAPLUS


CN 1H-Indene-1-acetic acid, 4-[[1-[2-(2-chloro-5-methyl-4-pyrimidinyl)-4-piperidinyl]oxy]-2,3-dihydro- (CA INDEX NAME)



RN 724470-65-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[6-(4-ethylphenyl)-2-pyridinyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-66-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(methylphenylamino)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-71-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(4-methoxyphenyl)-3-methyl-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-72-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(3-methyl-2-pyridinyl)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-73-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(4-methylphenyl)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-74-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[6-(4-acetylphenyl)-2-pyridinyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-75-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(4-methoxyphenyl)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-76-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[6-(1,3-benzodioxol-5-yl)-2-pyridinyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724470-77-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[6-(4-chlorophenyl)-2-pyridinyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 724470-78-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[6-(4-fluorophenyl)-2-pyridinyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-79-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(6-phenyl-2-pyridinyl)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-80-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[6-(3-furanyl)-2-pyridinyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-81-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(4-(trifluoromethyl)phenyl)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-82-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(3-thienyl)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-83-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(4-morpholinyl)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-84-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(1-piperidinyl)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-85-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(4-methyl-1-piperazinyl)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-86-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[6-(1,3-benzodioxol-5-yl)-2-pyridinyl]ethoxy]-α-ethyl-2,3-dihydro-, (αS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-91-1 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-5-[2-[6-(4-ethylphenyl)-2-pyridinyl]ethoxy]-2,3-dihydro-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-92-2 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[6-(4-(trifluoromethyl)phenyl)-2-pyridinyl]ethoxy]-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-93-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[6-(4-ethylphenyl)-3-methyl-2-pyridinyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-94-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[3-methyl-6-(4-(trifluoromethyl)phenyl)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-95-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(6-ethyl-2-pyridinyl)ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-96-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(6-ethyl-2-pyridinyl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724471-03-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[3-[[4-(6,7-dihydro-5H-pyrano[3,2-d]thiazol-2-yl)-2-propylphenoxy]propyl]thio]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724471-04-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[[6-(4-acetylphenyl)-2-pyridinyl]oxy]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724471-05-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[[6-(1,3-benzodioxol-5-yl)-2-pyridinyl]oxy]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724471-06-1 CAPLUS

CN 1H-Indene-1-acetic acid, α-ethyl-5-[2-[[6-(4-ethylphenyl)-2-pyridinyl]oxy]ethoxy]-2,3-dihydro-, (αS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724471-07-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724471-08-3 CAPLUS

CN 4-Thiazoleacetic acid, 2-[4-[3-[[1S]-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]-3-propylphenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 724471-09-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-[5-(dimethylamino)-4-methyl-2-thiazolyl]-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724471-10-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(6,7-dihydro-5H-pyrano[2,3-d]thiazol-2-yl)-2-propoxyphenoxy]propoxy]-2,3-dihydro-, (1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724471-11-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(6,7-dihydro-5H-pyrano[2,3-d]thiazol-2-yl)-2-propoxyphenoxy]propylthio]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 724478-26-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(3-methoxyphenoxy)-5-methyl-4-pyrimidinyl)methylamino]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724478-27-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[5-cyano-6-(4-methoxyphenyl)-4-methyl-2-pyridinyl)methylamino]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




IT	80370-87-2P	105806-56-2P	162713-88-4P
	496061-79-1P	496061-80-4P	496062-96-5P
	496063-12-8P	496063-13-3P	619298-80-5P
	619298-82-7P	619298-84-9P	619300-61-7P
	724466-13-1P	724466-14-2P	724466-15-3P
	724466-33-5P	724466-73-3P	724466-76-6P
	724468-08-0P	724468-21-7P	724468-22-8P
	724468-35-3P	724468-37-5P	724470-33-1P
	724471-00-5P	724471-01-6P	724471-10-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indaneacetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)


RN 80370-87-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- (CA INDEX NAME)




RN 105806-56-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-methoxy-, ethyl ester (CA INDEX NAME)



RN 162713-88-4 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, ethyl ester (CA INDEX NAME)



RN 496061-79-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496061-80-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-96-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-,  
(αR,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496063-12-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-, methyl  
ester, (αR,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496063-13-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy- $\alpha$ -methyl-, methyl  
ester, (αR,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 619298-80-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-,  
(αS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-82-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-, methyl ester, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-84-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy- $\alpha$ -methyl-, methyl ester, ( $\alpha$ S,1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 619300-61-7 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-, ( $\alpha$ S,1S)-, compd. with ( $\alpha$ R)- $\alpha$ -methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 619298-80-5

CMF C13 H16 O3

Absolute stereochemistry.



CM 2

CRN 3886-69-9

CMF C8 H11 N


Absolute stereochemistry. Rotation (+).



RN 724466-13-1 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-1-hydroxy-5-methoxy-,  
( $\alpha$ S,1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-14-2 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-1-hydroxy-5-methoxy-,  
methyl ester, ( $\alpha$ S,1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-15-3 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-1,5-dihydroxy-, methyl  
ester, ( $\alpha$ S,1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-33-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-(3-bromopropoxy)-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-73-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-iodophenoxy)propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724466-76-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-bromo-2-methoxyphenoxy)propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724468-08-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-(3-bromopropoxy)-2,3-dihydro-α-methyl-, ethyl ester, (1S)- (CA INDEX NAME)

methyl ester, (αS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-21-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-(2,2-diethoxyethoxy)-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-22-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-(2-hydroxyethoxy)-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724468-35-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[[1,1-dimethylethoxy]carbonyl]amino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-37-5 CAPLUS


CN 1H-Indene-1-acetic acid, 5-(3-aminopropoxy)-2,3-dihydro-, (1S)-, ethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 724468-36-4

CMF C16 H23 N O3

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 724470-33-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-4-pyrimidinyl]oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724471-00-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[(dimethylamino)thioxomethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 724471-01-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[dimethylamino]carbonylthio]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724471-12-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, compound with (aS)-alpha-methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 80370-87-2

CMF C12 H14 O3



CM 2

CRN 2627-86-3

CMF C8 H11 N

Absolute stereochemistry. Rotation (-).



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:182368 CAPLUS Full-text  
 DOCUMENT NUMBER: 140:229401  
 TITLE: Three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands  
 INVENTOR(S): Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph  
 PATENT ASSIGNEE(S): Gpc Biotech Inc., USA; Gpc Biotech AG  
 SOURCE: U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040043388	A1	20040304	US 2002-234985	20020903 <--
US 7135550	B2	20061114		
US 20030165873	A1	20030904	US 2002-91177	20020304 <--
EP 1975620	A2	20081001	EP 2008-103127	20020304 <--
EP 1975620	A3	20081224		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI				
EP 1832589	A1	20070912	EP 2007-8359	20021015 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK				
US 20040266854	A1	20041230	US 2004-820453	20040407 <--
US 7605175	B2	20091020		

PRIORITY APPLN. INFO.:

US 2001-272932P	P	20010302 <--
US 2001-278233P	P	20010323 <--
US 2001-329437P	P	20011015 <--
US 2002-91177	A2	20020304 <--
US 2001-336962P	P	20011203 <--
EP 2002-723332	A3	20020304 <--
WO 2002-US6677	A2	20020304 <--
US 2002-234985	A2	20020903 <--
EP 2002-797047	A3	20021015 <--
WO 2002-US33052	A2	20021015 <--
US 2003-460921P	P	20030407
US 2003-531872P	P	20031223


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention provides compns. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g a methotrexate moiety linked by a polyethylene glycol moiety to dexamethasone, is described.

IT 666837-98-5D, conjugates  
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

RN 666837-98-5 CAPLUS

CN 1H-Indene-1-acetic acid, 3-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-2,3-dihydro-6-methoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)

L4 ANSWER 6 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:101148 CAPLUS Full-text

DOCUMENT NUMBER: 140:163867

TITLE: Preparation of indane, dihydrobenzofuran and tetrahydronaphthalene carboxylic acid derivatives as antidiabetic agents

INVENTOR(S): Wickens, Philip; Cantin, Louis-David; Chuang, Chih-Yuan; Dai, Miao; Hentemann, Martin F.; Kumarasinghe, Ellalahewage; Liang, Sidney X.; Lowe, Derek B.; Shelekhin, Tatiana E.; Wang, Yamin; Zhang, Chengzhi; Zhang, Hai-Jun; Zhao, Qian

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 204 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011446	A1	20040205	WO 2003-US23342	20030725 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003263814	A1	20040216	AU 2003-263814	20030725 <--
PRIORITY APPLN. INFO.:			US 2002-399095P	P 20020726 <--
			WO 2003-US23342	W 20030725
OTHER SOURCE(S):	MARPAT 140:163867			

GI



AB Title compds., e.g., I [X = O, S; n = 1-3; R1 = carboxy, carboxamide, alkylamino, etc.; R2-3 = H, F, alkyl; R4-6 = H, alkyl; R7 = H, alkoxy, OH, etc.; R9 = H, Br, Cl, I, alkyl, etc.]; R10 = H, OSO2CF3, etc.]; R11 = H, alkyl, etc.]; R12 = naphthyl, pyridyl, etc.] are prepared For instance, Et (S)-[5-hydroxy-2,3-dihydro-1H-inden-1-yl]acetate (preparation given) is coupled to 4-chloromethyl-5-methyl-2-phenylloxazole (preparation given; DMF, K2CO3, 3 h, 80°) to give II. I are useful in the treatment of diseases such as diabetes, diabetes-related disorders, obesity, hyperlipidemia and cardiovascular diseases.

IT 652980-38-6P, Ethyl (S)-[5-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652980-41-1P, Ethyl (S)-[6-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652980-74-0P 652980-93-3P 652981-05-6P, Ethyl [7-(3-chloro-4-fluorophenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652981-62-3P, Ethyl (S)-[5-[2-(2-iodo-5-methyl-1H-imidazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652981-66-7P, Ethyl (S)-[5-[2-[2-(2,4-dimethylphenyl)-5-methyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652981-94-7P, Ethyl (S)-[6-[2-(1,4-dimethyl-2-phenyl-1H-imidazol-5-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-16-6P, Ethyl (S)-[5-[(2-bromo-1-pentyl-1H-imidazol-5-yl)methoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-23-5P, Ethyl (S)-[5-[2-[2-(4-bromophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-28-0P, Methyl (2S)-2-[(1S)-5-[2-[2-(4-bromophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoate 652982-29-1P, Methyl (2S)-2-[(1S)-5-[2-[2-(3',4'-dimethyl-1,1'-biphenyl-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoate 652982-34-8P, (S)-[5-[2-[2-[4-(Benzylamino)phenyl]-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-39-3P, (S)-[5-[2-[2-(4-Allylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-73-5P 652982-94-0P, Ethyl (S)-[5-[2-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-95-1P, Ethyl (S)-[5-[2-[4-(4-tert-butylphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of indane, dihydrobenzofuran and tetrahydronaphthalene carboxylic acid derivs. as antidiabetic agents)

RN 652980-38-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652980-41-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 652980-74-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-6-[(1Z)-2-phenylethenyl]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 652980-93-3 CAPLUS

CN 1H-Indene-1-acetic acid, 4-(4-ethylphenyl)-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 652981-05-0 CAPLUS


CN 1H-Indene-1-acetic acid, 7-(3-chloro-4-fluorophenyl)-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ethyl ester (CA INDEX NAME)



RN 652981-82-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(2-iodo-4-methyl-1H-imidazol-5-yl)ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-86-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(2,4-dimethylphenyl)-4-methyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-94-7 CAPLUS

CN 1H-Indene-1-acetic acid, 6-[2-(1,4-dimethyl-2-phenyl-1H-imidazol-5-yl)ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-16-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[(2-bromo-1-pentyl-1H-imidazol-5-yl)methoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-23-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-(4-bromophenyl)-1,4-dimethyl-1H-imidazol-5-yl)ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-28-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-bromophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, methyl ester, ( $\alpha$ S,1S)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 652982-29-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, methyl ester, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-34-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-[4-[(phenylmethyl)amino]phenyl]-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 652982-39-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-[4-(2-propen-1-yl)phenyl]-1H-



imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-73-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-94-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-95-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-[4-(1,1-dimethylethyl)phenyl]-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 652980-35-7P, (S)-[5-[(5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-42-2P  
 (S)-[6-[3-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)propoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-57-9P, rel-Methyl  
 (2S)-2-[(1S)-3,3-dimethyl-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-indene-1-yl]butanoate 652980-64-8P,  
 rel-(2S)-2-[(1S)-3,3-Dimethyl-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-indene-1-yl]butanoic acid 652980-65-9P  
 , [3,3-Dimethyl-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-67-1P,  
 (S)-[5-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-6-(phenylethynyl)-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-71-7P,  
 (S)-[6-Allyl-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-72-8P, Ethyl  
 (S)-[5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-6-(2-phenylethyl)-2,3-dihydro-1H-inden-1-yl]acetate 652980-73-9P,  
 (S)-[5-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-6-(2-phenylethyl)-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-75-1P  
 652980-76-2P, [4-[2-[5-Methyl-2-(2-naphthyl)-1,3-oxazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-77-3P,  
 [4-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-78-4P,  
 [4-[2-[2-(4-Fluorophenyl)-5-methyl-1,3-oxazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-79-5P,  
 [4-[2-[2-(4-Fluoro-3-methylphenyl)-5-methyl-1,3-oxazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-80-8P,  
 [2-Methyl-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-94-4P,  
 [4-Methoxy-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-95-5P,  
 [4-Hydroxy-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-96-6P,  
 [4-(1,3-Benzodioxol-5-yl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-97-7P,  
 [4-(4-Isopropylphenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-98-8P,  
 [4-(4-Methoxyphenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-06-1P,  
 [7-(3-Chloro-4-fluorophenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-07-2P,  
 [7-(4-Methylphenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-08-3P,  
 [7-(4-Fluorophenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-09-4P,  
 [7-(4-Ethoxyphenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-10-7P,  
 [7-(4-Chlorophenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-11-8P,  
 [7-(4-Methoxyphenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-12-9P,  
 [5-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-7-[4-(methylsulfonyl)phenyl]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-13-0P, [7-(2-Methylphenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-14-1P, [7-(3-Methylphenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-15-2P, [7-(2,4-Dichlorophenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-16-3P, [7-(1,3-Benzodioxol-5-yl)-5-[2-(5-methyl-2-phenyl-

1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-17-4P, [7-(4-Isopropylphenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-18-5P, [7-(3,4-Dimethylphenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-19-6P, [7-(3-Methoxyphenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-20-9P, [5-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-7-[3-(trifluoromethyl)phenyl]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-21-0P, [7-(2-Methoxyphenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-22-1P, [5-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-7-[2-(trifluoromethyl)phenyl]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-23-2P, [7-(2,4-Difluorophenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-24-3P, [7-(4-tert-Butylphenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-25-4P, [7-(4-Fluoro-3-methylphenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-26-5P, [7-(4-Ethylphenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-27-6P, [5-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-7-phenyl-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-28-7P  
652981-33-4P, (S)-[5-[2-(5-Phenethyl-2-phenyloxazol-4-yl)ethoxy]indan-1-yl]acetic acid 652981-34-5P,  
(S)-[5-[2-[2-(4-Chlorophenyl)-5-[2-(4-methoxyphenyl)ethyl]oxazol-4-yl]ethoxy]indan-1-yl]acetic acid 652981-35-6P,  
(S)-[5-[2-[2-(4-Chlorophenyl)-5-[2-(2,6-dichlorophenyl)ethyl]oxazol-4-yl]ethoxy]indan-1-yl]acetic acid 652981-36-7P,  
(S)-[5-[2-[2-(4-Chlorophenyl)-5-(2-m-tolyethyl)oxazol-4-yl]ethoxy]indan-1-yl]acetic acid 652981-37-8P,  
(S)-[5-[2-[2-(4-Chlorophenyl)-5-(2-p-tolyethyl)oxazol-4-yl]ethoxy]indan-1-yl]acetic acid 652981-38-9P,  
(S)-[5-[2-[2-(4-Chlorophenyl)-5-[2-(4-chlorophenyl)ethyl]oxazol-4-yl]ethoxy]indan-1-yl]acetic acid 652981-39-0P,  
(S)-[5-[2-[5-Methyl-2-(6-phenyl-3-pyridinyl)-1,3-oxazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-42-5P,  
(2S)-2-[(1S)-5-[2-[5-Methyl-2-(6-phenyl-3-pyridinyl)-1,3-oxazol-4-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
652981-47-0P, (S)-[5-[2-[2-[(Cyclohexylcarbonyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-49-2P, (S)-[5-[2-(2-Amino-5-methyl-1,3-thiazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid trifluoroacetate  
652981-50-5P, Ethyl (S)-[5-[2-[2-[(Anilino)carbonyl]amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate  
652981-51-6P, (S)-[5-[2-[2-[(Anilino)carbonyl]amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-52-7P, (S)-[5-[2-[5-Methyl-2-[(phenylsulfonyl)amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-53-8P, (S)-[5-[2-[5-Methyl-2-[(methylsulfonyl)amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-54-9P, (S)-[5-[2-[2-[(4-Methoxybenzoyl)amino]-5-methylthiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid  
652981-55-0P, (S)-[5-[2-[2-(Benzoylamino)-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-56-1P,  
(S)-[5-[2-[2-[(4-Fluorobenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-57-2P,  
(S)-[5-[2-[2-(Acetylamino)-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-58-3P,  
(S)-[5-[2-[2-[(Cyclobutylcarbonyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-

2,3-dihydro-1H-inden-1-yl]acetic acid 652981-59-4P,  
 (S)-[5-[2-[2-[(1,1'-Biphenyl-4-yl)carbonyl)amino]-5-methylthiazol-4-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]acetic acid 652981-60-7P  
 , (S)-[5-[2-[2-[(2-Methoxybenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-61-8P,  
 (S)-[5-[2-[2-[(4-Chlorobenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-62-9P,  
 (S)-[5-[2-[2-[(3,4-Dichlorobenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-63-0P,  
 (S)-[5-[2-[2-[(3-Methoxybenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-64-1P,  
 (S)-[5-[2-[5-Methyl-2-((naphthalen-1-yl)carbonyl)amino)-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-65-2P,  
 (S)-[5-[2-[5-Methyl-2-[(3-methylbenzoyl)amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-66-3P,  
 (S)-[5-[2-[5-Methyl-2-[(4-methylbenzoyl)amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-67-4P,  
 (S)-[5-[2-[5-Methyl-2-[(4-nitrobenzoyl)amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-68-5P,  
 (S)-[5-[2-[5-Methyl-2-[(3-nitrobenzoyl)amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-69-6P,  
 (S)-[5-[2-[5-Methyl-2-[(2-nitrobenzoyl)amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-70-9P,  
 (S)-[5-[2-[2-[(3-Chlorobenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-71-0P,  
 (S)-[5-[2-[2-[(2-Chlorobenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-72-1P,  
 (S)-[5-[2-[2-[(2-Fluorobenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-73-2P,  
 (S)-[5-[2-[5-Methyl-2-[(2-methylbenzoyl)amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-74-3P,  
 (S)-[5-[2-[5-Methyl-2-[[[(4-methylphenyl)amino]carbonyl]amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-75-4P  
 , (S)-[5-[2-[2-[[[(4-Fluorophenyl)amino]carbonyl]amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-76-5P,  
 [4-[2-[2-(4-Fluorophenyl)-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-84-5P,  
 Ethyl (S)-[5-[2-[2-(4-methoxyphenyl)-4-methyl-1-pentyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652981-85-6P,  
 Ethyl (S)-[5-[2-(2-Iodo-5-methyl-1-pentyl-1H-imidazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652981-87-8P,  
 (S)-[5-[2-[2-(2,4-Dimethylphenyl)-5-methyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-95-8P,  
 (S)-[6-[2-(1,4-Dimethyl-2-phenyl-1H-imidazol-5-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-96-9P,  
 [5-[2-[5-Methyl-2-(4-methoxyphenyl)-1-pentyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-97-0P,  
 [5-[2-[2-(4-Methoxyphenyl)-4-methyl-1-pentyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-98-1P,  
 (S)-[5-[2-(1-Benzyl-5-methyl-2-phenyl-1H-imidazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-99-2P,  
 (S)-[5-[2-(1-Benzyl-4-methyl-2-phenyl-1H-imidazol-5-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-00-8P,  
 (S)-[5-[2-[1-Benzyl-5-methyl-2-[4-(methylsulfonyl)phenyl]-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-01-9P,  
 (S)-[5-[2-[1-Benzyl-2-(3-nitrophenyl)-5-methyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-02-0P, Ethyl  
 (S)-[5-[2-[2-(4-methoxyphenyl)-5-methyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-03-1P,  
 (S)-[5-[2-[5-Methyl-2-(4-methylphenyl)-1-pentyl-1H-imidazol-4-yl]ethoxy]-

2,3-dihydro-1H-inden-1-yl]acetic acid 652982-04-2P,  
 (S)-[5-[2-[2-(4-Methoxyphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-05-3P,  
 (S)-[5-[2-[2-(1,1'-Biphenyl-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-06-4P,  
 (S)-[5-[2-[2-(4-Ethylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-07-5P, Ethyl  
 (S)-[5-[2-[2-(1,1'-biphenyl-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-09-7P, Ethyl  
 (S)-[5-[2-[2-(4-ethylphenyl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-10-0P,  
 (S)-[5-[2-(1,5-Dimethyl-2-phenyl-1H-imidazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-11-1P,  
 (S)-[5-[2-[2-(4-Ethylphenyl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-12-2P,  
 (S)-[5-[2-[2-(1,1'-Biphenyl-4-yl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-13-3P,  
 (S)-[5-[2-[2-(4-Methoxyphenyl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-17-7P,  
 (S)-[5-[(1-Pentyl-2-phenyl-1H-imidazol-5-yl)methoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-18-8P,  
 (S)-[5-[(2-(4-Methoxyphenyl)-1-pentyl-1H-imidazol-5-yl)methoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-19-9P,  
 (S)-[5-[(1-Pentyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-5-yl)methoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-20-2P,  
 (S)-[5-[(2-(1,3-Benzodioxol-5-yl)-1-pentyl-1H-imidazol-5-yl)methoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-21-3P,  
 (S)-[5-[(2-(3,4-Dimethylphenyl)-1-pentyl-1H-imidazol-5-yl)methoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-22-4P,  
 (S)-[5-[(1-Pentyl-2-(4-pyridinyl)-1H-imidazol-5-yl)methoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-30-4P,  
 (2S)-2-[(1S)-5-[2-[2-(3',4'-Dimethyl-1,1'-biphenyl-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid 652982-31-5P,  
 (S)-[5-[2-[2-(1,4-Dimethyl-2-(4-methylphenyl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-32-6P,  
 (2S)-2-[(1S)-5-[2-[2-(3'-Methoxy-1,1'-biphenyl-3-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid 652982-33-7P, Ethyl  
 (S)-[5-[2-[2-[4-(benzylamino)phenyl]-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-35-9P,  
 (S)-[5-[2-[2-(4-Aminophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-36-0P, Ethyl  
 (S)-[5-[2-[2-(4-vinylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-37-1P,  
 (S)-[5-[2-[2-(4-Vinylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-38-2P, Ethyl  
 (S)-[5-[2-[2-(4-allylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-40-6P,  
 (S)-[5-[2-[2-(4-Propylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-42-8P,  
 (2S)-2-[(1S)-5-[2-[2-(1,1'-Biphenyl-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid trifluoroacetate 652982-44-0P,  
 (2S)-2-[(1S)-5-[2-[2-(4-Ethylphenyl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid trifluoroacetate 652982-46-2P,  
 (2S)-2-[(1S)-5-[2-[2-(4-Ethylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid trifluoroacetate 652982-47-3P,  
 (S)-[5-[2-[2-(4-Bromophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-48-4P,  
 (S)-[5-[2-[2-(1,4-Dimethyl-2-[4-(1H-pyrrol-2-yl)phenyl]-

1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid  
 652982-49-5P, (2S)-2-[(1S)-5-[2-[2-(4-Bromophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
 652982-50-8P, (2S)-2-[(1S)-5-[2-(1,4-Dimethyl-2-phenyl-1H-imidazol-5-yl)ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
 652982-51-9P, (2S)-2-[(1S)-5-[2-[2-(4-Allylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
 652982-52-0P, (2S)-2-[(1S)-5-[2-[2-(4-Butylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
 652982-53-1P, (2S)-2-[(1S)-5-[2-[1,4-Dimethyl-2-(4-methylphenyl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
 652982-54-2P, (2S)-2-[(1S)-5-[2-[2-(4'-Methoxy-1,1'-biphenyl-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
 652982-55-3P, (2S)-2-[(1S)-5-[2-[2-[4-(1,3-Benzodioxol-5-yl)phenyl]-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid 652982-56-4P,  
 (2S)-2-[(1S)-5-[2-[2-(4'-Fluoro-1,1'-biphenyl-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
 652982-57-5P, (2S)-2-[(1S)-5-[2-[1,4-Dimethyl-2-(3'-methyl-1,1'-biphenyl-4-yl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid 652982-58-6P,  
 (2S)-2-[(1S)-5-[2-[1,4-Dimethyl-2-(4'-methyl-1,1'-biphenyl-4-yl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
 652982-59-7P, (2S)-2-[(1S)-5-[2-[2-(4'-Fluoro-3'-methyl-1,1'-biphenyl-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid 652982-60-0P,  
 (2S)-2-[(1S)-5-[2-[2-[4-(2,4-Dihydroxy-5-pyrimidinyl)phenyl]-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
 652982-61-1P, (2S)-2-[(1S)-5-[2-[2-(4'-Ethyl-1,1'-biphenyl-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
 652982-62-2P, (2S)-2-[(1S)-5-[2-[2-[4-(3,5-Dimethyl-4-isoxazolyl)phenyl]-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid 652982-63-3P,  
 (2S)-2-[(1S)-5-[2-[2-(4-Iodophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid 652982-64-4P,  
 (2S)-2-[(1S)-5-[2-[1,4-Dimethyl-2-(4-propylphenyl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
 652982-65-5P, (2S)-2-[(1S)-5-[2-[2-(1,1'-Biphenyl-3-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
 652982-66-6P, (2S)-2-[(1S)-5-[2-[1,4-Dimethyl-2-(3'-methyl-1,1'-biphenyl-3-yl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid 652982-67-7P,  
 (2S)-2-[(1S)-5-[2-[2-(3-(1,3-Benzodioxol-5-yl)phenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
 652982-68-8P, (2S)-2-[(1S)-5-[2-[2-(2',4'-Difluoro-1,1'-biphenyl-3-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid 652982-69-9P,  
 (2S)-2-[(1S)-5-[2-[2-(4'-Ethyl-1,1'-biphenyl-3-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
 652982-70-2P, (2S)-2-[(1S)-5-[2-[2-(3-Bromophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoic acid  
 652982-74-6P, (S)-[5-[2-[3-Phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-75-7P,  
 (S)-[4-Fluoro-5-[2-[3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-76-8P,  
 (S)-[6-Chloro-5-[2-[3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-78-0P  
 , (S)-[6-Bromo-5-[2-[3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-80-4P,  
 (S)-[5-[2-(5-Ethoxy-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydroindene-1-


yl]acetic acid 652982-81-5P,  
 (S)-4-[1-[2-[(1-(Carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy)ethyl]-5-ethoxy-1H-pyrazol-3-yl]benzoic acid 652982-82-6P,  
 (S)-[5-[2-(4-Fluoro-5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-83-7P,  
 (S)-[5-[2-(4-Chloro-5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-84-8P,  
 (S)-[5-[2-(4-Bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-85-9P,  
 (S)-[5-[2-[5-Methoxy-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-86-0P,  
 (S)-[5-[2-[5-Methoxy-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-87-1P,  
 (S)-[5-[2-[4-Fluoro-5-methoxy-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-88-2P,  
 (S)-[5-[2-[4-Fluoro-5-methoxy-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-89-3P,  
 (S)-[5-[2-[4-Bromo-5-methoxy-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-90-6P,  
 (S)-[5-[2-(5-Methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-91-7P,  
 2-[5-[2-(5-Methyl-3-phenylpyrazol-1-yl)ethoxy]indan-1-yl]butyric acid 652982-92-8P, [4-[2-(5-Methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-96-2P,  
 (S)-[5-[2-[4-(4-tert-Butylphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-97-3P,  
 (S)-[5-[2-[4-(4-Methoxyphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-99-5P,  
 (S)-[5-[2-[3,5-Dimethyl-4-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652983-01-2P,  
 (S)-[5-[2-[4-(1,3-Benzodioxol-5-yl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652983-02-3P,  
 (S)-[5-[2-(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652983-03-4P,  
 (S)-[5-[2-[4-(4-Ethylphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652983-04-5P,  
 (S)-[5-[2-(3,5-Dimethyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652983-05-6P,  
 (S)-4-[1-[2-[(1-(Carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy)ethyl]-3,5-dimethyl-1H-pyrazol-4-yl]benzoic acid 652983-06-7P,  
 (S)-[5-[2-[3,5-Dimethyl-4-(4-methylphenyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652983-07-8P,  
 (S)-[5-[2-[4-(2-Methoxyphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652983-08-9P,  
 (S)-[5-[2-[3,5-Dimethyl-4-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 654650-46-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indane, dihydrobenzofuran and tetrahydronaphthalene carboxylic acid derivs. as antidiabetic agents)

RN 652980-39-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652980-42-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652980-57-9 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-3,3-dimethyl-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 652980-64-8 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-3,3-dimethyl-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.





RN 652980-65-9 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-3,3-dimethyl-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 652980-67-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-6-(2-phenylethynyl)-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652980-71-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-6-(2-propen-1-yl)-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652980-72-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-6-(2-phenylethyl)-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652980-73-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-6-(2-phenylethyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 652980-75-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-6-[(1Z)-2-phenylethenyl]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 652980-76-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-[2-[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 652980-77-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652980-78-4 CAPLUS

CN 1H-Indene-1-acetic acid, 4-[2-[2-(4-phenyl-5-methyl-4-oxazolyl)ethoxy]-2,3-dihydro-1H-indene-1-yl]- (CA INDEX NAME)




RN 652980-79-5 CAPLUS

CN 1H-Indene-1-acetic acid, 4-[2-[2-(4-fluoro-3-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 652980-80-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-2-methyl-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652980-94-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-methoxy-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652980-95-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-hydroxy-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652980-96-6 CAPLUS

CN 1H-Indene-1-acetic acid, 4-(1,3-benzodioxol-5-yl)-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652980-97-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-[4-(1-methylethyl)phenyl]-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652980-98-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(4-methoxyphenyl)-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652981-06-1 CAPLUS

CN 1H-Indene-1-acetic acid, 7-(3-chloro-4-fluorophenyl)-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652981-07-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-7-(4-methylphenyl)-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652981-08-3 CAPLUS

CN 1H-Indene-1-acetic acid, 7-(4-fluorophenyl)-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652981-09-4 CAPLUS

CN 1H-Indene-1-acetic acid, 7-(4-ethoxyphenyl)-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652981-10-7 CAPLUS

CN 1H-Indene-1-acetic acid, 7-(4-chlorophenyl)-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652981-11-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-7-(4-methoxyphenyl)-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652981-12-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-[4-(methylthio)phenyl]- (CA INDEX NAME)




RN 652981-13-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-7-(2-methylphenyl)-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652981-14-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-7-(3-methylphenyl)-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 652981-15-2 CAPLUS


CN 1H-Indene-1-acetic acid, 7-(2,4-dichlorophenyl)-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 652981-16-3 CAPLUS


CN 1H-Indene-1-acetic acid, 7-(1,3-benzodioxol-5-yl)-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)






RN 652981-17-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-7-[4-(1-methylethyl)phenyl]-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652981-18-5 CAPLUS

CN 1H-Indene-1-acetic acid, 7-(3,4-dimethylphenyl)-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652981-19-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-7-(3-methoxyphenyl)-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652981-20-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 652981-21-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-7-(2-methoxyphenyl)-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652981-22-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 652981-23-2 CAPLUS

CN 1H-Indene-1-acetic acid, 7-(2,4-difluorophenyl)-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652981-24-3 CAPLUS

CN 1H-Indene-1-acetic acid, 7-[4-(1,1-dimethylethyl)phenyl]-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652981-25-4 CAPLUS

CN 1H-Indene-1-acetic acid, 7-(4-fluoro-3-methylphenyl)-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 652981-26-5 CAPLUS

CN 1H-Indene-1-acetic acid, 7-(4-ethylphenyl)-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 652981-27-6 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-phenyl- (CA INDEX NAME)



RN 652981-28-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-(2-phenylethyl)-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-33-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-phenyl-5-(2-phenylethyl)-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-34-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-[2-(4-methoxyphenyl)ethyl]-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-35-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-[2-(2,6-dichlorophenyl)ethyl]-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-36-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-[2-(3-methylphenyl)ethyl]-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-37-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-[2-(4-methylphenyl)ethyl]-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-38-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-[2-(4-chlorophenyl)ethyl]-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-39-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(6-phenyl-3-pyridinyl)-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-[5-methyl-2-(6-phenyl-3-pyridinyl)-4-oxazolyl]ethoxy]-, ( $\alpha$ S,1S)- (CA INDEX NAME)

CC1=C(C(=O)O)C[C@H]2Cc3ccc(OCCc4c(C)c5oc(cc45)c6ccc(cc6)C)cc3cc21

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(cyclohexylcarbonyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

CC1=C(CSC1NC(=O)C2CCCCC2)CCOC3=CC=C4C(=C3)S[C@H](C4)C(=O)O

CN 1H-Indene-1-acetic acid, 5-[2-(2-amino-5-methyl-4-thiazolyl)ethoxy]-2,3-dihydro-, (1S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CMF C17 H20 N2 O3 S


Cc1nc(N)sc1CCCOc2ccc3c(c2)sc(C[C@@H](C3)C(=O)O)

CMF C2 H F3 O2




RN 652981-50-5 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-  
 [(phenylamino)carbonyl]amino]-4-thiazolyl]ethoxy]-, ethyl ester, (1S)-  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 652981-51-6 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-  
 [(phenylsulfonyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX  
 NAME)

Absolute stereochemistry.



RN 652981-52-7 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-  
 [(phenylsulfonyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-53-8 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-  
 [(methylsulfonyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 652981-54-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[(4-methoxybenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-55-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(benzoylamino)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-56-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(4-fluorobenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-57-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(acetylamino)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-58-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(cyclobutylcarbonyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-59-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(1,1'-biphenyl)-4-ylcarbonyl]amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-60-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[(2-methoxybenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-61-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(4-chlorobenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-62-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(3,4-dichlorobenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-63-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[(3-methoxybenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-64-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[(1-naphthalenylcarbonyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-65-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[(3-methylbenzoyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-66-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[(4-methylbenzoyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-67-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[(4-nitrobenzoyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-68-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[(3-nitrobenzoyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-69-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[(2-nitrobenzoyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-70-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(3-chlorobenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-71-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(2-chlorobenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-72-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[(2-fluorobenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-73-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[(2-methylbenzoyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-74-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[[[(4-methylphenyl)amino]carbonyl]amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-75-4 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-[2-[[[(4-fluorophenyl)amino]carbonyl]amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 652981-76-5 CAPLUS


CN 1H-Indene-1-acetic acid, 4-[2-[2-(4-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 652981-84-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-4-methyl-1-pentyl-1H-imidazol-5-yl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 652981-85-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(2-iodo-5-methyl-1-pentyl-1H-

imidazol-4-yl)ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-87-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(2,4-dimethylphenyl)-4-methyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-95-8 CAPLUS


CN 1H-Indene-1-acetic acid, 6-[2-(1,4-dimethyl-2-phenyl-1H-imidazol-5-yl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 652981-96-9 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-1H-imidazol-4-yl]ethoxy]- (CA INDEX NAME)





RN 652981-97-0 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-4-methyl-1-pentyl-1H-imidazol-5-yl]ethoxy]- (CA INDEX NAME)



RN 652981-98-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-phenyl-1-(phenylmethyl)-1H-imidazol-4-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-99-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-phenyl-1-(phenylmethyl)-1H-imidazol-5-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-00-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(methylthio)phenyl]-1-(phenylmethyl)-1H-imidazol-4-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-01-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(3-nitrophenyl)-1-phenylmethyl)-1H-imidazol-4-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-02-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-4-methyl-1H-imidazol-5-yl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-03-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-1-pentyl-1H-imidazol-4-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-04-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-05-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-06-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-(4-ethylphenyl)-1,4-dimethyl-1H-imidazol-5-yl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-07-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-09-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethylphenyl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-10-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(1,5-dimethyl-2-phenyl-1H-imidazol-4-yl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-11-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethylphenyl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-12-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-13-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(4-methoxyphenyl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-17-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[(1-pentyl-2-phenyl-1H-imidazol-5-yl)methoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-18-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[[2-(4-methoxyphenyl)-1-pentyl-1H-imidazol-5-yl]methoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 652982-19-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[[1-pentyl-2-[4-

(trifluoromethyl)phenyl]-1H-imidazol-5-yl]methoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-20-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[2-(1,3-benzodioxol-5-yl)-1-pentyl-1H-imidazol-5-yl]methoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-21-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[2-(3,4-dimethylphenyl)-1-pentyl-1H-imidazol-5-yl]methoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-22-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[[1-pentyl-2-(4-pyridinyl)-1H-imidazol-5-yl]methoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-30-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, (aS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-31-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-(4-methylphenyl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-32-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(3'-methoxy[1,1'-biphenyl]-3-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]- $\alpha$ -methyl-, (aS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-33-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-[4-  
[(phenylmethyl)amino]phenyl]-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, ethyl  
ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-35-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-aminophenyl)-1,4-dimethyl-1H-imidazol-  
5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-36-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethenylphenyl)-1,4-dimethyl-1H-  
imidazol-5-yl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 652982-37-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethenylphenyl)-1,4-dimethyl-1H-  
imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 652982-38-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-(4-(2-propen-1-yl)phenyl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-40-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-(4-propylphenyl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 652982-42-8 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-α-methyl-, (αS,1S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 652982-41-7

CMF C31 H32 N2 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 652982-44-0 CAPLUS


CN 1H-Indene-1-acetic acid, 5-(2-[2-(4-ethylphenyl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy)-2,3-dihydro-α-methyl-, (αS,1S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 652982-43-9

CMF C27 H32 N2 O3

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 652982-46-2 CAPLUS  
 CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, (*aS*,1*S*)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 652982-45-1  
 CMF C27 H32 N2 O3

Absolute stereochemistry.




CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2



RN 652982-47-3 CAPLUS  
 CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-bromophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1*S*)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-48-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-[4-(1H-pyrrol-2-yl)phenyl]-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-49-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-bromophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-50-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(1,4-dimethyl-2-phenyl-1H-imidazol-5-yl)ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-51-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-[4-(2-propen-1-yl)phenyl]-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-52-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-butylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-53-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-(4-methylphenyl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-54-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4'-methoxy[1,1'-biphenyl]-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-55-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(1,3-benzodioxol-5-yl)phenyl]-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, (1S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-56-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4'-fluoro[1,1'-biphenyl]-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, (1S,1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 652982-57-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-(3'-methyl[1,1'-biphenyl])-4-yl]-2,3-dihydro-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, (1S,1S)- (CA INDEX NAME)

yl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 652982-58-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-(4'-methyl[1,1'-biphenyl]-4-yl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 652982-59-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4'-fluoro-3'-methyl[1,1'-biphenyl]-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-60-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-[4-(1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)phenyl]-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha S, 1S$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-61-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4'-ethyl[1,1'-biphenyl]-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha S, 1S$ )- (CA INDEX NAME)

Absolute stereochemistry.




RN 652982-62-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(3,5-dimethyl-4-isoxazolyl)phenyl]-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha S, 1S$ )- (CA INDEX NAME)

Absolute stereochemistry.






RN 652982-63-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-(1-iodophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy)]-α-methyl-, (αS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-64-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-(4-propylphenyl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-α-methyl-, (αS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-65-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-3-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-α-methyl-, (αS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-66-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-(3'-methyl[1,1'-biphenyl]-3-yl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-67-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(1,3-benzodioxol-5-yl)phenyl]-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-68-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(2',4'-difluoro[1,1'-biphenyl]-3-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-69-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4'-ethyl[1,1'-biphenyl]-3-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-70-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-bromophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-74-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethoxy]-1, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-75-7 CAPLUS

CN 1H-Indene-1-acetic acid, 4-fluoro-2,3-dihydro-5-[2-[3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-76-8 CAPLUS

CN 1H-Indene-1-acetic acid, 6-chloro-2,3-dihydro-5-[2-[3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-78-0 CAPLUS

CN 1H-Indene-1-acetic acid, 6-bromo-2,3-dihydro-5-[2-[3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-80-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(5-ethoxy-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-81-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[3-(4-carboxyphenyl)-5-ethoxy-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-82-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(4-fluoro-5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-83-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(4-chloro-5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-84-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-85-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methoxy-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-86-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methoxy-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-87-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-fluoro-5-methoxy-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-88-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-fluoro-5-methoxy-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-89-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-bromo-5-methoxy-3-(4-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-90-6 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 652982-91-7 CAPLUS

CN 1H-Indene-1-acetic acid, alpha-ethyl-2,3-dihydro-5-[2-(5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]- (CA INDEX NAME)



RN 652982-92-8 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-[2-(5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]- (CA INDEX NAME)



RN 652982-96-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-(1,1-dimethylethyl)phenyl]-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-97-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-(4-methoxyphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 652982-99-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 652983-01-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-(1,3-benzodioxol-5-yl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652983-02-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-bromo-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652983-03-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-(4-ethylphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 652983-04-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethoxy]-2,3-

dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652983-05-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-(4-carboxyphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652983-06-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[3,5-dimethyl-4-(4-methylphenyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652983-07-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652983-08-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[3,5-dimethyl-4-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 654650-48-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(1,1-dimethylethoxy)carbonyl]amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 652980-44-4, (S)-[5-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-69-3, Ethyl (S)-[5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of indane, dihydrobenzofuran and tetrahydronaphthalene carboxylic acid derivs. as antidiabetic agents)

RN 652980-44-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652980-69-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 80370-67-2P, (5-Methoxy-2,3-dihydro-1H-inden-1-yl)acetic acid  
 162713-88-4P, Ethyl (5-methoxy-2,3-dihydro-1H-inden-1-yl)acetate  
 496060-61-8P, (2S)-2-((1S)-5-Methoxy-2,3-dihydro-1H-indene-1-yl)butanoic acid 496060-63-0P, Methyl  
 (2S)-2-((1S)-5-methoxy-2,3-dihydro-1H-indene-1-yl)butanoate  
 496060-64-1P, Methyl (2S)-2-((1S)-5-hydroxy-2,3-dihydro-1H-indene-1-yl)butanoate 496061-78-0P,  
 (S)-(5-Methoxy-2,3-dihydro-1H-inden-1-yl)acetic acid  
 496061-79-1P, Ethyl (S)-(5-methoxy-2,3-dihydro-1H-inden-1-yl)acetate 496061-80-4P, Ethyl  
 (S)-(5-hydroxy-2,3-dihydro-1H-inden-1-yl)acetate 496062-95-4P  
 496063-15-1P, Methyl 2-(5-hydroxy-2,3-dihydro-1H-inden-1-yl)butanoate 496063-17-3P 619298-80-5P,  
 (2S)-2-((1S)-5-Methoxy-2,3-dihydro-1H-indene-1-yl)propanoic acid  
 619298-82-7P, Methyl (2S)-2-((1S)-5-methoxy-2,3-dihydro-1H-indene-1-yl)propanoate 619298-84-9P 619300-61-7P  
 652980-32-0P, Methyl (2R)-2-((1R)-5-hydroxy-2,3-dihydro-1H-indene-1-yl)propanoate 652980-33-1P,  
 (2R)-2-((1R)-5-Methoxy-2,3-dihydro-1H-indene-1-yl)propanoic acid  
 652980-34-2P, Methyl (2R)-2-((1R)-5-methoxy-2,3-dihydro-1H-indene-1-yl)propanoate 652980-61-5P,  
 rel-(2S)-2-((1S)-5-Methoxy-3,3-dimethyl-2,3-dihydro-1H-indene-1-yl)butanoic acid 652980-62-6P, rel-Methyl  
 (2S)-2-((1S)-5-methoxy-3,3-dimethyl-2,3-dihydro-1H-indene-1-yl)butanoate  
 652980-63-7P, rel-Methyl (2S)-2-((1S)-5-hydroxy-3,3-dimethyl-2,3-dihydro-1H-indene-1-yl)butanoate 652980-66-0P, Methyl  
 [3,3-dimethyl-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652980-68-2P, Ethyl  
 (S)-[6-bromo-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652980-70-6P, Ethyl  
 (S)-[5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-6-(phenylethynyl)-2,3-dihydro-1H-inden-1-yl]acetate 652980-89-7P, Ethyl  
 [4-methoxy-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652980-90-0P, Ethyl  
 [4-hydroxy-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652980-91-1P, Ethyl  
 [5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-4-[[trifluoromethyl)sulfonyl]oxy]-2,3-dihydro-1H-inden-1-yl]acetate  
 652980-92-2P, Ethyl [4-(4-ethylphenyl)-5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate  
 652980-99-9P, Ethyl [5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-7-[[trifluoromethyl)sulfonyl]oxy]-2,3-dihydro-1H-inden-1-yl]acetate 652981-02-7P, Ethyl  
 [7-(benzyloxy)-5-methoxy-2,3-dihydro-1H-inden-1-ylidene]ethanoate  
 652981-03-8P, Ethyl (7-hydroxy-5-methoxy-2,3-dihydro-1H-inden-1-yl)acetate 652981-04-9P, Ethyl  
 [5-hydroxy-7-[[trifluoromethyl)sulfonyl]oxy]-2,3-dihydro-1H-inden-1-yl]acetate 652981-41-4P, Ethyl  
 (S)-[5-[2-(5-methyl-2-(6-phenyl-3-pyridinyl)-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652981-43-6P, Methyl  
 (2S)-2-[(1S)-5-[2-(5-methyl-2-(6-phenyl-3-pyridinyl)-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-indene-1-yl]propanoate 652981-46-9P,

Ethyl (S)-[5-[2-(2-amino-5-methyl-1,3-thiazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652981-83-4P, Ethyl (S)-[5-[2-(2-iodo-5-methyl-1-trityl-1H-imidazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-77-9P, Ethyl (S)-2-[6-chloro-5-[2-[3-phenyl-5-(trifluoromethyl)pyrazol-1-yl]ethoxy]indan-1-yl]acetate 652982-79-1P, Ethyl (S)-2-[6-bromo-5-[2-[3-phenyl-5-(trifluoromethyl)pyrazolyl]ethoxy]indan-1-yl]acetate  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indane, dihydrobenzofuran and tetrahydronaphthalene carboxylic acid derivs. as antidiabetic agents)


RN 80370-87-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- (CA INDEX NAME)



RN 162713-88-4 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, ethyl ester (CA INDEX NAME)



RN 496060-61-8 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-methoxy-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496060-63-0 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-methoxy-, methyl ester, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496060-64-1 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-hydroxy-, methyl ester, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496061-78-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496061-79-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496061-80-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 496062-95-4 CAPLUS


CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-methoxy-,  
( $\alpha$ S,1S)-, compd. with ( $\alpha$ R)- $\alpha$ -methylbenzenemethanamine  
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 496060-61-8

CMF C14 H18 O3

Absolute stereochemistry.



CM 2

CRN 3886-69-9


CMF C8 H11 N

Absolute stereochemistry. Rotation (+).




RN 496063-15-1 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-hydroxy-, methyl  
ester (CA INDEX NAME)



RN 496063-17-3 CAPLUS


CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-methoxy-, methyl ester (CA INDEX NAME)



RN 619298-80-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-82-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-, methyl ester, ( $\alpha$ S,1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619298-84-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy- $\alpha$ -methyl-, methyl ester, ( $\alpha$ S,1S)- (CA INDEX NAME)

Absolute stereochemistry.





RN 619300-61-7 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-,  
( $\alpha$ S,1S)-, compd. with ( $\alpha$ R)- $\alpha$ -methylbenzenemethanamine  
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 619298-80-5

CMF C13 H16 O3

Absolute stereochemistry.



CM 2

CRN 3886-69-9

CMF C8 H11 N


Absolute stereochemistry. Rotation (+).



RN 652980-32-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy- $\alpha$ -methyl-, methyl  
ester, ( $\alpha$ R,1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652980-33-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-,  
( $\alpha$ R,1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652980-34-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-, methyl  
ester, ( $\alpha$ R,1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652980-61-5 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-methoxy-3,3-dimethyl-,  
( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 652980-62-6 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-methoxy-3,3-dimethyl-,  
methyl ester, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 652980-63-7 CAPLUS


CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-hydroxy-3,3-dimethyl-, methyl ester, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 652980-66-0 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-3,3-dimethyl-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 652980-68-2 CAPLUS

CN 1H-Indene-1-acetic acid, 6-bromo-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652980-70-6 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-6-(2-phenylethynyl)-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 652980-89-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-methoxy-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ethyl ester (CA INDEX NAME)




RN 652980-90-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-hydroxy-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ethyl ester (CA INDEX NAME)




RN 652980-91-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-4-[(trifluoromethyl)sulfonyloxy]-, ethyl ester (CA INDEX NAME)




RN 652980-92-2 CAPLUS

CN 1H-Indene-1-acetic acid, 4-(4-ethylphenyl)-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ethyl ester (CA INDEX NAME)




RN 652980-99-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-[[trifluoromethyl)sulfonyl]oxy]-, ethyl ester (CA INDEX NAME)




RN 652981-02-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-7-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)




RN 652981-03-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-7-hydroxy-5-methoxy-, ethyl ester (CA INDEX NAME)



RN 652981-04-9 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy-7-  
[[trifluoromethylsulfonyl]oxy]-, ethyl ester (CA INDEX NAME)



RN 652981-41-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(6-phenyl-3-pyridinyl)-4-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-43-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-[5-methyl-2-(6-phenyl-3-pyridinyl)-4-oxazolyl]ethoxy]-, methyl ester, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-46-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-amino-5-methyl-4-thiazolyl)ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-83-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-iodo-5-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-77-9 CAPLUS

CN 1H-Indene-1-acetic acid, 6-chloro-2,3-dihydro-5-[2-[3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-79-1 CAPLUS

CN 1H-Indene-1-acetic acid, 6-bromo-2,3-dihydro-5-[2-[3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:971736 CAPLUS Full-text  
 DOCUMENT NUMBER: 140:16656  
 TITLE: cis-N-(Quinolin-4-yl)cyclohexane-1,4-diamine  
 derivatives as antagonists of melanin concentrating  
 hormone (MCH) and their pharmaceutical compositions  
 and therapeutic uses, e.g., for treatment of obesity  
 INVENTOR(S): Kym, Philip R.; Hartandi, Kresna; Gao, Ju; Phelan,  
 Kathleen M.; Akritopoulou-Zanze, Irini; Collins,  
 Christine A.; Vasudevan, Anil; Verzal, Mary K.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: U.S. Pat. Appl. Publ., 89 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030229119	A1	20031211	US 2003-372359	20030221 <--
US 6818772	B2	20041116		
PRIORITY APPLN. INFO.:			US 2002-359081P	P 20020222 <--
OTHER SOURCE(S):	MARPAT	140:16656		

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention is directed to the compds. of formula I, or therapeutically  
 suitable salts, esters, prodrugs, or zwitterions thereof [R1, R2, R3 = H,  
 alkyl, alkoxy, halo, haloalkyl, haloalkoxy, OH, NH2 and derivs.; R4 = H,  
 alkyl; R5 = -(CH2)mYAB; m = 0-6; A = bond, alkoxyalkylene, alkylene, or  
 hydroxyalkylene; B = H, alkyl, aryl, aroyl, arylsulfonyl, aralkenyl,  
 aryloxyalkyl, biaryl, biarylalkyl, cycloalkyl, heterocyclyl,  
 heterocyclcarbonyl, heterocyclsulfonyl, haloalkyl, NH2 or derivs.,  
 carbamoyl or derivs., OH or derivs., SH or derivs.; Y = CO, S, SO, SO2, or  
 bond; R6 = H, alkyl, arylcarboxyalkyl; R7, R8, R9, R10 = H, alkyl, alkoxy,  
 halo, haloalkyl, haloalkoxy, OH; or R7R8 = oxo; with 4 provisos]. The  
 invention further relates to the antagonism of the effects of melanin-  
 concentrating hormone (MCH) through the MCH receptor, which is useful for the  
 prevention or treatment of eating disorders, weight gain, obesity,  
 abnormalities in reproduction and sexual behavior, thyroid hormone secretion,  
 diuresis and water/electrolyte homeostasis, sensory processing, memory,  
 sleeping, arousal, anxiety, depression, seizures, neurodegeneration and  
 psychiatric disorders. Approx. 450 synthetic examples of I are given. For  
 instance, reaction of N-(7-chloroquinolin-4-yl)cyclohexane-1,4-diamine (cis  
 isomer) with 4-chloro-2,8-bis(trifluoromethyl)quinoline in N-  
 methylpyrrolidinone the presence of Et3N at 150° gave title compound II. In a  
 fluorescence assay for release of intracellular Ca++ induced by activation of  
 MCHR, a more preferred group of compds. I inhibited MCH-induced fluorescence  
 in a range of 90-100% at 10 µM. A more preferred group of I also gave 90-100%  
 inhibition of 125I-MCH binding to human MCHR1 at 2 µM (no addnl. data).  
 IT 24467-92-3, 5-Methoxy-1-indanone-3-acetic acid  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (starting material; preparation of quinolinylcyclohexanediamine derivs. as  
 MCH receptor antagonists)  
 RN 24467-92-3 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)






OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)  
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2003:887675 CAPLUS Full-text  
DOCUMENT NUMBER: 139:381751  
TITLE: Preparation of substituted  $\beta$ -alanine derivatives  
as cell adhesion inhibitors  
INVENTOR(S): Durette, Philippe L.; Hagmann, William K.; Kopka, Thor  
E.; MacCoss, Malcolm; Mills, Sander G.; Mumford,  
Richard A.; Magriotis, Plato A.  
PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
SOURCE: U.S., 45 pp., Cont.-in-part of U.S. Ser. No. 198,680,  
abandoned.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6645939	B1	20031111	US 1999-317789	19990524 <--
WO 2000071572	A1	20001130	WO 2000-US14017	20000519 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		US 1997-66484P P 19971124 <-- US 1998-198680 B2 19981124 <-- US 1999-317789 A2 19990524 <--		
OTHER SOURCE(S):		MARPAT 139:381751		

GI




AB  $\beta$ -Alanine derivs. I [A = C; B = a bond, O, S, CH<sub>2</sub>; R1 = Ph optionally substituted by 1 or 2 halo, alkoxy, or trifluoromethyl groups; R2 = H, Me; R3 = (un)substituted (hetero)aryl, (hetero)aryl-(hetero)aryl; R4, R5, R6 = H, alkyl, halo] were prepared as antagonists of VLA-4 and/or  $\alpha 4\beta 7$  and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. Thus, N-[(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)- carbonyl]-3(S)-(3,4-methylenedioxyphenyl)-3-aminopropionic acid was prepared by amidation of N-(tert-butoxycarbonyl)-1,2,3,4-tetrahydro-3- isoquinolinecarboxylic acid with Me (S)-3-amino-3-(3,4-methylenedioxyphenyl)propanoate, deblocking, sulfonylation with 3,4-dimethoxybenzenesulfonyl chloride, and saponification

IT 309977-21-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of substituted  $\beta$ -alanine derivs. as cell adhesion inhibitors)

RN 309977-21-7 CAPLUS

CN 1H-Indene-1-acetic acid, 1-[[[(2S)-1-[(3,5-dichlorophenyl)sulfonyl]-2-pyrrolidinyl]carbonyl]amino]-2,3-dihydro-6-methoxy-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:855915 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 139:350727

TITLE: Preparation of indaneacetic acid derivatives for treating diabetes or diabetes-related disorders

INVENTOR(S): Wickens, Philip; Cantin, Louis-David; Kumarasinghe, Ellalahewage; Chuang, Chih-Yuan; Liang, Sidney X.

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 119 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003089418	A1	20031030	WO 2003-US11725	20030416 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CN 1854118	A	20061101	CN 2006-10004609	20020725 <--
CA 2482714	A1	20031030	CA 2003-2482714	20030416 <--
AU 2003221960	A1	20031103	AU 2003-221960	20030416 <--
EP 1497271	A1	20050119	EP 2003-718423	20030416 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005526834	T	20050908	JP 2003-586139	20030416 <--
US 20050107392	A1	20050519	US 2004-506270	20040830 <--
US 7476742	B2	20090113		
US 20050075338	A1	20050407	US 2004-949119	20040922 <--
US 7112597	B2	20060926		
US 20060205723	A1	20060914	US 2006-429136	20060505 <--
US 7358386	B2	20080415		
US 20090047687	A1	20090219	US 2008-59706	20080331 <--
PRIORITY APPLN. INFO.:			US 2002-373048P	P 20020416 <--
			US 2001-308500P	P 20010727 <--
			CN 2002-818676	A3 20020725 <--
			US 2002-205839	A1 20020725 <--
			WO 2003-US11725	W 20030416
			US 2004-949119	A3 20040922
			US 2006-429136	A3 20060505

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OTHER SOURCE(S): MARIAT 139:350727

GI



I



II

AB The title compds. [I; R, R1 = H, alkyl; R2 = H, alkyl, (un)substituted Ph; R3 = H, halo, NO2, etc.; R4 = cycloalkyl, alkenyl, NO2, etc.; X = O, S], useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases, were prepared and formulated. E.g., a multi-step synthesis of (IS)-II, was given.

IT 496062-18-1P 496062-21-6P 496062-22-7P  
 496062-23-8P 496062-24-9P 496062-25-0P  
 496062-26-1P 496062-27-2P 496062-28-3P  
 496062-29-4P 496062-30-7P 496062-31-6P  
 496062-32-9P 496062-34-1P 496062-35-2P  
 496062-36-3P 496062-37-4P 496062-38-5P  
 496062-39-6P 496062-40-9P 496062-41-0P  
 496062-42-1P 496062-44-3P 496062-45-4P  
 496062-46-5P 496062-48-7P 496062-62-5P  
 496062-63-6P 496062-64-7P 619299-00-2P  
 619299-01-3P 619299-02-4P 619299-03-5P  
 619299-04-6P 619299-05-7P 619299-06-8P  
 619299-07-9P 619299-08-0P 619299-10-4P  
 619299-12-6P 619299-13-7P 619299-14-6P  
 619299-15-9P 619299-16-0P 619299-17-1P  
 619299-18-2P 619299-19-3P 619299-20-6P  
 619299-21-7P 619299-22-8P 619299-23-9P  
 619299-24-0P 619299-25-1P 619299-26-2P  
 619299-28-4P 619299-29-5P 619299-30-8P  
 619299-31-9P 619299-32-0P 619299-33-1P  
 619299-34-2P 619299-35-3P 619299-36-4P  
 619299-37-5P 619299-38-6P 619299-39-7P  
 619299-40-0P 619299-41-1P 619299-42-2P  
 619299-43-3P 619299-44-4P 619299-45-5P  
 619299-46-6P 619299-47-7P 619299-48-8P  
 619299-49-9P 619299-50-2P 619299-51-3P  
 619299-52-4P 619299-53-5P 619299-54-6P  
 619299-55-7P 619299-56-8P 619299-57-9P  
 619299-58-0P 619299-59-1P 619299-60-4P  
 619299-61-5P 619299-62-6P 619299-63-7P  
 619299-64-8P 619299-65-9P 619299-67-1P  
 619299-68-2P 619299-69-3P 619299-70-6P  
 619299-71-7P 619299-72-8P 619299-73-9P  
 619299-75-1P 619299-76-2P 619299-77-3P  
 619299-78-4P 619299-79-5P 619299-80-6P  
 619299-81-9P 619299-82-0P 619299-83-1P  
 619299-84-2P 619299-85-3P 619299-86-4P  
 619299-87-5P 619299-88-6P 619299-89-7P  
 619299-90-0P 619299-91-1P 619299-92-2P  
 619299-93-3P 619299-94-4P 619299-95-5P  
 619299-96-6P 619299-97-7P 619299-98-8P  
 619299-99-9P 619300-00-4P 619300-01-5P  
 619300-02-6P 619300-03-7P 619300-04-8P  
 619300-05-9P 619300-06-0P 619300-08-2P  
 619300-09-3P 619300-10-6P 619300-11-7P  
 619300-13-9P 619300-16-2P 619300-17-3P  
 619300-18-4P 619300-19-5P 619300-20-8P  
 619300-21-9P 619300-22-0P 619300-23-1P  
 619300-24-2P 619300-25-3P 619300-26-4P  
 619300-27-5P 619300-28-6P 619300-29-7P  
 619300-30-0P 619300-31-1P 619300-32-2P  
 619300-33-3P 619300-34-4P 619300-35-5P  
 619300-36-6P 619300-37-7P 619300-38-8P  
 619300-39-9P 619300-40-2P 619300-41-3P

619300-42-4P 619300-43-5P 619300-44-6P  
 619300-45-7P 619300-46-8P 619300-47-9P  
 619300-49-1P 619300-50-4P 619300-52-6P  
 619300-54-8P 619300-55-9P 619300-56-0P  
 619300-57-1P 619300-58-2P 619300-59-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indaneacetic acid derivs. for treating diabetes or diabetes-related disorders)

RN 496062-18-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-21-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-22-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-23-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(1,3-benzodioxol-5-yl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-24-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-25-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-26-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-cyanophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-27-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-chloro-4-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-28-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-29-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-30-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-31-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-methylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-32-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(dimethylamino)phenyl]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 496062-34-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-amino-4-methylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 496062-33-0

CMF C24 H26 N2 O3 S

Absolute stereochemistry.





CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 496062-35-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(2-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-36-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-37-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-38-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-39-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(3-methylphenyl)-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-40-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-41-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-42-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,5-dimethylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-44-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-45-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(2-(3-methoxyphenyl)-5-methyl-4-thiazolyl)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-46-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-48-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(4-methyl-2-phenyl-5-oxazolyl)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-62-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-(4-methylphenyl)-5-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-63-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluoro-4-methylphenyl)-4-methyl-5-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-64-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-00-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(dimethylamino)-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-01-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-(methylamino)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-02-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(acetylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-03-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-[(methylsulfonyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-04-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(acetylmethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-05-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(methyl(methylsulfonyl)amino)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-06-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-07-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(ethylamino)-2-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-08-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(diethylamino)-2-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-10-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(dimethylamino)-3-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-12-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(4-morpholinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619299-13-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(phenylmethyl)aminophenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 619299-14-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(methylamino)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-15-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-methyl(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-16-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-aminophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-17-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-[methyl(1-oxopropyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-18-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[[[(dimethylamino)carbonyl]methylamino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-19-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-[(1-oxopropyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-20-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[[[(dimethylamino)carbonyl]amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-21-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[(ethylsulfonyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-22-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-[(1-methylethylsulfonyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-23-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[[dimethylamino)sulfonyl]amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-24-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[bis[(dimethylamino)sulfonyl]amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-25-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(ethylmethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-26-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 619299-28-4 CAPLUS


CN Benzenaminium, 3-[4-[2-[[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]ethyl]-5-methyl-2-oxazolyl]-N,N,N-trimethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 619299-27-3

CMF C26 H31 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 619299-29-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[[3,5-dimethyl-4-isoxazolyl)sulfonyl]aminophenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619299-30-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[[1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]aminophenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CO<sub>2</sub>H

RN 619299-31-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CO<sub>2</sub>H

RN 619299-32-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(diethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-33-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(diethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-34-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[ethyl(phenylmethyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-35-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-[(phenylmethyl)propylamino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-36-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[butyl(phenylmethyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-37-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(ethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-38-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(propylamino)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619299-39-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(butylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 619299-40-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[3-[(2-methoxyethyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-41-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[(2-ethoxyethyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-42-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-[(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-43-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-[5-methyl-2-[4-methyl-3-[(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-44-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-amino-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-45-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-amino-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-46-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-methyl(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-47-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[ethyl(phenylmethyl)amino]-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-48-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-[5-methyl-2-[4-methyl-3-[methyl(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-49-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[ethyl(phenylmethyl)amino]-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-52-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-[5-methyl-2-[4-methyl-3-[(phenylmethyl)propylamino]phenyl]-4-oxazolyl]ethoxy]-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-53-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[butyl(phenylmethyl)amino]-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-54-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(ethylamino)-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-55-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-(propylamino)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-56-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(butylamino)-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-57-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-[5-methyl-2-[4-methyl-3-(methylamino)phenyl]-4-oxazolyl]ethoxy]-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-58-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(ethylamino)-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-59-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(butylamino)-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-60-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(diethylamino)-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-61-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(dimethylamino)-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-62-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(diethylamino)-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha S,1S$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-63-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-[5-methyl-2-[4-methyl-3-(propylamino)phenyl]-4-oxazolyl]ethoxy]-, ( $\alpha S,1S$ )- (CA INDEX NAME)

Absolute stereochemistry.




RN 619299-64-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-amino-4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha S,1S$ )- (CA INDEX NAME)

Absolute stereochemistry.






RN 619299-65-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-amino-4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 619299-67-1 CAPLUS


CN Benzenaminium, 5-[4-[2-[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]ethyl]-5-methyl-2-oxazolyl]-2-methoxy-N,N,N-trimethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 619299-66-0

CMF C27 H33 N2 O5

Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 619299-68-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(diethylamino)-4-methoxyphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-69-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(ethylamino)-4-methoxyphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-70-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(dipropylamino)-4-methoxyphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-71-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[4-methoxy-3-(propylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-72-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(dibutylamino)-4-methoxyphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-73-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(butylamino)-4-methoxyphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 619299-75-1 CAPLUS


CN Benzenaminium, 5-[4-[2-[[[(1S)-1-[(1S)-1-carboxyethyl]-2,3-dihydro-1H-inden-5-yl]oxy]ethyl]-5-methyl-2-oxazolyl]-2-methoxy-N,N,N-trimethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 619299-74-0

CMF C28 H35 N2 O5

Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 619299-76-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(diethylamino)-4-methoxyphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-α-methyl-, (αS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-77-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(diethylamino)-4-methoxyphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-α-methyl-, (αS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-78-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(dimethylamino)-4-methoxyphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-79-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(dimethylamino)-4-methoxyphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-80-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(4-thiomorpholinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-81-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1-piperidinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-82-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(4-methyl-1-piperazinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-83-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(dipropylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-84-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1-pyrrolidinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619299-85-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-[4-(phenylmethyl)-1-piperazinyl]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CO<sub>2</sub>H

RN 619299-86-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-[(2-ethoxyethyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-87-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-[(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-88-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-aminophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619299-89-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(diethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 619299-90-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-91-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-[(ethylsulfonyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-92-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619299-93-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CO<sub>2</sub>H

RN 619299-94-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-95-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[(propylsulfonyl)amino]phenyl]-4-oxazolyl]ethoxy-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-96-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(acetylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-97-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-[(1-oxopropyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-98-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-[(2-methyl-1-oxopropyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-99-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-[[[(dimethylamino)carbonyl]aminol]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-00-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-[(2-thienylcarbonyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-01-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-[[[2-(methylthio)-3-pyridinyl]carbonyl]aminol]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-02-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-methyl-4-[(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-03-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[2-methyl-4-[(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-04-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-amino-3-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-05-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-amino-2-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-06-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(diethylamino)-3-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 619300-08-2 CAPLUS


CN Benzenaminium, 4-[4-[2-[[1S]-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]ethyl]-5-methyl-2-oxazolyl]-N,N,N,3-tetramethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 619300-07-1

CMF C27 H33 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 619300-09-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(dipropylamino)-2-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-10-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(2-methyl-4-(propylamino)phenyl)-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-11-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(dimethylamino)-2-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-13-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(2,4-dimethoxy-5-pyrimidinyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-16-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-ethenylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619300-17-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-ethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 619300-18-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(5-pyrimidinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-19-5 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[4-[2-[[1S]-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]ethyl]-5-methyl-2-oxazolyl]phenyl]-, 1-(1,1-dimethylethyl) ester (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-20-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(3,5-dimethyl-4-isoxazolyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-21-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(3-pyridinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-22-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(4-pyridinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-23-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4'-carboxy[1,1'-biphenyl]-4-yl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-24-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(3'-nitro[1,1'-biphenyl]-4-yl)-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-25-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-(1H-pyrrol-2-yl)phenyl)-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-26-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3'-acetyl[1,1'-biphenyl]-4-yl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-27-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(1,3-benzodioxol-5-yl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-28-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(4-pyridinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-29-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(3-pyridinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-30-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(2,4-dimethoxy-5-pyrimidinyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-31-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(3,5-dimethyl-4-isoxazolyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619300-32-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]-5-methyl-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




—CO<sub>2</sub>H

RN 619300-33-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4'-amino[1,1'-biphenyl]-3-yl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-34-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(1,3-benzodioxol-5-yl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-35-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(5-acetyl-2-thienyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-36-6 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[3-(4-methoxy-3-pyridinyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[3-(4-methoxy-3-pyridinyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-37-7 CAPLUS  
CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-cyclopentylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-cyclopentylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-38-8 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(5-pyrimidinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(5-pyrimidinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-39-9 CAPLUS  
CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-bromophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-bromophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-40-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-bromo-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-41-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-bromo-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619300-42-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-bromo-4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 619300-43-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-bromo-4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-44-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methyl-3-(1H-pyrrol-2-yl)phenyl)-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-45-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4'-amino-6-methyl[1,1'-biphenyl]-3-yl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-46-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-(5-pyrimidinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-47-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-α-methyl-5-[2-[5-methyl-2-[4-methyl-3-(1H-pyrrol-2-yl)phenyl]-4-oxazolyl]ethoxy]-, (αS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-49-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4'-amino-6-methyl[1,1'-biphenyl]-3-yl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-α-methyl-, (αS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-50-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-[5-methyl-2-[4-methyl-3-(5-pyrimidinyl)phenyl]-4-oxazolyl]ethoxy]-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-52-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(3-methoxy-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-54-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxy-3-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-55-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[4-methoxy-3-(1H-pyrrol-2-yl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-56-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4'-amino-6-methoxy[1,1'-biphenyl]-3-yl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-57-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3'-amino-6-methoxy[1,1'-biphenyl]-3-yl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-58-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3'-amino-6-methyl[1,1'-biphenyl]-3-yl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-59-3 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[5-[4-[2-[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]ethyl]-5-methyl-2-oxazolyl]-2-methoxyphenyl]-, 1-(1,1-dimethylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




IT 496063-18-4 619300-62-8

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of indaneacetic acid derivs. for treating diabetes or diabetes-related disorders)

RN 496063-18-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-bromophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-62-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-aminophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 80370-87-2P 162713-88-4P 496060-61-8P  
496061-78-0P 496061-79-1P 496061-80-4P  
496062-17-0P 496062-47-6P 496062-59-0P  
496062-60-3P 496062-61-4P 496062-96-5P  
496063-11-7P 496063-12-8P 496063-13-9P  
619298-80-5P 619298-82-7P 619298-84-9P  
619298-92-9P 619298-93-0P 619298-94-1P  
619298-95-2P 619298-96-3P 619298-97-4P  
619298-98-5P 619298-99-6P 619299-11-5P  
619300-12-8P 619300-14-0P 619300-15-1P  
619300-60-6P 619300-61-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of indaneacetic acid derivs. for treating diabetes or  
diabetes-related disorders)


RN 80370-87-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, ethyl ester (CA INDEX NAME)



RN 162713-88-4 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, ethyl ester (CA INDEX NAME)



RN 496060-61-8 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-methoxy-,  
( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496061-78-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496061-79-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496061-80-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-17-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-bromo-5-methyl-4-thiazolyl)ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-47-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(4-methyl-2-phenyl-5-oxazolyl)ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-59-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-(4-(trifluoromethyl)phenyl)-5-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-60-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-(4-methylphenyl)-5-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 496062-61-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluoro-4-methylphenyl)-4-methyl-5-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)




Absolute stereochemistry.



RN 496062-96-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-,  
( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496063-11-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-thiazolyl]ethoxy]-, ethyl ester, (1S)-  
(NAME)


Absolute stereochemistry.



RN 496063-12-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-, methyl  
ester, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496063-13-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy- $\alpha$ -methyl-, methyl ester, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 619298-80-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-82-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-, methyl ester, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-84-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy- $\alpha$ -methyl-, methyl ester, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-92-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-bromo-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-93-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-[(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-94-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-amino-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-95-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(dimethylamino)-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-96-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-(methylamino)phenyl]-4-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-97-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(acetylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-98-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[bis(methylsulfonyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-99-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(acetylmethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-11-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(4-morpholinyl)phenyl]-4-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619300-12-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(2,4-dimethoxy-5-pyrimidinyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OEt

RN 619300-14-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-ethenylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-15-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-ethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 619300-60-6 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-, ( $\alpha$ R,1R)-rel-, compd. with ( $\alpha$ R)- $\alpha$ -methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 496062-96-5

CMF C13 H16 O3

Relative stereochemistry.



CM 2

CRN 3886-69-9

CMF C8 H11 N

Absolute stereochemistry. Rotation (+).



RN 619300-61-7 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-,  
( $\alpha$ S,1S)-, compd. with ( $\alpha$ R)- $\alpha$ -methylbenzenemethanamine  
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 619298-80-5

CMF C13 H16 O3

Absolute stereochemistry.



CM 2

CRN 3886-69-9

CMF C8 H11 N

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT:	4	THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:818385 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 139:323344

TITLE: Preparation of aralkoxyphenoxyindanylcaboxylates as  
thyroid receptor ligands

INVENTOR(S): Rahimi-Ghadim, Mahmoud; Garg, Neeraj; Malm, Johan

PATENT ASSIGNEE(S): Karo Bio AB, Swed.

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English



FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084915	A1	20031016	WO 2003-EP1304	20030210 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2481976	A1	20031016	CA 2003-2481976	20030210 <--
AU 2003210234	A1	20031020	AU 2003-210234	20030210 <--
EP 1492756	A1	20050105	EP 2003-745755	20030210 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005522476	T	20050728	JP 2003-582114	20030210 <--
CN 1649819	A	20050803	CN 2003-809937	20030210 <--
CN 1324001	C	20070704		
US 20050171104	A1	20050804	US 2005-510645	20050401 <--
GB 2002-8384				A 20020411 <--
WO 2003-EP1304				W 20030210

PRIORITY APPLN. INFO.:

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:323344

GI



I

AB Title compds. [I; R1 = CO<sub>2</sub>H, PO(OH)<sub>2</sub>, PO(OH)NH<sub>2</sub>, SO<sub>2</sub>OH, CONHOH, NHCOCO<sub>2</sub>H, NHCOCO<sub>2</sub>CO<sub>2</sub>H, any other possible bioisosteric equivalent of the groups above; R2, R3 = Cl, Br, iodo, alkyl, (Ra-substituted) bioisosteric equivalent; R4, R6 = H, halo, alkyl, bioisosteric equivalent optionally substituted with Ra; R5 = Rb-(substituted) aryl, heteroaryl; Ra = F, Cl; Rb = halo, CN, CO<sub>2</sub>H, CHO, NH<sub>2</sub>, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy, alkylthio, alkenylthio, alkynylthio, aryl, heteroaryl, cycloalkyl, amino, bioisosteric equivalent; n = 1, 2, 3; stereoisomers thereof; prodrug ester forms thereof; and radioactive forms thereof], were prepared as antagonists, partial antagonists or partial agonists for the treatment of cardiac and metabolic disorders such as cardiac arrhythmias, thyrotoxicosis, subclin. hyperthyroidism, and liver diseases. Thus, Et [4,6-dibromo-5-(3-isopropyl-4-hydroxyphenoxy)indan-1-yl]acetate (preparation given), K<sub>2</sub>CO<sub>3</sub>, and MeCN were stirred at room temperature for 30 min; 2-bromomethylnaphthalene in MeN was added and the reaction mixture was stirred at 80° for 16 h to give 17% 4,6-dibromo-5-[3-isopropyl-4-(naphthalen-

2-ylmethoxy)phenoxy]indan-1-yl]acetic acid. I bound to the ThRa receptor with affinities in the range of 100-500 nM.


IT 612842-68-9P 612842-76-9P 612842-86-5P  
612842-85-0P 612842-87-2P 612842-88-3P  
612842-89-4P 612842-90-7P 612842-91-8P  
612842-92-9P 612842-93-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aralkoxyphenoxyindanylcarboxylates as thyroid receptor ligands)


RN 612842-76-9 CAPLUS

CN 1H-Indene-1-acetic acid, 4,6-dibromo-2,3-dihydro-5-[3-(1-methylethyl)-4-(2-naphthalenylmethoxy)phenoxy]- (CA INDEX NAME)




RN 612842-76-9 CAPLUS

CN 1H-Indene-1-acetic acid, 4,6-dibromo-5-[4-[(4-fluorophenyl)methoxy]-3-(1-methylethyl)phenoxy]-2,3-dihydro- (CA INDEX NAME)



RN 612842-80-5 CAPLUS


CN 1H-Indene-1-acetic acid, 4,6-dibromo-5-[3-(1-methylethyl)-4-[(5-methyl-3-isoxazolyl)methoxy]phenoxy]- (CA INDEX NAME)



RN 612842-85-0 CAPLUS


CN 1H-Indene-1-acetic acid, 4,6-dibromo-2,3-dihydro-5-[3-(1-methylethyl)-4-(2-

pyridinylmethoxy)phenoxy]- (CA INDEX NAME)




RN 612842-87-2 CAPLUS

CN 1H-Indene-1-acetic acid, 4,6-dibromo-2,3-dihydro-5-[3-(1-methylethyl)-4-[(5-phenyl-1,2,4-oxadiazol-3-yl)methoxy]phenoxy]- (CA INDEX NAME)




RN 612842-88-3 CAPLUS

CN 1H-Indene-1-acetic acid, 4,6-dibromo-5-[4-[(4-carboxyphenyl)methoxy]-3-(1-methylethyl)phenoxy]-2,3-dihydro- (CA INDEX NAME)




RN 612842-89-4 CAPLUS

CN 1H-Indene-1-acetic acid, 4,6-dibromo-2,3-dihydro-5-[4-[2-(1H-indol-2-yl)ethoxy]-3-(1-methylethyl)phenoxy]- (CA INDEX NAME)




RN 612842-90-7 CAPLUS

CN 1H-Indene-1-acetic acid, 4,6-dibromo-2,3-dihydro-5-[3-(1-methylethyl)-4-  
[[5-(3-thienyl)-1,2,4-oxadiazol-3-yl]methoxy]phenoxy]- (CA INDEX NAME)




RN 612842-91-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[4-[[4-amino-6-(phenylamino)-1,3,5-triazin-2-  
yl]methoxy]-3-(1-methylethyl)phenoxy]-4,6-dibromo-2,3-dihydro- (CA INDEX  
NAME)




RN 612842-92-9 CAPLUS

CN 1H-Indene-1-acetic acid, 4,6-dibromo-2,3-dihydro-5-[3-(1-methylethyl)-4-  
[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]- (CA INDEX NAME)




RN 612842-93-0 CAPLUS


CN 1H-Indene-1-acetic acid, 4,6-dibromo-5-[4-[(3,5-dimethyl-4-  
isoxazolyl)methoxy]-3-(1-methylethyl)phenoxy]-2,3-dihydro- (CA INDEX  
NAME)




IT 612842-96-3P 612842-97-4F 612842-98-5F  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of aralkoxyphenoxyindanylcarboxylates as thyroid receptor  
 ligands)  
 RN 612842-96-3 CAPLUS  
 CN 1H-Indene-1-acetic acid, 4,6-dibromo-2,3-dihydro-1-hydroxy-5-[4-methoxy-3-  
 (1-methylethyl)phenoxy]-, ethyl ester (CA INDEX NAME)



RN 612842-97-4 CAPLUS  
 CN 1H-Indene-1-acetic acid, 4,6-dibromo-2,3-dihydro-5-[4-methoxy-3-(1-  
 methylethyl)phenoxy]-, ethyl ester (CA INDEX NAME)




RN 612842-98-5 CAPLUS  
 CN 1H-Indene-1-acetic acid, 4,6-dibromo-2,3-dihydro-5-[4-hydroxy-3-(1-  
 methylethyl)phenoxy]-, ethyl ester (CA INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)  
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2003:719304 CAPLUS Full-text  
DOCUMENT NUMBER: 139:246020  
TITLE: Preparation of thiazolylmethoxyindoleacetates and  
related compounds as modulators of peroxisome  
proliferator activating receptor (PPAR) activity  
Cheng, Xue-min; Filzen, Gary Frederick; Geyer, Andrew  
George; Lee, Chitase; Trivedi, Bharat Kalidas  
INVENTOR(S): Warner-Lambert Company Llc, USA  
PATENT ASSIGNEE(S):  
SOURCE: PCT Int. Appl., 131 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074051	A1	20030912	WO 2003-IB882	20030303 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030207915	A1	20031106	US 2002-324266	20021219 <--
US 6867224	B2	20050315		
CA 2478164	A1	20030912	CA 2003-2478164	20030303 <--
AU 2003207914	A1	20030916	AU 2003-207914	20030303 <--
EP 1480641	A1	20041201	EP 2003-704916	20030303 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008202	A	20041221	BR 2003-8202	20030303 <--
JP 2005527509	T	20050915	JP 2003-572568	20030303 <--
MX 2004008627	A	20041206	MX 2004-8627	20040906 <--
US 20050113422	A1	20050526	US 2004-20391	20041222 <--
US 20050107442	A1	20050519	US 2004-25271	20041224 <--
US 7109222	B2	20060919		
PRIORITY APPLN. INFO.:			US 2002-362411P	P 20020307 <--
			US 2002-324266	A3 20021219 <--
			WO 2003-IB882	W 20030303
OTHER SOURCE(S):			MARPAT 139:246020	
GI				




- AB Title compds. [I; V1 = (unsatd.) (substituted) (heteroatom-containing) hydrocarbon chain having 3-6 atoms; X, X1 = O, S; X2 = absent, O, S, NR4; Ar1 = (substituted) aryl, heteroaryl; R1, R2, R3 = H, alkyl, alkoxy, thioalkoxy, O(CH2)pCF3, halo, NO2, cyano, OH, SH, CF3, S(O)pAlkyl, S(O)pAryl, (CH2)mOR4, (CH2)mNR5R6, COR4, CO2H, CO2R4, NR5R6; R1R2 form (substituted) (unsatd.) cycloalkyl, heterocycloalkyl; R4 = H, alkyl, alkenyl, alkynyl, aryl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, SO2Alkyl, SO2Aryl; R5R6 form 4-7 membered ring having 0-3 heteroatoms; m = 0-5; n = 0-5; p = 0-2], were prepared Thus, 5-mercaptoindan-2-carboxylic acid Me ester (preparation given), 5-chloromethyl-4-methyl-2-(4- trifluoromethylphenyl)thiazole, and Cs2CO3 were stirred overnight in MeCN to give Me 5-[4-methyl-2-(4- trifluoromethylphenyl)thiazol-5- ylmethylsulfanyl]indan-2-carboxylate. The latter was refluxed overnight with LiOH.H2O in MeOH/THF to give 5-[4-methyl-2-(4- trifluoromethylphenyl)thiazol-5-ylmethylsulfanyl]indan-2-carboxylic acid. In a transient transfections assay using the HepG2 hepatoma cell line, the latter showed EC50 = 177.7 nM and 384 nM for Hep G2-hβ and Hep G2-hα, resp.
- IT 600166-47-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of thiazolylmethoxyindoleacetates and related compds. as modulators of peroxisome proliferator activating receptor (PPAR) activity)
- RN 600166-47-0 CAPLUS
- CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-5-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]- (CA INDEX NAME)




- IT 91284-09-2P 600167-40-6P 600167-41-7P  
 600167-42-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of thiazolylmethoxyindoleacetates and related compds. as modulators of peroxisome proliferator activating receptor (PPAR) activity)
- RN 91284-09-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-, ethyl ester (CA INDEX NAME)




RN 600167-40-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-(chlorosulfonyl)-2,3-dihydro-6-methoxy-, ethyl ester (CA INDEX NAME)




RN 600167-41-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-mercapto-6-methoxy-, ethyl ester (CA INDEX NAME)



RN 600167-42-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-5-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



ACCESSION NUMBER: 2003:678662 CAPLUS Full-text  
 DOCUMENT NUMBER: 139:214342  
 TITLE: cis-N-(Quinolin-4-yl)cyclohexane-1,4-diamine  
 derivatives as antagonists of melanin concentrating  
 hormone (MCH) and their pharmaceutical compositions  
 and therapeutic uses, e.g., for treatment of obesity  
 INVENTOR(S): Kym, Philip R.; Hartandi, Kresna; Gao, Ju; Phelan,  
 Kathleen M.; Akritopoulou-Zanze, Irini; Collins,  
 Christine A.; Vasudevan, Anil; Verzal, Mary K.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: PCT Int. Appl., 207 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070244	A1	20030828	WO 2003-US5510	20030221 <--
W: CA, JP, MX RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			US 2002-81675	A 20020222 <--
OTHER SOURCE(S):			MARPAT 139:214342	

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention is directed to the compds. of formula I, or therapeutically  
 suitable salts, esters, prodrugs, or zwitterions thereof [R1, R2, R3 = H,  
 alkyl, alkoxy, halo, haloalkyl, haloalkoxy, OH, NH2 and derivs.; R4 = H,  
 alkyl; R5 = -(CH2)mYAB; m = 0-6; A = bond, alkoxyalkylene, alkylene, or  
 hydroxyalkylene; B = H, alkyl, aryl, aroyl, arylsulfonyl, aralkenyl,  
 aryloxyalkyl, biaryl, biarylalkyl, cycloalkyl, heterocyclyl,  
 heterocyclylcarbonyl, heterocyclylsulfonyl, haloalkyl, NH2 or derivs.,  
 carbamoyl or derivs., OH or derivs., SH or derivs.; Y = CO, S, SO, SO2, or  
 bond; R6 = H, alkyl, arylcarboxyalkyl; R7, R8, R9, R10 = H, alkyl, alkoxy,  
 halo, haloalkyl, haloalkoxy, OH; or R7R8 = oxo; with 4 provisos]. The  
 invention further relates to the antagonism of the effects of melanin-  
 concentrating hormone (MCH) through the MCH receptor, which is useful for the  
 prevention or treatment of eating disorders, weight gain, obesity,  
 abnormalities in reproduction and sexual behavior, thyroid hormone secretion,  
 diuresis and water/electrolyte homeostasis, sensory processing, memory,  
 sleeping, arousal, anxiety, depression, seizures, neurodegeneration and  
 psychiatric disorders. Approx. 450 synthetic examples of I are given. For  
 instance, reaction of N-(7-chloroquinolin-4-yl)cyclohexane-1,4-diamine (cis  
 isomer) with 4-chloro-2,8-bis(trifluoromethyl)quinoline in N-  
 methylpyrrolidinone the presence of Et3N at 150° gave title compound II. In a  
 fluorescence assay for release of intracellular Ca++ induced by activation of  
 MCHR, a more preferred group of compds. I inhibited MCH-induced fluorescence  
 in a range of 90-100% at 10 µM. A more preferred group of I also gave 90-100%  
 inhibition of 125I-MCH binding to human MCHR1 at 2 µM (no addnl. data).  
 IT 24467-92-3, 5-Methoxy-1-indanone-3-acetic acid  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (starting material; preparation of quinolinylcyclohexanediamine derivs. as  
 MCH receptor antagonists)


RN 24467-92-3 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)




OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)  
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:356252 CAPLUS Full-text  
 DOCUMENT NUMBER: 138:368891  
 TITLE: Preparation of arylazolecarboxamides for the treatment of obesity  
 INVENTOR(S): Coish, Philip D. G.; O'Connor, Stephen J.; Wickens, Philip; Zhang, Chengzhi; Zhang, Hai-Jun  
 PATENT ASSIGNEE(S): Bayer Corporation, USA  
 SOURCE: PCT Int. Appl., 253 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037332	A1	20030508	WO 2002-US32895	20021015 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2463441	A1	20030508	CA 2002-2463441	20021015 <--
AU 2002348440	A1	20030512	AU 2002-348440	20021015 <--
EP 1435951	A1	20040714	EP 2002-782159	20021015 <--
EP 1435951	B1	20060118		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005507932	T	20050324	JP 2003-539676	20021015 <--
ES 2256560	T3	20060716	ES 2002-782159	20021015 <--
US 20050014805	A1	20050120	US 2004-490826	20040326 <--
MX 2004002931	A	20050411	MX 2004-2931	20040329 <--
PRIORITY APPLN. INFO.:			US 2001-329236P	P 20011012 <--
			WO 2002-US32895	W 20021015 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):	MARPAT 138:368891			




- AB Title compds. [I; R1 = ZCR11R12CO2R13; Z = O, S; R11-R15 = H, alkyl; R2, R3 = H, Me; R1R2 = CH2CH2CH(CHR15CO2R14); Y = NR4, O, S; R4 = H, alkyl, alkoxyalkyl, aryloxyalkyl; R5 = H, alkyl, Ph, halophenyl, alkylphenyl, alkoxyphenyl; R6 = COR61; R61 = OH, alkoxy, benzyloxy, amino, etc.], were prepared for treatment of obesity and complications (no data). Thus, tert-Bu 2-methyl-2-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]thio]propionate (preparation given), Me 2-bromo-1H-imidazole-4-carboxylate (preparation given), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II).CH2Cl2, and aqueous NaHCO3 were heated at 85° in PhMe for 48 h to give 99% coupling product. The latter was sequentially saponified with aqueous KOH in EtOH, amidated with (COC1)2/2,4-dimethylainiline, hydrolyzed with CF3CO2H in CH2Cl2, and salified with NaOH in H2O/MeCN to give Na 2-[[4-[4-[[[(2,4-dimethylphenyl)amino]carbonyl]-1-pentyl-1H-imidazol-2-yl]phenyl]thio]-2-methylpropionate.
- IT 496063-15-1P 496063-17-3P 521034-27-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of arylazolecarboxamides for the treatment of obesity)
- RN 496063-15-1 CAPLUS
- CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-hydroxy-, methyl ester (CA INDEX NAME)



- RN 496063-17-3 CAPLUS
- CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-methoxy-, methyl ester (CA INDEX NAME)



RN 521084-27-5 CAPLUS  
 CN 1H-indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-  
 [[trifluoromethylsulfonyl]oxy]-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
 (10 CITINGS)  
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:235492 CAPLUS Full-text  
 DOCUMENT NUMBER: 138:248501  
 TITLE: Methods using a phosphodiesterase 10 (PDE10) inhibitor  
 for the treatment of renal cell carcinoma  
 INVENTOR(S): Thompson, W. Joseph; Fetter, John R.; Bellet, Robert  
 E.; Li, Han  
 PATENT ASSIGNEE(S): Cell Pathways, USA  
 SOURCE: U.S., 32 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6538029	B1	20030325	US 2002-157526	20020529 <--
PRIORITY APPLN. INFO.:			US 2002-157526	20020529 <--
OTHER SOURCE(S):	MARPAT 138:248501			

AB A method of treating renal cell carcinoma in a mammal with that disease  
 comprises administering to the mammal a physiologically effective amount of an  
 inhibitor of PDE10. The inventors have found that PDE10 is present in renal  
 cell carcinoma, and that its inhibition leads to death of such cells.  
 Preparation and biol. testing of e.g. (Z)-5-fluoro-2-methyl-(4-pyridylidene)-  
 3-(N-benzyl)indenylacetamide hydrochloride is described.


IT 27961-10-6F  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(phosphodiesterase 10 inhibitor for treatment of renal cell carcinoma)

RN 27961-10-0 CAPLUS

CN 1H-indene-1-acetic acid, 2,3-dihydro-1-hydroxy-6-methoxy-2-methyl-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)  
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:117811 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:153524

TITLE: Preparation of indaneacetic acid derivatives for  
treating diabetes, obesity, hyperlipidemia, and  
atherosclerotic diseases

INVENTOR(S): Lowe, Derek B.; Wickens, Philip L.; Ma, Xin; Zhang,  
Mingbao; Bullock, William H.; Coish, Philip D. G.;  
Mugge, Ingo A.; Stolle, Andreas; Wang, Ming; Wang,  
Yamin; Zhang, Chengzhi; Zhang, Hai-Jun; Zhu, Lei;  
Tsutsumi, Manami; Livingston, James N.

PATENT ASSIGNEE(S): Bayer Corporation, USA  
SOURCE: PCT Int. Appl., 189 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English



FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011842	A1	20030213	WO 2002-US23614	20020725 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2455620	A1	20030213	CA 2002-2455620	20020725 <--
AU 2002319693	A1	20030217	AU 2002-319693	20020725 <--
AU 2002319693	B2	20080807		
US 20030216391	A1	20031120	US 2002-205839	20020725 <--
US 6828335	B2	20041207		
EP 1414809	A1	20040506	EP 2002-750297	20020725 <--
EP 1414809	B1	20080312		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK						
JP	2005508308	T	20050331	JP	2003-517034	20020725 <--
BR	2002011502	A	20050920	BR	2002-11502	20020725 <--
NZ	531351	A	20060929	NZ	2002-531351	20020725 <--
CN	1854118	A	20061101	CN	2006-10004609	20020725 <--
HU	2007000105	A2	20070928	HU	2007-105	20020725 <--
RU	2314298	C2	20080110	RU	2004-105925	20020725 <--
AT	388944	T	20080315	AT	2002-750297	20020725 <--
ES	2302825	T3	20080801	ES	2002-750297	20020725 <--
KR	2009125225	A	20091203	KR	2009-723801	20020725 <--
MX	2004000599	A	20050217	MX	2004-599	20040120 <--
NO	2004000356	A	20040319	NO	2004-356	20040126 <--
IN	2004DN00258	A	20050401	IN	2004-DN258	20040205 <--
ZA	2004001517	A	20050310	ZA	2004-1517	20040225 <--
US	20050075338	A1	20050407	US	2004-949119	20040922 <--
US	7112597	B2	20060926			
US	20060205723	A1	20060914	US	2006-429136	20060505 <--
US	7358386	B2	20080415			
US	20090047687	A1	20090219	US	2008-59706	20080331 <--
IN	2008DN06690	A	20081024	IN	2008-DN6690	20080801 <--
NO	2008003411	A	20040319	NO	2008-3411	20080804 <--
AU	2008237581	A1	20081120	AU	2008-237581	20081029 <--
PRIORITY APPLN. INFO.:				US	2001-308500P	P 20010727 <--
				US	2002-373048P	P 20020416 <--
				AU	2002-319693	A3 20020725 <--
				CN	2002-818676	A3 20020725 <--
				US	2002-205839	A1 20020725 <--
				WO	2002-US23614	W 20020725 <--
				KR	2004-701188	A3 20040127 <--
				IN	2004-DN258	A3 20040205 <--
				US	2004-949119	A3 20040922 <--
				US	2006-429136	A3 20060505 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): MARPAT 138:153524  
 GI



AB The title compds. I [R = H, alkyl; R1 = H, CO2R, cycloalkyl, etc.; R2 = H, halo, alkyl, etc.; R3 = H, alkyl, (un)substituted Ph; X = O, S; R4 = alkyl,

cycloalkyl, Ph, etc.; R5 = H, halo, alkyl optionally substituted with oxo], useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases, were prepared and formulated. Thus, reacting 2-(4-methyl-2-phenyl-1,3-oxazol-5-yl)ethanol with Me 5-hydroxy-2,3-dihydroinden-1-yl-2-butanolate (prepn.s. given) in the presence of DEAD and PPh3 in THF followed by hydrolysis of the ester afforded the acid II.

IT 496061-78-0P


RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indane acetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 496061-78-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 496063-03-7P

RL: BYP (Byproduct); PREP (Preparation)

(preparation of indane acetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 496063-03-7 CAPLUS

CN 1H-Indene-1-acetic acid, 4,6-dibromo- $\alpha$ -ethyl-2,3-dihydro-5-hydroxy-, methyl ester (CA INDEX NAME)



IT 496060-66-3P 496060-82-3P 496060-86-7P

496061-14-4P 496061-15-5P 496061-26-0P

496061-91-5P 496062-47-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of indane acetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 496060-66-3 CAPLUS


CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]-, methyl ester, ( $\alpha$ S,1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 496060-82-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-α-propyl-, ethyl ester (CA INDEX NAME)




RN 496060-86-7 CAPLUS

CN 1H-Indene-1-acetic acid, 6-(4-chlorophenyl)-α-ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 496061-14-4 CAPLUS


CN Propanedioic acid, 2-[2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-1H-inden-1-yl]-, 1,3-diethyl ester (CA INDEX NAME)



RN 496061-15-5 CAPLUS




CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ethyl ester (CA INDEX NAME)



RN 496061-26-8 CAPLUS


CN 1H-Indene-1-acetic acid, 6-acetyl- $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 496061-81-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-47-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(4-methyl-2-phenyl-5-oxazolyl)ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



496060-67-4P	496060-68-5P	496060-69-6P
496060-70-9P	496060-71-0P	496060-72-1P
496060-73-2P	496060-74-3P	496060-75-4P
496060-76-5P	496060-77-6P	496060-78-7P
496060-79-8P	496060-80-1P	496060-81-2P
496060-83-4P	496060-84-5P	496060-85-6P
496060-88-9P	496060-89-0P	496060-90-3P
496060-91-4P	496060-92-5P	496060-93-6P
496060-94-7P	496060-95-8P	496060-96-9P
496060-97-0P	496060-98-1P	496060-99-2P
496061-00-8P	496061-01-9P	496061-02-0P
496061-03-1P	496061-04-2P	496061-05-3P
496061-06-4P	496061-07-5P	496061-08-6P
496061-09-7P	496061-10-0P	496061-11-1P
496061-12-2P	496061-13-3P	496061-16-6P
496061-17-7P	496061-18-8P	496061-19-9P
496061-20-2P	496061-21-3P	496061-22-4P
496061-23-5P	496061-24-6P	496061-25-7P
496061-27-3P	496061-28-0P	496061-29-1P
496061-30-4P	496061-31-5P	496061-32-6P
496061-33-7P	496061-34-8P	496061-35-9P
496061-36-0P	496061-37-1P	496061-38-2P
496061-39-3P	496061-40-6P	496061-41-7P
496061-42-8P	496061-43-9P	496061-44-0P
496061-45-1P	496061-46-2P	496061-47-3P
496061-48-4P	496061-49-5P	496061-50-8P
496061-51-9P	496061-52-0P	496061-53-1P
496061-54-2P	496061-55-3P	496061-56-4P
496061-57-5P	496061-58-6P	496061-59-7P
496061-60-0P	496061-61-1P	496061-62-2P
496061-63-3P	496061-64-4P	496061-65-5P
496061-66-6P	496061-67-7P	496061-68-8P
496061-69-9P	496061-70-2P	496061-71-3P
496061-72-4P	496061-73-5P	496061-74-6P
496061-75-7P	496061-76-8P	496061-77-9P
496061-82-6P	496061-83-7P	496061-84-8P
496061-85-9P	496061-86-0P	496061-87-1P
496061-88-2P	496061-89-3P	496061-90-6P
496061-91-7P	496061-92-8P	496061-93-9P
496061-94-0P	496061-95-1P	496061-96-2P
496061-97-3P	496061-98-4P	496061-99-5P
496062-00-1P	496062-01-2P	496062-02-3P
496062-03-4P	496062-04-5P	496062-05-6P
496062-06-7P	496062-07-8P	496062-08-9P
496062-09-0P	496062-10-3P	496062-11-4P
496062-12-5P	496062-13-6P	496062-14-7P
496062-18-1P	496062-21-6P	496062-22-7P
496062-23-8P	496062-24-9P	496062-25-0P
496062-26-1P	496062-27-2P	496062-28-3P
496062-29-4P	496062-30-7P	496062-31-8P
496062-32-9P	496062-34-1P	496062-35-2P
496062-36-3P	496062-37-4P	496062-38-5P
496062-39-6P	496062-40-9P	496062-41-0P
496062-42-1P	496062-44-3P	496062-45-4P
496062-46-5P	496062-48-7P	496062-59-0P
496062-60-3P	496062-61-4P	496062-62-5P
496062-63-6P	496062-64-7P	496062-65-8P
496062-66-9P	496062-67-0P	496062-68-1P
496062-69-2P	496062-70-5P	496062-71-6P

496062-75-7P	496062-73-8P	496062-74-9P
496062-75-0P	496062-76-1P	496062-77-2P
496062-78-3P	496062-79-4P	496062-80-7P
496062-81-8P	496062-82-9P	496062-83-0P
496062-84-1P	496062-85-2P	496062-86-3P
496062-87-4P	496062-88-5P	496062-89-6P
496062-90-9P	496062-91-0P	496062-92-1P
496063-11-7P	496063-19-5P	496063-20-8P
496063-21-9P	496063-22-0P	496063-23-1P
496063-25-3P	496063-26-4P	496063-27-5P
496063-28-6P	496063-29-7P	496063-30-0P
496063-31-1P	496063-32-2P	496063-34-4P
496063-35-5P	496063-37-7P	496063-38-8P
496063-39-9P	496063-40-2P	496063-41-3P
496063-42-4P	496063-43-5P	496063-44-6P
496063-45-7P	496063-46-8P	496063-47-9P
496063-48-0P	496063-49-1P	496063-53-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indane acetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 496060-67-4 CAPLUS


CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]-, ( $\alpha$ S,1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 496060-68-5 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 496060-69-6 CAPLUS


CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 496060-70-9 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496060-71-0 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ( $\alpha$ S,1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496060-72-1 CAPLUS


CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]-, ( $\alpha$ R,1R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 496060-73-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2-[2,3-dihydro- $\alpha$ -methyl-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496060-74-3 CAPLUS

CN Propanedioic acid, 2-[2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-1H-inden-1-yl]- (CA INDEX NAME)




RN 496060-75-4 CAPLUS

CN Propanedioic acid, 2-[2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-1H-inden-1-yl]-, 1-ethyl ester (CA INDEX NAME)



RN 496060-76-5 CAPLUS


CN 1H-Indene-1-acetic acid, 2-[2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- $\alpha$ -(3-phenylpropyl)- (CA INDEX NAME)



RN 496060-77-6 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-[5-methyl-2-(4-

methylphenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496060-78-7 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -butyl-2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496060-79-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]- $\alpha$ -(2-methylpropyl)- (CA INDEX NAME)




RN 496060-80-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]- $\alpha$ -(2-methyl-2-propen-1-yl)- (CA INDEX NAME)




RN 496060-81-2 CAPLUS

CN 1H-Indene-1-acetic acid, 6-chloro- $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496060-83-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- $\alpha$ -propyl- (CA INDEX NAME)




RN 496060-84-5 CAPLUS

CN 1H-Indene-1-acetic acid, 6-bromo- $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 496060-85-6 CAPLUS


CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-6-phenyl- (CA INDEX NAME)



RN 496060-88-9 CAPLUS


CN 1H-Indene-1-acetic acid, 6-(4-chlorophenyl)- $\alpha$ -ethyl-2,3-dihydro-5-[2-

(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496060-89-0 CAPLUS

CN 1H-Indene-1-acetic acid, α-ethyl-2,3-dihydro-6-methyl-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)




RN 496060-90-3 CAPLUS

CN 1H-Indene-1-acetic acid, α-ethyl-2,3-dihydro-6-methyl-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 496060-91-4 CAPLUS


CN 1H-Indene-1-acetic acid, α-ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-6-(2-thienyl)-, methyl ester (CA INDEX NAME)



RN 496060-92-5 CAPLUS




CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-6-(2-thienyl)- (CA INDEX NAME)




RN 496060-93-6 CAPLUS

CN 1H-Indene-1-acetic acid, 4,6-dibromo- $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)




RN 496060-94-7 CAPLUS

CN 1H-Indene-1-acetic acid, 4,6-dibromo- $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496060-95-8 CAPLUS

CN 1H-Indene-1-acetic acid, 6-acetyl- $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496060-96-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2,5-diphenyl-4-oxazolyl)ethoxy]- $\alpha$ -ethyl-2,3-dihydro-, methyl ester (CA INDEX NAME)




RN 496060-97-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2,5-diphenyl-4-oxazolyl)ethoxy]- $\alpha$ -ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496060-98-1 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-(1-methylethyl)-2-phenyl-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)




RN 496060-99-2 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-(1-methylethyl)-2-phenyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-00-8 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-5-[2-(5-ethyl-2-phenyl-4-oxazolyl)ethoxy]-2,3-dihydro-, methyl ester (CA INDEX NAME)




RN 496061-01-9 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-5-[2-(5-ethyl-2-phenyl-4-oxazolyl)ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-02-0 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)




RN 496061-03-1 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496061-04-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(2,3-dihydro-6-benzofuranyl)-5-methyl-4-oxazolyl]ethoxy]- $\alpha$ -ethyl-2,3-dihydro-, methyl ester (CA INDEX NAME)




RN 496061-05-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(2,3-dihydro-6-benzofuranyl)-5-methyl-4-oxazolyl]ethoxy]- $\alpha$ -ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-06-4 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethoxy-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496061-07-5 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(4-methyl-2-phenyl-5-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496061-08-6 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(4-methyl-2-(4-methylphenyl)-5-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496061-09-7 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(4-methyl-2-propyl-5-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496061-10-0 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-methyl-2-(phenoxyethyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 496061-11-1 CAPLUS


CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-methyl-2-(phenylmethyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 496061-12-2 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496061-13-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-α-(3-phenylpropyl)-, methyl ester (CA INDEX NAME)




RN 496061-16-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-α-methoxy-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496061-17-7 CAPLUS

CN 1H-Indene-1-acetic acid, α-ethoxy-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ethyl ester (CA INDEX NAME)




RN 496061-18-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-α-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 496061-19-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- $\alpha$ -(2,2,2-trifluoroethyl)-, ethyl ester (CA INDEX NAME)




RN 496061-20-2 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -cyclopropyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)




RN 496061-21-3 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -cyclopropyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496061-22-4 CAPLUS

CN 1,3-Benzodioxole-5-acetic acid,  $\alpha$ -[2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-1H-inden-1-yl]- (CA INDEX NAME)




RN 496061-23-5 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]- (CA INDEX NAME)




RN 496061-24-6 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 496061-25-7 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]- (CA INDEX NAME)



RN 496061-27-9 CAPLUS


CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-6-(4-methoxyphenyl)-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)






RN 496061-28-0 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-6-(4-methoxyphenyl)-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496061-29-1 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-6-(4-pyridinyl)-, methyl ester (CA INDEX NAME)




RN 496061-30-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-cyclopentyl-5-methyl-4-oxazolyl)ethoxy]- $\alpha$ -ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-31-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-cyclohexyl-5-methyl-4-oxazolyl)ethoxy]- $\alpha$ -ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-32-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)ethoxy]-α-ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-33-7 CAPLUS

CN Propanedioic acid, 2-[2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]-1H-inden-1-yl]-, 1,3-diethyl ester (CA INDEX NAME)




RN 496061-34-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]-α-(phenylmethyl)- (CA INDEX NAME)




RN 496061-35-9 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -butyl-2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]-, ethyl ester (CA INDEX NAME)




RN 496061-36-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]-, ethyl ester (CA INDEX NAME)




RN 496061-37-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]- $\alpha$ -(phenylmethyl)-, ethyl ester (CA INDEX NAME)




RN 496061-38-2 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-39-3 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-40-6 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-5-[2-[2-[(4-fluorophenyl)methyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-41-7 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-5-[2-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-42-8 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-5-[2-[2-(4-ethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-43-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(4-chlorophenoxy)methyl]-5-methyl-4-oxazolyl]ethoxy]-α-ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-44-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-α-ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-45-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-methyl-4-thiazolyl]ethoxy]-α-ethyl-2,3-dihydro-, methyl ester (CA INDEX NAME)




RN 496061-46-2 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-47-3 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]-, methyl ester (CA INDEX NAME)




RN 496061-48-4 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-49-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-butylphenyl)-5-methyl-4-oxazolyl]ethoxy]- $\alpha$ -ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-50-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]- $\alpha$ -ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-51-9 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-methyl-2-(3-methylphenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-52-0 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-53-1 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-methyl-2-(3-methyl-5-isoxazolyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-54-2 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-5-[2-[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-55-3 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-5-[2-[2-(3-fluoro-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496061-56-4 CAPLUS


CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-5-[2-[2-(4-fluoro-3-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496061-57-5 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-chlorophenyl)-5-methyl-4-thiazolyl]ethoxy]- $\alpha$ -ethyl-2,3-dihydro-, methyl ester (CA INDEX NAME)






RN 496061-58-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-α-ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-59-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-chlorophenyl)-5-methyl-4-thiazolyl]ethoxy]-α-ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-60-0 CAPLUS

CN 1H-Indene-1-acetic acid, α-ethyl-2,3-dihydro-5-[2-[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-61-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3,5-bis(trifluoromethyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-α-ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-62-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-α-ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-63-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-α-ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-64-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(2,3-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-α-ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-65-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]- $\alpha$ -ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-66-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(1,3-benzodioxol-5-yl)-5-methyl-4-oxazolyl]ethoxy]- $\alpha$ -ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-67-7 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-methyl-2-(2-thienyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-68-8 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-69-9 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-(2-methylphenyl)-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496061-70-2 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-5-[2-(2-(2-furanyl)-5-methyl-4-oxazolyl)ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-71-3 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-5-[2-(2-(2-fluorophenyl)-5-methyl-4-oxazolyl)ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-72-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-benzo[b]thien-2-yl-5-methyl-4-oxazolyl)ethoxy]- $\alpha$ -ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-73-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(2,6-difluorophenyl)-5-methyl-4-oxazolyl]ethoxy]- $\alpha$ -ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-74-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-difluorophenyl)-5-methyl-4-oxazolyl]ethoxy]- $\alpha$ -ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-75-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(2,4-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]- $\alpha$ -ethyl-2,3-dihydro- (CA INDEX NAME)




RN 496061-76-8 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-methyl-2-(1-naphthalenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 496061-77-9 CAPLUS


CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-[5-methyl-2-(1-piperidinyl)-4-thiazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 496061-82-6 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 496061-83-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-84-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-85-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-86-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-87-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-88-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-89-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-butylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-90-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(1,3-benzodioxol-5-yl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496061-91-7 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496061-92-8 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)






RN 496061-93-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-94-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-benzo[b]thien-2-yl-5-methyl-4-oxazolyl)ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-95-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-96-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-cyclopentyl-5-methyl-4-oxazolyl)ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-97-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-cyclohexyl-5-methyl-4-oxazolyl)ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-98-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(phenylmethyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-99-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-fluoro-3-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-00-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluoro-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-01-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-02-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(5-ethyl-2-phenyl-4-oxazolyl)ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-03-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-04-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(2-phenyl-5-propyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496062-05-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-06-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-07-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(3-methylphenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496062-08-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-09-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-10-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-11-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496062-12-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[5-ethyl-2-(4-ethylphenyl)-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-13-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496062-14-7 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-[5-ethyl-2-(4-methoxyphenyl)-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496062-18-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-(1-methylethyl)phenyl)-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-21-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-22-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-23-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(1,3-benzodioxol-5-yl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-24-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-25-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-26-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-cyanophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-27-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-chloro-4-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 496062-28-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 496062-29-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-30-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-31-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-acetylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-32-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(dimethylamino)phenyl]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 496062-34-1 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-amino-4-methylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 496062-33-0

CMF C24 H26 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 496062-35-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(2-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-36-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-37-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-38-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-39-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(3-methylphenyl)-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-40-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-41-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-42-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,5-dimethylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-44-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-45-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(3-methoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-46-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-thiazolyl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-48-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(4-methyl-2-phenyl-5-oxazolyl)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-59-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-(4-(trifluoromethyl)phenyl)-5-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-60-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-(4-methylphenyl)-5-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-61-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluoro-4-methylphenyl)-4-methyl-5-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-62-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-(4-methylphenyl)-5-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-63-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluoro-4-methylphenyl)-4-methyl-5-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-64-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-(4-(trifluoromethyl)phenyl)-5-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-65-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-α-methyl-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, (αR,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496062-66-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-α-methyl-, (αS,1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 496062-67-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-α-methyl-, (αR,1R)-rel- (CA INDEX NAME)

Relative stereochemistry.






RN 496062-68-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496062-69-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-70-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-[5-methyl-2-(3-methylphenyl)-4-oxazolyl]ethoxy]-, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496062-71-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]-, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496062-72-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-73-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]-, ( $\alpha$ R,1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-74-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496062-75-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496062-76-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-77-2 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ R,1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 496062-78-3 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl- (CA INDEX NAME)



RN 496062-79-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ R,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-80-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-81-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]- $\alpha$ -methyl-, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496062-82-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]- $\alpha$ -methyl-, ( $\alpha$ R,1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-83-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-84-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-butylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496062-85-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-86-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-(1,1-dimethylethyl)phenyl)-5-ethyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496062-87-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl-, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496062-88-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro- $\alpha$ -methyl-5-[2-[5-methyl-2-(4-methylphenyl)-4-thiazolyl]ethoxy]-, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496062-89-6 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(5-acetyl-2-thienyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 496062-90-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[3-(1H-indol-5-yl)phenyl]-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 496062-91-0 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 496062-92-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(5-acetyl-2-thienyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)






RN 496063-11-7 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-thiazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 496063-19-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-α-methyl- (CA INDEX NAME)




RN 496063-20-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-α-methyl-5-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496063-21-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]- $\alpha$ -methyl- (CA INDEX NAME)




RN 496063-22-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- $\alpha$ -methyl- (CA INDEX NAME)




RN 496063-23-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]- (CA INDEX NAME)




RN 496063-25-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(1,3-benzodioxol-5-yl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-26-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]- (CA INDEX NAME)




RN 496063-27-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)




RN 496063-28-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-cyanophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-29-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)




RN 496063-30-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-chloro-4-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-31-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-32-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496063-34-4 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496063-35-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-acetylphenyl)-5-methyl-4-

thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-37-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-amino-4-methylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 496063-36-6

CMF C24 H26 N2 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 496063-38-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(2-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-39-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-40-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-41-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-42-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(3-methylphenyl)-4-thiazolyl]ethoxy]- (CA INDEX NAME)




RN 496063-43-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)




RN 496063-44-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-45-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,5-dimethylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-46-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)




RN 496063-47-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(3-methoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]- (CA INDEX NAME)




RN 496063-48-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496063-49-1 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-[5-ethyl-2-(4-ethylphenyl)-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496063-53-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[4-(hydroxymethyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)





IT 496063-15-1 496063-16-2 496063-17-3


496063-16-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of indane acetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)


RN 496063-15-1 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-hydroxy-, methyl ester (CA INDEX NAME)




RN 496063-16-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ethyl ester (CA INDEX NAME)



RN 496063-17-3 CAPLUS


CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-methoxy-, methyl ester (CA INDEX NAME)



RN 496063-18-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-bromophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 80370-87-2P 162713-88-4P 496060-61-8P  
 496060-62-9P 496060-63-0P 496060-64-1P  
 496061-79-1P 496061-80-4P 496062-17-0P  
 496062-95-4P 496062-96-5P 496062-97-6P  
 496062-99-8P 496063-00-4P 496063-01-5P  
 496063-02-6P 496063-04-8P 496063-05-9P  
 496063-06-0P 496063-07-1P 496063-09-3P  
 496063-10-6P 496063-12-8P 496063-13-9P  
 496063-14-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indane acetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)


RN 80370-87-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- (CA INDEX NAME)



RN 162713-88-4 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, ethyl ester (CA INDEX NAME)



RN 496060-61-8 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-methoxy-, (aS,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496060-62-9 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-methoxy-,  
( $\alpha$ R,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496060-63-0 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-methoxy-, methyl  
ester, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496060-64-1 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-hydroxy-, methyl  
ester, ( $\alpha$ S,1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496061-79-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496061-80-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-17-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-bromo-5-methyl-4-thiazolyl)ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 496062-95-4 CAPLUS


CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-methoxy-, ( $\alpha$ S,1S)-, compd. with ( $\alpha$ R)- $\alpha$ -methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 496060-61-8

CMF C14 H18 O3

Absolute stereochemistry.



CM 2

CRN 3886-69-9

CMF C8 H11 N


Absolute stereochemistry. Rotation (+).



RN 496062-96-5 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-,  
( $\alpha$ R,1R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 496062-97-6 CAPLUS

CN Propanedioic acid, 2-(2,3-dihydro-5-hydroxy-1H-inden-1-yl)-, 1,3-diethyl  
ester (CA INDEX NAME)




RN 496062-99-8 CAPLUS

CN Propanedioic acid, 2-[2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-1H-inden-1-yl]-2-ethyl-, 1,3-diethyl ester (CA INDEX NAME)




RN 496063-00-4 CAPLUS

CN 1H-Indene-1-acetic acid, 6-chloro- $\alpha$ -ethyl-2,3-dihydro-5-hydroxy-, methyl ester (CA INDEX NAME)




RN 496063-01-5 CAPLUS

CN 1H-Indene-1-acetic acid, 6-chloro- $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 496063-02-6 CAPLUS


CN 1H-Indene-1-acetic acid, 6-bromo- $\alpha$ -ethyl-2,3-dihydro-5-hydroxy-, methyl ester (CA INDEX NAME)



RN 496063-04-8 CAPLUS


CN 1H-Indene-1-acetic acid, 6-bromo- $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-

2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)




RN 496063-05-9 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-6-phenyl-, methyl ester (CA INDEX NAME)




RN 496063-06-0 CAPLUS

CN 1H-Indene-1-acetic acid, 6-acetyl- $\alpha$ -ethyl-2,3-dihydro-5-methoxy-, methyl ester (CA INDEX NAME)




RN 496063-07-1 CAPLUS

CN 1H-Indene-1-acetic acid, 6-acetyl- $\alpha$ -ethyl-2,3-dihydro-5-hydroxy-, methyl ester (CA INDEX NAME)



RN 496063-09-3 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -ethyl-2,3-dihydro-5-[2-(4-methyl-2-phenyl-5-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 496063-10-6 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, (1S)-, compd. with ( $\alpha$ S)- $\alpha$ -methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 496061-78-0

CMF C12 H14 O3

Absolute stereochemistry.



CM 2

CRN 2627-86-3

CMF C8 H11 N

Absolute stereochemistry. Rotation (-).




RN 496063-12-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ -methyl-, methyl ester, ( $\alpha$ R,1R)-rel- (CA INDEX NAME)

Relative stereochemistry.






RN 496063-13-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy-α-methyl-, methyl ester, (αR,1R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 496063-14-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-α-methyl-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester, (αR,1R)-rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:84260 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:385146

TITLE: Cyclization procedures toward the synthesis of some

conformationally restricted nitrogen heterocycles


AUTHOR(S): Moglioni, Albertina G.; Moltrasio Iglesias, Graciela Y.

CORPORATE SOURCE: Departamento de Quimica Organica, Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, Buenos Aires, 1113, Argent.


SOURCE: Boletin de la Sociedad Chilena de Quimica ( 2002), 47(1), 25-31

CODEN: BOCQAX; ISSN: 0366-1644

PUBLISHER: Sociedad Chilena de Quimica  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 138:385146  
 AB An attempt was made to synthesize conformationally restricted nitrogen heterocycles by means of the Bischler-Napieralski reaction and Tsuda modification. Observed results prompted the authors to speculate on the nature of the effects which may be controlling such cyclization processes.  
 IT 91284-10-5  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (attempted preparation of conformationally restricted nitrogen heterocycles via use of cyclodehydrating reagent)  
 RN 91284-10-5 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy-, ethyl ester (CA INDEX NAME)



IT 62956-65-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (attempted preparation of conformationally restricted nitrogen heterocycles via use of cyclodehydrating reagent)  
 RN 62956-65-4 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:23109 CAPLUS Full-text  
 DOCUMENT NUMBER: 138:86096  
 TITLE: Identification of interacting molecules using nonnucleic acid target molecules and structurally similar molecules lacking target molecule activity  
 INVENTOR(S): James, Robert; Eddie, Lawrence; Kazenwadel, Jan; O'Connor, Susan; Razzino, Pasquale; Ward, David  
 PATENT ASSIGNEE(S): Medimolecular Pty. Ltd., Australia  
 SOURCE: PCT Int. Appl., '72 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003003012	A1	20030109	WO 2002-AU856	20020628 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU 2002315567 A1 20030303 AU 2002-315567 20020628 <-- PRIORITY APPLN. INFO.: AU 2001-5986 A 20010629 <-- WO 2002-AU856 W 20020628 <--				


OTHER SOURCE(S): MARPAT 138:86096

AB The present invention provides a method for identifying a protein capable of binding to a specific target mol. The method involves allowing candidate proteins to bind to the target mol. in the presence of a second mol. which is structurally similar to the non-nucleic acid target mol., but deficient in a desired activity of the target mol., and isolating the proteins that bind to the target mol. The invention also provides analogs of flurbiprofen and sulindac as target mols. for use in the methods of the invention.

IT 482294-42-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (in preparation of analog of sulindac sulfide; identification of interacting mols. using nonnucleic acid target mols. and structurally similar mols. lacking target mol. activity)

RN 482294-42-8 CAPLUS

CN 1H-Indene-1-acetic acid, 6-[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-fluoro-2,3-dihydro-1-hydroxy-2-methyl-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:864384 CAPLUS Full-text

DOCUMENT NUMBER: 137:346209

TITLE: Methods for treatment of type I diabetes

INVENTOR(S): Whitehead, Clark M.; Earle, Keith A.; Alila, Hector W.; Thompson, W. Joseph

PATENT ASSIGNEE(S): Cell Pathways, Inc., USA

SOURCE: U.S., 42 pp.  
 CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6479493	B1	20021112	US 2001-935802	20010823 <--
WO 2003017925	A2	20030306	WO 2002-US25524	20020809 <--
WO 2003017925	A3	20040311		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002327440	A1	20030310	AU 2002-327440	20020809 <--
EP 1435962	A2	20040714	EP 2002-763431	20020809 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			

PRIORITY APPLN. INFO.: US 2001-935802 A 20010823 <--  
WO 2002-US25524 W 20020809 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB Substituted condensation products of -benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of type I diabetes.

IT 454453-17-9

RL: PRPH (Prophetic)  
(Methods for treatment of type I diabetes)

RN 454453-17-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-1-hydroxy-6-methoxy- $\alpha$ ,2-dimethyl-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:690155 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 137:232486

TITLE: Synthesis of combinatorial libraries of compounds reminiscent of natural products

INVENTOR(S): Schreiber, Stuart L.; Shair, Matthew D.; Tan, Derek S.; Foley, Michael A.; Stockwell, Brent R.

PATENT ASSIGNEE(S): President and Fellows of Harvard College, USA

SOURCE: U.S., 129 pp., Cont.-in-part of U.S. Ser. No. 951,930.

CODEN: USXXAM

DOCUMENT TYPE: Patent


LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6448443	B1	20020910	US 1998-121922	19980725 <--
WO 2000006525	A2	20000210	WO 1999-US16753	19990722 <--
WO 2000006525	A3	20001116		
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9953200	A	20000221	AU 1999-53200	19990722 <--
US 20030082830	A1	20030501	US 2002-185364	20020627 <--
US 7109377	B2	20060919		

PRIORITY APPLN. INFO.:


US 1996-29128P	P	19961016 <--
US 1997-49864P	P	19970606 <--
US 1997-951930	A2	19971015 <--
US 1998-121922	A	19980725 <--
WO 1999-US16753	W	19990722 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): CASREACT 137:232486; MARPAT 137:232486  
 GI



AB The present invention provides complex compds., e.g., I [R1, R2, R4 - R8, R10-R12, R14 - R18, X = H, linear or branched (un)substituted alkyl, aryl, alkenyl, aminoalkyl, acylamino, acyloxy, alkoxycarbonyl, alkoxy, alkylaryl, hydroxyalkyl, thioalkyl, acyl, NH2, OH, SH, aryloxy, alkylthio, arylalkoxy, alkynyl, halogen, CN, CONH2, NO2, CF3, phosphine, heterocycle; R2R3 = O, NO; R3 = OR16; R8R9 = epoxide; R9 = OR17; R12R13 = O ( $\gamma$ -lactone); R13 = OR18, NHR18], reminiscent of natural products and libraries thereof, as well as methods for their production. The inventive compds. and libraries of compds. are reminiscent of natural products in that they contain one or more stereocenters, and a high d. and diversity of functionality. In general, the inventive libraries are synthesized from diversifiable scaffold structures, which are synthesized from readily available or easily synthesizable template structures. In certain embodiments, the inventive compds. and libraries are generated from diversifiable scaffolds synthesized from a shikimic acid based epoxyl template. In other embodiments, the inventive compds. and libraries are generated from diversifiable scaffolds synthesized from the pyridine-based template isonicotinamide. The present invention also provides a novel ortho-nitrobenzyl photolinker and a method for its synthesis. Furthermore, the present invention provides methods and kits for determining one or more biol. activities of members of the inventive libraries. Addnl., the present invention provides pharmaceutical compns. containing one or more library members.

IT 24467-92-3, 5-Methoxy-1-indanone-3-acetic acid  
 RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)  
 (claimed reactant for hydroxyamide intermediate; synthesis of combinatorial libraries of compds. reminiscent of natural products)  
 RN 24467-92-3 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:675836 CAPLUS Full-text

DOCUMENT NUMBER: 137:201337

TITLE: Methods for treatment of inflammatory bowel disease and preparation of indenylacetamides for said treatment

INVENTOR(S): Earle, Keith A.; Alila, Hector W.; Whitehead, Clark M.

PATENT ASSIGNEE(S): Cell Pathways, Inc., USA

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002067936	A1	20020906	WO 2002-US4831	20020220 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002240410	A1	20020912	AU 2002-240410	20020220 <--
US 6699894	B1	20040302	US 2002-252286	20020923 <--
PRIORITY APPLN. INFO.:			US 2001-789848	A 20010221 <--
			WO 2002-US4831	W 20020220 <--

OTHER SOURCE(S): MARPAT 137:201337

AB Claimed is a method of treating inflammatory bowel disease in a mammal with that disease comprising administering to the mammal a physiologically effective amount of an inhibitor of both PDE2 and PDE5. (Z)-5-Fluoro-2-methyl-(4-pyridylidene)-3-(N-benzyl)indenylacetamide hydrochloride (I) was prepared I

had an IC50 value of 14  $\mu$ M for PDE2 and IC50 value of 4  $\mu$ M for PDE5. The inflammatory bowel disease in humans is quite similar to the inflammatory bowel disease (IBD) in dogs. In fact, the IBD treatments in dogs are very similar to those in humans, and the success rates are similarly disappointing; the number of dogs with IBD is estimated to be in the millions in the U.S. Hence for proof of principle for both humans and animals, the authors commenced a trial involving I in seven dogs. A female 10 1/2 yr-old English sheepdog was near death after a 4-mo history of severe IBD. During 6 wk of combined conventional therapy and I (800 mg bid) followed by 6 wk of I (800 mg bid) alone, the dog steadily improved and became clin. normal.


IT 27961-10-0P 454453-17-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; methods for treatment of inflammatory bowel disease and preparation of indenylacetamides for said treatment in both human and veterinary medicine)


RN 27961-10-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-1-hydroxy-6-methoxy-2-methyl-, ethyl ester (CA INDEX NAME)



RN 454453-17-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-1-hydroxy-6-methoxy- $\alpha$ ,2-dimethyl-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:608506 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 137:294752

TITLE: Synthesis of a Novel Series of Benzocycloalkene

Derivatives as Melatonin Receptor Agonists


AUTHOR(S): Fukatsu, Kohji; Uchikawa, Osamu; Kawada, Mitsuru; Yamano, Toru; Yamashita, Masayuki; Kato, Koki; Hirai, Keisuke; Hinuma, Shuji; Miyamoto, Masaomi; Ohkawa, Shigenori

CORPORATE SOURCE: Pharmaceutical Research Division, Takeda Chemical Industries Ltd., Osaka, 532-8686, Japan

SOURCE: Journal of Medicinal Chemistry (2002),

45(19), 4212-4221  
 CODEN: JMCMAR; ISSN: 0022-2623  
 American Chemical Society  
 Journal  
 English  
 CASREACT 137:294752

PUBLISHER:  
 DOCUMENT TYPE:  
 LANGUAGE:  
 OTHER SOURCE(S):  
 GI



AB A novel series of amidoalkyl-substituted benzocycloalkanes, e.g. I (R1 = H, Me, Et, Pr, Me2CH; R2 = H, Me, MeO; R3 = H, Ph, PhCH2; R4 = Me, F3C, Et, Pr, Me2CH, 4-BrC6H4; n, m = 1-3), was prepared and their binding affinities to melatonin receptors were evaluated. To control the spatial position of the amide group, one of the important pharmacophores, an endo double bond, an exo double bond (E- and Z-configurations), and a chiral center (R- and S-configurations) were incorporated at position 1. The indan derivs. with the S-configuration at position 1 were the most promising in terms of potency and selectivity for the human melatonin receptor (MT1 site), while compds. with the R-configuration showed little potential. The most favorable conformation of the methoxy group, the other important pharmacophore for binding to the MT1 receptor, was also investigated. The introduction of a Me group at position 5 of the indene ring conserved affinity; however, at position 7, it caused a decrease in affinity. These results suggested that the substitution at position 7 forced the methoxy group to adopt an unfavorable orientation. The optimization of the condensed ring size and substituents led to (S)-I [R1 = Me, R2 = R3 = H, R4 = Et, n = 1, m = 2; (II)], which had high affinity for the human MT1 receptor (Ki = 0.041 nM) but no significant affinity for the hamster MT3 receptor (Ki = 3570 nM). In addition, a practical synthetic method of chiral II and its (R)-isomer employing asym. hydrogenation with (S)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl-Ru was established.


IT 91284-09-2F

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(multi-step preparation of (amidopropyl)indan as melatonin receptor agonist via reduction of (indanyl)acetate, bromination of (indanyl)ethanol, and cyanation of (indanyl)bromoethane)

RN 91284-09-2 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-, ethyl ester (CA INDEX NAME)





OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)  
 REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:510485 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 137:370343  
 TITLE: N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): in vitro and in vivo activities  
 AUTHOR(S): Inguibert, Nicolas; Poras, Herve; Teffo, Franck; Beslot, Francoise; Selkti, Mohamed; Tomas, Alain; Scalbert, Elizabeth; Bennejean, Caroline; Renard, Pierre; Fournie-Zaluski, Marie-Claude; Roques, Bernard-Pierre  
 CORPORATE SOURCE: Departement de Pharmacochimie Moleculaire Structurale, UFR Sciences Pharmaceutiques et Biologiques, Paris, 75270, Fr.  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(15), 2001-2005  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 137:370343  
 GI




AB We have previously reported the design of a lead compound for the joint inhibition of neprilysin (NEP, EC 3.4.24.11), angiotensin converting enzyme (ACE, EC 3.4.15.1) and endothelin converting enzyme (ECE-1, EC 3.4.24.71), three metallopeptidases which are implicated in the regulation of fluid homeostasis and vascular tone. We report here the synthesis and biol. activities of analogs derived from this lead with inhibitory potencies in the nanomolar range for the three enzymes. Compds. (I) and (II) are the most potent triple inhibitors described to date.

IT 475475-79-7P 475475-80-0P 475475-82-2P  
 475475-83-3P 475475-84-4P 475475-85-5P  
 475475-88-8P 475476-06-3P 475476-07-4P  
 475476-09-6P 475476-10-9P 475476-11-0P  
 475476-12-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction of in the preparation of dipeptide simultaneous neprilysin, angiotensin converting enzyme, and endothelin converting enzyme inhibitors)


RN 475475-79-7 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -(diethoxyphosphinyl)-2,3-dihydro-5-methoxy-, ethyl ester (CA INDEX NAME)




RN 475475-80-0 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -(diethoxyphosphinyl)-2,3-dihydro-5-(methylthio)-, ethyl ester (CA INDEX NAME)




RN 475475-82-2 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -(diethoxyphosphinyl)-5-ethoxy-2,3-dihydro-, ethyl ester (CA INDEX NAME)




RN 475475-83-3 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -(diethoxyphosphinyl)-2,3-dihydro-5,6-dimethoxy-, ethyl ester (CA INDEX NAME)




RN 475475-84-4 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -(diethoxyphosphinyl)-2,3-dihydro-4-methoxy-, ethyl ester (CA INDEX NAME)




RN 475475-85-5 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -(diethoxyphosphinyl)-2,3-dihydro-6-methoxy-, ethyl ester (CA INDEX NAME)




RN 475475-88-8 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -[(acetylthio)methyl]-2,3-dihydro-5-hydroxy-, ethyl ester (CA INDEX NAME)




RN 475476-06-3 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -[(acetylthio)methyl]-2,3-dihydro-5-methoxy-, ethyl ester (CA INDEX NAME)




RN 475476-07-4 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -[(acetylthio)methyl]-2,3-dihydro-5-(methylthio)- (CA INDEX NAME)




RN 475476-09-6 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -[(acetylthio)methyl]-5-ethoxy-2,3-dihydro- (CA INDEX NAME)




RN 475476-10-9 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -[(acetylthio)methyl]-2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)




RN 475476-11-0 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -[(acetylthio)methyl]-2,3-dihydro-4-methoxy- (CA INDEX NAME)



RN 475476-12-1 CAPLUS  
 CN 1H-Indene-1-acetic acid,  $\alpha$ -[(acetylthio)methyl]-2,3-dihydro-6-methoxy- (CA INDEX NAME)




OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)  
 REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 23 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:293637 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 136:325563  
 TITLE: Preparation of aryl-indane compounds as inhibitors of P-glycoprotein-mediated transport  
 INVENTOR(S): Melikian-Badalian, Anita  
 PATENT ASSIGNEE(S): Avlan Limited, UK  
 SOURCE: PCT Int. Appl., 87 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030915	A2	20020418	WO 2001-US32017	20011011 <--
WO 2002030915	A3	20030327		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002024372	A	20020422	AU 2002-24372	20011011 <--
US 20020128231	A1	20020912	US 2001-976929	20011011 <--
PRIORITY APPLN. INFO.:			US 2000-240345P	P 20001011 <--
			WO 2001-US32017	W 20011011 <--


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): MARPAT 136:325563  
 GI



- AB The title compds. [I; R1, R2 = OR9, NR10R11; R3-R8 = H, alkyl, Ph, etc.; R9 = alkylene, alkenylene, alkylidene, etc., all of which may be (un)substituted; R10, R11 = alkylene, alkenylene, phenylene, etc., all of which may be (un)substituted; X, Y = CH2, CO, CH2SO2, etc.] which may be used as inhibitors of P-glycoprotein-mediated transport, were prepared Thus, reacting 1-carboxymethyl-3-(3,4-dimethoxyphenyl)-5,6-dimethoxyindan-2-carboxylic acid with 4-benzylpiperidine in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.HCl, Et3N and dimethylaminopyridine in THF afforded 37% I [X = CH2CO; Y = CO; R1, R2 = 4-benzylpiperidin-1-yl; R3 = 5-MeO; R4 = 6-MeO; R5 = H; R6 = 3-MeO; R7 = 4-MeO; R8 = H] which showed 81.4% inhibition of Rhodamine 123 transport. Use of the compds. I to enhance bioavailability and to modulate multi-drug resistance to chemotherapeutic agents is disclosed.
- IT 53669-41-3 412315-93-6 412315-94-7  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of aryl-indane compds. as inhibitors of P-glycoprotein-mediated transport)
- RN 53669-41-3 CAPLUS
- CN 1H-Indene-1-acetic acid, 2-carboxy-3-(3,4-dimethoxyphenyl)-2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)




- RN 412315-93-6 CAPLUS
- CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-6-methoxy-2-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)



RN 412315-94-7 CAPLUS

CN 1H-Indene-1-acetic acid, 3-(3,4-dimethoxyphenyl)-2,3-dihydro-5,6-dimethoxy-2-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)



IT 412315-52-7P 412315-53-8P 412315-55-0P

412315-57-2P 412315-58-3P 412315-60-7P

412315-61-8P 412315-63-0P 412315-64-1P

412315-72-1P 412315-73-2P 412315-78-7P


412315-80-1P 412315-82-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aryl-indane compds. as inhibitors of P-glycoprotein-mediated transport)



RN 412315-52-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-2-(methoxycarbonyl)-3-[3-methoxy-4-(phenylmethoxy)phenyl]-5-(phenylmethoxy)-, methyl ester (CA INDEX NAME)





RN 412315-53-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2-carboxy-2,3-dihydro-6-methoxy-3-[3-methoxy-4-(phenylmethoxy)phenyl]-5-(phenylmethoxy)- (CA INDEX NAME)




RN 412315-55-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2-carboxy-2,3-dihydro-5-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-6-methoxy- (CA INDEX NAME)





RN 412315-57-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-ethoxy-3-(4-ethoxy-3-methoxyphenyl)-2,3-dihydro-6-methoxy-2-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)



RN 412315-58-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2-carboxy-5-ethoxy-3-(4-ethoxy-3-methoxyphenyl)-2,3-dihydro-6-methoxy- (CA INDEX NAME)




RN 412315-60-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-butoxy-3-(4-butoxy-3-methoxyphenyl)-2,3-dihydro-





6-methoxy-2-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)




RN 412315-61-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-butoxy-3-(4-butoxy-3-methoxyphenyl)-2-carboxy-2,3-dihydro-6-methoxy- (CA INDEX NAME)





RN 412315-63-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-(decyloxy)-3-[4-(decyloxy)-3-methoxyphenyl]-2,3-dihydro-6-methoxy-2-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)




RN 412315-64-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2-carboxy-5-(decyloxy)-3-[4-(decyloxy)-3-methoxyphenyl]-2,3-dihydro-6-methoxy- (CA INDEX NAME)





RN 412315-72-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-2-(methoxycarbonyl)-3-(3-methoxy-4-propoxyphenyl)-5-propoxy-, methyl ester (CA INDEX NAME)





RN 412315-73-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2-carboxy-2,3-dihydro-6-methoxy-3-(3-methoxy-4-propoxyphenyl)-5-propoxy- (CA INDEX NAME)





RN 412315-78-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2-carboxy-3-(3,4-diethoxyphenyl)-5,6-diethoxy-2,3-dihydro- (CA INDEX NAME)





RN 412315-80-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2-carboxy-3-(3,4-dipropoxyphenyl)-2,3-dihydro-5,6-dipropoxy- (CA INDEX NAME)



RN 412315-82-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5,6-dibutoxy-2-carboxy-3-(3,4-dibutoxyphenyl)-2,3-dihydro- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)


REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:240734 CAPLUS Full-text  
 DOCUMENT NUMBER: 136:263104  
 TITLE: Preparation of isoquinolinone compounds as potassium channel inhibitors  
 INVENTOR(S): Claremon, David A.; McIntyre, Charles J.; Liverton, Nigel J.  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 96 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024655	A1	20020328	WO 2001-US29013	20010917 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2421819	A1	20020328	CA 2001-2421819	20010917 <--
AU 2002012969	A	20020402	AU 2002-12969	20010917 <--
EP 1322619	A1	20030702	EP 2001-981316	20010917 <--
EP 1322619	B1	20080123		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509868	T	20040402	JP 2002-529068	20010917 <--
AU 2002212969	B2	20060706	AU 2002-212969	20010917 <--
AT 384701	T	20080215	AT 2001-981316	20010917 <--
US 20040044030	A1	20040304	US 2003-362484	20030225 <--
US 6870055	B2	20050322		

PRIORITY APPLN. INFO.: US 2000-234389P P 20000920 <--  
 WO 2001-US29013 W 20010917 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): MARPAT 136:263104  
 GI



I



II

AB Isoquinolinone compds. of formula I [R1 = H, alkoxy, perfluoroalkyl, perfluoroalkoxy, halo; R2 = alkyl, etc.; R3 = (substituted) NH2, heterocyclyl,

aminoacyl, etc.; R4, R5 = H, alkyl, cycloalkyl, halo, perfluoroalkyl; R4R5 = cycloalkyl; n = 1-3] are prepared. The compds. are inhibitors of voltage-dependent potassium channels or currents, such as Kv1.5 and IKur, that could serve as targets for the treatment of cardiac arrhythmias especially atrial arrhythmias (no data). Thus, II hydrochloride was prepared by cyclization of 2-benzyl-4-methoxy-N-methylbenzamide (preparation given) with acetyl chloride, then bromination and addition of dimethylamine.


IT 24467-92-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of isoquinolinone compds. as potassium channel inhibitors)

RN 24467-92-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)  
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:925731 CAPLUS Full-text

DOCUMENT NUMBER: 139:6704

TITLE: Dimerisations of cinnamates using acidic and acidic/oxidative conditions. [Erratum to document cited in CA136:37435]

AUTHOR(S): Pelter, Andrew; Ward, Robert S.; Venkateswarlu, Reveru; Kamakshi, Chakicherla; Moinuddin, Syed G. A.; Subhash, Pithani V.; Hursthouse, Michael B.; Coles, Simon J.; Light, Mark E.

CORPORATE SOURCE: Department of Chemistry, University of Wales Swansea, Swansea, SA2 8PP, UK

SOURCE: Tetrahedron (2002), 58(1), 205

CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The corresponding authors should have appeared as Andrew Pelter and Reveru Venkateswarlu.


IT 380153-10-6P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and mol. structure (Erratum))

RN 380153-10-6 CAPLUS

CN 1H-Indene-1-acetic acid, 3-(3,4-dimethoxyphenyl)-2,3-dihydro-5,6-dimethoxy-2-(methoxycarbonyl)-, methyl ester, (1R,2R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L4 ANSWER 26 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:818769 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 136:102269

TITLE: Synthesis and Structure-Activity Relationships of  
N-(1-Benzylpiperidin-4-yl)arylacетamide Analogues as  
Potent  $\sigma_1$  Receptor Ligands

AUTHOR(S): Huang, Yunsheng; Hammond, Philip S.; Wu, Li; Mach,  
Robert H.

CORPORATE SOURCE: Department of Radiology and Department of Physiology  
and Pharmacology, Wake Forest University School of  
Medicine, Winston-Salem, NC, 27157, USA

SOURCE: Journal of Medicinal Chemistry (2001),  
44(25), 4404-4415

CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:102269

GI



AB A series of N-(1-benzylpiperidin-4-yl)arylacетamides (I) were synthesized and evaluated for their binding properties for  $\sigma_1$  and  $\sigma_2$  receptors. In agreement with previously reported  $\sigma_1/\sigma_2$  receptor binding data for N-(1-benzylpiperidin-4-yl)phenylacetamide, all of the N-(1-benzylpiperidin-4-yl)arylacетamide compds. reported below displayed higher affinity for  $\sigma_1$  vs  $\sigma_2$  receptors. Replacement of the Ph ring of the phenylacetamide moiety with a thiophene, naphthyl, or indole aromatic ring had no significant effect on the  $\sigma_1$  receptor affinity. Replacement of the Ph ring with an imidazole or pyridyl aromatic ring resulted in a >60-fold loss in affinity for  $\sigma_1$  receptors and no significant binding affinity for  $\sigma_2$  receptors. Substitution on the aromatic ring of the benzyl group showed a similar or slightly decreased affinity for  $\sigma_1$  receptors. Substitution on the aromatic rings of both the phenylacetamide moiety and the benzyl group with a halogen resulted in a similar affinity for


$\sigma 1$  receptors and a significantly increased affinity for  $\sigma 2$  receptors. Comparative mol. field anal. revealed that electrostatic properties of the substituents in the phenylacetamide aromatic ring strongly influenced binding to  $\sigma 1$  receptors. I [R = 2-thienyl, 3-indolyl, R1 = H; R = Ph, R1 = 3-F, 4-I; R = 3-FC6H4, R1 = 4-I; R = 3-ClC6H4, R1 = 4-F] showed the highest selectivity for  $\sigma 1$  receptors with Ki ( $\sigma 2$ ) to Ki ( $\sigma 1$ ) ratios of 100, >92, >122, 77, 74, and 80, resp. In agreement with previously reported results, the phenylacetamide analogs had no binding affinity for dopamine receptors (D2/D3).

IT 24467-92-3

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation and structure-activity relationships of  
N-(1-benzylpiperidin-4-yl)arylacetamides as potent  $\sigma 1$  receptor  
ligands)

RN 24467-92-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)  
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:629482 CAPLUS Full-text

DOCUMENT NUMBER: 136:37435

TITLE: Dimerisations of cinnamates using acidic and acidic/oxidative conditions

AUTHOR(S): Pelter, A.; Ward, R. S.; Venkateswarlu, R.; Kamakshi, C.; Moinuddin, S. G. A.; Subhash, P. V.; Hursthouse, M. B.; Coles, S. J.; Light, M. E.

CORPORATE SOURCE: Department of Chemistry, University of Wales Swansea, Swansea, SA2 8PP, UK

SOURCE: Tetrahedron (2001), 57(36), 7755-7763  
CODEN: TETRA; ISSN: 0040-4020

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:37435

AB It is confirmed that the dimerization of Me dialkoxycinnamates in acidic conditions yields trisubstituted indanes. When the reactions are carried out for 1.5 h/0°C in acidic conditions in the presence of DDQ then a variety of lignan types result, two of which represent new classes of lignans.


IT 380153-10-6F

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(preparation and mol. structure)

RN 380153-10-6 CAPLUS

CN 1H-Indene-1-acetic acid, 3-(3,4-dimethoxyphenyl)-2,3-dihydro-5,6-dimethoxy-2-(methoxycarbonyl)-, methyl ester, (1R,2R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)  
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 28 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2001:241752 CAPLUS Full-text  
DOCUMENT NUMBER: 134:266206  
TITLE: Preparation of  
11-piperidinylbenzo[5,6]cyclohepta[1,2-b]pyridines and  
related compounds as inhibitors of farnesyl protein  
transferase.  
INVENTOR(S): Remiszewski, Stacy W.; Doll, Ronald J.; Alvarez,  
Carmen; Lalwani, Tarik  
PATENT ASSIGNEE(S): Schering Corporation, USA  
SOURCE: U.S., 57 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6211193	B1	20010403	US 1998-94720	19980615 <--
US 20010007870	A1	20010712	US 2001-768918	20010124 <--
US 6410541	B2	20020625		


PRIORITY APPLN. INFO.: US 1997-49953P P 19970617 <--  
US 1998-94720 A3 19980615 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OTHER SOURCE(S): MARPAT 134:266206  
GI





I




II

AB The title compds. [I; A = N, NO; R1, R3 = halo; R2, R4 = H, halo provided that  $\geq 1$  = H; X = C, CH, N; R = substituted cycloalkyl, heterocycloalkyl; dotted lines = optional double bonds; m = 0-2; R = substituted cyclobutyl(idene), cyclopentyl(idene), cyclohexyl(idene), indanyl(idene), azetidiny, piperidiny, etc.], were prepared Thus, tested I including title compound (II) inhibited farnesyl protein transferase with IC50's in the range 1.9 nM to 170 nM.

IT 24467-92-3, 5-Methoxy-1-indanone-3-acetic acid  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of 11-piperidinybenzo[5,6]cyclohepta[1,2-b]pyridines and related compds. as inhibitors of farnesyl protein transferase)

RN 24467-92-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:162869 CAPLUS Full-text

DOCUMENT NUMBER: 134:347956

TITLE: Design, syntheses, and structure-activity relationships of indan derivatives as endothelin antagonists; new lead generation of non-peptidic antagonist from peptidic leads

AUTHOR(S): Morimoto, H.; Fukushima, C.; Yamauchi, R.; Hosino, T.; Kikkawa, K.; Yasuda, K.; Yamada, K.

CORPORATE SOURCE: Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd, Toda-shi, Saitama, 335-8505, Japan

SOURCE: Bioorganic & Medicinal Chemistry (2001), 9(2), 255-268

PUBLISHER: CODEN: BMECEP; ISSN: 0968-0896

DOCUMENT TYPE: Elsevier Science Ltd.


Journal

LANGUAGE: English  
OTHER SOURCE(S): CASREACT 134:347956

AB A new lead generation of non-peptidic ETA antagonists from two peptidic ETA-selective ones, BQ-123 and FR139317, was performed. Using computer assisted mol. modeling, a putative pharmacophore was constructed from the superposition of the reported three-dimensional structure of the cyclic peptide BQ-123 and a presumable  $\beta$ -turn active conformation of the linear peptide FR139317 formed by an intramol. hydrogen bond. According to this model, a new series of indan derivs. were designed and synthesized. Among these, 5-isobutyltrylamino-6-(1-naphthylmethoxy)-3-(2-thienyl)-1-indancarboxylic acid showed a moderate ETA antagonistic activity (IC<sub>50</sub>=28  $\mu$ M).


IT 329309-82-9F  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation and structure-activity relationships of indan derivs. as endothelin antagonists)

RN 339309-82-9 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[(2-methyl-1-oxopropyl)amino]-6-(1-naphthalenylmethoxy)-3-(2-thienyl)- (CA INDEX NAME)



IT 339309-66-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and structure-activity relationships of indan derivs. as  
endothelin antagonists)

RN 339309-66-9 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[(2-methyl-1-oxopropyl)amino]-6-(1-naphthalenylmethoxy)-3-(2-thienyl)-, methyl ester (CA INDEX NAME)




OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
(5 CITINGS)

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 30 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2000:842163 CAPLUS Full-text  
 DOCUMENT NUMBER: 134:17729  
 TITLE: Preparation of substituted  $\beta$ -alanine derivatives  
 as cell adhesion inhibitors  
 INVENTOR(S): Durette, Philippe L.; Hagmann, William K.; Kopka, Thor  
 E.; Maccoss, Malcolm; Mills, Sander G.; Mumford,  
 Richard A.; Magriotis, Plato A.  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 96 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000071572	A1	20001130	WO 2000-US14017	20000519 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GE, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6645939	B1	20031111	US 1999-317789	19990524 <--
PRIORITY APPLN. INFO.:			US 1999-317789	A2 19990524 <--
			US 1997-66484P	P 19971124 <--
			US 1998-198680	B2 19981124 <--
OTHER SOURCE(S):	MARPAT 134:17729			

GI



AB  $\beta$ -Alanine derivs. I [the ring system containing A-B-Z and R4-R6 is azetidine, oxazolidine, or thiazolidine; X = CO<sub>2</sub>H, PO<sub>3</sub>H<sub>2</sub>, PH(O)OH, SO<sub>2</sub>H, SO<sub>3</sub>H or their derivs., esters or amides, 5-tetrazolyl; Y = CO, OCO, NHCO, SO<sub>2</sub>, etc.; R1 = (un)substituted alkyl, alkenyl, alkynyl, Cy (Cy = cycloalkyl, heterocyclyl, aryl, heteroaryl), Cy-alkyl, -alkenyl, or -alkynyl; R2 = H, (un)substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl; R3 = H, (un)substituted alkyl, Cy, Cy-alkyl; R7-R10 = H, alkyl, alkenyl, alkynyl, etc.] were prepared as antagonists of VLA-4 and/or  $\alpha 4 \beta 7$  and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. Thus, N-(3,5-dichlorobenzenesulfonyl)-2(S)-prolyl-3(R)-amino- 3-

(4-trifluoromethoxyphenyl)propionic acid was prepared by coupling of N-(3,5-dichlorobenzenesulfonyl)-L-proline with 3(R)-amino-3-(4-trifluoromethoxyphenyl)propionic acid Et ester acetate (synthesis given), followed by saponification

IT 309977-21-7P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted  $\beta$ -alanine derivs. as cell adhesion inhibitors)

RN 309977-21-7 CAPLUS

CN 1H-Indene-1-acetic acid, 1-[[[(2S)-1-[(3,5-dichlorophenyl)sulfonyl]-2-pyrrolidinyl]carbonyl]amino]-2,3-dihydro-6-methoxy-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)  
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:323639 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 133:129508

TITLE: Indeno[1,2-b]pyrazine-2,3-diones: A New Class of Antagonists at the Glycine Site of the NMDA Receptor with Potent in Vivo Activity

AUTHOR(S): Jimonet, Patrick; Ribeill, Yves; Bohme, Georg Andreas; Boireau, Alain; Cheve, Michel; Damour, Dominique; Doble, Adam; Genevois-Borella, Arielle; Herman, Frederic; Imperato, Assunta; Le Guern, Sylvain; Manfre, Franco; Pratt, Jeremy; Randle, John C. R.; Stutzmann, Jean-Marie; Mignani, Serge

CORPORATE SOURCE: Department of Medicinal Chemistry, CNS Program Aventis Pharma S.A. Centre de Recherche de Vitry-Alfortville, Vitry-sur-Seine, 94403, Fr.

SOURCE: Journal of Medicinal Chemistry (2000), 43(12), 2371-2381

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Indeno[1,2-b]pyrazine-2,3-diones have been identified as a novel series of potent ligands on the glycine site of the NMDA receptor. To improve their in vivo activities, an acetic acid-type side chain was introduced to the 5-position, giving water-soluble compds. when formulated as the sodium salt (>10

mg/mL). Introduction of a chlorine atom in the 8-position led to a dramatic improvement of anticonvulsant activity, and this was surprising since this change did not improve binding affinity. A plausible explanation is a reduced recognition by a Na<sup>+</sup>,K<sup>+</sup>-ATPase active transport system responsible for the excretion of these compds. from the brain and kidney. This promising new chemical series led to the optically active isomer (-)-(8-chloro-5-methyl-2,3-dioxo-1,4-dihydro-5H-indeno[1,2-b]pyrazin-5-yl)acetic acid (RPR 118723), a glycine/NMDA antagonist with nanomolar binding affinity and in vivo activity in an animal model of convulsions and electrophysiol. at doses in the range of 2-3 mg/kg following iv administration.

IT 286959-33-9P 286959-91-9P 286959-99-7P


286960-08-5P 286960-16-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of; in indeno[1,2-b]pyrazine-2,3-dione derivative synthesis as a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity)


RN 286959-83-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-1-methyl-3-oxo-5-(trifluoromethoxy)- (CA INDEX NAME)




RN 286959-91-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-1-methyl-3-oxo-5-(trifluoromethoxy)-, ethyl ester (CA INDEX NAME)




RN 286959-99-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-2-(hydroxyimino)-1-methyl-3-oxo-5-(trifluoromethoxy)-, ethyl ester (CA INDEX NAME)




RN 286960-08-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2-amino-2,3-dihydro-1-methyl-3-oxo-5-(trifluoromethoxy)-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 286960-16-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2-[(2-ethoxy-2-oxoacetyl)amino]-2,3-dihydro-1-methyl-3-oxo-5-(trifluoromethoxy)-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)  
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 32 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:161128 CAPLUS Full-text

DOCUMENT NUMBER: 132:194288

TITLE: Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity

INVENTOR(S): Tang, Peng Cho; Miller, Todd Anthony; Sun, Li; Tran, Ngoc My; Nematala, Asaad; Nguyen, Anh Thi  
Sugen, Inc., USA

PATENT ASSIGNEE(S):  
SOURCE: PCT Int. Appl., 131 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012084	A1	20000309	WO 1999-US19948	19990830 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


CA 2342222	A1	20000309	CA 1999-2342222	19990830 <--
EP 1117397	A1	20010725	EP 1999-945362	19990830 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002523455	T	20020730	JP 2000-567201	19990830 <--
US 6525072	B1	20030225	US 1999-385974	19990830 <--
US 20030199510	A1	20031023	US 2003-342194	20030115 <--
US 6642251	B2	20031104		

PRIORITY APPLN. INFO.:  
 US 1998-98660P P 19980831 <--  
 US 1999-385974 A3 19990830 <--  
 WO 1999-US19948 W 19990830 <--


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 132:194288

GI



I




II

AB The invention relates to novel geometrically restricted 2-indolinones I and physiol. acceptable salts thereof [wherein R1 = H, alkyl, cycloalkyl, aryl, OH, alkoxy, amido, etc.; A, B, D, E = C, N; F, G, J, K = C, N, O, S, with provisos; R2-R9 = H, alkyl, trihaloalkyl, aryl, heteroaryl, OH, aryloxy, cyano, NO2, etc., or may combine as OCH2O or OCH2CH2O; R10 = H, alkyl, halo, cyano, OH, alkoxy, acyloxy, amino, etc.; n = 0, 1; Z = O, S]. The compds. modulate the activity of protein kinases, and therefore are expected to be useful in the prevention and treatment of a variety of protein kinase-related cellular disorders, particularly cancer. Prepns. of 14 compds. are described. For instance, condensation of 3-methyl-1-indanone with oxindole in piperidine-DMF mixture at 130° (sealed tube) gave title compound II. The activities of all 14 compds. I against representative receptor tyrosine kinases, and the in vivo antitumor activity of one compound (24-63% inhibition), are described.

IT 36286-00-7, 5-Methoxyindan-3-one-1-acetic acid  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (starting material; preparation of geometrically restricted indolinone derivs. as modulators of protein kinase activity)


RN 36286-00-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD  
(6 CITINGS)  
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 33 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1999:596166 CAPLUS [Full-text](#)  
DOCUMENT NUMBER: 132:22896  
TITLE: Synthesis and Preliminary Evaluation of a Library of  
Polycyclic Small Molecules for Use in Chemical Genetic  
Assays  
AUTHOR(S): Tan, Derek S.; Foley, Michael A.; Stockwell, Brent R.;  
Shair, Matthew D.; Schreiber, Stuart L.  
CORPORATE SOURCE: Howard Hughes Medical Institute Department of  
Chemistry and Chemical Biology and Harvard Institute  
of Chemistry and Cell Biology, Harvard University,  
Cambridge, MA, 02138, USA  
SOURCE: Journal of the American Chemical Society (1999  
) , 121(39), 9073-9087  
CODEN: JACSAT; ISSN: 0002-7863  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI




I

AB (-)-Shikimic acid, was converted into both enantiomers of 2-hydroxyoxabicyclo[4.1.0]hept-3-ene-4-carboxylic acid which were attached to a solid support via a photocleavable linker. Tandem acylation-1,3-dipolar cycloaddn. with nitrones yielded tetracyclic templates I. After development of several efficient coupling reactions of I and completion of extensive validation protocols, a split-pool synthesis yielded a binary encoded library calculated to contain 2.18 million polycyclic compds. These compds. are compatible with miniaturized cell-based forward chemical genetic assays designed to explore biol. pathways and reverse chemical genetic assays designed to explore protein function. As a simple illustration of the potential of these compds., several were shown to activate a TGF- $\beta$ -responsive reporter gene in mammalian cells.



IT 24467-92-3, 5-Methoxy-1-indanone-3-acetic acid  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of a alkynylbenzyl(acyloxy)benzisoxazole dicarboxamide library  
 for use in genetic assays)  
 RN 24467-92-3 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 135 THERE ARE 135 CAPLUS RECORDS THAT CITE THIS  
 RECORD (137 CITINGS)  
 REFERENCE COUNT: 94 THERE ARE 94 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 34 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:9837 CAPLUS Full-text

DOCUMENT NUMBER: 130:81410

TITLE: Preparation of  
 11-piperidinylbenzo[5,6]cyclohepta[1,2-b]pyridines and  
 related compounds as inhibitors of farnesyl protein  
 transferase.

INVENTOR(S): Remiszewski, Stacy W.; Doll, Ronald J.; Alvarez,  
 Carmen

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857955	A1	19981223	WO 1998-US11494	19980615 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2294351	A1	19981223	CA 1998-2294351	19980615 <--
CA 2294351	C	20080902		
AU 9878151	A	19990104	AU 1998-78151	19980615 <--
EP 993459	A1	20000419	EP 1998-926276	19980615 <--
EP 993459	B1	20021106		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
HU 2000002186	A2	20010428	HU 2000-2186	19980615 <--
HU 2000002186	A3	20020429		
JP 2002504143	T	20020205	JP 1999-504489	19980615 <--
AT 227281	T	20021115	AT 1998-926276	19980615 <--

ES 2182324	T3	20030301	ES 1998-926276	19980615 <--
MX 9912090	A	20000430	MX 1999-12090	19991217 <--
HK 1024686	A1	20030321	HK 2000-102386	20000420 <--
PRIORITY APPLN. INFO.:			US 1997-877739	A 19970617 <--
			WO 1998-US11494	W 19980615 <--

OTHER SOURCE(S):                    MARPAT 130:81410  
GI



I




II

AB Title compds. (I; A = N, NO; R1, R3 = halo; R2, R4 = H, halo provided that  $\geq 1$  = H; X = C, CH, N; R = substituted cycloalkyl, heterocycloalkyl; dotted lines = optional double bonds; m = 0-2; R = substituted cyclobutyl(idene), cyclopentyl(idene), cyclohexyl(idene), indanyl(idene), azetidiny, piperidiny, etc.), were prepared Thus, tested I including title compound (II) inhibited farnesyl protein transferase with IC50's in the range 1.9 nM to >160 nM.

IT 24467-92-3, 5-Methoxy-1-indanone-3-acetic acid  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of 11-piperidinybenzo[5,6]cyclohepta[1,2-b]pyridines and related compds. as inhibitors of farnesyl protein transferase)

RN 24467-92-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT:            1        THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT:                8        THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 35 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER:            1998:698798 CAPLUS [Full-text](#)  
DOCUMENT NUMBER:            130:119054  
TITLE:                            SAR analysis of the Epstein-Barr virus DNA polymerase inhibitors  
AUTHOR(S):                      Lin, Mei-Tsu; Liu, Karin C. S. Chen; Kuo, Yueh-Hsiung; Chiou, Jwo-Farn; Ren, Shijun; Lien, Eric J.

CORPORATE SOURCE: School of Pharmacy, College of Medicine, National  
Taiwan University, Taipei, Taiwan  
SOURCE: Chinese Pharmaceutical Journal (Taipei) (1998  
, 50(1), 13-24  
CODEN: CPHJEP; ISSN: 1016-1015  
PUBLISHER: Pharmaceutical Society of Republic of China  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB A semiquant. structure-activity relation of forty-nine compds. including  
lignans, phenols and  $\alpha,\beta$ -unsatd.- $\gamma$ -lactones was analyzed by using a parameter-  
frame-setting method. Based on the result, a quant. anal. was performed and a  
statistically significant correlation was obtained between the inhibitory  
activities ( $\log 1/IC_{50}$ ) of 16 compds. against Epstein-Barr virus DNA  
polymerase (EBV-DP) and physicochem. parameters (calculated molar refractivity  
(CMR), calculated partition coefficient in octanol/water (Clog P) and mol.  
dipole moment ( $\mu$ )). The structural requirements for the optimum activity  
against EBV-DP of these groups of compds. were identified. These findings  
provide physicochem. bases for further structural modification and  
optimization of the lead natural products for antiviral activity.

IT 219795-21-8  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); PRP (Properties); BIOL (Biological study)  
(QSAR anal. of Epstein-Barr virus DNA polymerase inhibitors in relation  
to antiviral activity)  
RN 219795-21-8 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy-3-(4-hydroxy-3-  
methoxyphenyl)-6-methoxy-2-(methoxycarbonyl)-, methyl ester, (1S,2R,3R)-  
(CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)  
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 36 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1998:503326 CAPLUS Full-text  
DOCUMENT NUMBER: 129:244668  
ORIGINAL REFERENCE NO.: 129:49815a,49816a  
TITLE: Stereoselective Synthesis of over Two Million  
Compounds Having Structural Features Both Reminiscent  
of Natural Products and Compatible with Miniaturized  
Cell-Based Assays  
AUTHOR(S): Tan, Derek S.; Foley, Michael A.; Shair, Matthew D.;

CORPORATE SOURCE: Schreiber, Stuart L.  
Department of Chemistry Chemical Biology Harvard  
Institute of Chemistry Cell Biology, Howard Hughes  
Medical Institute Harvard University, Cambridge, MA,  
02138, USA

SOURCE: Journal of the American Chemical Society (1998  
) , 120(33), 8565-8566  
CODEN: JACSAT; ISSN: 0002-7863  
American Chemical Society


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 129:244668

GI




AB A combinatorial library of 2.18 million octahydrobenzoxisoxazoles I (R = 2-I, 3-I, 4-I, 2-R4C.tplbond.C, 3-R4C.tplbond.C, 4-R4C.tplbond.C; R1 = alkyl, cycloalkyl, arylalkyl; R2 = alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl; R3 = NH2, CH2CONH2, (CH2)5CONH2; R4 = alkyl, aryl, arylalkyl) has been generated to give a set rigid, stereochem. defined, and structurally diverse mols. The libraries are prepared in six steps from either enantiomer of oxacycloheptane II by linking to a solid support with one of three linkers, esterification and dipolar cycloaddn. with arylmethyl glycine nitrones, Sonogashira coupling of the product iodoaryl derivs. with alkynes, lactone cleavage with amines, acylation of the free alcs. with acids and acyl coupling reagents, and photochem. cleavage from the resin. Sublibraries of I were prepared to test the reactivity of alkynes, amines, and acids in the preparative sequence towards I and the purity of the products generated. Libraries generated by this sequence are spatially separated and encoded, allowing for controlled release of libraries into solution and for cell-based testing of the libraries.

IT 24467-92-3  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of a sublibrary as a test for the reactivity of alkynes, acids, and amines in couplings and the purity of the products formed)

RN 24467-92-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 157 THERE ARE 157 CAPLUS RECORDS THAT CITE THIS RECORD (158 CITINGS)  
REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 37 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:491329 CAPLUS Full-text

DOCUMENT NUMBER: 129:197343

ORIGINAL REFERENCE NO.: 129:39901a,39904a

TITLE: Highly enantioselective HPLC separations using the covalently bonded macrocyclic antibiotic, ristocetin A, chiral stationary phase

AUTHOR(S): Ekborg-Ott, K.; Liu, Youbang; Armstrong, Daniel W.

CORPORATE SOURCE: Department Chemistry, University Missouri-Rolla, Rolla, MO, USA

SOURCE: Chirality (1998), 10(5), 434-483

CODEN: CHRLEP; ISSN: 0899-0042

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The macrocyclic glycopeptide, ristocetin A, was covalently bonded to a silica gel support and evaluated as a liquid chromatog. (LC) chiral stationary phase (CSP). Over 230 racemates were resolved in either the reversed-phase mode, the normal-phase mode, or the polar-organic mode. The retention behavior and selectivity of this CSP were examined in each mode. Optimization of sepsns. on this column is discussed. The ristocetin A CSP appeared to be complimentary to other glycopeptide CSPs (i.e., vancomycin and teicoplanin). Column stability was excellent. The CSP was not irreversibly altered when going from one mobile phase mode to another.

IT 24467-92-3 211681-96-8 211681-98-0

RL: ANT (Analyte); PEP (Physical, engineering or chemical process); PRP (Properties); ANST (Analytical study); PROC (Process)  
(enantiomeric separation by HPLC using covalently bonded macrocyclic antibiotic ristocetin A as chiral stationary phase)

RN 24467-92-3 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



RN 211681-96-8 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 211681-98-0 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 104 THERE ARE 104 CAPLUS RECORDS THAT CITE THIS RECORD (105 CITINGS)  
 REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 38 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1998:457267 CAPLUS Full-text  
 DOCUMENT NUMBER: 129:122563  
 ORIGINAL REFERENCE NO.: 129:25113a,25116a  
 TITLE: Preparation of lactone compounds for treating patient with precancerous lesions  
 INVENTOR(S): Gross, Paul; Sperl, Gerhard; Pamukcu, Rifat; Brendel, Klaus  
 PATENT ASSIGNEE(S): Cell Pathways, Inc., USA; University of Arizona  
 SOURCE: U.S., 21 pp., Cont.-in-part of U. S. Ser. No. 265,396. CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5776962	A	19980707	US 1995-481601	19950607 <--
US 5696159	A	19971209	US 1994-265396	19940803 <--
CA 2172710	A1	19960215	CA 1995-2172710	19950731 <--
WO 9603987	A1	19960215	WO 1995-US8912	19950731 <--
W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT			
RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9532704	A	19960304	AU 1995-32704	19950731 <--

AU 689305 B2 19980326  
 EP 723442 A1 19960731 EP 1995-929312 19950731 <--  
 R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE  
 JP 09506114 T 19970617 JP 1995-506533 19950731 <--  
 PRIORITY APPLN. INFO.: US 1994-265396 A2 19940803 <--  
 US 1995-481601 A 19950607 <--  
 WO 1995-US8912 W 19950731 <--  
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): MARPAT 129:122563  
 GI




AB The title compds. I [X = C, or R6X = N; R1, R2 = H, amino, etc.; or R1R2 = carbonyl, etc.; or R2R3 = double bond; R3 = H, halo, etc.; R4 = H, OH, etc.; R5 = H, OH, halo, etc.; R6 = H, alkyl, etc.; R7 = H, alkyl, etc.; R8, R9 = H, alkyl, OH, etc.; R10, R11 = H, halo, etc.; R12 = H, halo, etc.] are prepared  
 Compds. of this invention in vitro showed IC50 values of 0.081  $\mu$ M to 110  $\mu$ M against the tumor HT-29 cell lines.  
 IT 145900-48-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of lactone compds. for treating patient with precancerous lesions)  
 RN 145900-48-7 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-1-hydroxy-6-methoxy-2-methyl-, methyl ester (CA INDEX NAME)




REFERENCE COUNT: 109 THERE ARE 109 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 39 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN


ACCESSION NUMBER: 1998:395276 CAPLUS [Full-text](#)  
DOCUMENT NUMBER: 129:90274  
ORIGINAL REFERENCE NO.: 129:18447a,18450a  
TITLE: Synthesis and in vitro serotonin-3-antagonist activities of some newer 1,3,4-oxadiazole-2-thiones  
AUTHOR(S): Pramanik, S. S.; Mukherjee, A.  
CORPORATE SOURCE: Division of Pharmaceutical Technology, Department of Chemical Technology, University of Calcutta, Calcutta, 700 009, India  
SOURCE: Journal of the Indian Chemical Society (1998), 75(1), 53-54  
CODEN: JICSAH; ISSN: 0019-4522  
PUBLISHER: Indian Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 129:90274  
AB 1,3,4-Oxadiazole-2-thiones were prepared by the cyclization of the acid hydrazides with carbon disulfide. Some of the compds. had good 5-HT3 antagonist activity.  
IT 24467-92-3 36266-18-7 62956-65-4  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation and in vitro 5-HT3 antagonist activity of oxadiazole thiones)  
RN 24467-92-3 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



RN 36266-18-7 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy-3-oxo- (CA INDEX NAME)




RN 62956-65-4 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)







IT 25574-42-9P 36286-02-9P 209726-90-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and in vitro 5-HT3 antagonist activity of oxadiazole thiones)  
 RN 25574-42-9 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo-, methyl ester (CA  
 INDEX NAME)



RN 36286-02-9 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy-3-oxo-, methyl ester  
 (CA INDEX NAME)



RN 209726-90-9 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy-, methyl ester (CA  
 INDEX NAME)




OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD  
 (6 CITINGS)  
 REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 40 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1998:211137 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 128:294609  
 ORIGINAL REFERENCE NO.: 128:58387a,58390a  
 TITLE: Preparation of  
 (sulfonylamino)alkyl-1,2,3,4-tetrahydronaphthalen-6-  
 ylcaboxylic acids, thromboxane antagonists containing

INVENTOR(S): them, and their intermediates  
Shinozaki, Katsuo; Yamanaka, Kenji; Chikazawa,  
Atsushi; Kurimoto, Tadashi  
PATENT ASSIGNEE(S): Zeria Pharmaceutical Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 30 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10087602	A	19980407	JP 1996-257394	19960909 <--
PRIORITY APPLN. INFO.:			JP 1996-257394	19960909 <--
OTHER SOURCE(S):	MARPAT 128:294609			

GI



AB Title compds. I (Z = SO2R1; R1 = C1-12 alkyl, benzyl, styryl, naphthyl, (substituted) Ph, (substituted) thienyl; R2 = OH, CO2H, SO3H, C2-4 alkoxy, carbonyl; R3 = H, halo, NO2, NH2; Y = (CH2)1, oxymethylene, vinylene; YR2 = CO(CH2)q, CH(OH)(CH2)q, CH2CONH(CH2)q; l = 0-5; q = 1-4; p, m = 0-3; p + m ≥ 2; n = 0-4; if R3 = H, then p = m ≠ 1 and n ≠ 1-4) and their salts, useful as thromboxane antagonists for treatment of asthma, thrombus, and vasospasm, etc., are prepared by reaction of aminoalkylbenzenes I (Z = H; R2, R3, Y, l, q, p, m, n = same as above) with XS02R1 (R1 = same as above; X = halo). Et 3-benzylaminomethyl-1-oxo-1,2,3,4-tetrahydronaphthalen-6-ylacetate hydrochloride was reduced with Pd/C in the presence of H2SO4 in AcOH-H2O mixture under H and 3.5-4.0 atm at 70° for 6 h to give 65% I hydrochloride (Z = H, R2 = CO2Et, Y = CH2, R3 = H, p = 2, m = n = 1) (II). II was condensed with 2-naphthylsulfonyl chloride in H2O in the presence of AcOEt and NaHCO3 at room temperature for 2 h to give 87% I (Z = SO2R1, R1 = 2-naphthyl, R2, Y, R3, p, m, n = same as II), which was reacted with NaOH in MeOH-H2O at room temperature for 3 h and reacted with NaHCO3 in H2O under heating to give I (Z = SO2R1, R1 = 2-naphthyl, R2 = CO2Na, Y, R3, p, m, n = same as II) (III). III in vitro showed pIC50 of 6.29 against guinea pig platelet aggregation.


IT 162713-88-4P 206112-59-6P 206112-60-9P  
206112-61-9P 206112-62-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (sulfonylamino)naphthalenes by condensation of aminonaphthalenes with sulfonyl halides)


RN 162713-88-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, ethyl ester (CA INDEX NAME)




RN 206112-59-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy- (CA INDEX NAME)




RN 206112-60-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy-, phenylmethyl ester (CA INDEX NAME)




RN 206112-61-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-(2-ethoxy-2-oxoethoxy)-2,3-dihydro-, phenylmethyl ester (CA INDEX NAME)



RN 206112-62-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-(2-ethoxy-2-oxoethoxy)-2,3-dihydro- (CA INDEX NAME)



L4 ANSWER 41 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:341754 CAPLUS [Full-text](#)  
DOCUMENT NUMBER: 127:47693  
ORIGINAL REFERENCE NO.: 127:9035a,9038a  
TITLE: Isolation and synthesis of new antioxidants from  
sunflower seeds  
AUTHOR(S): Kato, Tadahiro; Takahashi, Wataru; Suzuki, Yoshiaki  
CORPORATE SOURCE: Fac. Sci., Sci. Univ. Tokyo, Tokyo, 162, Japan  
SOURCE: Natural Product Letters (1997), 9(3),  
161-165  
CODEN: NPLEEF; ISSN: 1057-5634  
PUBLISHER: Harwood  
DOCUMENT TYPE: Journal  
LANGUAGE: English


AB Structure elucidation and synthesis of 2 aryindane-type phenolic antioxidants from sunflower seeds is reported. The structures were determined by extensive spectroscopic anal., and finally were confirmed by comparison of their spectral data with those of authentic samples prepared by dimerization of 3,4-dihydroxycinnamate with CF3CO2H.

IT 191280-19-0P 191280-20-3P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (isolation, synthesis, and structure of antioxidative (hydroxyphenyl)indanes from sunflower seeds)

RN 191280-19-0 CAPLUS

CN 1H-Indene-1-acetic acid, 3-(3,4-dihydroxyphenyl)-2,3-dihydro-5,6-dihydroxy-2-(methoxycarbonyl)-, methyl ester, (1R,2R,3R)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.  
Currently available stereo shown.




RN 191280-20-3 CAPLUS

CN 1H-Indene-1-acetic acid, 3-(3,4-dihydroxyphenyl)-2,3-dihydro-5,6-dihydroxy-2-(methoxycarbonyl)-, methyl ester, (1R,2S,3S)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.  
Currently available stereo shown.



L4 ANSWER 42 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1997:281054 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 126:264219  
 ORIGINAL REFERENCE NO.: 126:51181a  
 TITLE: Structural Amendment and Stereoselective Synthesis of Mutisianthol  
 AUTHOR(S): Ho, Tse-Lok; Lee, Kwang-Yuan; Chen, Chun-Kuei  
 CORPORATE SOURCE: Department of Applied Chemistry, National Chiao Tung University, Hsinchu, Taiwan  
 SOURCE: Journal of Organic Chemistry (1997), 62(10), 3365-3369  
 CODEN: JOCEAH; ISSN: 0022-3263  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI




AB Cis-1-(5-acetoxy-3,6-dimethyl-1-indanyl)-2-methyl-1-propene synthesized from 3,6-dimethyl-1-indanone was found to be different from mutisianthol by spectral comparison. The presence of a high-field signal in the NMR spectrum of the final product and various intermediates, characteristic of the cis-1,3-dialkylindanes but absent in the spectrum of the natural terpene, suggested a revision of the structure of mutisianthol to the trans isomer. The trans-indane which was subsequently obtained indeed exhibits data fully agreeable with mutisianthol (I). A similar stereochem. revision to the trans configuration for jungianol was also indicated.

IT 199441-81-8P 199441-81-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (stereoselective synthesis and relative configuration of mutisianthol)

RN 188441-81-8 CAPLUS  
 CN 1H-Indene-1-acetic acid, 5-(acetyloxy)-2,3-dihydro-3,6-dimethyl-, ethyl ester, (1R,3R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188441-87-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-(acetyloxy)-2,3-dihydro-3,6-dimethyl-, methyl ester, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 43 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:244353 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 126:225317

ORIGINAL REFERENCE NO.: 126:43579a

TITLE: 1-[2-(2,3-Dihydro-1H-inden-1-yl)ethyl]-4-(naphthalen-1-yl)piperazine derivatives, preparation thereof, and therapeutic use as 5-HT receptor ligands

INVENTOR(S): George, Pascal; Sevrin, Mireille; Manoury, Philippe; Peynot, Michel; De Peretti Daniele; Gibert, Jean Francois; Tixidre, Arlette; Machnik, David

PATENT ASSIGNEE(S): Synthelabo S. A., Fr.; George, Pascal; Sevrin, Mireille; Manoury, Philippe; Peynot, Michel; De Peretti, Daniele; Gibert, Jean, Francois; Tixidre, Arlette; Machnik, David

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9706155	A1	19970220	WO 1996-FR1216	19960801 <--
W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

FR 2737724	A1	19970214	FR 1995-9684	19950809 <--
FR 2737724	B1	19970905		
CA 2228843	A1	19970220	CA 1996-2228843	19960801 <--
AU 9667053	A	19970305	AU 1996-67053	19960801 <--
AU 707372	B2	19990708		
EP 843670	A1	19980527	EP 1996-927120	19960801 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1199398	A	19981118	CN 1996-197512	19960801 <--
BR 9609977	A	19990112	BR 1996-9977	19960801 <--
HU 9802546	A2	19990201	HU 1998-2546	19960801 <--
HU 9802546	A3	19991028		
JP 2000501699	T	20000215	JP 1997-508161	19960801 <--
ZA 9606772	A	19970219	ZA 1996-6772	19960808 <--
US 5929078	A	19990727	US 1998-11807	19980203 <--
NO 9800529	A	19980414	NO 1998-529	19980206 <--
PRIORITY APPLN. INFO.:			FR 1995-9684	A 19950809 <--
			WO 1996-FR1216	W 19960801 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):		MARPAT 126:225317		
GI				



I


AB Title compds. I [X = H, OH, Cl-3 alkoxy, cyclopropylmethoxy; Y = H, OH, OMe], including bases, salts, enantiomers, and enantiomeric mixts., are provided for a wide variety of therapeutic uses. A list of approx. 15 I, five synthetic examples, and general results of assays against four 5-HT receptor subtypes are given. For instance, 2,3-dihydro-1H-indene-1-ethanol was treated with p-MeC6H4SO2Cl in pyridine to give the tosylate ester, which was condensed with 1-(7-methoxynaphthalen-1-yl)piperazine by heating the mixture neat at 130°, to give title compound I [X = OMe, Y = H, isolated as the (1:1) fumarate]. Compds. I had strongest affinity for 5-HT<sub>1</sub> receptor subtypes, and moderate affinity for the 5-HT<sub>2</sub> subtype, with IC<sub>50</sub> ranges as follows: 1A: 1-300 nM, 1C: 5-500 nM, 1D: < 40 nM, and 2: 50-1500 nM.

IT 188358-62-5P 188358-65-8P  
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of  
 [(dihydroindenyl)ethyl](naphthalenyl)piperazine derivs. as 5-HT  
 receptor ligands)

RN 188358-62-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 188358-65-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-, (+)- (CA INDEX NAME)

Rotation (+).



IT 62956-64-3P, 2,3-Dihydro-6-methoxy-1H-indene-1-acetic acid

188358-63-6P 188358-66-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of

[(dihydroindenyl)ethyl](naphthalenyl)piperazine derivs. as 5-HT receptor ligands)

RN 62956-64-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy- (CA INDEX NAME)



RN 188358-63-6 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-, (-)-, compd. with (R)- $\alpha$ -methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 188358-62-5

CMF C12 H14 O3

Rotation (-).



CM 2

CRN 3886-69-9

CMF C8 H11 N

Absolute stereochemistry. Rotation (+).






RN 188358-66-9 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-, (+)-, compd. with  
 (S)- $\alpha$ -methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 188358-65-8  
 CMF C12 H14 O3

Rotation (+).



CM 2

CRN 2627-86-3  
 CMF C8 H11 N

Absolute stereochemistry. Rotation (-).



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
 (5 CITINGS)  
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 44 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1996:431399 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 125:86333  
 ORIGINAL REFERENCE NO.: 125:16269a,16272a  
 TITLE: Preparation of benzocycloalkene-derivative melatonin  
 receptor ligands  
 INVENTOR(S): Ohkawa, Shigenori; Uchikawa, Osamu; Miyamoto, Masaomi  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: PCT Int. Appl., 139 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9608466	A1	19960321	WO 1995-JP1796	19950911 <--
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2193398	A1	19960321	CA 1995-2193398	19950911 <--
CA 2193398	C	20070814		
AU 9533998	A	19960329	AU 1995-33998	19950911 <--
JP 08134030	A	19960528	JP 1995-232981	19950911 <--
JP 3908798	B2	20070425		
EP 781271	A1	19970702	EP 1995-930728	19950911 <--
EP 781271	B1	20000607		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1156443	A	19970806	CN 1995-194800	19950911 <--
AT 193700	T	20000615	AT 1995-930728	19950911 <--
FI 9700997	A	19970310	FI 1997-997	19970310 <--
US 6235789	B1	20010522	US 1997-530148	19970528 <--
PRIORITY APPLN. INFO.:				
			JP 1994-217188	A 19940912 <--
			WO 1995-JP1796	W 19950911 <--

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 125:86333

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; R1, R2 = H, (un)substituted hydrocarbonyl, (un)substituted heterocyclyl; CR1R2 = spiro ring; R3 = (un)substituted hydrocarbonyl, substituted amino, substituted hydroxyl, (un)substituted heterocyclyl; R4 = H, (un)substituted alkyl; m, n = 1-4; ... means a single or double bond], which are ligands for melatonin receptors and are useful in regulating sleep-awake or circadian rhythms (no data), are prepared. Thus, 1-(2-aminoethyl)-6-methoxyindane was reacted with trifluoroacetic anhydride, producing indane deriv, II, m.p. 66-67°, which demonstrated a IC50 of 0.64 nM against 2-[125I]iodomelatonin in a chicken forebrain-derived melatonin receptor study.


IT 91284-09-2F

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzocycloalkene-derivative melatonin receptor ligands)

RN 91284-09-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 45 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN


ACCESSION NUMBER: 1996:383029 CAPLUS Full-text

DOCUMENT NUMBER: 125:96264

ORIGINAL REFERENCE NO.: 125:17935a,17938a  
 TITLE: Comparison and Modeling Study of Vancomycin,  
 Ristocetin A, and Teicoplanin for CE  
 Enantioseparations  
 AUTHOR(S): Gasper, Mary P.; Berthod, Alain; Nair, Usha B.;  
 Armstrong, Daniel W.  
 CORPORATE SOURCE: Department of Chemistry, University of Missouri Rolla,  
 Rolla, MO, 65401, USA  
 SOURCE: Analytical Chemistry (1996), 68(15),  
 2501-2514  
 CODEN: ANCHAM; ISSN: 0003-2700  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The structurally related glycopeptide antibiotics vancomycin, ristocetin A, and teicoplanin can all be used as chiral selectors in capillary electrophoresis (CE). Both exptl. and modeling studies were done to elucidate their similarities and differences. There are identifiable morphol. differences in the aglycon macrocyclic portions of these three compds. In addition, there are other structural distinctions that can affect their CE enantioselectivity, migration times, and efficiency. Teicoplanin is the most distinct of the three and is the only one that is surface active. Its aggregational properties appear to affect its enantioselectivity among other things. The similar but not identical structures of the three glycopeptides produce similar but not identical enantioselectivities. This leads to the empirically useful "principle of complementary sepnns.", in which a partial resolution with one chiral selector can be brought to baseline with one of the others. Overall, ristocetin A appears to have the greatest applicability for CE enantiosepnns.

IT 24467-92-3  
 RL: ANT (Analyte); ANST (Analytical study)  
 (enantiomeric separation of drugs by capillary electrophoresis using vancomycin, ristocetin a and teicoplanin as chiral selectors)  
 RN 24467-92-3 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 150 THERE ARE 150 CAPLUS RECORDS THAT CITE THIS  
 RECORD (151 CITINGS)

L4 ANSWER 46 OF 111 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 1996:362842 CAPLUS Full-text

DOCUMENT NUMBER: 125:143276



ORIGINAL REFERENCE NO.: 125:26841a,26844a

TITLE: A solution-phase strategy for the synthesis of  
 chemical libraries containing small organic molecules:  
 a universal and dipeptide mimetic template

AUTHOR(S): Cheng, Soan; Tarby, Christine M.; Comer, Daniel D.;  
 Williams, John P.; Caporale, Lynn H.; Myers, Peter L.;  
 Boger, Dale L.

CORPORATE SOURCE: CombiChem, Inc., San Diego, CA, 92121, USA

SOURCE: Bioorganic & Medicinal Chemistry (1996),  
4(5), 727-737  
CODEN: BMECEP; ISSN: 0968-0896  
PUBLISHER: Elsevier  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI



AB A general approach to the solution phase, parallel synthesis of chemical libraries, which allows the preparation of multi-milligram quantities of each individual member, is exemplified with both a universal template I and dipeptide mimetic template II. In each step of the sequence, the reactants, unreacted starting material, reagents and their byproducts are removed by simple liquid/liquid or liquid/solid extns. providing the desired intermediates and final compds. in high purities (≥90-100%) independent of the reaction yields and without deliberate reaction optimization. Thus, ring opening of I with any alc., amine, or thiol nucleophile R<sub>1</sub>XH, followed by further condensation with alcs., amines, or thiols R<sub>2</sub>XH, deprotection, and acylation with R<sub>3</sub>CO<sub>2</sub>H gives combinatorial libraries R<sub>1</sub>XCOCH<sub>2</sub>N(COR<sub>3</sub>)CH<sub>2</sub>COX<sub>2</sub>. Combinatorial libraries are made with II using similar conditions.

IT 62956-64-3


RL: RCT (Reactant); RACT (Reactant or reagent)

(a solution-phase strategy for the synthesis of chemical libraries containing

small organic mols. using universal and dipeptide mimetic templates)

RN 62956-64-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 85 THERE ARE 85 CAPLUS RECORDS THAT CITE THIS RECORD (85 CITINGS)

L4 ANSWER 47 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:161083 CAPLUS Full-text

DOCUMENT NUMBER: 124:277971

ORIGINAL REFERENCE NO.: 124:51095a,51098a

TITLE: Studies on hypocholesterolemic activity of some simple and substituted indan-1-acetic acids

AUTHOR(S): Adak, M.; Lahiri, S. C.

CORPORATE SOURCE: Dept. Pharmaceutical Technology, Jadavpur University, Calcutta, 700032, India

SOURCE: Indian Drugs (1995), 32(11), 561-3  
 CODEN: INDRBA; ISSN: 0019-462X  
 PUBLISHER: Indian Drug Manufacturers' Association  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English


AB High plasma lipoprotein concns. are considered to be intimately connected with atherosclerosis and associated with various coronary disorders. Current treatment targets these centers though strict control of dietary intake of fats and cholesterol in the first instance, with drug treatment playing a secondary but increasingly important role. Indan acids, belong to the class of arylalkanoic acids, which were screened for their anticholesterolemic activity in diet-induced hypercholesterolemia followed by secondary screening in normolipidemic animal models. The plasma cholesterol level showed a varying degree of fall though less significant than the standard drug, clofibrate. A suitable structural modification may produce a better lead compound with better tolerance and lower toxicity profile.

IT 24467-92-3 36286-18-7 62956-64-3  
 62956-65-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hypocholesterolemic activity of simple and substituted indanacetic acids in relation to structure)


RN 24467-92-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)




RN 36286-18-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy-3-oxo- (CA INDEX NAME)




RN 62956-64-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy- (CA INDEX NAME)



RN 62956-65-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)



L4 ANSWER 48 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:148859 CAPLUS Full-text

DOCUMENT NUMBER: 124:242482

ORIGINAL REFERENCE NO.: 124:44713a,44716a

TITLE: Capillary electrophoretic enantiomeric separations

using the glycopeptide antibiotic, teicoplanin

AUTHOR(S): Rundlett, Kimber L.; Gasper, Mary P.; Zhou, Eve Y.;  
Armstrong, Daniel W.

CORPORATE SOURCE: University Missouri, Rolla, MO, USA

SOURCE: Chirality (1996), 8(1), 88-107

CODEN: CHRLEP; ISSN: 0899-0042

PUBLISHER: Wiley-Liss

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Teicoplanin is the third in a series of macrocyclic glycopeptide antibiotics that has been evaluated as a chiral selector in capillary electrophoresis (CE). It was used to resolve over 100 anionic racemates at low selector concns. Like the other related glycopeptide antibiotics, its enantioselectivity tends to be opposite to that of the ansa-type antibiotics which prefers cationic compds., particularly amines. Factors that affect teicoplanin-based enantiosepsns. include the selector as well as the enantiosepn. Teicoplanin exhibited some features that were not noted with the other glycopeptide antibiotics. it forms micelles in aqueous solns. and this influence its enantioselectivity. Unlike the other studied glycopeptides, teicoplanin ppts. in alc.-water mixts. It also binds less to the capillary wall than vancomycin as evidenced by the faster electroosmotic flow velocity. The micellization of teicoplanin is pH dependent so that the effect of pH on enantio recognition is more complex for teicoplanin than for other chiral selectors. Also it is shown that the simple model proposed to explain the role of organic modifiers in cyclodextrin-based CE enantiosepsns. may not apply to these and other systems.


IT 24467-92-3

RL: ANT (Analyte); ANST (Analytical study)

(enantiomeric separation of drugs by capillary electrophoresis using teicoplanin as a chiral selector)


RN 24467-92-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 73 THERE ARE 73 CAPLUS RECORDS THAT CITE THIS RECORD (73 CITINGS)

L4 ANSWER 49 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1995:834144 CAPLUS [Full-text](#)  
DOCUMENT NUMBER: 124:55651  
ORIGINAL REFERENCE NO.: 124:10517a,10520a  
TITLE: Studies on acidic dimerization of 3,4-dioxygenated cinnamate or 1-phenylpropene to arylindane lignans  
AUTHOR(S): Kuo, Yueh-Hsiung; Wu, Chien-Huang; Wu, Rong-En; Lin, Sheng-Tsai  
CORPORATE SOURCE: Dep. Chem., Natl. Taiwan Univ., Taipei, Taiwan  
SOURCE: Chemical & Pharmaceutical Bulletin (1995), 43(8), 1267-71  
CODEN: CPBTAL; ISSN: 0009-2363  
PUBLISHER: Pharmaceutical Society of Japan  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 124:55651  
GI




AB The TsOH-catalyzed dimerization of (E)-ferulic acid gave the arylindane lignans I [R1 = H, CO2H, CO2Me, R2 = CO2Me; R1 = CO2Me, R2 = CO2H]. The HCO2H-catalyzed dimerization of (E)-ferulate similarly gave I [R1 = H, CO2Me, R2 = CO2Me]. These I were converted to some other derivs. The structures of the products were elucidated and a mechanism is proposed for the reactions.

IT 144878-41-1P 144878-42-2P 172092-18-1P  
172092-19-2P 172092-21-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(dimerization of ferulate to arylindane lignans)

RN 144878-41-1 CAPLUS  
CN 1H-Indene-1-acetic acid, 3-(3,4-dimethoxyphenyl)-2,3-dihydro-5,6-dimethoxy-2-(methoxycarbonyl)-, methyl ester, (1a,2a,3β)- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 144878-42-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-6-methoxy-2-(methoxycarbonyl)-, methyl ester, (1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 172092-18-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2-carboxy-2,3-dihydro-5-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-6-methoxy-,  $\alpha$ -methyl ester, (1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ )- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 172092-19-2 CAPLUS



CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-6-methoxy-2-(methoxycarbonyl)-,  
(1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 172092-21-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-2-(methoxycarbonyl)-3-[3-methoxy-4-(phenylmethoxy)phenyl]-5-(phenylmethoxy)-, methyl ester,  
(1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ )- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 172092-20-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(dimerization of ferulate to arylindan lignans)

RN 172092-20-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-(acetyloxy)-3-[4-(acetyloxy)-3-methoxyphenyl]-2,3-dihydro-6-methoxy-2-(methoxycarbonyl)-, methyl ester,  
(1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ )- (9CI) (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)

L4 ANSWER 50 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:790900 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 124:134742

ORIGINAL REFERENCE NO.: 124:24730h,24731a

TITLE: Characterization of Potent and Selective Antagonists at Postsynaptic 5-HT<sub>1A</sub> Receptors in a Series of N4-Substituted Arylpiperazines

AUTHOR(S): Peglion, Jean-Louis; Canton, Herve; Bervoets, Karin; Audinot, Valerie; Brocco, Mauricette; Gobert, Alain; Le Marouille-Girardon, Sylvie; Millan, Mark J.

CORPORATE SOURCE: Institut de Recherches Servier, Suresnes, 92150, Fr.  
SOURCE: Journal of Medicinal Chemistry (1995), 38(20), 4044-55

CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 124:134742


GI



AB Benzocycloalkyl and benzocycloalkenyl moieties linked, directly or via an alkyl chain, to oxygen-bearing heteroarylpiperazines were synthesized, in an attempt to obtain potent and selective antagonists at postsynaptic 5-HT<sub>1A</sub> receptors. From the numerous arylpiperazines described in the literature, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine was chosen as a model of an arylpiperazine in view of its selectivity for 5-HT<sub>1A</sub> receptors vs.  $\alpha_1$ -,  $\alpha_2$ -, and  $\beta$ -adrenergic receptors, as well as dopamine D<sub>1</sub> and D<sub>2</sub> receptors. Two other closely-related arylpiperazines, 1-(1,5-benzodioxepin-6-yl)piperazine and 1-(benzofuran-7-yl)piperazine, were also examined in this study. All compds. showed high affinity at 5-HT<sub>1A</sub> sites ( $8.10 \leq \text{pK}_i < 9.35$ ), and the

majority behaved as antagonists in vivo in blocking the hypothermia induced by the 5-HT1A agonist 8-OH-DPAT in the absence of a marked effect alone at equivalent doses. An in vivo evaluation of dopamine D2 receptor antagonist properties revealed that the majority of compds. was devoid of activity at this site, in marked contrast to BMY 7378 which displayed virtually no selectivity for 5-HT1A vs. dopamine D2 receptors. Moreover, six compds. of the present series, including I, showed >10-fold selectivity in vitro for 5-HT1A vs.  $\alpha$ 1-adrenergic receptors. I displayed an optimal compromise between potency ( $pK_i = 8.75$ ), marked antagonist activity, and selectivity toward  $\alpha$ 1-adrenergic (81-fold) and dopamine D2 195-fold receptors. These characteristics clearly distinguish I from previously-reported ligands such as the postsynaptic 5-HT1A antagonist BMY 7378 and the weak partial agonist NAN 190 which, in contrast to the compds. of this series, belong to the well-exemplified class of imido derivs. of (o-methoxyphenyl)piperazines. The availability of I (S 15535) should facilitate the further elucidation of the functional role and potential therapeutic significance of 5-HT1A receptors.

IT 62956-65-4, 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy-  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (potent and selective antagonists at postsynaptic 5-HT1A receptors in a series of N4-substituted arylpiperazines)  
 RN 62956-65-4 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 27 THERE ARE 27 CAPLUS RECORDS THAT CITE THIS RECORD (27 CITINGS)

L4 ANSWER 51 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:652432 CAPLUS Full-text

DOCUMENT NUMBER: 123:55499

ORIGINAL REFERENCE NO.: 123:9983a,9986a

TITLE: Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds

INVENTOR(S): Pamukcu, Rifat; Brendel, Klaus

PATENT ASSIGNEE(S): University of Arizona, USA; Egn, Inc.

SOURCE: U.S., 13 pp., Cont.-in-part of U.S. Ser. No. 666,796, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5401774	A	19950328	US 1992-839203	19920220 <--
AU 9211400	A	19920910	AU 1992-11400	19920303 <--
AU 650720	B2	19940630		
EP 508586	A1	19921014	EP 1992-301821	19920303 <--

EP 508586	B1	19950531		
R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
CA 2062422	A1	19920909	CA 1992-2062422	19920306 <--
CA 2062422	C	19971014		
JP 06087739	A	19940329	JP 1992-100767	19920309 <--
JP 2704082	B2	19980126		
KR 150646	B1	19981015	KR 1992-3855	19920309 <--
US 5643959	A	19970701	US 1994-361291	19941222 <--
US 20020107248	A1	20020808	US 2001-40601	20011228 <--
PRIORITY APPLN. INFO.:			US 1991-666796	B2 19910308 <--
			US 1992-839203	A 19920220 <--
			US 1994-361291	A1 19941222 <--
			US 1997-851943	B1 19970507 <--
			US 1999-243659	B1 19990202 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 123:55499

GI



I

AB A method is claimed for treating a patient with precancerous lesions comprising administering a physiologically effective amount of an indenyl sulfonyl acetic acid I wherein R1 is selected from the group consisting of hydrogen or lower alkyl; wherein R2 is lower alkyl; wherein R3 is a halogen; wherein R4 is hydrogen; wherein R5 is loweralkyl sulfonyl; and wherein M is hydroxy. Thus, e.g., condensation of p-fluorobenzaldehyde with propionic anhydride/sodium propionate afforded p-fluoro- $\alpha$ -methylcinnamic acid; hydrogenation of the latter to the hydrocinnamic acid, followed by cyclization in polyphosphoric acid afforded 6-fluoro-2-methylindanone; reaction of the latter with cyanoacetic acid/ammonium acetate afforded 5-fluoro-2-methylindenyl-3-acetic acid; reaction of the latter with p-(methylthio)benzaldehyde afforded 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid; successive oxidation of the latter afforded 5-fluoro-2-methyl-1-(p-methylsulfonylbenzylidene)-3-indenylacetic acid (II). II was assayed against various cell lines to ascertain the degree of growth inhibition: IC50 ( $\mu$ M) for colonic adenocarcinoma = 51-183; for lung carcinoma = 128; for breast carcinoma = 90; for melanoma = 90.


IT 145900-59-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(use of substituted sulfonyl indenylacetic and -propionic acids and esters for treatment of precancerous lesions)

RN 145900-59-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-fluoro-2,3-dihydro-1-hydroxy-6-methoxy-2-methyl-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 38 THERE ARE 38 CAPLUS RECORDS THAT CITE THIS RECORD (39 CITINGS)  
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 52 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:481881 CAPLUS Full-text

DOCUMENT NUMBER: 122:265958

ORIGINAL REFERENCE NO.: 122:48577a,48580a

TITLE: Conformationally Constrained Phosphotyrosyl Mimetics  
Designed as Monomeric src Homology 2 Domain Inhibitors  
AUTHOR(S): Burke, Terrence R., Jr.; Barchi, Joseph J.; George, Clifford; Wolf, Gert; Shoelson, Steven E.; Yan, Xinjian

CORPORATE SOURCE: Division of Cancer Treatment, National Cancer Institute, Bethesda, MD, 20892, USA

SOURCE: Journal of Medicinal Chemistry (1995), 38(8), 1386-96



CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Inhibitors of specific src homol. 2 (SH2) domain binding interactions could potentially afford new therapeutic approaches toward a variety of diseases, including several cancers. To date SH2 domain inhibitors have been confined to small phosphotyrosyl (pTyr)-containing peptides that appear to bind along the surface of SH2 domains with specific recognition features protruding into the protein. Among these protrusions is the pTyr residue itself, which is inserted into a well-formed binding pocket. Monomeric pTyr mimetics were prepared having key aspects of their structure constrained to conformations of the bound pTyr residue observed in the previously reported X-ray structure of a pTyr-peptide bound to the Lck SH2 domain. The resulting constrained pTyr mimetics were examined for inhibitory potency in six SH2 domain constructs: Lck, Src, Grb2, the C-terminal SH2 domains of PLC $\gamma$  (PLC $\gamma$ -C) and the p85 subunit


of PI-3 kinase (p85-C), and the N-terminal SH2 domain of SH PTP2. Although inhibition consts. were in the millimolar range, capping pTyr as its Na-acetyl carboxamide [(L)-1] provided a roughly (2-3)-fold increase in potency relative to free pTyr. Diastereomeric indanylglycine-based analogs (±)-I were essentially inactive. Of note was benzazocine (±)-II. While being racemic and a partial pTyr structure, this analog retained full binding potency of the enantiomerically pure Na-acetyl pTyr amide (L)-1. Modification and elaboration of II could potentially result in small mol. inhibitors having greater potency.

IT 80370-87-2P 162713-88-4P 162713-93-1P  
 162713-97-5P 162714-00-3P 162714-01-4P  
 162714-02-5P 162714-04-7P 162714-07-0P  
 162714-10-5P 162714-11-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of conformationally constrained phosphotyrosyl mimetics designed as SH2 domain inhibitors)


RN 80370-87-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- (CA INDEX NAME)



RN 162713-88-4 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-, ethyl ester (CA INDEX NAME)



RN 162713-93-1 CAPLUS

CN 1H-Indene-1-acetic acid, α-azido-2,3-dihydro-5-methoxy-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162713-97-5 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -cyano-2,3-dihydro-5-methoxy-, ethyl ester, (R\*,S\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 162714-00-3 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -amino-2,3-dihydro-5-methoxy-, methyl ester, (R\*,R\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 162714-01-4 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -(acetylamino)-2,3-dihydro-5-methoxy-, methyl ester, (R\*,R\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 162714-02-5 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -(acetylamino)-2,3-dihydro-5-methoxy-, (R\*,R\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 162714-04-7 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -cyano-2,3-dihydro-5-methoxy-, ethyl ester, (R\*,R\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 162714-07-0 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -amino-2,3-dihydro-5-methoxy-, methyl ester, (R\*,S\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 162714-10-5 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -(acetylamino)-2,3-dihydro-5-methoxy-, methyl ester, (R\*,S\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 162714-11-6 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -(acetylamino)-2,3-dihydro-5-methoxy-, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.






IT 162714-08-1P 162714-09-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of conformationally constrained phosphotyrosyl mimetics  
designed as SH2 domain inhibitors)

RN 162714-08-1 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -amino-2,3-dihydro-5-methoxy-, methyl  
ester, hydrochloride (1:1), ( $\alpha$ R,1R)-rel- (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 162714-09-2 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -amino-2,3-dihydro-5-methoxy-, methyl  
ester, hydrochloride (1:1), ( $\alpha$ R,1S)-rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

OS.CITING REF COUNT: 57 THERE ARE 57 CAPLUS RECORDS THAT CITE THIS  
RECORD (58 CITINGS)

L4 ANSWER 53 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:58372 CAPLUS Full-text

DOCUMENT NUMBER: 122:133436

ORIGINAL REFERENCE NO.: 122:24895a,24898a

TITLE: On the structures of mutisianthol and jungianol

AUTHOR(S): Ho, Tse-Lok; Chen, Chun-Kuei

CORPORATE SOURCE: Dep. Chem., National Taiwan Univ., Taipei, Taiwan

SOURCE: Natural Product Letters (1994), 4(4), 313-20

CODEN: NPLEEF; ISSN: 1057-5634

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A synthesis of cis-1-(5-acetoxy-3,6-dimethyl-1-indanyl)-2-methyl-1-propene was accomplished starting from 3,6-dimethyl-1-indanone. The spectral data differ significantly from those reported for mutisianthol, particularly in the presence of a high-field signal in the NMR spectrum of the final product and various intermediates, consistent with cis-1,3-dialkylindanes. This discrepancy together with similarities in other parts of the spectra suggest a revision of the structure of mutisianthol to the trans isomers. A similar revision for jungianol is also indicated.


IT 168441-81-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of mutisianthol stereoisomer)

RN 188441-81-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-(acetyloxy)-2,3-dihydro-3,6-dimethyl-, ethyl ester, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 54 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:508490 CAPLUS Full-text

DOCUMENT NUMBER: 121:108490

ORIGINAL REFERENCE NO.: 121:19579a,19582a

TITLE: Syntheses and Anticholinesterase Activity of Tetrahydrobenzazepine Carbamates

AUTHOR(S): Chen, Yuhpyng L.; Liston, Dane; Nielsen, Jann; Chapin, Douglas; Dunaikis, Audrey; Hedberg, Kirk; Ives, Jeffery; Johnson, Jonathan Jr.; Jones, Shawn

CORPORATE SOURCE: Departments of Medicinal Chemistry and Neuroscience, Pfizer Inc., Groton, CT, 06340, USA


SOURCE: Journal of Medicinal Chemistry (1994), 37(13), 1996-2000

CODEN: JMCNAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Title carbamates I [R = heptyl, hexyl, Bu, Me; R1 = Me, H; R2 = Et, Me] were prepared from indanacetic acids. Many of these compds. are potent

acetylcholinesterase (AChE) inhibitors. The in vitro AChE inhibition, cholinergic effects, acute toxicity, and elevation of brain acetylcholine levels in vivo of this series of compds. are described. A representative compound, I [R = hexyl, R1 = H, R2 = Me] (5.6 mg/kg, po), was able to reverse hemicholinium-3-induced amnesia in the mouse passive avoidance assay.

IT 156693-37-7P 156693-39-8P 156693-39-9P  
156693-40-2P 156693-41-3P 156693-42-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation and reaction of, in preparation of tetrahydrobenzazepine carbamate

acetylcholinesterase inhibitors)

RN 156693-37-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-3-(hydroxyimino)-6-methoxy-1-methyl-, methyl ester, (3E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 156693-38-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-3-(hydroxyimino)-6-methoxy-1-methyl-, methyl ester, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 156693-39-9 CAPLUS

CN 1H-Indene-1-acetic acid, 3-amino-2,3-dihydro-6-methoxy-1-methyl-, methyl ester, hydrochloride (1:1), (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 156693-40-2 CAPLUS

CN 1H-Indene-1-acetic acid, 3-amino-2,3-dihydro-6-methoxy-1-methyl-, methyl ester, hydrochloride (1:1), (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 156693-41-3 CAPLUS

CN 1H-Indene-1-acetic acid, 3-amino-2,3-dihydro-6-methoxy-1-methyl-, hydrochloride (1:1), (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 156693-42-4 CAPLUS

CN 1H-Indene-1-acetic acid, 3-amino-2,3-dihydro-6-methoxy-1-methyl-, hydrochloride (1:1), (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.




● HCl

IT 39160-47-9

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, in preparation of tetrahydrobenzazepine carbamate  
acetylcholinesterase inhibitors)

RN 39160-47-9 CAPLUS

CN 1H-indene-1-acetic acid, 2,3-dihydro-6-methoxy-1-methyl-3-oxo-, methyl  
ester (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD  
(6 CITINGS)

L4 ANSWER 55 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:134235 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 120:134235

ORIGINAL REFERENCE NO.: 120:23635a,23638a

TITLE: Synthesis and structure activity relationships of cis-  
and trans-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-  
c]pyridines for 5-HT receptor subtypes

AUTHOR(S): Meyer, Michael D.; DeBernardis, John F.; Hancock,  
Arthur A.

CORPORATE SOURCE: Abbott Lab., Abbott Park, IL, 60064, USA

SOURCE: Journal of Medicinal Chemistry (1994),  
37(1), 105-12


CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 120:134235

GI




AB Cis- and trans-fused hexahydroindeno[2,1-c]pyridines were prepared and evaluated for affinity and selectivity at the 5-HT1A subtype of the serotonin receptor. Using mol. modeling studies the authors predicted that the 5-methoxy-trans-fused members of this case would exhibit affinity for this site. In agreement with these predictions, trans-5-methoxy-N-propyl-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-c]pyridine (I) demonstrated moderate affinity and high selectivity for the 5-HT1A binding site, whereas the cis-fused isomer demonstrated virtually no affinity at this site. Addnl. trans-fused analogs from this series, where the N was substituted with alkylene imide containing appendages, demonstrated high (0.60-51 nM) affinity and excellent selectivity for the 5-HT1A site. Certain of these analogs, independent of ring-fusion stereochem., also demonstrated high affinity for the 5-HT2 binding site.

IT 152906-22-4P 152906-23-5P 152906-24-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as intermediate for tetrahydroindeno[2,1-c]pyridine (HT1A receptor agonist))

RN 152906-22-4 CAPLUS

CN 1H-Indene-1-acetic acid, 4-bromo-2-(diethoxymethyl)-2,3-dihydro-7-methoxy-, ethyl ester, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152906-23-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2-(ethoxycarbonyl)-2,3-dihydro-7-methoxy-, ethyl ester, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152906-24-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2-(ethoxycarbonyl)-2,3-dihydro-7-methoxy-, ethyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD  
(8 CITINGS)

L4 ANSWER 56 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:560138 CAPLUS Full-text

DOCUMENT NUMBER: 119:160138

ORIGINAL REFERENCE NO.: 119:28693a,28696a

TITLE: Preparation of benzoisoquinoline derivatives and  
analogs and their use in therapeutics

INVENTOR(S): Romero, Arthur Glenn

PATENT ASSIGNEE(S): Upjohn Co., USA

SOURCE: Eur. Pat. Appl., 48 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 539209	A1	19930428	EP 1992-309695	19921022 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
WO 9308166	A1	19930429	WO 1992-US7314	19920903 <--
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9225593	A	19930521	AU 1992-25593	19920903 <--
JP 07500333	T	19950112	JP 1992-507668	19920903 <--
PRIORITY APPLN. INFO.:			US 1991-782253	A 19911024 <--
			US 1991-795456	A 19911122 <--
			WO 1992-US7314	A 19920903 <--

OTHER SOURCE(S): MARPAT 119:160138


GI



I



II




III

AB Title compds. [I p, s = 1,2; R1 = halo, NC, HO2C, R1-1O2C, H2NCO, R1-1NCO, (R1-1)2NCO, HS, R1-1S, H2N, wherein R1-1 = H, except where p = 1 and s = 2, C1-8 alkyl, C1-8 alkenyl, C6 aryl, substituted heterocyclyl; R2 = H, halo, NC, F3C, HS, etc.; R3 = H, except where p = 1, s = 2, C1-8 alkyl, C1-8 alkenyl, C6 aryl, C3-10 cycloalkyl, substituted heterocyclyl or a salt thereof, showing oral potency and long durations in treatment of CNS disorders associated with serotonin and/or dopamine receptor activity, are prepared (-)-10-Bromo-7-chloro,1,2,3,4,4a,5,6,10b-trans-octahydrobenzo[f]isoquinoline (preparation given), Et3N and CH2Cl2 were combined followed by EtCOCl to give the N-propionyl derivative to which in Et2O was added LiAlH4 in Et2O to give (-)-trans-II. Similarly prepared was (-)-trans-III.

IT 149965-67-3P 149965-68-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction of, in preparation of drug for treatment of CNS disorders)


RN 149965-67-3 CAPLUS

CN 1H-Indene-1,2-diacetic acid, 4-chloro-2,3-dihydro-2-hydroxy-7-methoxy-, 1,2-diethyl ester (CA INDEX NAME)



RN 149965-68-4 CAPLUS

CN 1H-Indene-1,2-diacetic acid, 4-chloro-2,3-dihydro-7-methoxy-, 1,2-diethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L4 ANSWER 57 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:247181 CAPLUS Full-text

DOCUMENT NUMBER: 118:247181

ORIGINAL REFERENCE NO.: 118:42639a,42642a

TITLE: Prostaglandin biosynthesis inhibitory activity of some indan-1 acids in relation to their anti-inflammatory activity and ulcerogenic potency

AUTHOR(S): Mukhopadhyay, A.; Roy, A.; Lahiri, S. C.

CORPORATE SOURCE: Dep. Chem. Technol., Calcutta Univ., Calcutta, 700



SOURCE: 009, India  
 Indian Journal of Experimental Biology (1993  
 ), 31(4), 392-4  
 CODEN: IJEB6; ISSN: 0019-5189

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Continuation of our work towards development of some newer nonsteroidal anti-inflammatory agents led us to some substituted indan-1-acids with low ulcerogenic liability. Prostaglandin biosynthesis inhibitory activity of these indan acids and their acid dissociation consts. were evaluated in view of their activity profile.

IT 62956-64-3 62956-65-4  
 RL: BIOL (Biological study)  
 (prostaglandin formation by lung inhibition by, antiinflammatory and ulcerogenic activity in relation to)


RN 62956-64-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy- (CA INDEX NAME)



RN 62956-65-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
 (1 CITINGS)

L4 ANSWER 58 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:101671 CAPLUS Full-text

DOCUMENT NUMBER: 118:101671

ORIGINAL REFERENCE NO.: 118:17793a,17796a

TITLE: Substituted indenyl compounds useful for treatment of precancerous lesions

INVENTOR(S): Pamukcu, Rifat; Brendel, Klaus

PATENT ASSIGNEE(S): FGN, Inc., USA; University of Arizona

SOURCE: Eur. Pat. Appl., 22 pp.  
 CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 508586	A1	19921014	EP 1992-301821	19920303 <--

EP 508586 B1 19950531  
 R: BE, CH, DE, FR, GB, IT, LI, NL, SE  
 US 5401774 A 19950328 US 1992-839203 19920220 <--  
 PRIORITY APPLN. INFO.: US 1991-666796 A 19910308 <--  
 US 1992-839203 A 19920220 <--  
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): MARPAT 118:101671  
 GI




AB Title sulfones I [R1 = H, alkyl, haloalkyl; R2 = H, alkyl; R3, R4 = H, alkyl, acyloxy, alkoxy, NO2, NH2, acylamino, dialkylamino, dialkylaminoalkyl, sulfamyl, alkylthio, SH, OH, hydroxyalkyl, alkylsulfonyl, halo, cyano, CO2H, carbalkoxy, carbamido, haloalkyl, cycloalkoxy; R5 = alkylsulfonyl; m, n = 0, 1; M = OH, alkoxy, (di)(alkyl)amino, morpholino, hydroxyalkylamino, polyhydroxyamino, dialkylaminoalkylamino, aminoalkylamino, OG where G = cation], related to the antiinflammatory sulfoxide sulindac, and claimed for treatment of precancerous lesions (especially of the colon, breast, and skin), were prepared For example, p-FC6H4CHO was converted in 3 steps to 6-fluoro-2-methylindanone, which was condensed with cyanoacetic acid followed by hydrolysis to give 5-fluoro-2-methylindene-3-acetic acid. This underwent condensation with p-MeSC6H4CHO, followed by S-oxidation in 2 steps, to give I (R1 = R4 = H, R2 = Me, R3 = 5-F, R5 = p-SO2Me, M = OH, m = n = 0) (II). The IC50 of II against various cancer cell lines was (μM): colonic adenocarcinomas SW480, 141; Ht-29, 183; DLD-1, 51; lung carcinoma A-427, 128; breast carcinoma MCF-7, 90; and melanoma UACC 375, 90. The sulfones I do not greatly inhibit prostaglandin synthesis, but retain the antiproliferative effects of nonsteroidal antiinflammatories such as sulindac.

IT 145900-48-7P 145900-53-4P 145900-59-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as intermediate for anticancer agent)  
 RN 145900-48-7 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-1-hydroxy-6-methoxy-2-methyl-, methyl ester (CA INDEX NAME)




RN 145900-53-4 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-1-hydroxy-6-methoxy-α,2-dimethyl-, methyl ester (CA INDEX NAME)



RN 145900-59-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-fluoro-2,3-dihydro-1-hydroxy-6-methoxy-2-methyl-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)

L4 ANSWER 59 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:22000 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 118:22000

ORIGINAL REFERENCE NO.: 118:4133a,4136a

TITLE: Dimerization of 3,4-disubstituted cinnamic acids and esters

AUTHOR(S): Al-Farhan, Emile; Keehn, Philip M.; Stevenson, Robert

CORPORATE SOURCE: Dep. Chem., Brandeis Univ., Waltham, MA, 02254, USA

SOURCE: Synthesis (1992), (10), 959-61


CODEN: SYNIBF; ISSN: 0039-7881

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 118:22000

GI



AB Cinnamic (3-phenylpropenoic) acids and esters bearing hydroxy and/or alkoxy groups at C-3 and C-4 on the benzene ring, I (R1 = Me, Et, H, R2 = Me, R3 = Me, Et, H; R2R3 = CH2), undergo cyclodimerization on treatment with

trifluoroacetic acid to yield the corresponding [t-3-aryl-c-2-carboxy[or  
alkoxycarbonyl]-r-1-indanyl]acetic acids or esters II.


IT 144878-41-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and reduction of)

RN 144878-41-1 CAPLUS

CN 1H-Indene-1-acetic acid, 3-(3,4-dimethoxyphenyl)-2,3-dihydro-5,6-dimethoxy-  
2-(methoxycarbonyl)-, methyl ester, (1a,2a,3β)- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.



IT 128440-94-8P 144878-42-2P 144878-43-3P


144878-46-6P 144939-16-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 128440-94-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2-carboxy-2,3-dihydro-5-hydroxy-3-(4-hydroxy-3-  
methoxyphenyl)-6-methoxy-, (1a,2a,3β)- (9CI) (CA INDEX  
NAME)


Relative stereochemistry.



RN 144878-42-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy-3-(4-hydroxy-3-  
methoxyphenyl)-6-methoxy-2-(methoxycarbonyl)-, methyl ester,  
(1a,2a,3β)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 144878-43-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-ethoxy-3-(4-ethoxy-3-methoxyphenyl)-2,3-dihydro-6-methoxy-2-(methoxycarbonyl)-, methyl ester, (1a,2a,3β)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 144878-46-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2-carboxy-5-ethoxy-3-(4-ethoxy-3-methoxyphenyl)-2,3-dihydro-6-methoxy-, (1a,2a,3β)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 144939-16-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2-carboxy-3-(3,4-dimethoxyphenyl)-2,3-dihydro-5,6-dimethoxy-, (1a,2a,3β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)

L4 ANSWER 60 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:551017 CAPLUS Full-text

DOCUMENT NUMBER: 117:151017

ORIGINAL REFERENCE NO.: 117:26169a

TITLE: 1,4-Disubstituted piperazines, process for their  
preparation, and pharmaceutical compositions  
containing them as 5-HT1A receptor antagonists  
Peglion, Jean Louis; Millan, Mark; Rivet, Jean Michel  
Adir et Compagnie, Fr.

SOURCE: Eur. Pat. Appl., 23 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 490772	A1	19920617	EP 1991-403378	19911213 <--
EP 490772	B1	19950726		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2670491	A1	19920619	FR 1990-15631	19901214 <--
FR 2670491	B1	19930205		
CA 2057578	A1	19920615	CA 1991-2057578	19911213 <--
CA 2057578	C	20010911		
AU 9189762	A	19920618	AU 1991-89762	19911213 <--
AU 638368	B2	19930624		
ZA 9109845	A	19920930	ZA 1991-9845	19911213 <--
US 5194437	A	19930316	US 1991-807106	19911213 <--
ES 2077199	T3	19951116	ES 1991-403378	19911213 <--
JP 06025217	A	19940201	JP 1991-361024	19911216 <--
JP 07035377	B	19950419		

PRIORITY APPLN. INFO.: FR 1990-15631 A 19901214 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 117:151017

GI




AB Title compds. I [X1-X3 = H, halo, alkyl, OH, alkoxy, alkylthio, CF3, NO2, amino, NHAc; or 2 of X form OCH2O or OCH2CH2O; R1 = H, alkyl; DE = (CH2)nCH2 or CH:CH; m, n = 0-3; m+n ≥ 1; p = 0-6; AB = (CH2)2O, (CH2)3O, CH:CH, CH2CH2, COCH:CH], both racemic and optically active, are prepared for treatment of central nervous and neuroendocrine disorders (anxiety, depression, psychosis, diabetes, etc.). For example, N-alkylation of N-(benzodioxan-5-yl)piperazine by (benzocyclobutan-1-yl)methyl iodide and Na2CO3 in MIBK gave (after crystallization from iso-Pr2O) 29% racemic title compound II. In an in vitro test for binding to rat hippocampal 5-HT1A receptors (displacement of [3H]-8-OH-DPAT), pKi was 8.74 for II and 7.93 for buspirone. Addnl. data include 28 synthetic examples, and in vivo animal experiment results (tail flick, body posture, corticosterone secretion, and hypothermia) for selected I.

IT 62956-65-4P 91284-10-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as intermediate for 5-HT1A antagonist)


RN 62956-65-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)



RN 91284-10-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L4 ANSWER 61 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:503806 CAPLUS [Full-text](#)  
DOCUMENT NUMBER: 117:103806  
ORIGINAL REFERENCE NO.: 117:17845a,17848a  
TITLE: Evaluation of some newer non-steroidal  
anti-inflammatory indan-1-acids in various biological  
systems

AUTHOR(S): Mukhopadhyay, A.; Lahiri, S. C.  
CORPORATE SOURCE: Univ. Coll. Sci. Technol., Calcutta Univ., Calcutta,  
700 009, India  
SOURCE: Indian Journal of Experimental Biology (1992  
) , 30(7), 583-6  
CODEN: IJEBAG; ISSN: 0019-5189


DOCUMENT TYPE: Journal  
LANGUAGE: English

AB In line of the effort towards development of some newer indanyl non-steroidal  
anti-inflammatory agents and providing comprehensive SAR among this class of  
comps., some significantly active derivs. with low ulcerogenic potential were  
identified. Dealing with various long-chain and branched-chain comps. among  
this series, 3-(5,6-dimethoxy indan-1-yl)propionic acid, 2-(5,6-  
dimethoxyindan-1-yl)propionic acid and 3-(6-methoxyindan-1-yl) propionic acid  
were observed to have encouraging biol. activity. Screening in various animal  
models of inflammation suggests their longer duration of action and lower  
ulcerogenic liability.

IT 143164-49-2, 2-(5,6-Dimethoxyindan-1-yl)propionic acid  
RL: BIOL (Biological study)  
(as nonsteroidal inflammation inhibitor, ulcerogenic activity in  
relation to)

RN 143164-49-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy- $\alpha$ -methyl- (CA  
INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L4 ANSWER 62 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:497315 CAPLUS [Full-text](#)  
DOCUMENT NUMBER: 117:97315  
ORIGINAL REFERENCE NO.: 117:16811a,16814a  
TITLE: Esters and amides of substituted indenyl acetic acids  
for treatment of colonic polyps


INVENTOR(S): Pamukcu, Rifat; Gross, Paul; Brendel, Klaus  
PATENT ASSIGNEE(S): FGN, Inc., USA; University of Arizona  
SOURCE: Eur. Pat. Appl., 27 pp.  
CODEN: EPXXDW

DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 485172	A2	19920513	EP 1991-310225	199111105 <--
EP 485172	A3	19930127		
R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
AU 9186990	A	19920709	AU 1991-86990	199111104 <--
AU 650689	B2	19940630		
CA 2054952	A1	19920507	CA 1991-2054952	199111105 <--
JP 06025301	A	19940201	JP 1991-350575	199111106 <--
PRIORITY APPLN. INFO.:			US 1990-609829	A 19901106 <--
			US 1991-777429	A 19911011 <--
OTHER SOURCE(S):		MARPAT 117:97315		
GI				



AB Title compds. I (R1 = H, alkyl, haloalkyl; R2 = H, alkyl; R3, R4 = H, alkyl, acyloxy, alkoxy, O2N, H2N, HS, H2NSO2, etc.; R5 = alkylsulphenyl, -sulfinyl, -sulfonyl) useful for treatment or prevention of colonic polyps (no data), are prepared To Na in absolute alc. was added MeCH(CO2Et)2 and 4-(MeS)C6H4CH2Cl to give 4-(MeS)C6H4CH2CHMe(CO2Et)2, which was saponified with NaOH to give 4-(MeS)C6H4CH2CHMeCO2H (II). II was converted in 8 steps to I (R1 = R4 = H, R2 = Me, R3 = MeO, R5 = MeSO, n >10, Q = chitosan).


IT 142958-44-9P

RL: PREP (Preparation)

(preparation of, as intermediate in preparation of polyindenylnylacetyl derivs., for treatment of colon polyp)

RN 142958-44-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-2-methyl-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

L4 ANSWER 63 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN


ACCESSION NUMBER: 1992:448342 CAPLUS Full-text

DOCUMENT NUMBER: 117:48342

ORIGINAL REFERENCE NO.: 117:8618h,8619a  
 TITLE: Preparation of alkoxyhexahydrobenzindoles,  
 -indenopyrroles and -indenopyridines as selective 5-HT  
 receptor agents  
 INVENTOR(S): DeBernardis, John F.; Meyer, Michael D.; Sippy, Kevin  
 B.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: U.S., 25 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5049564	A	19910917	US 1989-438825	19891117 <--
US 5244888	A	19930914	US 1991-727503	19910709 <--
			US 1989-438825	A3 19891117 <--


PRIORITY APPLN. INFO.:  
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): CASREACT 117:48342; MARPAT 117:48342  
 GI




AB Title compds. (I; R1 = H, halo, HS, acylthio, alkylsulfido, O2N, cyano, Ac, etc.; R2 = H, alkyl, aralkyl; R3 = H, alkyl, alkoxy, arylalkylene, substituted benzo-, cyclohexano-, bicycloheterocyclyl, etc., R4 = H, halo, alkyl, alkoxy, arylalkyl; m = 1-3) or a salt thereof, useful as antihypertensives, antidepressants, and anxiolytics, are prepared To PhCH2NH2 in MePh was added Me3Al followed by di-Et 2,3-dihydro-7-methoxy-1H-indene-2-carboxylate-1-acetate (preparation given) in MePh and refluxed to give, after work-up, a mixture of cis- and trans-2-benzyl-5-methoxyhexahydroindenopyridine. The cis isomer was reduced to the cis-indenopiperidine derivative which was hydrogenolyzed over Pd/C to give the debenzylated derivative This derivative was treated with 1-bromo-3-(3,3-tetramethyleneglutarimidyl)propane to give cis-I.HCl [R1 = R4 = H, R2 = Me, R3 = 3-(3,3-tetramethyleneglutarimidyl)propyl, m = 1]. I showed 5-HT selectivity by radioligand binding assay, and in vivo by the ability of the compds. to affect arterial pressure in spontaneously hypertensive rats, e.g. 17.5% decrease in blood pressure at 30 mg/kg.

IT 131818-62-7P 131841-31-1P 138967-86-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction of, in preparation of 5-HT selective agents)


RN 131818-62-7 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2-(diethoxymethyl)-2,3-dihydro-7-methoxy-, ethyl ester (CA INDEX NAME)



RN 131841-31-1 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2-(ethoxycarbonyl)-2,3-dihydro-7-methoxy-, ethyl ester (CA INDEX NAME)




RN 138967-86-9 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2-formyl-2,3-dihydro-7-methoxy-, ethyl ester (CA INDEX NAME)




OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)  
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 64 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1992:255474 CAPLUS Full-text  
 DOCUMENT NUMBER: 116:255474  
 ORIGINAL REFERENCE NO.: 116:43311a,43314a  
 TITLE: Preparation of indanopyrrolidinyl carbamates and analogs as cholinesterase inhibitors and analgesic agents  
 INVENTOR(S): Chen, Yuhpyng L.  
 PATENT ASSIGNEE(S): Pfizer Inc., USA  
 SOURCE: PCT Int. Appl., 43 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9200961	A1	19920123	WO 1991-US4320	19910625 <--
W: CA, FI, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
EP 538314	A1	19930428	EP 1991-912538	19910625 <--
EP 538314	B1	19970618		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05503293	T	19930603	JP 1991-511778	19910625 <--
JP 07020933	B	19950308		
AT 154598	T	19970715	AT 1991-912538	19910625 <--
ES 2103816	T3	19971001	ES 1991-912538	19910625 <--
CA 2086433	C	20000125	CA 1991-2086433	19910625 <--
FI 104716	B1	20000331	FI 1993-92	19930111 <--
FI 2000000051	A	20000111	FI 2000-51	20000111 <--
PRIORITY APPLN. INFO.:			US 1990-551970	A2 19900712 <--
			WO 1991-US4320	W 19910625 <--
OTHER SOURCE(S):		MARPAT 116:255474		
GI				



I




II

AB Title compds. [I; R1 = H, (cyclo)alkyl, alkenyl, (substituted) phenyl(alkyl), heteroarylalkyl; R3, R4 = H, alkyl, OH, halo, alkoxy, (di)(alkyl)amino; R3R4 = O; R5, R6, R8 = H, alkyl, (substituted) Ph, etc.; R7 = OH, SH, alkoxy, O2CNH2, etc.; R9 = H, alkyl, alkoxy, OH; R10, R11 = H, alkyl, Ph, PhCH2] were prepared Thus, 1-methyl-6-methoxy-1-indene (preparation from 6-methoxy-1-indanone given) was cyclocondensed with Cl3CCOCl and the dehalogenated product oximated to give tricyclic oxime II (X = NOH, Z = bond) which was rearranged to give II (X = O, Z = NH). I (R1 = alkyl, R7 = OMe) were converted to N-alkyl carbamates of I (R1 = alkyl, R7 = OH) which had IC90 of 1-10  $\mu$ M against cholinesterase in vitro.

IT 25574-42-9P, Methyl 5-methoxy-1-indanone-3-acetate  
 36286-07-4P 39160-47-9P 39160-49-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction of, in preparation of analgesics and cholinesterase inhibitors)


RN 25574-42-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo-, methyl ester (CA INDEX NAME)




RN 36286-07-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-2-(hydroxyimino)-6-methoxy-3-oxo-, methyl ester (CA INDEX NAME)




RN 39160-47-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-1-methyl-3-oxo-, methyl ester (CA INDEX NAME)



RN 39160-49-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-2-(hydroxyimino)-6-methoxy-1-methyl-3-oxo-, methyl ester (CA INDEX NAME)




IT 24467-92-3, 5-Methoxy-1-indanone-3-acetic acid

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in preparation of analgesics and cholinesterase inhibitors)

RN 24467-92-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 65 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:235207 CAPLUS Full-text

DOCUMENT NUMBER: 116:235207

ORIGINAL REFERENCE NO.: 116:39825a,39828a

TITLE: Investigation on synthesis, hypotensive activity and highly selective adrenergic antagonistic activity of some simple and substituted indan derivatives

AUTHOR(S): Ray, S. M.; Lahiri, S. C.

CORPORATE SOURCE: Dep. Pharm. Technol., Jadavpur Univ., Calcutta, 700 032, India

SOURCE: Journal of the Indian Chemical Society (1991), 68(10), 549-55

CODEN: JICSAH; ISSN: 0019-4522

DOCUMENT TYPE: Journal

LANGUAGE: English


AB A few simple and substituted indan derivs. with C:(N-)N: terminal groups in the form of amidoximes, imidazolines, and tetrazoles as the pharmacophore were synthesized and were screened for hypotensive activity in rats. It was observed that nuclear methoxy substitution and chain length of the indan-1-alkanoic acids impart profound effects on the yields of indanylimidazolines. Some of the compds. were significantly active and two compds. on the contrary were found to be hypertensive. Some anomalous responses on autonomic challenge after administration of test agents suggested the existence of epinephrine-specific receptor system as the explanation.

IT 62956-64-3 62956-65-4

RL: RCT (Reactant); RACT (Reactant or reagent) (reactions of)


RN 62956-64-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy- (CA INDEX NAME)



RN 62956-65-4 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)




OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD

(5 CITINGS)

L4 ANSWER 66 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1992:214730 CAPLUS [Full-text](#)  
DOCUMENT NUMBER: 116:214730  
ORIGINAL REFERENCE NO.: 116:36401a,36404a  
TITLE: Cyclizations involving indan derivatives with aryl participation. A total synthesis of ( $\pm$ )-isolongifolene  
AUTHOR(S): Das, Swati; Karpha, Tapan K.; Ghosal, Manuka; Mukherjee, Debabrata  
CORPORATE SOURCE: Dep. Org. Chem., Indian Assoc. Cultiv. Sci., Calcutta, 700 032, India  
SOURCE: Tetrahedron Letters (1992), 33(9), 1229-32  
CODEN: TELEAY; ISSN: 0040-4039  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 116:214730  
GI




AB A total synthesis of ( $\pm$ )-isolongifolene (I) was accomplished using intramol. anionic cyclization of the bromophenol (II) as the key step. Aryl participated intramol. cyclization of the diazomethyl ketones III provided the dienedione IV and which was stereoselectively converted into the diketone V.  
IT 140869-39-2P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and conversion to diazomethyl ketone)  
RN 140869-39-2 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-7-methoxy-1,3,3-trimethyl- (CA INDEX NAME)




OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD

(4 CITINGS)

L4 ANSWER 67 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1992:194652 CAPLUS Full-text  
DOCUMENT NUMBER: 116:194652  
ORIGINAL REFERENCE NO.: 116:33001a,33004a  
TITLE: Syntheses, resolution, and structure-activity relationships of potent acetylcholinesterase inhibitors: 8-carbaphysostigmine analogs  
AUTHOR(S): Chen, Yuhpyng L.; Nielsen, Jann; Hedberg, Kirk; Dunaiskis, Audrey; Jones, Shawn; Russo, Lorena; Johnson, Jonathan; Ives, Jeffrey; Liston, Dane  
CORPORATE SOURCE: Cent. Res. Div., Pfizer Inc., Groton, CT, 06340, USA  
SOURCE: Journal of Medicinal Chemistry (1992), 35(8), 1429-34  
CODEN: JMCMAR; ISSN: 0022-2623  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI



AB The syntheses of a series of 1,2,3,3a,8,8a-hexahydroindeno[2,1-b]pyrrole 5-alkylcarbamates, e.g. I (R = hexyl, heptyl), and their resolution are reported. 1-Methyl-6-methoxy-3H-indene and 5-methoxy-1-indanone-3-acetic acid were used as starting materials. These compds. are structurally related to physostigmine with substitution of a methylene group in place of the NMe group at position 8 of physostigmine. Many of these 8-carbaphysostigmine analogs are more potent acetylcholinesterase inhibitors in vitro and less toxic in vivo than physostigmine. The (-)-enantiomer, e.g. I (R = hexyl, heptyl), possessing the same absolute configuration at C3a and C8a as that of physostigmine, is about 6 to 12-fold more potent at inhibiting acetylcholinesterase than the corresponding (+)-enantiomer, e.g. I (R = hexyl, heptyl).  
IT 24467-92-3  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(esterification of)  
RN 24467-92-3 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



IT 36285-07-4P 39160-49-1P




RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation and intramol. cyclization of)


RN 36286-07-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-2-(hydroxyimino)-6-methoxy-3-oxo-,  
methyl ester (CA INDEX NAME)



RN 39160-49-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-2-(hydroxyimino)-6-methoxy-1-methyl-3-oxo-, methyl ester (CA INDEX NAME)




IT 25574-42-9P 39160-47-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation and oximation of)


RN 25574-42-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo-, methyl ester (CA  
INDEX NAME)



RN 39160-47-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-1-methyl-3-oxo-, methyl  
ester (CA INDEX NAME)



OS.CITING REF COUNT: 26 THERE ARE 26 CAPLUS RECORDS THAT CITE THIS RECORD (27 CITINGS)

L4 ANSWER 68 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:128327 CAPLUS Full-text

DOCUMENT NUMBER: 116:128327

ORIGINAL REFERENCE NO.: 116:21707a,21710a

TITLE: Preparation of N-benzoyl-1-(5,6-dimethoxyindan-1-yl)ethan-1-one

AUTHOR(S): Tombari, D. G.; Moglioni, A. G.; Dominici, F. P.; Moltrasio de Iglesias, G. Y.

CORPORATE SOURCE: Fac. Farm. Bioquim., Univ. Buenos Aires, Buenos Aires, 1113, Argent.

SOURCE: Organic Preparations and Procedures International (1992), 24(1), 45-8


CODEN: OPPIAK; ISSN: 0030-4948

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 116:128327

GI




AB Title indan-1-ylmethanamine I was prepared from 5,6-dimethoxy-1-indanone by cyanation with tosylmethyl isocyanide, followed by reduction of the CN group with LiAlH<sub>4</sub> and acylation with BzCl.

IT 91284-10-5F

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and hydrazinolysis of)

RN 91284-10-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)

L4 ANSWER 69 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1992:41982 CAPLUS Full-text  
 DOCUMENT NUMBER: 116:41982  
 ORIGINAL REFERENCE NO.: 116:7233a,7236a  
 TITLE: Preparation of modified gangliosides and their  
 functional derivatives as drugs and pharmaceutical  
 compositions containing them  
 INVENTOR(S): Della Valle, Francesco; Romeo, Aurelio  
 PATENT ASSIGNEE(S): Fidia S.p.A., Italy  
 SOURCE: Eur. Pat. Appl., 49 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 433112	A1	19910619	EP 1990-403220	19901114 <--
EP 433112	B1	19981028		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
BR 9005758	A	19910924	BR 1990-5758	19901113 <--
US 5264424	A	19931123	US 1990-611700	19901113 <--
NO 174775	B	19940328	NO 1990-4921	19901113 <--
NO 174775	C	19940706		
CA 2029974	A1	19910515	CA 1990-2029974	19901114 <--
AU 9066624	A	19910523	AU 1990-66624	19901114 <--
AU 645766	B2	19940127		
HU 55403	A2	19910528	HU 1990-7124	19901114 <--
HU 210744	B	19950728		
CN 1051912	A	19910605	CN 1990-109290	19901114 <--
CN 1033031	C	19961016		
JP 03170491	A	19910724	JP 1990-310149	19901114 <--
AT 172737	T	19981115	AT 1990-403220	19901114 <--
ES 2124214	T3	19990201	ES 1990-403220	19901114 <--
US 5424294	A	19950613	US 1993-138184	19931020 <--
PRIORITY APPLN. INFO.:			IT 1989-48554	A 19891114 <--
			US 1990-611700	A3 19901113 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Title gangliosides, useful for treatment of cerebral ischemia, metabolic encephalopathies, encephalopathies of toxic origin, trauma, aging, epilepsy, neurodegenerative diseases, and/or mental disorders, are prepared from gangliosides which are extracted from animal tissues, e.g., bovine brain tissue. E.g., N-lyso GM1 (preparation from GM1 given) in DMF containing Et3N was treated with 2-furoic acid and 1-methyl-2-chloropyridinium iodide at room temperature for 18 h to give 75% N-2-furoyl-N-lyso GM1 (I). Detailed procedures for extracting gangliosides from bovine brain tissue is described. In a study on its ability to antagonize glutamate-induced neurotoxicity in primary cultures of cerebellar granule cells, I at 1 + 10-4 M effected a cell survival index of 0.12 ± 0.003 using MTT. Many pharmaceutical compns. containing title acyllysogangliosides were formulated.

IT 24467-92-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (acylation by, of lysoganglioside derivative)  
 RN 24467-92-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)




OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD  
(22 CITINGS)

L4 ANSWER 70 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:20791 CAPLUS Full-text  
DOCUMENT NUMBER: 116:20791  
ORIGINAL REFERENCE NO.: 116:3663a,3666a  
TITLE: Preparation of indane derivatives as herbicides  
INVENTOR(S): Chrystal, Ewan James Turner; Barton, John Edward  
Duncan; Cartwright, David  
PATENT ASSIGNEE(S): Imperial Chemical Industries PLC, UK  
SOURCE: Eur. Pat. Appl., 26 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 453066	A1	19911023	EP 1991-300956	19910206 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AU 9170889	A	19910822	AU 1991-70889	19910207 <--
US 5167696	A	19921201	US 1991-652815	19910207 <--
JP 05017386	A	19930126	JP 1991-216748	19910215 <--
PRIORITY APPLN. INFO.: GB 1990-3551			A 19900216 <--	
OTHER SOURCE(S): MARPAT 116:20791				

GI



AB Title compds. I [Ar = (substituted)aryl, (substituted) heterocyclyl; W = O, NR1; R1 = H, C1-3 alkyl; A = :CH, CH2 and B = :CR2, CR3R4, or C:R5 such that BA = CR2:CH or CR6R7XR8; or BA = CR3R4CH2, C:(R5)CH2; R2 = H; CR3R4 = CHCR6R7XR8, CHOCR6R7CR8, CR9OCOR10, CR9R10, CR9OR10, C(OR9)OR10, CHCH2CO2R11; R5 = CR7XR8, :NOCR6R7R8, :NOR11, :NOCOR11; X = (CH2)n, CH:CH, etc.; n = 0-2; R6, R7 = H, (substituted) alkyl, alkenyl or alkynyl, halo, NR9R10; or CR6R7 = cycloalkyl, etc.; R8 = CO2R12, cyano, COR12, CH2OR22, etc.; R9, R10 = H,


(substituted) alkyl, alkenyl, etc.; CR9R10 = cycloalkenyl, heterocyclyl; R11, R12 = H, (substituted) alkyl, aryl, alkenyl or alkynyl were prepared as herbicides. Thus, 3-chloro- $\alpha,\alpha,\alpha,4,5$ -pentafluorotoluene was condensed with 6-hydroxyindan-1-one in the presence of  $K_2CO_3$  and the product was condensed with  $(EtO)3P(O)CH_2CO_2Et$ . The olefin formed was hydrogenated in the presence of 5% Pd/C to give title compound II. II gave 90-100% preemergent control of *Amaranthus retroflexus* without damage to sugar beets, maize, winter wheat, or rice.

IT 138171-72-9P 138171-73-6P 138171-75-2P  
 138171-81-0P 138171-82-1P 138171-83-2P  
 138171-84-3P 138171-85-4P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide)


RN 138171-72-9 CAPLUS

CN 1H-Indene-1-acetic acid, 6-[2-chloro-6-fluoro-4-(trifluoromethyl)phenoxy]-2,3-dihydro- (CA INDEX NAME)




RN 138171-73-0 CAPLUS

CN 1H-Indene-1-acetic acid, 6-[2-chloro-6-fluoro-4-(trifluoromethyl)phenoxy]-2,3-dihydro-, methyl ester (CA INDEX NAME)




RN 138171-75-2 CAPLUS

CN 1H-Indene-1-acetic acid, 6-[2-chloro-6-fluoro-4-(trifluoromethyl)phenoxy]-2,3-dihydro-, ethyl ester (CA INDEX NAME)




RN 138171-81-0 CAPLUS

CN 1H-Indene-1-acetic acid, 6-[2-chloro-6-fluoro-4-(trifluoromethyl)phenoxy]-  
2,3-dihydro-, 1-methylethyl ester (CA INDEX NAME)




RN 138171-82-1 CAPLUS

CN 1H-Indene-1-acetic acid, 6-[2-chloro-6-fluoro-4-(trifluoromethyl)phenoxy]-  
2,3-dihydro-, 2-methoxyethyl ester (CA INDEX NAME)




RN 138171-83-2 CAPLUS

CN 1H-Indene-1-acetic acid, 6-[2-chloro-6-fluoro-4-(trifluoromethyl)phenoxy]-  
2,3-dihydro-, 2-oxopropyl ester (CA INDEX NAME)




RN 138171-84-3 CAPLUS

CN 1H-Indene-1-acetic acid, 6-[2-chloro-6-fluoro-4-(trifluoromethyl)phenoxy]-  
2,3-dihydro-, butyl ester (CA INDEX NAME)




RN 138171-85-4 CAPLUS  
 CN 1H-Indene-1-acetic acid, 6-[2-chloro-6-fluoro-4-(trifluoromethyl)phenoxy]-  
 2,3-dihydro-, 2-propyn-1-yl ester (CA INDEX NAME)




IT 138003-48-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as intermediate for herbicides)  
 RN 138003-48-2 CAPLUS  
 CN 1H-Indene-1-acetic acid, 6-[2-chloro-6-fluoro-4-(trifluoromethyl)phenoxy]-  
 2,3-dihydro-, ethyl ester, dihydro deriv. (9CI) (CA INDEX NAME)

CM 1

CRN 138171-75-2  
 CME C20 H17 Cl F4 O3



L4 ANSWER 71 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1992:6395 CAPLUS Full-text  
 DOCUMENT NUMBER: 116:6395  
 ORIGINAL REFERENCE NO.: 116:1263a,1266a  
 TITLE: A regiospecific synthesis of  
 8-methoxy-1,2,3,4,5,6-hexahydro-1,6-methano-3-  
 benzazocines  
 AUTHOR(S): Mazzocchi, P. H.; Kordoski, E. W.; Harrison, A. M.  
 CORPORATE SOURCE: Dep. Chem. Biochem., Univ. Maryland, College Park, MD,  
 20742, USA  
 SOURCE: Journal of Heterocyclic Chemistry (1991),  
 28(6), 1625-7  
 CODEN: JHTCAD; ISSN: 0022-152X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 116:6395  
 GI




AB Methoxyhexahydromethanobenzazocine I was prepared in 21% overall yield from 6-methoxy-1-indanone (II) via intramol. cyclocondensation of (aminoalkyl)(bromoalkyl)methoxyindans III (R = NH<sub>2</sub>, R<sub>1</sub> = Br, R = Br, R<sub>1</sub> = NH<sub>2</sub>).

IT 137813-05-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and hydride reduction of)

RN 137813-05-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-(methoxycarbonyl)-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L4 ANSWER 72 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1991:471419 CAPLUS Full-text

DOCUMENT NUMBER: 115:71419

ORIGINAL REFERENCE NO.: 115:12339a,12342a

TITLE: Preparation of benzazabicyclic carbamates as cholinesterase inhibitors

INVENTOR(S): Chen, Yuhpyng L.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: Eur. Pat. Appl., 25 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 415634	A2	19910306	EP 1990-309186	19900822 <--



EP 415634	A3	19920617		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
WO 9103467	A1	19910321	WO 1989-US3760	19890830 <--
W: FI, HU, NO, RO, SU, US				
CA 2024162	A1	19910301	CA 1990-2024162	19900828 <--
CA 2024162	C	19980127		
JP 03118366	A	19910520	JP 1990-229544	19900830 <--
JP 06092373	B	19941116		
US 5387590	A	19950207	US 1992-835904	19920228 <--
FI 98459	B	19970314	FI 1992-933	19920302 <--
FI 98459	C	19970625		
US 5594002	A	19970114	US 1994-328205	19941025 <--
PRIORITY APPLN. INFO.:			WO 1989-US3760	A 19890830 <--
			US 1992-835904	A3 19920228 <--
OTHER SOURCE(S):	MARPAT 115:71419			
GI				



AB The title compds. [I; R1 = H, C1-4 alkyl, C1-8 cycloalkyl, (substituted) aralkyl, etc.; R2 = C(Z)NR5R6 (wherein Z = O, S; R5R6N = heterocyclyl); R3 = H, C1-4 alkyl, alkoxy, NH2, etc.; R4 = H, cyano, C1-4 alkyl, halo, Ph, etc.; l, m, n, p, q, r = 0-3; X = O, S], effective cholinesterase inhibitors useful as memory enhancers and analgesics, are prepared. Acid hydrolysis of 4 g ester II (R = Me) in HCl gave 3.7 g acid II (R = H), which (3.6 g) was dissolved in pyridine and stirred with 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide-Me tosylate to give 1.1 g benzazapinone derivative III (Y = O) (IV). Reduction of 1.03 g IV with borane-THF complex gave 0.96 g benzazapine III (Y = 2H), which (0.9 g) was acetylated and reduced to give 0.83 g V (R7 = MeO) (VI). Hydrolysis of 0.6 g VI in 48% HBr gave 0.43 g phenol V (R7 = H), which was treated with 1.1 equiv NaH and 1.0 equiv Me(CH2)5NCO to give carbamate V [R7 = Me(CH2)5NHCO]. Also prepared were 11 addnl. I, which were active at 1-300 mg/day orally.


IT 33160-47-9

RL: RCT (Reactant); RACT (Reactant or reagent)


(oxidation of, in preparation of cholinesterase inhibitors)

RN 39160-47-9 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-1-methyl-3-oxo-, methyl ester (CA INDEX NAME)



IT 135110-32-6P 135110-33-7P 135110-34-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and reaction of, in preparation of cholinesterase inhibitors)  
 RN 135110-32-6 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-3-(hydroxyimino)-6-methoxy-1-methyl-,  
 methyl ester (CA INDEX NAME)




RN 135110-33-7 CAPLUS  
 CN 1H-Indene-1-acetic acid, 3-amino-2,3-dihydro-6-methoxy-1-methyl-, methyl  
 ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 135110-34-8 CAPLUS  
 CN 1H-Indene-1-acetic acid, 3-amino-2,3-dihydro-6-methoxy-1-methyl-,  
 hydrochloride (1:1) (CA INDEX NAME)





● HCl

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L4 ANSWER 73 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1991:81570 CAPLUS Full-text  
 DOCUMENT NUMBER: 114:81570  
 ORIGINAL REFERENCE NO.: 114:13917a,13920a  
 TITLE: Preparation of alkoxyindenopyrroles as selective  
 5-HT1A agonists.  
 INVENTOR(S): Debernardis, John F.; Meyer, Michael D.; Sippy, Kevin  
 B.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: PCT Int. Appl., 89 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9006927	A1	19900628	WO 1989-US5512	19891207 <--
W: AU, DK, JP, KR				
RW: AT, BE, CH, DE, ES, FR, GB, IT, LU, NL, SE				
AU 9047460	A	19900710	AU 1990-47460	19891207 <--
AU 626621	B2	19920806		
EP 422134	A1	19910417	EP 1990-900592	19891207 <--
EP 422134	B1	19960612		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
JP 03502701	T	19910620	JP 1990-500906	19891207 <--
AT 139230	T	19960615	AT 1990-900592	19891207 <--
ES 2090119	T3	19961016	ES 1990-900592	19891207 <--
CA 2005441	A1	19900615	CA 1989-2005441	19891213 <--
DK 9001944	A	19901012	DK 1990-1944	19900815 <--
DK 171061	B1	19960513		
DK 9500245	A	19950310	DK 1995-245	19950310 <--
PRIORITY APPLN. INFO.:			US 1988-285134	A 19881215 <--
			WO 1989-US5512	A 19891207 <--
OTHER SOURCE(S): MARPAT 114:81570				
GI				



AB Title compds. I (R1 = H, electron withdrawing group; R2 = H, alkyl, aralkyl; R3 = H, alkyl, alkoxy, arylalkyl, arylalkylene, heterocyclyl, etc.; R4 = H, halo, alkyl, alkoxy, arylalkyl, R2R4 = alkylenedioxy bridge; m, n = 1-3), useful in treatment of hypertension, anxiety and depression are prepared I [R1 = H, R2 = Me, R3 = 4-(3,3-tetramethyleneglutarimidyl)butyl, m = n = 1] [preparation starting from Et 3-(2-bromo-5-methoxyphenyl)propionate and diethyl oxalate given] in CH2Cl2 and AcOH cooled to 0° was treated with Cl1 in AcOH to give title compound II. II at 30 mg/kg in spontaneously hypertensive rats decreased blood pressure by 37%. Radioligand binding ability at 5-HT receptors for I is also shown.

IT 131818-62-7P 131818-63-8P 131819-15-3P


131841-31-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of serotonergic agonists)

RN 131818-62-7 CAPLUS


CN 1H-Indene-1-acetic acid, 2-(diethoxymethyl)-2,3-dihydro-7-methoxy-, ethyl ester (CA INDEX NAME)



RN 131818-63-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2-formyl-2,3-dihydro-7-methoxy-, ethyl ester, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 131819-15-3 CAPLUS


CN 1H-Indene-1-acetic acid, 2-formyl-2,3-dihydro-7-methoxy-, ethyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 131841-31-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2-(ethoxycarbonyl)-2,3-dihydro-7-methoxy-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 74 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1990:515001 CAPLUS Full-text

DOCUMENT NUMBER: 113:115001

ORIGINAL REFERENCE NO.: 113:19483a,19486a


TITLE: Hypervalent iodine oxidation of 5-keto acids and 4,6-diketo acids with [hydroxy(tosyloxy)iodo]benzene: synthesis of keto- $\gamma$ -lactones and diketo- $\delta$ -lactones

AUTHOR(S): Moriarty, R. M.; Vaid, R. K.; Hopkins, T. E.; Vaid, B. K.; Prakash, O.

CORPORATE SOURCE: Chem. Dep., Univ. Illinois, Chicago, IL, 60680, USA

SOURCE: Tetrahedron Letters (1990), 31(2), 201-4

DOCUMENT TYPE: CODEN: TELEAY; ISSN: 0040-4039  
 LANGUAGE: Journal  
 OTHER SOURCE(S): English  
 CASREACT 113:115001  
 GI




AB Hypervalent iodine oxidation of 5-ketoacids, using [hydroxy(tosyloxy)iodo]benzene (I) in CH<sub>2</sub>Cl<sub>2</sub> under refluxing conditions yielded keto-γ-lactones. Oxidation of 4,6-diketoacids with [hydroxy(tosyloxy)iodo]benzene at room temperature afforded the corresponding diketo-δ-lactones. Thus, oxidation of keto acid II with I in CH<sub>2</sub>Cl<sub>2</sub> gave 76% γ-lactone III whereas oxidation of diketo acid PrCOCH<sub>2</sub>COCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H under similar conditions gave δ-lactone IV.

IT 24467-92-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (oxidation of, with [hydroxy(tosyloxy)iodo]benzene, cyclization in)

RN 24467-92-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 28 THERE ARE 28 CAPLUS RECORDS THAT CITE THIS RECORD (30 CITINGS)

L4 ANSWER 75 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1990:474788 CAPLUS Full-text  
 DOCUMENT NUMBER: 113:74788  
 ORIGINAL REFERENCE NO.: 113:12577a,12580a  
 TITLE: Monomeric and dimeric phenolic constituents of plant cell walls - possible factors influencing wall biodegradability  
 AUTHOR(S): Eraso, Fatima; Hartley, Roy D.  
 CORPORATE SOURCE: Inst. Grassl. Anim. Prod., AFRC, Maidenhead/Berkshire, SL6 5LR, UK  
 SOURCE: Journal of the Science of Food and Agriculture ( 1990), 51(2), 163-70  
 CODEN: JSFAAE; ISSN: 0022-5142  
 DOCUMENT TYPE: Journal

LANGUAGE: English

AB A range of plant cell walls from graminaceous and leguminous plants was examined qual. and quant. for monomeric and dimeric phenolic constituents that were released by treatment with NaOH. The total amts. of phenolics released from the walls of the graminaceous plants varied from 8 to 28 mg g<sup>-1</sup> walls compared with <3 mg g<sup>-1</sup> walls from the legumes. p-Coumaric and ferulic acids were the major components of the monomeric fraction. The cell walls also contained substituted cyclobutanes having mol. wts. equal to two p-coumaric acid mols., two ferulic acid mols. or one p-coumaric plus one ferulic acid mol. All the walls contained dehydrodiferulic acid. If it is assumed that the substituted cyclobutanes and dehydrodiferulic acid arise from dimerization of feruloyl and p-coumaroyl groups linked to cell wall polysaccharides, then, for the graminaceous walls, it is calculated that between 5 and 14% of these groups had converted to dimers. This dimerization process may limit the biodegradability of the wall polysaccharides.

IT 128440-93-7 128440-94-8


RL: BIOL (Biological study)

(of plant cell walls, biodegradability in relation to)

RN 128440-93-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2-carboxy-2,3-dihydro-5-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-6-methoxy-, (1 $\alpha$ ,2 $\beta$ ,3 $\alpha$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 128440-94-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2-carboxy-2,3-dihydro-5-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-6-methoxy-, (1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ )- (9CI) (CA INDEX NAME)

Relative stereochemistry.




OS.CITING REF COUNT: 35 THERE ARE 35 CAPLUS RECORDS THAT CITE THIS RECORD (35 CITINGS)

L4 ANSWER 76 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1990:216969 CAPLUS Full-text  
 DOCUMENT NUMBER: 112:216969  
 ORIGINAL REFERENCE NO.: 112:36637a,36640a  
 TITLE: Azinylalkanoates as herbicides  
 INVENTOR(S): Kaku, Koichiro; Wada, Nobuhide; Sugiyama, Kazuhiko; Takeuchi, Akira; Toyokawa, Yasufumi; Miyazawa, Takeshige; Yoshida, Ryo  
 PATENT ASSIGNEE(S): Kumiai Chemical Industry Co., Ltd., Japan; Ihara Chemical Industry Co., Ltd.  
 SOURCE: Eur. Pat. Appl., 73 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 347811	A1	19891227	EP 1989-111133	19890619 <--
EP 347811	B1	19940330		
R: CH, DE, FR, GB, IT, LI, NL				
JP 02085262	A	19900326	JP 1989-154635	19890619 <--
JP 2771604	B2	19980702		
US 4968340	A	19901106	US 1989-368808	19890620 <--
US 5087289	A	19920211	US 1990-571118	19900823 <--
PRIORITY APPLN. INFO.:			JP 1988-150063	A 19880620 <--
			US 1989-368808	A3 19890620 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): CASREACT 112:216969; MARPAT 112:216969  
 GI



AB The title compds. [I; R = Q<sub>1</sub>, Q<sub>2</sub>, alkenyl, dihydronaphthyl, tetrahydronaphthyl, 1-oxo-1,2,3,4-tetrahydronaphthyl, epoxycycloalkyl, (substituted) indanyl; R<sub>1</sub> = H, (substituted) alkyl, alkenyl, alkynyl, Ph, amino, cycloalkyl, nitrophenylthioalkyl, halo, (substituted) benzyl; R<sub>R1</sub> = atoms to complete a ring; R<sub>2</sub>, R<sub>4</sub> = H, alkyl; R<sub>2</sub>R<sub>4</sub>C = (O-containing) ring; R<sub>3</sub> = H, halo, (substituted) alkyl, OH, cyano, thienyl, naphthyl, dihydronaphthyl, Q<sub>3</sub>; R<sub>5</sub>, R<sub>6</sub> = H, alkyl; R<sub>7</sub> = Ph, alkyl; R<sub>8</sub> = H, halo, NO<sub>2</sub>, alkyl, alkoxy, alkylsulfonyl, etc.; A = alkyl, alkoxy, alkylthio, halo, haloalkoxy, amino; B




= H, alkyl, alkoxy, haloalkoxy; X = O, S; Z = CH, N; m = 0-2], were prepared  
Thus, a mixture of Me2PhCCH(OH)CO2Et, 4,6-dimethoxy-2-methylsulfonylpyrimidine, and K2CO3 in DMF was stirred 3 h at 100° to give pyrimidinylxybutyrate II. II at 40 g/are postemergent gave complete control of barnyard grass.

IT 127014-51-1P 127014-52-2F

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide)


RN 127014-51-1 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -[(4,6-dimethoxy-2-pyrimidinyl)oxy]-2,3-dihydro-4-methoxy- (CA INDEX NAME)



RN 127014-52-2 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -[(4,6-dimethoxy-2-pyrimidinyl)oxy]-2,3-dihydro-4-methoxy-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

L4 ANSWER 77 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1989:633251 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 111:233251

ORIGINAL REFERENCE NO.: 111:38757a,38760a

TITLE: Selective reduction of dienones. Synthesis of intermediates for sesqui- and diterpenes

AUTHOR(S): Bhattacharyya, Sukanta; Kapha, Tapan K.; Mukherjee, Debabrata

CORPORATE SOURCE: Dep. Org. Chem., Indian Assoc. Cultiv. Sci., Calcutta, 700 032, India

SOURCE: Synthetic Communications (1989), 19(3-4), 673-8

CODEN: SYNCV; ISSN: 0039-7911

DOCUMENT TYPE: Journal

LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 111:233251  
 GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Tricyclic enones I (R = Me, R1 = H; R = H, R1 = Me), II (R2 = H, Me) and III, intermediates for several sesqui- and diterpenes, were prepared in high yields via selective hydrogenation of the disubstituted double bonds of IV-VI in the presence of (Ph3P)3RhCl catalyst.

IT 123870-30-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and chlorination of)

RN 123870-30-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-1,3,3-trimethyl- (CA INDEX NAME)




IT 123870-35-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and conversion of, to diazoketone)

RN 123870-35-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ ,3,3-trimethyl-, (R\*,R\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



IT 123870-38-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and deethoxycarbonylation of)

RN 123870-38-2 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -cyano-2,3-dihydro-5-methoxy-1,3,3-trimethyl-, ethyl ester (CA INDEX NAME)




IT 123870-34-8P 123870-41-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and hydrolysis of)

RN 123870-34-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ ,3,3-trimethyl-,  
methyl ester, (R\*,R\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 123870-41-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ ,3,3-trimethyl-,  
methyl ester, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 123870-43-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 123870-43-9 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- $\alpha$ ,3,3-trimethyl-,  
(R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD  
(4 CITINGS)

L4 ANSWER 78 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1988:473096 CAPLUS Full-text  
 DOCUMENT NUMBER: 109:73096  
 ORIGINAL REFERENCE NO.: 109:12229a,12232a  
 TITLE: Studies on the Friedel-Crafts reaction. Part III.  
 Friedel-Crafts reaction of 2,3-diarylpentanedioic  
 anhydride  
 AUTHOR(S): Khadilkar, B. M.; Joshi, U. R.; Samant, S. D.  
 CORPORATE SOURCE: Org. Chem. Lab., Univ. Dep. Chem. Technol., Bomba, 400  
 019, India  
 SOURCE: Indian Journal of Chemistry, Section B: Organic  
 Chemistry Including Medicinal Chemistry (1988  
 ), 27B(1), 96-8  
 CODEN: IJSBDB; ISSN: 0376-4699  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 109:73096  
 GI



AB 2,3-Diarylpentanedioic anhydrides (I; R, R1 given: H, H; MeO, H; H, MeO) on  
 Friedel-Crafts reaction in PhNO<sub>2</sub> in the presence of AlCl<sub>3</sub> gave  $\alpha$ -aryl-1-  
 oxoindane-3-acetic acids (II; R, R1 as above). The ring size was determined


by NMR and <sup>13</sup>C NMR. I react with anisole in the presence of AlCl<sub>3</sub> in PhNO<sub>2</sub> to form 5-anisyl-2,3-diaryl-5-oxopentanoic acids (III; R, R<sub>1</sub> as above).

IT 36286-00-7

RL: PRP (Properties)  
(carbon-13 NMR of)

RN 36286-00-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-3-oxo- (CA INDEX NAME)




IT 115662-89-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 115662-89-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-3-oxo- $\alpha$ -phenyl- (CA INDEX NAME)



L4 ANSWER 79 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1988:414803 CAPLUS Full-text

DOCUMENT NUMBER: 109:14803

ORIGINAL REFERENCE NO.: 109:2447a,2450a

TITLE: Photopolymerizable compositions for color proofing

INVENTOR(S): Sanders, James F.; Olson, David B.

PATENT ASSIGNEE(S): Minnesota Mining and Manufacturing Co., USA

SOURCE: Eur. Pat. Appl., 14 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 243159	A2	19871028	EP 1987-303517	19870422 <--
EP 243159	A3	19881130		
R: BE, DE, FR, GB, IT				
US 4710445	A	19871201	US 1986-854850	19860422 <--
US 4755450	A	19880705	US 1986-854851	19860422 <--
CA 1328762	C	19940426	CA 1987-533036	19870326 <--

JP 62284349	A	19871210	JP 1987-98459	19870421 <--
CA 1335479	C	19950509	CA 1992-616549	19921211 <--
PRIORITY APPLN. INFO.:			US 1986-854850	A 19860422 <--
			US 1986-854851	A 19860422 <--
			US 1986-854852	A 19860422 <--
			CA 1987-533036	A3 19870326 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 109:14803

AB A photoimaging composition for color process proofing contains: (1) a polyfunctional (meth)acryloyl group-containing monomer 10-60; (2) a (meth)acryloyl group-containing reactive polymer 10-60; (3) a nonreactive polyketone resin binder 10-60; and (4) a photoinitiator system 0.1-20 weight% containing a tert-amino aryl ketone dye having  $\geq 1$  carboxylic acid group and a free radical photoinitiator. The material is useful for surprint processes. The process for forming a colored image comprises coating a support with a strippable layer containing a colorant and the above composition, exposing, developing, adhering the image to a receptor sheet, and peeling off the support. Thus, a polyester substrate was coated with a composition containing pentaerythritol tetraacrylate, a reactive oligomer, Lawter 1717B (polyketone), diphenyliodonium hexafluorophosphate, (Me<sub>2</sub>N-p-C<sub>6</sub>H<sub>4</sub>CH:CH)2CO, C black, a dispersion aid, and a solvent. The coated film was exposed in contact with a photog. neg., developed with NaOH solution, and dried. A thermal adhesive-coated paper was prepared and the developed film was transferred by using heated rolls. When the laminate had cooled the polyester film was peeled off. A 2nd image was prepared and laminated in register to the previously imaged paper. The materials were capable of complete transfer.


IT 114824-76-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and use of, in photopolymerizable composition for color proofing)

RN 114824-76-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2-[[4-(dimethylamino)phenyl]methylene]-2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

L4 ANSWER 80 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1987:196269 CAPLUS Full-text

DOCUMENT NUMBER: 106:196269

ORIGINAL REFERENCE NO.: 106:31813a,31816a

TITLE: Hydrogenated pyridine derivatives, pharmaceuticals containing them, and their use as nootropic agents  
 INVENTOR(S): Von Sprecher, Georg; Froestl, Wolfgang; Zuest, Armin  
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Swiss.  
 SOURCE: Eur. Pat. Appl., 98 pp.  
 CODEN: EPXXDW

DOCUMENT TYPE: Patent  
 LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 213080	A2	19870304	EP 1986-810375	19860821 <--
EP 213080	A3	19871021		
EP 213080	B1	19920520		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
IL 79796	A	19910630	IL 1986-79796	19860821 <--
AT 76404	T	19920615	AT 1986-810375	19860821 <--
FI 8603398	A	19870228	FI 1986-3398	19860822 <--
FI 85693	B	19920214		
FI 85693	C	19920525		
DD 259189	A5	19880817	DD 1986-293839	19860825 <--
CA 1295332	C	19920204	CA 1986-516687	19860825 <--
DK 8604064	A	19870228	DK 1986-4064	19860826 <--
NO 8603414	A	19870302	NO 1986-3414	19860826 <--
NO 170016	B	19920525		
NO 170016	C	19920902		
AU 8661864	A	19870305	AU 1986-61864	19860826 <--
AU 606314	B2	19910207		
ZA 8606442	A	19870429	ZA 1986-6442	19860826 <--
HU 42442	A2	19870728	HU 1986-3696	19860826 <--
HU 198688	B	19891128		
ES 2001590	A6	19880601	ES 1986-1362	19860826 <--
HU 46886	A2	19881228	HU 1986-2209	19860826 <--
HU 197558	B	19890428		
JP 62051650	A	19870306	JP 1986-199202	19860827 <--
JP 05005828	B	19930125		
ES 2005777	A6	19890316	ES 1988-431	19880216 <--
US 4833169	A	19890523	US 1988-228849	19880803 <--
US 4939160	A	19900703	US 1988-281596	19881209 <--
PRIORITY APPLN. INFO.:			CH 1985-3669	A 19850827 <--
			CH 1986-2586	A 19860626 <--
			EP 1986-810375	A 19860821 <--
			US 1986-899132	B1 19860821 <--
			US 1988-228849	A3 19880803 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 106:196269


GI



AB    Hydropyridine derivs. I [R1 = CO2H, alkoxycarbonyl, (di)(alkyl)carbamoyl; R2 = H, optionally etherified or acylated OH, (un)acylated NH2; R3 = R, R2, R4Z1; R = C8-12 benzocycloalkenyl (un)substituted in benzo; R4 = C8-12 benzocycloalkylidene (un)substituted in benzo; Z = alkylene, alkylidene; Z1 = alkyl- $\omega$ -ylidene; dashed line = absence or presence of a double bond] and their tautomers and/or salts, useful as nootropics and thus in treating memory problems, such as amnesia (no data), were prepared by 7 methods, e.g., by reaction of R3X1 (R3  $\neq$  H, X1 = OH or reactive esterified OH) with I (R3 = H)

or a tautomer or salt thereof. 5-Methoxybenzocyclobuten-1-ylmethylamine in EtOH was treated with Et acrylate and the mixture refluxed 20 h to give di-Et N-[(5-methoxybenzocyclobuten-1-ylmethyl)iminodipropionate which, in PhMe, was cyclized with NaH at 110° to give Et 4-hydroxy-1-[(5-methoxybenzocyclobuten-1-yl)methyl]-1,2,5,6-tetrahydro-3- pyridinecarboxylate (II) or Et 1-[(5-methoxybenzocyclobuten-1-yl)methyl]-4- oxo-3-piperidinecarboxylate, characterized as the HCl salt. A tablet formulation for 1000 tablets comprised II.HCl 25.0, lactose 100.7, wheat starch 7.5, polyethylene glycol 6000 5.0, taic 5.0, Mg stearate 1.8 g, and demineralized H2O.

IT 62956-64-3, 6-Methoxy-1-indanacetic acid  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reduction of, with borohydride)  
 RN 62956-64-3 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy- (CA INDEX NAME)



L4 ANSWER 81 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1987:18158 CAPLUS Full-text  
 DOCUMENT NUMBER: 106:18158  
 ORIGINAL REFERENCE NO.: 106:3105a,3108a  
 TITLE: Indanylacetic acid derivatives  
 INVENTOR(S): Murase, Kiyoshi; Hara, Hiroshi; Mase, Toshiyasu;  
 Tomioka, Kenichi  
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61097241	A	19860515	JP 1984-217843	19841016 <--
PRIORITY APPLN. INFO.:			JP 1984-217843	19841016 <--
OTHER SOURCE(S):	CASREACT 106:18158			

GI For diagram(s), see printed CA Issue.

AB Title compds. I [R = alkyl, alkanoyl; R1 = alkyl; R2 = R3 = H, or R2 = H and R3 = OH, lower alkoxy; R2R3 = oxo; R4 = H, alkyl; Z = (OH-substituted) alkylene; n = 1, 2, 3; A = 5-6 membered ring; R3R4 may form lactone when R3 = OH and R4 = H], useful as antiallergic agents because of their inhibiting activities against slow reacting substance of anaphylaxis (no data), were prepared Thus, 1.48 g (bromopropoxy)indanylacetate II was treated with 1.18 g 2,4-dihydroxy-3-propylacetophenone in DMF over K2CO3 at 45° to give 930 mg (phenoxypropoxy)indanylacetate derivative III.

IT 105806-34-6  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (phenoxylation of)  
 RN 105806-34-6 CAPLUS  
 CN 1H-Indene-1-acetic acid, 4-(3-bromopropoxy)-2,3-dihydro-, ethyl ester (CA INDEX NAME)






IT 105806-56-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and bromopropylation of)

RN 105806-56-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-hydroxy-, ethyl ester (CA INDEX NAME)




IT 105806-39-1P 105806-40-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of, as antiallergic agent)


RN 105806-39-1 CAPLUS

CN 1H-Indene-1-acetic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-2,3-dihydro-, ethyl ester (CA INDEX NAME)




RN 105806-40-4 CAPLUS

CN 1H-Indene-1-acetic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-2,3-dihydro- (CA INDEX NAME)



L4 ANSWER 82 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1986:199764 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 104:199764  
 ORIGINAL REFERENCE NO.: 104:31427a,31430a  
 TITLE: Studies on antiinflammatory activity among a series of substituted indan acids. Part III  
 AUTHOR(S): Mukhopadhyay, A.; Roy, A.; Lahiri, S. C.  
 CORPORATE SOURCE: Dep. Pharm., Jadavpur Univ., Calcutta, 700 032, India  
 SOURCE: Journal of the Indian Chemical Society (1985), 62(9), 690-2  
 CODEN: JICSAH; ISSN: 0019-4522  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 104:199764  
 GI




I


AB Long-chain indan acid analogs I (R and R1 = H, OMe; n = 0-3) were synthesized by consecutive Arndt-Eistert synthesis starting with the corresponding indan-1-acetic acids. When screened for antiinflammatory activity using the carrageenin-induced rat paw-edema model, a definite gradation of activity profile among I was observed. Indiscriminate chain lengthening was not beneficial for biol. activity, as the activity appeared to reside in a small structural framework. Antiinflammatory activity was more prominent in the indan-1-acetic and indan-1-propionic acids; the carboxylic and butyric acids showed less activity. Biol. activity was potentiated by incorporating methoxyl substitution at the 5 and 6 positions. The inset of action of these compds. was slow; the antiinflammatory reached its peak 3 h after their oral administration; in some cases activity was observed even after 24 h.

IT 62956-64-3 62956-65-4  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (inflammation-inhibiting activity of)

RN 62956-64-3 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy- (CA INDEX NAME)



RN 62956-65-4 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)

L4 ANSWER 83 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1984:465680 CAPLUS Full-text

DOCUMENT NUMBER: 101:65680

ORIGINAL REFERENCE NO.: 101:9999a,10002a

TITLE: Antiinflammatory derivatives of indan-1-acetic acids  
with low gastric irritancy

AUTHOR(S): Roy, A.; Gupta, J. K.; Lahiri, S. C.

CORPORATE SOURCE: Dep. Pharm., Jadavpur Univ., Calcutta, 700 032, India

SOURCE: Indian Journal of Physiology and Pharmacology (

1983), 27(4), 329-33

CODEN: IJPPAZ; ISSN: 0019-5499

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The inflammatory activities of indan-1-acetic acids were tested in rats. The antiinflammatory activity of Et esters were almost equal to those of parent acids and phenylbutazone while other derivs. were less potent. The Et esters were also less ulcerogenic than phenylbutazone.

IT 91284-09-2 91284-10-5


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(antiinflammatory activity of and ulcer from)

RN 91284-09-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-, ethyl ester (CA INDEX NAME)



RN 91284-10-5 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy-, ethyl ester (CA  
 INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
 (1 CITINGS)

L4 ANSWER 84 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1984:209870 CAPLUS Full-text

DOCUMENT NUMBER: 100:209870

ORIGINAL REFERENCE NO.: 100:31875a,31878a

TITLE: Benzoylpiperazine esters

INVENTOR(S): Fujii, Setsuo; Hattori, Eizuo; Hirata, Mitsuteru;  
 Watanabe, Koichiro; Onogi, Kazuhiro; Nagakura,  
 Masahiko

PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 27 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 98713	A2	19840118	EP 1983-303583	19830622 <--
EP 98713	A3	19841227		
EP 98713	B1	19870812		
R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
JP 58225080	A	19831227	JP 1982-109192	19820625 <--
JP 03039063	B	19910612		
JP 59204173	A	19841119	JP 1983-75868	19830428 <--
JP 02051427	B	19901107		
AU 8315931	A	19840105	AU 1983-15931	19830620 <--
AU 545463	B2	19850718		
AT 28868	T	19870815	AT 1983-303583	19830622 <--
DK 8302905	A	19831226	DK 1983-2905	19830623 <--
DK 158983	B	19900813		
DK 158983	C	19910107		
ZA 8304600	A	19840829	ZA 1983-4600	19830623 <--
CA 1210005	A1	19860819	CA 1983-431034	19830623 <--
US 4898876	A	19900206	US 1985-796525	19851112 <--
PRIORITY APPLN. INFO.:				
			JP 1982-109192	A 19820625 <--
			JP 1983-75868	A 19830428 <--
			EP 1983-303583	A 19830622 <--


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 100:209870

GI



I



II


AB Benzoylpiperazines I (R = acyloxy; R1 = alkyl, cycloalkyl, cycloalkylalkyl, aralkyl) were prepared. Thus II was prepared by esterifying the hydroxybenzoylpiperazine with fluorenylideneacetic acid. II had a chymotrypsin-inhibiting ED50 of  $1 + 10^{-7}M$ .

IT 90230-85-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and chymotrypsin-inhibiting activity of)

RN 90230-85-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-,  
4-[[4-(1-methylethyl)-1-piperazinyl]carbonyl]phenyl ester (CA INDEX NAME)




IT 90185-97-0P 90186-02-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 90185-97-0 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-,  
4-[[4-(1-methylethyl)-1-piperazinyl]carbonyl]phenyl ester, hydrochloride  
(1:1) (CA INDEX NAME)




● HCl

RN 90186-02-0 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo-,  
4-[[4-(1-methylethyl)-1-piperazinyl]carbonyl]phenyl ester (CA INDEX NAME)



L4 ANSWER 85 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1983:612466 CAPLUS Full-text  
 DOCUMENT NUMBER: 99:212466  
 ORIGINAL REFERENCE NO.: 99:32695a,32698a  
 TITLE: Synthesis and antiinflammatory activity of a few  
 5-(indan-1'-yl)methyltetrazoles  
 AUTHOR(S): Roy, A.; Gupta, J. K.; Lahiri, S. C.  
 CORPORATE SOURCE: Dep. Pharm., Jadavpur Univ., Calcutta, 700 032, India  
 SOURCE: Journal of the Indian Chemical Society (1983  
 ), 60(4), 377-80  
 CODEN: JICSAH; ISSN: 0019-4522  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 99:212466  
 GI




AB Title compds. I (R, R1 = H, MeO) were synthesized from indanacetic acids via the amides and nitriles and subjected to antiinflammatory screening. Two of them showed antiinflammatory potency close to that of phenylbutazone in both acute (carrageenin-induced edema) and chronic (adjuvant-induced arthritis) animal test models. The compds. have high LD50, high therapeutic index, and appreciable analgesic and antipyretic activity.  
 IT 62956-64-3 62956-65-4  
 RL: PROC (Process)  
 (conversion of, to tetrazole derivative)  
 RN 62956-64-3 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy- (CA INDEX NAME)



RN 62956-65-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD  
(7 CITINGS)

L4 ANSWER 86 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1983:65208 CAPLUS Full-text

DOCUMENT NUMBER: 98:65208

ORIGINAL REFERENCE NO.: 98:9833a,9836a

TITLE: Further studies on antiinflammatory activity of two potent indan-1-acetic acids

AUTHOR(S): Roy, A.; Gupta, J. K.; Lahiri, S. C.

CORPORATE SOURCE: Dep. Pharm., Jadavpur Univ., Calcutta, 700 032, India

SOURCE: Indian Journal of Physiology and Pharmacology (


1982), 26(3), 207-14

CODEN: IJPPAZ; ISSN: 0019-5499

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I, R=N

II, R=OMe

AB The antiinflammatory activity of 6-methoxyindan-1-acetic acid (I) [ 62956-64-2] and 5,6-dimethoxyindan-1-acetic acid (II) [ 62956-65-4] was evaluated in various acute, subacute, and chronic models of inflammation. Apparently, these drugs have equal or slightly more antiinflammatory activity than phenylbutazone, a standard antiinflammatory drug. Of the 2 compds., II appeared to be slightly more active than I.


IT 62956-64-3 62956-65-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiinflammatory activity of)


RN 62956-64-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy- (CA INDEX NAME)



RN 62956-65-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L4 ANSWER 87 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1982:35568 CAPLUS Full-text

DOCUMENT NUMBER: 96:35568

ORIGINAL REFERENCE NO.: 96:5893a,5896a

TITLE: Studies on intramolecular cyclizations. Synthesis of ring systems related to sesquiterpenoids

AUTHOR(S): Basu, Basudeb; Maity, Sanat K.; Mukherjee, Debabrata

CORPORATE SOURCE: Dep. Org. Chem., Indian Assoc. Cultiv. Sci., Calcutta, 700 032, India


SOURCE: Synthetic Communications (1981), 11(10), 803-9

CODEN: SYNCAV; ISSN: 0039-7911

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB The tricyclic diones I, II, and III (R = H, Me) were prepared from an appropriate indan, indanone, or tetralone derivative The key step involved




the intramol. cyclization of IV and V (n = 2, R1 = H, R2 = COCH2OH; n = 1, R1 = H, R2 = COCHN2; n = 1, R1 = Me, R2 = COCHN2), resp.

IT 80370-37-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and chlorination of)

RN 80370-87-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- (CA INDEX NAME)




IT 80370-85-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and decarboxylation of)

RN 80370-85-0 CAPLUS

CN 1H-Indene-1-acetic acid,  $\alpha$ -cyano-2,3-dihydro-5-methoxy-, ethyl ester  
(CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)

L4 ANSWER 88 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1981:185395 CAPLUS Full-text

DOCUMENT NUMBER: 94:185395

ORIGINAL REFERENCE NO.: 94:30187a,30190a

TITLE: Studies on antiinflammatory, analgesic and antipyretic activities of some indan acids

AUTHOR(S): Roy, A.; Gupta, J. K.; Lahiri, S. C.

CORPORATE SOURCE: Dep. Pharm., Jadavpur Univ., Calcutta, 700 032, India

SOURCE: Indian Journal of Physiology and Pharmacology (


1980), 24(4), 310-16

CODEN: IJPPAZ; ISSN: 0019-5499

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I


AB Twelve indan-1-acids I (X and Y = H or OMe, Z = 2H or O, n = 0 or 1) were screened for antiinflammatory activity. All the compds. had varying degrees of antiinflammatory activity in the carrageenin-induced paw edema test. They also exhibited appreciable antipyretic and analgesic activity in various animal test models. 6-Methoxyindan-1-acetic acid (I; Y = H, X = OMe, Z = 2H, n = 1) [62956-64-3] and 5,6-dimethoxyindan-1-acetic acid (I; X = Y = OMe, Z = 2H, n = 1) [62956-65-4] had activity profiles close to that of phenylbutazone having prolonged action and lower toxicity than the latter.

IT 24467-92-3 36286-18-7 62956-64-3  
62956-65-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(inflammation inhibiting activity of)


RN 24467-92-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)




RN 36286-18-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy-3-oxo- (CA INDEX NAME)




RN 62956-64-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy- (CA INDEX NAME)



RN 62956-65-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)

L4 ANSWER 89 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1980:110633 CAPLUS Full-text

DOCUMENT NUMBER: 92:110633

ORIGINAL REFERENCE NO.: 92:18049a,18052a

TITLE: Compounds having antitremorine activity; biscarbamate derivatives of 1,3-diamino-2-phenylpropanes

AUTHOR(S): Askam, Vernon; Tehrani-Moaled, Manoucheher

CORPORATE SOURCE: Welsh Sch. Pharm., Univ. Wales Inst. Sci. Technol., Cardiff, CF1 3NU, UK

SOURCE: Journal of Chemical Research, Synopses (1979), (7), 234


CODEN: JRPSDC; ISSN: 0308-2342

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 92:110633

GI




AB 3,4-RR1C6H3CH(CH2NHC(=O)CH2Ph)2 [I; R = H, R1 = H, MeO (II); R = R1 = MeO (III)] were prepared in 15-53% yields by treatment of 3,4-RR1C6H3CH(CH2COR2) (IV; R2 = NHNH2) with HNO2, followed by Curtius rearrangement of the resulting diazides. Phenylpyrimidinones V (R = H, R1 = H, MeO; R = R1 = MeO) were obtained by hydrolytic rearrangement of the diazides. The preparation of I (R = MeO, R1 = MeSO2NH) from IV (R = MeO, R1 = R2 = H) is also described. The potencies of II and III against tremorine-induced tremors in mice were ED50 250 and 80 mg kg-1, resp.; at these doses the compds. inhibited the peripheral cholinergic symptoms by .apprx.65%. The acute LD50 in mice of II and III was > 2 g kg-1.


IT 72976-19-3F

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and hydrogenation of)

RN 72976-19-3 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-methoxy-7-nitro-3-oxo- (CA INDEX NAME)




IT 72976-23-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 72976-23-9 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-5-nitro-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
 (1 CITINGS)

L4 ANSWER 90 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1979:71935 CAPLUS Full-text  
 DOCUMENT NUMBER: 90:71935  
 ORIGINAL REFERENCE NO.: 90:11375a,11378a  
 TITLE: Synthesis of indan derivatives as possible  
 antihypertensive agents. Part II  
 Ghoshal, P. N.; Pathak, B.  
 AUTHOR(S): Dep. Appl. Chem., Calcutta, India  
 CORPORATE SOURCE: Journal of the Indian Chemical Society (1978  
 SOURCE: ), 55(9), 897-901  
 CODEN: JICSAH; ISSN: 0019-4522  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 90:71935  
 GI




I, Z=O  
 III, Z=H2

AB Cyclization of 3-RC6H4CH(CH2CO2H)2 (R = H, MeO) by polyphosphoric acid gave indanones I (R1 = CO2H) (II), Clemmensen reduction of II gave III (R1 = CO2H) (IV), amidation of IV gave III (R1 = CONHMe) (V), reduction of V by LiAlH4 gave III (R1 = CH2NHMe) (VI) and N-alkylation of VI with ethylene oxide gave III (R1 = CH2NMeCH2CH2OH), esterification of which with R2COCl (R2 = Ph, 3,4,5-(MeO)3C6H2, PhCH:CH) gave the corresponding III [R1 = CH2NMe(CH2)nCH2O2CR2, n = 1] (VII). N-alkylation of VI with Cl(CH2)nCH2O2CR2 (R2 as above, n = 1-3) also gave VII (n = 1-3). VII (R = MeO, n = 2, R2 = Ph) was highly antihypertensive at 2 mg/kg i.v. for 2 h.

IT 24467-92-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and Clemmensen reduction of)

RN 24467-92-3 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



IT 62956-64-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and amination of)

RN 62956-64-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy- (CA INDEX NAME)



L4 ANSWER 91 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1979:22678 CAPLUS Full-text

DOCUMENT NUMBER: 90:22678

ORIGINAL REFERENCE NO.: 90:3735a,3738a

TITLE: Carboxylic acid esters containing indan- or tetrahydronaphthalene residues

INVENTOR(S): Haas, Georges; Rossi, Alberto

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Patentschrift (Switz.), 7 pp.  
 CODEN: SWXXAS

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CH 601172	A5	19780630	CH 1977-10942	19761108 <--
CH 601166	A5	19780630	CH 1974-2094	19740214 <--
SE 7500628	A	19750815	SE 1975-628	19750121 <--
SE 426484	B	19830124		
SE 426484	C	19830511		
DK 7500286	A	19751006	DK 1975-286	19750129 <--
DK 149230	B	19860324		
DK 149230	C	19860811		
GB 1470468	A	19770414	GB 1975-5102	19750206 <--
US 4057573	A	19771108	US 1975-548956	19750211 <--
FR 2260998	A1	19750912	FR 1975-4321	19750212 <--
AU 7578131	A	19760812	AU 1975-78131	19750212 <--
CA 1039300	A1	19780926	CA 1975-219900	19750212 <--
BE 825473	A1	19750813	BE 1975-153307	19750213 <--
ZA 7500921	A	19760128	ZA 1975-921	19750213 <--
AT 7501079	A	19761015	AT 1975-1079	19750213 <--
AT 337166	B	19770610		
HU 169466	B	19761128	HU 1975-CI1545	19750213 <--
IL 46630	A	19781031	IL 1975-46630	19750213 <--
NL 7501776	A	19750818	NL 1975-1776	19750214 <--
JP 50116463	A	19750911	JP 1975-18096	19750214 <--
JP 60006933	B	19850221		
CS 208141	B2	19810831	CS 1975-991	19750214 <--
AT 7606412	A	19771015	AT 1976-6412	19760830 <--
AT 7606414	A	19771015	AT 1976-6414	19760830 <--
AT 343647	B	19780612	AT 1976-6410	19760830 <--
AT 343649	B	19780612	AT 1976-6413	19760830 <--
CH 593898	A5	19771230	CH 1976-14033	19761108 <--
CH 593899	A5	19771230	CH 1976-14058	19761108 <--
CH 596131	A5	19780228	CH 1976-14060	19761108 <--
CH 598182	A5	19780428	CH 1976-14059	19761108 <--
CH 601171	A5	19780630	CH 1976-14034	19761108 <--
US 4272547	A	19810609	US 1977-825637	19770818 <--
CS 208142	B2	19810831	CS 1977-6223	19770926 <--
CS 208143	B2	19810831	CS 1977-6224	19770926 <--
CS 208144	B2	19810831	CS 1977-6225	19770926 <--
CS 208145	B2	19810831	CS 1977-6226	19770926 <--
PRIORITY APPLN. INFO.:			CH 1974-2094	A 19740214 <--
			US 1975-548956	A3 19750211 <--
			AT 1975-1079	A 19750213 <--
			CS 1975-991	A3 19750214 <--

GI



AB Twenty-one title carboxylate esters I [one of R1 and R2 = aroyl, the other H, alkyl, OH (optionally esterified or etherified), NH2 (optionally acylated); R3 = H, alkyl, hydroxyalkyl, R4 = esterified CO2H; n = 1, 2; n = 0, 1], optionally as their salts, useful as antiinflammatory agents, analgesics, and antipyretics at 25-250 mg/75 kg daily in warm-blooded animals, were prepared


by esterification of the corresponding I (R4 = CO2H) with alcs. containing a small amount of concentrated H2SO4.

IT 58491-23-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 58491-23-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-benzoyl-2,3-dihydro-6-hydroxy-, methyl ester  
(CA INDEX NAME)



L4 ANSWER 92 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1979:7040 CAPLUS Full-text

DOCUMENT NUMBER: 90:7040

ORIGINAL REFERENCE NO.: 90:1279a,1282a

TITLE: Carboxylic acids, their esters and amides containing  
indan- or tetrahydronaphthalene rings

INVENTOR(S): Haas, Georges; Rossi, Alberto

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Patentschrift (Switz.), 8 pp.

CODEN: SWXXAS

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CH 602548	A5	19780731	CH 1977-10944	19740214 <--
CH 601166	A5	19780630	CH 1974-2094	19740214 <--
SE 7500628	A	19750815	SE 1975-628	19750121 <--
SE 426484	B	19830124		
SE 426484	C	19830511		
DK 7500286	A	19751006	DK 1975-286	19750129 <--
DK 149230	B	19860324		
DK 149230	C	19860811		
GB 1470468	A	19770414	GB 1975-5102	19750206 <--
US 4057573	A	19771108	US 1975-548956	19750211 <--
FR 2260998	A1	19750912	FR 1975-4321	19750212 <--
AU 7578131	A	19760812	AU 1975-78131	19750212 <--
CA 1039300	A1	19780926	CA 1975-219900	19750212 <--
BE 825473	A1	19750813	BE 1975-153307	19750213 <--
ZA 7500921	A	19760128	ZA 1975-921	19750213 <--
AT 7501079	A	19761015	AT 1975-1079	19750213 <--
AT 337166	B	19770610		
HU 169466	B	19761128	HU 1975-CI1545	19750213 <--
IL 46630	A	19781031	IL 1975-46630	19750213 <--
NL 7501776	A	19750818	NL 1975-1776	19750214 <--
JP 50116463	A	19750911	JP 1975-18096	19750214 <--
JP 60006933	B	19850221		
CS 208141	B2	19810831	CS 1975-991	19750214 <--

AT 7606412	A	19771015	AT 1976-6412	19760830 <--
AT 7606414	A	19771015	AT 1976-6414	19760830 <--
AT 343647	B	19780612	AT 1976-6410	19760830 <--
AT 343649	B	19780612	AT 1976-6413	19760830 <--
CH 593898	A5	19771230	CH 1976-14033	19761108 <--
CH 593899	A5	19771230	CH 1976-14058	19761108 <--
CH 596131	A5	19780228	CH 1976-14060	19761108 <--
CH 598182	A5	19780428	CH 1976-14059	19761108 <--
CH 601171	A5	19780630	CH 1976-14034	19761108 <--
US 4272547	A	19810609	US 1977-825637	19770818 <--
CS 208142	B2	19810831	CS 1977-6223	19770926 <--
CS 208143	B2	19810831	CS 1977-6224	19770926 <--
CS 208144	B2	19810831	CS 1977-6225	19770926 <--
CS 208145	B2	19810831	CS 1977-6226	19770926 <--
			CH 1974-2094	A 19740214 <--
			US 1975-548956	A3 19750211 <--
			AT 1975-1079	A 19750213 <--
			CS 1975-991	A3 19750214 <--

PRIORITY APPLN. INFO.:

GI




AB Forty-two title compds. I [one of R1 and R2 = aroyl, the other H, alkyl, OH (optionally esterified or etherified), NH2 (optionally acylated); R3 = H, alkyl, hydroxyalkyl; R4 = CO2H (optionally esterified or amidated); m = 1, 2; n = 0, 1] and their salts, useful as inflammation inhibitors, antipyretics, and analgesics at 25-250 mg/kg daily for warm-blooded animals, were prepared by acylation of the corresponding I (one of R1 and R2 = H, the other is given above). Thus, powdered AlCl3 was added to Me 6-methoxyindan-1-carboxylate and BzCl in CH2Cl2 at 20° and the mixture stirred overnight to give I (R1 = OH, R2 = Bz, R3 = H, R4 = CO2Me, m = 1, n = 0).

IT 58491-22-8

RL: RCT (Reactant); RACT (Reactant or reagent)  
(benzoylation of)

RN 58491-22-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-, methyl ester (CA INDEX NAME)



IT 58491-23-9P 58491-24-9P


RL: PREP (Preparation)  
(preparation of)

RN 58491-23-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-benzoyl-2,3-dihydro-6-hydroxy-, methyl ester




(CA INDEX NAME)



RN 58491-24-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-benzoyl-2,3-dihydro-6-hydroxy- (CA INDEX NAME)



L4 ANSWER 93 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1978:579814 CAPLUS Full-text

DOCUMENT NUMBER: 89:179814

ORIGINAL REFERENCE NO.: 89:27923a,27926a

TITLE: Possible antineoplastic agents: part IV. Synthesis and antineoplastic potency of N-substituted  $\alpha$ -(4,5-dimethoxyphthalimido)glutarimides and N-substituted  $\beta$ -(4-bromophenyl)glutarimides

AUTHOR(S): De, A. U.; Ghose, A. K.

CORPORATE SOURCE: Dep. Pharm., Jadavpur Univ., Calcutta, India


SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1978), 16B(6), 510-12  
CODEN: IJSBDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 89:179814

GI



I, X=NR  
III, X=O




II, X=NR  
IV, X=O

AB  $\alpha$ -(4,5-Dimethoxyphthalimido)glutarimides I and  $\beta$ -(4-bromophenyl)glutarimides II (R = H, alkyl, cyclohexyl, Ph, PhCH<sub>2</sub>) were prepared by treating III and IV with RNH<sub>2</sub> and tested in Ehrlich Ascites carcinoma in Swiss albino mice. Some I possess significant anticancer activity at a dose level of 50 mg/kg i.p.

IT 36286-18-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and oxidation of)

RN 36286-18-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L4 ANSWER 94 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1978:562890 CAPLUS Full-text

DOCUMENT NUMBER: 89:162890

ORIGINAL REFERENCE NO.: 89:25237a,25240a

TITLE: Studies on the dissociation constants of indan acids and their hypoglycemic activities

AUTHOR(S): Chattopadhyay, A. K.; Lahiri, S. C.; Lahiri, Samir C.; Gupta, Jayanta K.

CORPORATE SOURCE: Dep. Chem., Kalyani Univ., Kalyani, India

SOURCE: Journal of the Indian Chemical Society (1977), 54(8), 808-10

CODEN: JICSAH; ISSN: 0019-4522

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The dissociation consts. of some indan acids, structurally related to hypoglycemic indole acids, were determined spectrophotometrically. Efforts have been made to correlate the dissociation consts. with their hypoglycemic activities without much success. The highest activity is observed in compds. containing one MeO substituent in the benzenoid part.

IT 24467-92-3 36286-18-7 62956-64-3


62956-65-4

RL: PRP (Properties)


(dissociation constant of)

RN 24467-92-3 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)




RN 36286-18-7 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy-3-oxo- (CA INDEX NAME)



RN 62956-64-3 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy- (CA INDEX NAME)




RN 62956-65-4 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)




L4 ANSWER 95 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1977:601150 CAPLUS Full-text  
 DOCUMENT NUMBER: 87:201150  
 ORIGINAL REFERENCE NO.: 87:31839a,31842a  
 TITLE: Effects of remote unsaturated bonds on nucleophilic aromatic substitution in polyfluoroaromatic compounds. Profound effect of a remote carbonyl group  
 AUTHOR(S): Brooke, Gerald M.; Matthews, Raymond S.; Young, Alan C.  
 CORPORATE SOURCE: Chem. Dep., Univ. Durham, Durham, UK  
 SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1977), (12), 1411-17

DOCUMENT TYPE:  
LANGUAGE:  
GI


CODEN: JCPRB4; ISSN: 0300-922X  
Journal  
English





- AB Approx. values of the second-order rate consts. for F substitution by Me<sub>2</sub>CHO- in a series of unsatd. and related saturated 5,6,7,8-tetrafluoro-1,4-bridged naphthalenes were determined For substitution of I (R = R<sub>1</sub> = F, R<sub>2</sub>R<sub>3</sub> = O) to give I (R<sub>2</sub>R<sub>3</sub> = O) (R = Me<sub>2</sub>CHO, R<sub>1</sub> = F; R = F, R<sub>1</sub> = Me<sub>2</sub>CHO), as the major products, the rate constant (extrapolated to 25°) is 100 times greater than that for substitution of I (R = R<sub>1</sub> = F, R<sub>2</sub> = MeO, R<sub>3</sub> = H) to give I (R<sub>2</sub> = MeO, R<sub>3</sub> = H) (R = Me<sub>2</sub>CHO, R<sub>1</sub> = F; R = F, R<sub>1</sub> = Me<sub>2</sub>CHO). These results are rationalized in terms of the field effect of the carbonyl group and the exclusion of regiospecific homoconjugation in the transition state for reaction of C-6. All other systems examined reacted with similar rate consts., irrespective of remote unsatd. or saturated bonds.
- IT 64746-43-6P 64746-44-7P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)
- RN 64746-43-6 CAPLUS
- CN 1H-Indene-1-acetic acid, 4,5,7-trifluoro-2,3-dihydro- $\alpha$ , $\alpha$ -dimethyl-6-(1-methylethoxy)-, 1-methylethyl ester (CA INDEX NAME)



- RN 64746-44-7 CAPLUS
- CN 1H-Indene-1-acetic acid, 4,5,7-trifluoro-2,3-dihydro- $\alpha$ , $\alpha$ -dimethyl-5-(1-methylethoxy)-, 1-methylethyl ester (CA INDEX NAME)




L4 ANSWER 96 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1977:405683 CAPLUS Full-text  
 DOCUMENT NUMBER: 87:5683  
 ORIGINAL REFERENCE NO.: 87:909a,912a  
 TITLE: Studies on indan acids as potential oral hypoglycemic agents  
 AUTHOR(S): Lahiri, Samir C.; Gupta, Jayanta K.  
 CORPORATE SOURCE: Dep. Pharm., Jadavpur Univ., Calcutta, India  
 SOURCE: Journal of the Indian Chemical Society (1976), 53(10), 1041-3  
 CODEN: JICSAH; ISSN: 0019-4522  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 87:5683  
 GI




AB Indan acids I ( $n = 0, 1$ ; X, Y = MeO, H) and II, structurally related to hypoglycemic indole acids, were prepared and screened for hypoglycemic activity. Some of these acids had appreciable activity both in normal and in alloxan-diabetic animals. The highest activity was observed in compds. containing a monomethoxy substituent in the benzenoid part of the indan moiety.


IT 24467-92-3P 36286-18-7P 62956-64-3P  
 62956-65-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation and antidiabetic activity of)  
 RN 24467-92-3 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)




RN 36286-18-7 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy-3-oxo- (CA INDEX NAME)



RN 62956-64-3 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy- (CA INDEX NAME)



RN 62956-65-4 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)




OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
(5 CITINGS)

L4 ANSWER 97 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1976:105276 CAPLUS Full-text  
DOCUMENT NUMBER: 84:105276  
ORIGINAL REFERENCE NO.: 84:17139a,17142a  
TITLE: Hydroaromatic compounds  
INVENTOR(S): Haas, Georges; Rossi, Alberto  
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.  
SOURCE: Ger. Offen., 65 pp.  
CODEN: GWXXBX  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 6  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2505106	A1	19750821	DE 1975-2505106	19750207 <--

CH 601166	A5	19780630	CH 1974-2094	19740214 <--
SE 7500628	A	19750815	SE 1975-628	19750121 <--
SE 426484	B	19830124		
SE 426484	C	19830511		
DK 7500286	A	19751006	DK 1975-286	19750129 <--
DK 149230	B	19860324		
DK 149230	C	19860811		
GB 1470468	A	19770414	GB 1975-5102	19750206 <--
US 4057573	A	19771108	US 1975-548956	19750211 <--
FR 2260998	A1	19750912	FR 1975-4321	19750212 <--
AU 7578131	A	19760812	AU 1975-78131	19750212 <--
CA 1039300	A1	19780926	CA 1975-219900	19750212 <--
BE 825473	A1	19750813	BE 1975-153307	19750213 <--
ZA 7500921	A	19760128	ZA 1975-921	19750213 <--
AT 7501079	A	19761015	AT 1975-1079	19750213 <--
AT 337166	B	19770610		
HU 169466	B	19761128	HU 1975-CI1545	19750213 <--
IL 46630	A	19781031	IL 1975-46630	19750213 <--
NL 7501776	A	19750818	NL 1975-1776	19750214 <--
JP 50116463	A	19750911	JP 1975-18096	19750214 <--
JP 60006933	B	19850221		
CS 208141	B2	19810831	CS 1975-991	19750214 <--
AT 7606412	A	19771015	AT 1976-6412	19760830 <--
AT 7606414	A	19771015	AT 1976-6414	19760830 <--
AT 343647	B	19780612	AT 1976-6410	19760830 <--
AT 343649	B	19780612	AT 1976-6413	19760830 <--
CH 593898	A5	19771230	CH 1976-14033	19761108 <--
CH 593899	A5	19771230	CH 1976-14058	19761108 <--
CH 596131	A5	19780228	CH 1976-14060	19761108 <--
CH 598182	A5	19780428	CH 1976-14059	19761108 <--
CH 601171	A5	19780630	CH 1976-14034	19761108 <--
US 4272547	A	19810609	US 1977-825637	19770818 <--
CS 208142	B2	19810831	CS 1977-6223	19770926 <--
CS 208143	B2	19810831	CS 1977-6224	19770926 <--
CS 208144	B2	19810831	CS 1977-6225	19770926 <--
CS 208145	B2	19810831	CS 1977-6226	19770926 <--
PRIORITY APPLN. INFO.:			CH 1974-2094	A 19740214 <--
			US 1975-548956	A3 19750211 <--
			AT 1975-1079	A 19750213 <--
			CS 1975-991	A3 19750214 <--

OTHER SOURCE(S): MARPAT 84:105276  
GI




AB Aromatic carboxylic acids I (R = H, Me, HOCH<sub>2</sub>; R<sub>1</sub> = H, Bz, 4-ClC<sub>6</sub>H<sub>4</sub>CO, thenoyl, etc.; R<sub>2</sub> = HO, MeO, Bz, AcO, etc.; m = 0, 1; n = 1, 2), as well as the corresponding esters, amides, etc., were prepared. Thus, II (R = Me, R<sub>1</sub> = H) reacted with BzCl and AlCl<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> to give II (R = H, R<sub>1</sub> = Bz), which was saponified to the corresponding acid. I are useful as antipyretic and antiinflammatory agents; pharmaceutical formulations were given.

IT 58491-22-8

RL: RCT (Reactant); RACT (Reactant or reagent)  
(acylation of)

RN 58491-22-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-, methyl ester (CA INDEX NAME)




IT 58491-23-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and hydrolysis of)

RN 58491-23-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-benzoyl-2,3-dihydro-6-hydroxy-, methyl ester  
(CA INDEX NAME)




IT 58491-24-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 58491-24-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-benzoyl-2,3-dihydro-6-hydroxy- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L4 ANSWER 98 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1975:15802 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 82:15802

ORIGINAL REFERENCE NO.: 82:2529a,2532a

TITLE: Carbon-13 NMR spectra of lignins. 1. Chemical shifts  
of monomeric and dimeric model substances


AUTHOR(S): Luedemann, Hans D.; Nimz, Horst

CORPORATE SOURCE: Fachbereich Biol., Univ. Regensburg, Regensburg, Fed.




SOURCE: Rep. Ger.  
Makromolekulare Chemie (1974), 175(8),  
2393-407  
CODEN: MACEAK; ISSN: 0025-116X  
DOCUMENT TYPE: Journal  
LANGUAGE: German


GI For diagram(s), see printed CA Issue.  
AB The <sup>13</sup>C chemical shifts of 14 monomeric, e.g., I (R<sub>1</sub> = H, R = CHO; R<sub>1</sub> = OH, R = CO<sub>2</sub>H) and 25 dimeric, e.g., II, lignin model benzene derivs. were determined. The influence of the MeO group, ortho to the phenolic OH or OR group, on the chemical shifts of the aromatic C atoms was examined. These compds. were used for the assignment of the <sup>13</sup>C NMR of angio- and gymnosperm lignins.  
IT 53669-39-9 53669-40-2 53669-41-3  
RL: PRP (Properties)  
(carbon-13 NMR of)  
RN 53669-39-9 CAPLUS  
CN 1H-Indene-1-acetic acid, 2-(ethoxycarbonyl)-2,3-dihydro-5-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-6-methoxy-, ethyl ester (CA INDEX NAME)



RN 53669-40-2 CAPLUS  
CN 1H-Indene-1-acetic acid, 5-(acetyloxy)-3-[4-(acetyloxy)-3-methoxyphenyl]-2-(ethoxycarbonyl)-2,3-dihydro-6-methoxy-, ethyl ester (CA INDEX NAME)



RN 53669-41-3 CAPLUS  
CN 1H-Indene-1-acetic acid, 2-carboxy-3-(3,4-dimethoxyphenyl)-2,3-dihydro-5,6-dimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)

L4 ANSWER 99 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1974:47522 CAPLUS Full-text

DOCUMENT NUMBER: 80:47522

ORIGINAL REFERENCE NO.: 80:7741a,7744a

TITLE: Synthetic studies on terpenoids. XVII. Synthetic approaches to hirsutic acid

AUTHOR(S): Sarkar, Tarun K.

CORPORATE SOURCE: Dep. Org. Chem., Indian. Assoc. Cultiv. Sci.,  
Calcutta, India

SOURCE: Journal of the Chemical Society, Perkin Transactions  
1: Organic and Bio-Organic Chemistry (1972-1999) (  
1973), (21), 2454-60

CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB The isomers (I, R = Me, R1 = CO2Me; R = CO2Me, R1 = Me) of Me 3-methyl-6-oxo-  
cis-bicyclo[3.3.0]octane-3-carboxylate, Me 1,2,3,3aa,8,8aa-hexahydro-6-  
methoxy-2β- methylcyclopent[a]indene-2-carboxylate (II, R = Me), and Me  
1,2,3,3aa,8,8aa-hexahydro-6-methoxy-2β-  
[(methoxycarbonyl)methyl]cyclopent[a]indene-2-carboxylate (II, R = CH2CO2Me),  
precursors of hirsutic acid, were prepared stereoselectively from Me 1-methyl-  
2-oxocyclopentanecarboxylate.


IT 51115-34-5P 51115-35-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 51115-34-5 CAPLUS

CN 1H-Indene-1,2-diacetic acid, 2,3-dihydro-5-methoxy-, dimethyl ester, cis-  
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 51115-35-6 CAPLUS

CN 1H-Indene-1,2-diacetic acid, 2,3-dihydro-5-methoxy-, cis- (9CI) (CA INDEX  
NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)

L4 ANSWER 100 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1973:29619 CAPLUS Full-text  
DOCUMENT NUMBER: 78:29619  
ORIGINAL REFERENCE NO.: 78:4671a,4674a  
TITLE: Substituted indeno[2,1-b]pyrroles as analgesic or  
antiinflammatory agents  
INVENTOR(S): Cavalla, John Frederick; Simpson, Roy; White, Alan  
Chapman  
PATENT ASSIGNEE(S): John Wyeth and Brother Ltd.  
SOURCE: U.S., 8 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3703529	A	19721121	US 1970-23055	19700326 <--
GB 1304175	A	19730124	GB 1969-16670	19690331 <--
PRIORITY APPLN. INFO.:			GB 1969-16670	A 19690331 <--


GI For diagram(s), see printed CA Issue.

AB About 25 indeno[2,1-b]-pyrroles I (R = H, AcO, BzO, OH; R1 = H, HC.tplbond.CCH2, allyl, Ac, Bz, Me; R2 = H, Me; R3 = H, OH, MeO) were prepared by cyclization of phenylglutaric acids and reductive cyclization of oximes of the resulting indanes. Thus, 3-methyl-3-phenylglutaric acid was treated with polyphosphoric acid and the resulting 1-methyl-3-oxoindan-1-ylacetic acid esterified and treated with HCl and pentyl nitride to give the 2-oxime, which was hydrogenated to give the dione (II). II was reduced with LiAlH4 to give II (R = R1 = H, R2 = Me) (III), which was treated with Ac2O in pyridine to give II (R = R1 = Ac, R2 = Me). III was analgesic in mice at 50 mg/kg and antiinflammatory at 30 mg/kg.


IT 39160-47-9P 39160-48-0P 39160-49-1P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 39160-47-9 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-1-methyl-3-oxo-, methyl ester (CA INDEX NAME)



RN 39160-48-0 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-1-methyl-3-oxo- (CA INDEX NAME)



RN 39160-49-1 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-2-(hydroxyimino)-6-methoxy-1-methyl-3-oxo-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)


L4 ANSWER 101 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1972:113056 CAPLUS Full-text  
 DOCUMENT NUMBER: 76:113056  
 ORIGINAL REFERENCE NO.: 76:18253a,18256a  
 TITLE: Analgesic indeno[2,1-b]pyrroles and their salts  
 INVENTOR(S): Hayes, Norman F.  
 PATENT ASSIGNEE(S): Allen and Hanburys Ltd.  
 SOURCE: Ger. Offen., 39 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2132810	A	19720105	DE 1971-2132810	19710701 <--
GB 1351754	A	19740501	GB 1970-32120	19700702 <--
ZA 7104137	A	19720329	ZA 1971-4137	19710624 <--
CA 948206	A1	19740528	CA 1971-116503	19710624 <--
IL 37146	A	19741022	IL 1971-37146	19710624 <--
BE 769303	A1	19711230	BE 1971-105302	19710630 <--
FR 2100854	A5	19720324	FR 1971-24127	19710701 <--
FR 2100854	A1	19720324		
AT 305996	B	19730326	AT 1971-5706	19710701 <--
AT 310731	B	19731010	AT 1972-3077	19710701 <--


SE 377117	B	19750623	SE 1971-8558	19710701 <--
NL 7109212	A	19720104	NL 1971-9212	19710702 <--
CH 570980	A5	19751231	CH 1971-9786	19710702 <--

PRIORITY APPLN. INFO.:  
 GI For diagram(s), see printed CA Issue.  
 AB Maleate, tartrate, and picrate salts of I are prepared with R1 = H, Me, MeCH:CMech2, PhCH2CH2, benzyl, allyl, Me2N(CH2)3, or Me2NCH2CH2, R2 = H or Me, R3 = H, Me, or Ph, R4 = H or MeO, R5 = H, MeO, Me, EtO, iso-PrO, allyloxy, hexyloxy, Me2NCH2CH2O, PhCH2CH2O, HOCH2CH2O, OH, or EtCO2, R6 = H or MeO, and R7 = H, Me, or Ph and with ≤2 of R1-R7 being other than H in each I. The salts have analgesic and antitussive activity. Thus, a mixture of di-Et acetamidomalonalate, EtOH, Na, and Et m-methoxycinnamate is heated to prepare 3-(m-methoxyphenyl)-5-oxo-2,2-pyrrolidinedi-carboxylic acid monohydrate, heated to 160° to remove 1 carboxy group, treated with polyphosphoric acid to prepare 1,3,3a,8a-tetrahydro-5-methoxyindeno[2,1-b]pyrrole-2,8-dione, hydrogenated over Pd to remove the 8-oxo group, reduced with LiAlH4 in THF to prepare I (R5 = MeO, R1 - R4 = R6 - R7 = H) which is obtained as the maleate salt.


IT 36285-98-0P 36286-00-7P 36286-01-8P  
 36286-02-9P 36286-04-1P 36286-05-2P  
 36286-06-3P 36286-07-4P 36286-08-5P  
 36286-13-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 36285-98-0 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6,7-dimethoxy-3-oxo- (CA INDEX NAME)



RN 36286-00-7 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-3-oxo- (CA INDEX NAME)




RN 36286-01-8 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6,7-dimethoxy-3-oxo-, methyl ester  
 (CA INDEX NAME)




RN 36286-02-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy-3-oxo-, methyl ester  
(CA INDEX NAME)




RN 36286-04-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-3-oxo-, methyl ester (CA  
INDEX NAME)




RN 36286-05-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-2-(hydroxyimino)-6,7-dimethoxy-3-oxo-  
, methyl ester (CA INDEX NAME)




RN 36286-06-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-2-(hydroxyimino)-5,6-dimethoxy-3-oxo-  
, methyl ester (CA INDEX NAME)




RN 36286-07-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-2-(hydroxyimino)-6-methoxy-3-oxo-, methyl ester (CA INDEX NAME)




RN 36286-08-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-2-(hydroxyimino)-5-methoxy-3-oxo-, methyl ester (CA INDEX NAME)



RN 36286-18-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5,6-dimethoxy-3-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L4 ANSWER 102 OF 111 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 1970:403699 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 73:3699

ORIGINAL REFERENCE NO.: 73:625a,628a


TITLE: Indenylaliphatic acid derivatives

INVENTOR(S): Shen, Tsung-Ying; Linn, Bruce O.  
 PATENT ASSIGNEE(S): Merck and Co., Inc.  
 SOURCE: Ger. Offen., 67 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1943568	A	19700305	DE 1969-1943568	19690827 <--
US 3622623	A	19711123	US 1968-755798	19680828 <--
NL 6912332	A	19700303	NL 1969-12332	19690813 <--
GB 1257210	A	19711215	GB 1969-1257210	19690825 <--
FR 2016503	A5	19700508	FR 1969-29262	19690827 <--
FR 2016503	B1	19730713		
BR 6911907	D0	19730426	BR 1969-211907	19690827 <--
			US 1968-755798	A 19680828 <--

PRIORITY APPLN. INFO.:  
 AB Title compds. (i) and their 2,3-dihydroxy derivs. are prepared To obtain I, a substituted benzaldehyde is treated with a substituted acetate or  $\alpha$ -halopropionate, followed by reduction of the unsatd. ester obtained and hydrolysis to the  $\beta$ -arylpropionic acid, which heated in the presence of polyphosphoric acid or a Friedel-Crafts catalyst gives the corresponding inadonone; this condensed with an  $\alpha$ -halo ester, followed by dehydration or by the Wittig reaction with an  $\alpha$ -triphenylphosphinyl ester, gives I. Thus, to 36.2 g Zn dust, a mixture of 80 ml anhydrous C<sub>6</sub>H<sub>6</sub>, 20 ml anhydrous Et<sub>2</sub>O, 80 g p-anisaldehyde, and 98 g MeCHBrCO<sub>2</sub>Et is added slowly, with vigorous stirring, to maintain refluxing, and the mixed refluxed 30 min on a water bath to give 69% Et  $\beta$ -hydroxy- $\beta$ -(p-methoxyphenyl)- $\alpha$ -methylpropionate, b<sub>p</sub> 155-65°. This compound is transformed into the 6-methoxy-2-methylindanone (II) also obtained by adding 15 g  $\alpha$ -methyl- $\beta$ -(p-methoxyphenyl)-propionic acid to 170 g polyphosphoric acid at 50° and heating 2 hr at 83-90°, to give 9.1 g II. A solution of 13.4 g II and 21 g BrCH<sub>2</sub>CO<sub>2</sub>Et in 45 ml C<sub>6</sub>H<sub>6</sub> is added over 5 min to 21 g Zn amalgam in 110 ml C<sub>6</sub>H<sub>6</sub> and 40 ml anhydrous Et<sub>2</sub>O, a few iodine crystals added, the mixture maintained at reflux, 2 portions of 10 g Zn amalgam and 10 g BrCH<sub>2</sub>CO<sub>2</sub>Et added at an interval of 3 hr, and the mixture refluxed 8 hr to give 18 g crude Et (1-hydroxy-2-methyl-6-methoxyindanyl)acetate. This, 20 g p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H.H<sub>2</sub>O, and 20 g anhydrous CaCl<sub>2</sub> in 250 ml MePh is refluxed overnight to give 70% Et 5-methoxy-2-methyl-3-indenylacetate, yellow oil. Also obtained were .apprx.45 other compds. These antiinflammatory and antipyretic compds. for arthritic and dermatological disorders, with low ulcerogenic side effect, are administered orally, locally, or i.v. at dosage levels of 10-2000 mg/day.

IT 27961-10-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 27961-10-0 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-1-hydroxy-6-methoxy-2-methyl-, ethyl ester (CA INDEX NAME)





OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD  
(4 CITINGS)

L4 ANSWER 103 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1970:55227 CAPLUS Full-text

DOCUMENT NUMBER: 72:55227

ORIGINAL REFERENCE NO.: 72:10097a,10100a

TITLE: Azabicyclo chemistry. I. Synthesis of  
1,5-methano-7-methoxy-2,3,4,5-tetrahydro-1H-2-  
benzazepines. B-norbenzomorphans

AUTHOR(S): Jacobson, Arthur E.; Mokotoff, Michael

CORPORATE SOURCE: Lab. of Chem., Nat. Inst. of Health, Bethesda, MD, USA

SOURCE: Journal of Medicinal Chemistry (1970),

13(1), 7-9

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 72:55227

GI For diagram(s), see printed CA Issue.

AB 1,5-Methano-7-methoxy-2,3,4,5-tetrahydro-1H-2-benzazepine (I) and its N-methyl  
derivative (II) (B-norbenzomorphans) were synthesized from 5-methoxyindan-1-  
one-3-acetic acid via the oxime (III), which was converted to the amino acid  
IV. Cyclization was effected by carbodiimides to the lactam (V), which was  
reduced to I, N-methylation of which gave II. Both I and II have analgetic  
activity, the former, half that of codeine, and II comparable to codeine.


IT 25574-42-9F 25574-43-0P 25574-44-1P

25574-45-2F

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 25574-42-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo-, methyl ester (CA  
INDEX NAME)




RN 25574-43-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-3-(hydroxyimino)-6-methoxy-, methyl  
ester (CA INDEX NAME)



RN 25574-44-1 CAPLUS


CN 1H-Indene-1-acetic acid, 3-amino-2,3-dihydro-6-methoxy-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 25574-45-2 CAPLUS

CN 1H-Indene-1-acetic acid, 3-amino-2,3-dihydro-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L4 ANSWER 104 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1968:78021 CAPLUS Full-text

DOCUMENT NUMBER: 68:78021

ORIGINAL REFERENCE NO.: 68:15047a,15050a

TITLE: Experiments directed toward the total synthesis of polycyclic terpenes. II. The synthesis and some reactions of 2-methoxycarbonylmethyl-3-methoxycarbonyl-5-methoxyindanone

AUTHOR(S): Ogawa, Tomoya; Matsui, Masanao

CORPORATE SOURCE: Univ. Tokyo, Tokyo, Japan

SOURCE: Agricultural and Biological Chemistry (1967), 31(11), 1332-6

CODEN: ABCHA6; ISSN: 0002-1369

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Synthesis of the title compound is described. A mixture of 710 g. m-MeOC6H4CHO and 1 kg. di-Et malonate in 2.1. C6H6 was refluxed with 25 g. piperidine and 25 ml. HOAc with continuous removal of water 10 hrs. to give 95% Et m-methoxybenzalmalonate, b<sub>4</sub> 170-95°. This compound (690 g.) in 2 l. 99% alc. was refluxed with 165 g. KCN in 200 ml. water 18 hrs., EtOH and water were removed, and the residue was refluxed 16 hrs. in 6N KOH and poured over H2SO4-ice to give 80% m-methoxyphenylsuccinic acid, m. 178-80°. This acid (250 g.) was stirred 50 min. in polyphosphoric acid at 95-100° and the


resulting slurry was poured into 4 g. ice to give 90% I (R = R1 = H, R2 = CO2H, R3 = OMe), m. 187-8° (Me2CO). This acid (83 g.) was refluxed 10 hrs. with 500 ml. MeOH and 1 ml. H2SO4 to give 61% I (R = R1 = H, R2 = CO2Me, R3 = OMe) (II), m. 117-18° (MeOH). II (130 g.) and 180 g. Me2CO in 400 ml. C6H6 was added dropwise to a suspension of NaNH2, prepared from 45 g. Na, in 300 ml. ether and the mixture was refluxed 8 hrs., kept overnight at room temperature, and mixed with 300 ml. HOAc and ice. The organic layer was evaporated to give an oil which was dissolved in 600 ml. C6H6 and mixed with methanolic NaOMe, prepared from 11 g. Na and 150 ml. MeOH. This mixture was refluxed 3 hrs. with 70 g. CH2BrCO2Me and kept overnight at room temperature, water added, and the organic layer concentrated to an oil. This oil was refluxed 15 hrs. in 400 ml. concentrated HCl and 200 ml. dioxane to give 45% I (R =  $\beta$ -CH2CO2H, R1 = H, R2 =  $\alpha$ -CO2H, R3 = OMe), m. 174-5° (Me2CO-hexane). This oxo acid (20 g.) was refluxed 6 hrs. in 200 ml. MeOH containing 1 ml. H2SO4 to give 68% I (R =  $\beta$ -CHCO2Me, R1 = H, R2 =  $\alpha$ -CO2Me, R3 = OMe), m. 97-8° (MeOH). This diester (500 mg.) was stirred 15 min. at 15-20° with 200 mg. 50% NaH in 15 ml. anisole, 200 mg. MeCOCH:CH2 in 5 ml. anisole added dropwise in 30 min., the mixture stirred 1 hr., neutralized, and extracted with EtOAc, and the extract stripped of solvent, chromatographed over Al2O3, and eluted with 10:1 C6H6-EtOAc to give 36% ( $\pm$ )-2 $\beta$ -carboxymethyl-3 $\beta$ -methoxycarbonyl-5-methoxy-8 $\alpha$ -methyl-8 $\beta$ -oxy-2,3-propanoindanone 2  $\rightarrow$  8 lactone (III), m. 164-5°. II (1.1 g.) in methanolic NaOMe was treated with 750 mg. CH2BrCO2Me as above to give 45% I (R = H, R1 = CH2CO2Me, R2 = CO2Me, R3 = OMe), m. 134-7°. Similar treatment of 10 g. I (R = R1 = R3 = H, R2 = CO2Me) with CH2BrCO2Me gave 12% I (R = R3 = H, R1 = CH2CO2Me, R2 = CO2Me), m. 101-3° (MeOH).

IT 17825-46-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 17825-46-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-1-(methoxycarbonyl)-3-oxo-,  
methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L4 ANSWER 105 OF 111 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 1962:436169 CAPLUS Full-text

DOCUMENT NUMBER: 57:36169

ORIGINAL REFERENCE NO.: 57:7183h-i,7184a-i,7185a

TITLE: Application of the Darzens glycidic ester synthesis to

indan-1-one and related ketones

AUTHOR(S): Bone, A. H.; Cort, L. A.

CORPORATE SOURCE: Battersea Coll. Technol., London

SOURCE: Journal of the Chemical Society (1962)

1986-93

CODEN: JCSOA9; ISSN: 0368-1769

DOCUMENT TYPE: Journal  
LANGUAGE: Unavailable


## OTHER SOURCE(S):

CASREACT 57:36169


AB The attempted synthesis of a series of glycidic esters of indan-1-ones by the Darzens reaction demonstrated a pronounced tendency of these esters to rearrange to enol esters or  $\alpha$ -oxo esters. The compound previously formulated by Newman and Magerlein (CA 44, 533e), as indan-1-spiro-2'-oxiran-3'-carboxylic acid was shown to be inden-1(or 3)-ylglycolic acid (I). The Darzens reaction with PhCH<sub>2</sub>CH<sub>2</sub>Bz (II) proceeds normally with the formation of the expected products. Et inden-ylideneglycolate, m. 85-7° (all m.ps. are corrected), was prepared in 85% yield at 0° by the method of Thiele [Ber. 33, 851 (1900)] and reduced to the Et ester (III) of I, b<sub>15</sub>, 183-4° Claisen hydrolysis of 6.7 g. III yielded 0.3 g. inden-1-ylideneglycolic acid (IV) (p-bromophenacyl ester, m. 153° and 4.2 g. I, m. 112° (decomposition). Indan-1-one condensed with ClCH<sub>2</sub>CO<sub>2</sub>Et by the method described previously (CA 55, 24694i) gave III, b<sub>0.35</sub> 120-2° III hydrolyzed gave I, m. 112° (decomposition), which decarboxylated in HCl yielded 1-formylindan (IV). IV (1 g.) yielded 0.9 g. semicarbazone, needles, m. 168-9° (EtOH); 4-phenylsemicarbazone, needles, m. 137-8° (aqueous EtOH). I esterified with MeCHN<sub>2</sub> in Et<sub>2</sub>O and the product hydrolyzed gave a mixture of IV and I. III with N<sub>2</sub>H<sub>4</sub>.HO in MeOH gave the hydrazide of I, needles, m. 155-6° (EtOH), which yielded a benzylidene derivative, plates, m. 157° (EtOH). I (0.034%) in 5 cc. EtOH treated with 0.5 cc. 10N NaOH at 22°, aliquots (1.62 cc.) taken immediately upon mixing and after 10 and 30 min., diluted to 50 cc. with EtOH, and the absorption maximum at 250, 260, and 327 m measured demonstrated the conversion of I to IV. III reduced with LiAlH<sub>4</sub> in Et<sub>2</sub>O yielded 76% inden-1(or 3)-ylethylene glycol (VI), leaflets, m. 116°; monotrityl ether of VI, prisms, m. 153-4° (EtOH). VI in EtOH hydrogenated at room temperature and 30 atmospheric over Pd yielded gave sirupy inden-1-ylethylene glycol (VII); di(p-nitrobenzoate), plates, m. 154° (aqueous C<sub>5</sub>H<sub>5</sub>N). VII (1.1 g.) in 3.5 cc. EtOH treated with cooling with 1.4 g. H<sub>2</sub>SO<sub>6</sub> in 2.5 cc. H<sub>2</sub>O, shaken occasionally during 40 min., diluted with H<sub>2</sub>O, and extracted with Et<sub>2</sub>O gave 0.9 cc. V; semicarbazone m. 169° m-MeOC<sub>6</sub>H<sub>4</sub>ICH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H heated 1 hr. at 80° with 20 g. polyphosphoric acid/g. acid gave 25 g. mixture of 5-methoxyindan-1-one (VIII) and its 7-MeO isomer; the mixture recrystd. from aqueous EtOH and iso-Pr<sub>2</sub>O yielded 61% VIII, needles, m. 111°. VIII (23.5 g.) in 40 cc. Et<sub>2</sub>O, 19 g. ClCH<sub>2</sub>CO<sub>2</sub>Et, Me<sub>3</sub>COK from 7.15 g. K, and 190 cc. Me<sub>3</sub>COH yielded by the method of Johnson, et al. (CA 48, 13639d), 3.5 g. Et 5-methoxyindan-1-ylglycolate (IX), platelets, m. 140° (EtOH); the mother liquor yielded 11.6 g. brown viscous oil. IX with alc. FeCl<sub>2</sub> produced an intense purple color. Claisen hydrolysis of IX gave the free acid which yielded a p-bromophenacyl ester, needles, m. 196° (EtOH). The viscous brown oil subjected to a Claisen hydrolysis, the resulting amorphous Na salt (6.0 g.) dissolved in H<sub>2</sub>O, and the solution acidified yielded 3.5 g. orange 5-methoxyinden-1-ylideneglycolic acid (X), m. 205° (decomposition) (inserted at 205°); p-bromophenacyl ester, yellow needles, m. 145° (EtOH). X in EtOH hydrogenated at 100°/100 atmospheric over Raney Ni gave 5-methoxyindan-1-ylacetic acid (IX), m. 82-3° (petr. ether). VIII (12.9 g.) in C<sub>6</sub>H<sub>6</sub> treated in the usual manner with 14.0 g. BrCH<sub>2</sub>CO<sub>2</sub>Et and 5.2 g. Zn yielded 8.4 g. distillate, b<sub>06</sub> 140-67°, m. 53-5° (petr. ether), which hydrogenated catalytically gave 5-methoxyindan-1-ylacetic acid, needles, m. 83-4° (petr. ether); p-bromophenacyl ester, needles, m. 98-9° (EtOH). Polyphosphoric acid (500 g.) and 10 g. p-MeOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H stirred 6 min. at 120°, cooled, diluted with iced H<sub>2</sub>O, and extracted with C<sub>6</sub>H<sub>6</sub> yielded 2.7 g. 6-methoxyindan-1-one (XI), m. 108-9° (petr. ether). XI (17.8 g.) condensed in the usual manner with ClCH<sub>2</sub>CO<sub>2</sub>Et and Me<sub>3</sub>COK in Me<sub>3</sub>COH yielded 7.2 g. solid product which was separated into 0.2 g. Et 5-methoxyinden-3-ylglycolate (or Et 6-methoxyinden-1-ylglycolate), cream-colored plates, m. 75-6° (aqueous Me<sub>2</sub>CO), and 4.8 g. residue which hydrolyzed gave 1.5 g. 6-methoxyinden-1-ylideneglycolic acid, orange needles, m. 180° (inserted to 180°). 2,2-Dimethylindan-1-one (XII) treated in the usual manner with ClCH<sub>2</sub>CO<sub>2</sub>Et and 1.25 mole equivs. Me<sub>3</sub>COK in Me<sub>2</sub>COH gave 70% unchanged ketone. XII (19.5 g.) in a similar run with 5 mole equivs. Me<sub>3</sub>COK gave 8 cc. EtOCH<sub>2</sub>CO<sub>2</sub>Et, b<sub>761</sub> 163-4° (which was hydrolyzed to

EtOCH<sub>2</sub>CO<sub>2</sub>H; p-bromophenacyl ester m. 105°), and 4.2 g. distillate, b<sub>15</sub> 130-50°; the distillate hydrolyzed and the Na salt (3.5 g.) treated with p-BrC<sub>6</sub>H<sub>4</sub>COCH<sub>2</sub>Br gave the p-bromophenacyl ester of 2,2-dimethylindan-1-spiro-2'-oxiran-3'-carboxylic acid (XIII), plates, m. 92° (EtOH). The free XIII from the Na salt gave a 2,4-dinitrophenylhydrazone, m. 170° (decomposition with sintering at 160°) (aqueous AcOH), probably the derivative of 2,2-dimethylindan-1-yglyoxylic acid. II (21 g.) in 13.4 cc. ClCH<sub>2</sub>CO<sub>2</sub>Et and 20 cc. Me<sub>3</sub>COH treated under N at 8-10° dropwise during 1.5 hrs. with stirring with 4.87 g. K in 125 cc. dry Me<sub>3</sub>COH, diluted with 10 cc. C<sub>6</sub>H<sub>6</sub>, stirred 1.5 hrs., concentrated, and extracted with Et<sub>2</sub>O yielded 24.8 g. Et ester (XIV) of α,β-epoxy-β,δ-diphenylvaleric acid (XV), b<sub>06</sub> 167-70°; a 12-g. portion hydrolyzed in the usual manner gave 4.3 g. XV, needles, m. 114° (decomposition) (CCl<sub>4</sub>); p-bromophenacyl ester, needles, m. 109-10° (EtOH). XV (0.5 g.) heated 20 min. at 120-200°/4 mm. and 10 min. at 200° with soft-glass powder yielded 0.3 g. PhCH<sub>2</sub>CH<sub>2</sub>CHPhCHO; semicarbazone, needles, m. 133-4° (EtOH).

IT 80370-87-2F, 1-Indanacetic acid, 5-methoxy-  
 94550-56-8F, 1-Indanacetic acid, 5-methoxy-, ester with  
 4'-bromo-2-hydroxyacetophenone  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 80370-87-2 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- (CA INDEX NAME)




RN 94550-56-8 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy-,  
 2-(4-bromophenyl)-2-oxoethyl ester (CA INDEX NAME)



L4 ANSWER 106 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1958:77185 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 52:77185  
 ORIGINAL REFERENCE NO.: 52:13697i,13698a-d  
 TITLE: Synthesis of 5-oxo-9-methoxy-1,2,3,4,4a,5,6,6a,11a,11b-decahydrochrysofluorene  
 AUTHOR(S): Chatterjee, Amareshwar; Chatterjee, Ramesh C.;  
 Bhattacharyya, Bidut K.  
 CORPORATE SOURCE: Jadavpur Univ., Calcutta  
 SOURCE: Journal of the Indian Chemical Society (1957)  
 ), 34, 855-8  
 CODEN: JICSAB; ISSN: 0019-4522  
 DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

- AB To an ice-cooled solution of 1.15 g. K in 29 ml. tert-BuOH was added, under N, a solution of 4 g. 1-acetyl-1-cyclohexene and 4.3 g. 5-methoxy-1-indanone in 50 ml. dry thiophene-free C6H6, the mixture allowed to stand 48 hrs. at room temperature, refluxed 4 hrs., acidified with cold. dilute HOAc, the crude solid isolated as described by Banerjee, et al. (C.A. 52, 7255i), and sublimed at 190-5°/0.2. The 2.5 g. of material obtained, m. 150-2°, was dissolved in 9:1 b. 60-80° petr. ether-C6H6, chromatographed on 75 g. activated Al2O3, and eluted with the above solvent mixture. Fractions 3-20 gave a total of 1.9 g. 5-oxo-9-methoxy-1,2,3,4,4a,5,11a,11b-octahydrochrysofluorene (I), m. 155-6° (MeOH),  $\lambda$  244, 292 and 323 m $\mu$ , log  $\epsilon$  3.87, 4.04 and 4.35; 2,4-dinitrophenylhydrazones, m. 246-7° (C6H6-EtOAc). Catalytic hydrogenation of 620 mg. I over 10% Pd-C gave 520 mg. title compound (II), m. 140-1° (MeOH),  $\lambda$  279 m $\mu$ , log  $\epsilon$  3.4; 2,4-dinitrophenylhydrazones, m. 202° (C6H6-EtOAc, then EtOAc). A solution of 7 ml. 3% PhCO3H in CHCl3 added to 200 mg. II in a test tube covered with black paper and the mixture allowed to stand 24 hrs. in a refrigerator gave 90 mg. lactone (III) of 5-methoxy-2-(2'-hydroxycyclohexyl)hydrindene-1-acetic acid (IV), m. 173° (C6H6-petr. ether, b. 60-80°). Allowing the above reaction mixture to stand (a) 48 hrs. in the refrigerator and (b) 48 hrs. in the refrigerator then 24 hrs. at room temperature yielded III 80 and 40 mg., resp. To a solution of 170 mg. III in 2 ml. distilled MeOH was added 4 ml. 10% MeOH-KOH, the mixture refluxed 4 hrs., most of the MeOH removed, 10 ml. H2O added, the solution extracted with Et2O, the aqueous solution acidified with 2% H2SO4, and the white solid filtered off and crystallized (Et2O-petr. ether, b. 60-80°) giving 122 mg. IV, m. 145-6°. IV (10 mg.) heated 2 hrs. with 20% H2SO4 gave 6 mg. III, m. 172-3°.
- IT 101892-14-2P, 1-Indanacetic acid, 2-(2-hydroxycyclohexyl)-5-methoxy-  
RL: PREP (Preparation)  
(preparation of)
- RN 101892-14-2 CAPLUS
- CN 1H-Indene-1-acetic acid, 2,3-dihydro-2-(2-hydroxycyclohexyl)-5-methoxy-  
(CA INDEX NAME)



L4 ANSWER 107 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1957:25469 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 51:25469

ORIGINAL REFERENCE NO.: 51:5045a-f

TITLE: Syntheses in the estrogenic hormone group. XI. 4- and 5-Methoxyindanone derivatives

AUTHOR(S): Novak, Ludvik; Protiva, Miroslav

CORPORATE SOURCE: Pharm. Biochem. Research Inst., Prague

SOURCE: Chemické Listy pro Vědu a Průmysl (1956), 50, 1995-2003


CODEN: CLPRAN; ISSN: 0366-6832

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB cf. C.A. 51, 3533a. 5-Methoxyindanone (I), obtained in 39-g. yield by adding under cooling 160 g.  $\text{SnCl}_4$  to 84 g. m-methoxyhydrocinnamic acid, 500 ml. C<sub>6</sub>H<sub>6</sub>, and 84 g.  $\text{PCl}_5$ , decomposing the red complex with excess HCl, extracting with Et<sub>2</sub>O, and recrystg. from MeOH, m. 106°. I (10.0 g.) gave, on treatment with  $\text{PhMgBr}$  and decomposition with  $\text{NH}_4\text{Cl}$  solution, 7.0 g. 3-phenyl-6-methoxyindene (II), b<sub>0.1</sub> 155-60°. Reaction of 12 g. I with p-MeOC<sub>6</sub>H<sub>4</sub>MgBr followed by treatment of the reaction products with Girard P reagent yielded in the nonketonic fraction 13.4 g. 1-(4-methoxyphenyl)-5-methoxyindanol (III), b<sub>0.2</sub> 165-70°. I (8.1 g.), 4.0 g. Zn, 10.0 g.  $\text{BrCH}_2\text{CO}_2\text{Et}$ , 10 ml. dry C<sub>6</sub>H<sub>6</sub>, and a grain of iodine was refluxed 2 hrs., the product decomposed with dilute  $\text{H}_2\text{SO}_4$ , extracted with Et<sub>2</sub>O, and distilled in vacuo to give 5.9 g. Et 5-methoxy-1-indanylideneacetate (IV), b<sub>0.3</sub> 130-50°, m. 50-1°. IV (4.0 g.) gave, on boiling 4 hrs. with 1.6 g. KOH in EtOH, 2.7 g. 5-methoxy-1-indanylideneacetic acid (V), m. 192-6° (decomposition, from xylene). Reduction of V (6.1 g.) by stirring 6 hrs. with Na-Hg gave 3.0 g. 5-methoxy-1-indanylacetic acid, m. 79° (from ligroine). Reduction of 3.0 g. I with Li and EtOH in liquid  $\text{NH}_3$  and EtOH gave hydrinda-1(8),4(9)-dien-5-one, isolated as the red 2,4-dinitrophenylhydrazone (0.22 g.), m. 175-6° (from AcOEt). 4-Methoxyindanone (VI) (5.0 g.) (cf. Loudon and Razdan, C.A. 49, 14746d), characterized by the new orange 2,4-dinitrophenylhydrazone, m. 250-1° (from C<sub>6</sub>H<sub>6</sub>-pyridine), was reduced with  $\text{LiAlH}_4$  to 5.0 g. 4-methoxyindanol (VII), m. 75-6° (ligroine). Reduction of 8.0 g. VI by boiling with 18 g. Zn-Hg, 50 ml. PhMe, 20 ml.  $\text{H}_2\text{O}$ , and 26 ml. concentrated HCl 30 hrs. under reflux gave 4.5 g. 4-methoxyindan (VIII), b<sub>0</sub> 107°. Reduction of VII and VIII with Li and EtOH in liquid  $\text{NH}_3$  resulted in hydrogenolysis yielding 4-methoxyhydrinda-4,7-diene, b<sub>0.1</sub> 60-3°, which isomerized, on boiling with 2,4-(NO<sub>2</sub>)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>NNH<sub>2</sub>, to give red 2,4-dinitrophenylhydrazone of 4-oxo-2,3,4,5,6,7-hexahydroindan, m. 241-2° (from AcOEt). Et  $\alpha,\beta$ -dicyano- $\beta$ -(p-methoxyphenyl)propionate (IX), obtained in 25-g. yield by warming slightly a mixture of 23.1 g. Et  $\alpha$ -cyano-p-methoxycinnamate, 10 g. NaCN, and 40 ml. 50% EtOH, cooling and decomposing with diluted HCl, extracting the oily product with Et<sub>2</sub>O, evaporating and crystallizing from EtOH, m. 63-4°. The compound described by Siddiqui (C.A. 36, 54702) as IX was found to be the hitherto undescribed p-methoxyphenylsuccinonitrile, m. 70° (from EtOH).

IT 80370-87-2F, 1-Indanacetic acid, 5-methoxy-  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 80370-87-2 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-methoxy- (CA INDEX NAME)



L4 ANSWER 108 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1956:27848 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 50:27848  
 ORIGINAL REFERENCE NO.: 50:5611g-i,5612a-e  
 TITLE: Hydroxybenzotropones. I. Synthesis of a dimethoxybenzocyclohepta-1,4-diene-3,7-dione  
 AUTHOR(S): Sorrie, A. J. S.; Thomson, R. H.  
 CORPORATE SOURCE: Univ. Aberdeen, UK

SOURCE: Journal of the Chemical Society (1955)  
2233-8  
CODEN: JCSCOA9; ISSN: 0368-1769

DOCUMENT TYPE: Journal  
LANGUAGE: Unavailable  
OTHER SOURCE(S): CASREACT 50:27848


AB A mixture of 6.4 g. glutaric acid and 6 g. quinol (I) was added with stirring to a molten mixture of 90 g. anhydrous AlCl<sub>3</sub> and 20 g. NaCl at 180-95°, the mixture stirred a further 10 min., cooled, and decomposed with 12% HCl to yield 0.5 g. 4,7-dihydroxy-3-oxo-1-indanylacetic acid (II), m. 208°, λ 206, 232, 256, and 348 mμ (log ε 4.05, 4.32, 3.83, and 3.64) (all ultraviolet spectra determined in MeOH); p-nitrophenylhydrazone, m. 224° (decomposition) (from aqueous EtOH); diacetate, m. 181° (from aqueous MeOH). The ultraviolet absorption curve of II was almost identical to that of 4,7-dihydroxy-3-methylindan-1-one. II was remarkably resistant to decarboxylation. The formation of II was analogous to the cyclization of β-aroilacrylic acids. Glutaric acid (13.2 g.) and 11 g. II similarly treated at 180-200° with AlCl<sub>3</sub> and NaCl gave 9 g. 1',4'-dihydroxybenzo[5',6',1,2]cycloheptene-3,7-dione (III), m. 149° (from light petroleum), λ 216, 260, 410 mμ (log ε 4.25, 3.90, and 3.92), gave a dark green FeCl<sub>3</sub> color and dissolved in aqueous Na<sub>2</sub>CO<sub>3</sub>; di-Me ether (IV), λ 214 and 330 mμ (log ε 4.29 and 3.55) [oxime of IV, m. 175° (from light petroleum)]. IV (2 g.) refluxed 11 hrs. in 20 ml. 1,2,4-C<sub>6</sub>H<sub>3</sub>Cl<sub>3</sub> with 10% Pd-C under N gave unchanged IV and the mono-Me ether of III, m. 86° (from light petroleum). Further attempts at dehydrogenation of IV with various catalysts and solvents had no effect, and S dehydrogenation gave a tar. IV (1 g.) in concentrated HCl left 3 days with 0.3 g. AcH gave 0.7 g. 4-ethylidene-1',4'-dimethoxybenzo[5',6',1,2]cycloheptene-3,7-dione (V), m. 228° (from C<sub>6</sub>H<sub>6</sub>-light petroleum). IV (1 g.) with 0.4 g. BzH in HCl gave 0.8 g. 4-benzylidene derivative (VI), m. 204° (from glacial AcOH). VI (0.5 g.) warmed 11 hrs. at 60° with AcOH saturated with anhydrous HBr gave 100 mg. Br derivative (VII), m. 157°, and 70 mg. of an isomer (VIII), m. 157° (depressed on admixture with VII). VII with Me<sub>2</sub>SO<sub>4</sub>-K<sub>2</sub>CO<sub>3</sub> in refluxing Me<sub>2</sub>CO gave VI. A solution of VII or VIII left 1 day in warm C<sub>5</sub>H<sub>5</sub>N, then poured into dilute HBr gave 4-benzylidene-1',4'-dihydroxybenzo[5',6',1,2]cycloheptene-3,7-dione (IX), m. 99° (from light petroleum). Methylation of IX gave VI. IV (1 g.), 2 ml. H<sub>2</sub>C:CM<sub>2</sub>O<sub>2</sub>CM<sub>2</sub> (X), and 1 drop concentrated H<sub>2</sub>SO<sub>4</sub> refluxed 2 hrs. yielded 1 g. 3-monoacetate (XI), m. 120°. XI (1 g.) refluxed 3.5 hrs. with X and H<sub>2</sub>SO<sub>4</sub> and the Me<sub>2</sub>CO allowed to distill off gave 0.7 g. dienol acetate (XII), m. 151°. XII was obtained in 30% yield directly from IV. 1',4'-Dimethoxybenzo[5',6',1,2]cyclohepta-1,4-diene-3,7-dione (XIII), was prepared from XI or XII by the same procedure. XI or XII (2 g.) in 75 cc. CCl<sub>4</sub> refluxed 2 hrs. with 1 mole N-bromosuccinimide resulted in an oil which was treated by one of two methods: (a) leaving the oil 12 hrs. in C<sub>5</sub>H<sub>5</sub>N, and the mixture poured into dilute HBr gave crystals, m. 125° (subsequent treatment as in b gave the final product in low yield); (b) the oil warmed 0.5 hr. with 25 ml. 5% MeOH-KOH, cooled, poured into H<sub>2</sub>O, acidified with dilute HCl, extracted with CHCl<sub>3</sub>, dried, the CHCl<sub>3</sub> extract dild: with hot light petroleum (b.p. 100-20°), and most of the CHCl<sub>3</sub> distilled off to yield XIII (17% from XI or 37% from XII), m. 163-4° (from light petroleum), λ 208, 225 (inflection), and 370 mμ (log ε 4.38, 4.13, and 3.72) [dioxime, m. 300-1° (decomposition)]. XIII (0.1 g.) hydrogenated over PtO<sub>2</sub> in AcOH gave IV, m. 149°.

IT 658225-43-1, 1-Indanacetic acid, 4,7-dihydroxy-3-oxo-  
(and derivs.)

RN 858225-43-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-4,7-dihydroxy-3-oxo- (CA INDEX NAME)





OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L4 ANSWER 109 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1955:39399 CAPLUS Full-text

DOCUMENT NUMBER: 49:39399

ORIGINAL REFERENCE NO.: 49:7539c-i

TITLE: Dimeric cinnamic acids and alcohols

AUTHOR(S): Freudenberg, Karl; Schuhmacher, Gunter

CORPORATE SOURCE: Univ. Heidelberg, Germany

SOURCE: Chemische Berichte (1954), 87, 1882-7

CODEN: CHBEAM; ISSN: 0009-2940

DOCUMENT TYPE:

Journal

LANGUAGE:

Unavailable



GI For diagram(s), see printed CA Issue.

AB 3,4 (MeO)2C6H3CH:CHCO2Et with LiAlH4 at below 0° gave 87% 3,4-(MeO)2C6H3CH:CHCH2OH (I), needles, m. 78° (from H2O-MeOH); it polymerized in concentrated HCl. A melt of 6 g. 3,4-(MeO)2C6H3CH:CHCO2Me and 2 drops 20% aqueous HClO4 heated 14 h. on a water bath gave 42% dimer (II, R = CO2Me, R' = Me), needles, m. 142-2.5° (from MeOH); from the mother liquors was isolated 25% of a dimorphic or stereoisomeric form, rods, m. 127-8°. Similarly, Et ferulate was dimerized to 20% II (R = CO2Et, R' = H), rods, m. 156.5-7.5° diacetate, plates, m. 98-8.5° (from BuOH). II (R = CO2Me, R' = Me) (5 g.) and 1.5 g. LiAlH4 in THF gave 73% dimer (IIa) of I (II, R = CH2OH, R' = Me), m. 150-1° after recrystn. from C6H6 and drying at 120° in vacuo; dimethanesulfonate, needles, m. 155-6° (from Me2CO-H2O). The di-p-tosylate (2 g.) of IIa and 3.5 g. NaI in 30 cc. absolute Me2CO refluxed 24 h. gave 72% II (R = CH2I, R' = Me), prisms, m. 151.5-2° (from MeOH); this (1 g.) in 90 cc. MeOH and 10 cc. H2O with 3 g. 20% Pd-BaSO4 catalyst under H gave 76% diisoeugenol di-Me ether (II, R = R' = Me), m. 105.5-6.5° (from MeOH-H2O). II (R = CO2Me, R' = Me) (3 g.) in 100 cc. HOAc oxidized with 3 g. CrO3 in 25 cc. HOAc and 5 cc. H2O 14 h. at 20° and the neutral product crystallized from MeOH gave 29% diketone [2,3,4-MeO2CCH2CO(MeO)2C6H2CH[C6H3(OMe)2-3,4]COCO2Me or 2,4,5-[3,4-(MeO)2C6H3CO](MeO)2C6H2CH(CH2CO2Me)COCO2Me], m. 182.5-3°; UV maximum (neutral medium) at 236, 282, and 318 mμ; acid medium, H2SO4-HOAc at 265, 332, 365, 465, and 600 mμ, indicative of the formation of a benzopyrylium compound. From the MeOH mother liquors was isolated an amorphous ketone (III) which gave a crystalline 2,4-dinitrophenylhydrazone, red, m. 249-50°. From the acid fraction of the oxidation reaction mixture was isolated o-veratroylveratric acid, m. 221-2°. These oxidation products are analogous to those obtained by A. Muller (C.A. 39, 2745.1) by the oxidation of II (R, R' = Me).


IT 412315-55-0, 1-Indanacetic acid,  
2-carboxy-5-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-6-methoxy-  
(esters)

RN 412315-55-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2-carboxy-2,3-dihydro-5-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-6-methoxy- (CA INDEX NAME)



IT 412315-94-7P, 1-Indanacetic acid,  
2-carboxy-3-(3,4-dimethoxyphenyl)-5,6-dimethoxy-, dimethyl ester  
RL: PREP (Preparation)  
(preparation of)  
RN 412315-94-7 CAPLUS  
CN 1H-Indene-1-acetic acid, 3-(3,4-dimethoxyphenyl)-2,3-dihydro-5,6-dimethoxy-  
2-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L4 ANSWER 110 OF 111 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1955:32312 CAPLUS Full-text

DOCUMENT NUMBER: 49:32312

ORIGINAL REFERENCE NO.: 49:6201g-i,6202a-i

TITLE: Cyclization studies in the syntheses of  
monomethoxy-1-phenyl-4-hydroxy-2-naphthoic acids

AUTHOR(S): Klemm, L. H.; Largman, Theodore

CORPORATE SOURCE: Univ. of Oregon, Eugene

SOURCE: Journal of the American Chemical Society (1954  
) , 76, 1688-91

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable


OTHER SOURCE(S): CASREACT 49:32312

AB m-MeOC6H4Bz (I) underwent with (CH2CO2Et)2 a Stobbe condensation to yield a mixture (II) of the mono-Et esters of cis- and trans-MeOC6H4CPh:C(CO2H)CH2CO2H, cyclized with NaOAc and Ac2O to 2 (of the possible 3) mono-MeO derivs. of 1,4,2-Ph(HO)C10H5CO2H (III), for which tentative structures have been assigned on the basis of chemical and phys. properties. II was hydrolyzed and subsequently reduced to yield 2 new acids. Ph2C:C(CO2Et)CH2CO2H (9 g.) in 40 cc. Ac2O refluxed 6 hrs., the Ac2O removed in vacuo, and the residue hydrolyzed with 100 cc. 10% aqueous NaOH gave 7 g. (91%) III, m. 214-16°. PhMgBr from 40.7 g. Mg, 267 g. PhBr, and 2.1 l. dry

Et2O cooled a few degrees below room temperature, treated with 166 g. CdCl2 portionwise during 20 min., and the mixture refluxed 2 hrs. with stirring, treated dropwise during 15 min. with 130 g. m-MeOC6H4COCl in 200 cc. dry Et2O, stirred, and refluxed 14 hrs., and poured into ice and dilute H2SO4 gave 90 g. (56%) I, pale yellow oil, b.p. 153-5°, which partially solidified to cubic crystals, m. 37°; 2,4-dinitrophenylhydrazone, orange prisms, m. 233-4° (decomposition). I (21.2 g.), 35 cc. (CH2CO2Et)2, and 6 g. NaH treated with 0.5 cc. absolute EtOH, the mixture diluted after 1 hr. with 100 cc. dry C6H6 to facilitate stirring, stirred 10 hrs., acidified, extracted with Et2O, the Et2O solution extracted with 10% aqueous Na2CO3, the alkaline solution acidified, extracted with Et2O, the extract dried with Drierite, evaporated, and the residue dried 0.5 hr. at 90° gave 26-32 g. II, red viscous oil. A similar Stobbe condensation was carried out during 27 hrs. with 35 cc. (CH2CO2Me)2 after initiating the reaction by warming to yield 29 g. mixture (IV) of the Me half-esters, dark red viscous oil. IV (2 g.) heated 2 hrs. with 4 g. p-MeC6H4-NH2 at 160-70°, the mixture extracted with Et2O, the extract washed with excess 6N HCl, evaporated, and the residual oil crystallized twice from EtOH gave 1-p-tolyl-3-[phenyl(3-methoxyphenyl)-methylene]-2,5-pyrrolidinedione (V), m. 154.5-5.5°. II (28 g.), 85 cc. Ac2O, and 10 g. fused NaOAc refluxed 5-6 hrs. under N with stirring, the volatile materials removed in vacuo with gentle warming, the residue refluxed 3 hrs. with stirring with 250 cc. 10% aqueous NaOH and 30 cc. EtOH under N, the mixture boiled 0.5 hr. with about 2 g. Darco, filtered, cooled, acidified, the black oily precipitate dissolved in dilute aqueous NaOH, treated with Darco, passed through a 2-in. column of 10:1 Al2O3-Celite, and the filtrate partially neutralized with cold concentrated HCl gave 2.5 g. cream-colored gummy solid; the filtrate treated with excess acid, and the precipitate crystallized from EtOH gave 13 g. tan solid; each fraction recrystd. repeatedly from aqueous EtOH gave 3.7 g. (15%) product, designated compound A, needles, m. 279.5-80° (presumably VI, R = MeO, R' = H) [acetate, platelets with a pale yellow tinge, m. 228-9° (from EtOH)], and 10.6 g. (44%) product, designated compound B, needles, m. 211-12° [presumably 5,4,2,1-R(HO)(HO2C)C10H4C6H4R'-3 (VI) where R = H, R' = MeO] [acetate, spherical aggregates, m. 187-8° (from aqueous EtOH)]. The crude filtrate from the Al2O3-celite column acidified with excess concentrated HCl, the brown-black precipitate washed with CHCl3 to remove most of the color, and the residue fractionally crystallized from dilute EtOH gave compds. A and B. Either A or B (1 g.), 0.5 g. Cu bronze, and 10 cc. quinoline heated 2 hrs. at 215-30°, cooled, extracted with Et2O, the extract washed with 1:5 dilute HCl, 5% aqueous NaHCO3, and H2O, evaporated, and the residue dissolved in EtOH, treated with Nuchar C, and distilled at 1.5 mm. yielded 0.1-0.2 g. oil which gave a pos. FeCl3 test. Either A or B (0.1 g.) and 2.5 g. Zn dust pyrolyzed yielded a light green oil which gave a pos. FeCl3 test. Compound B (1 g.) in 5 cc. HI (d. 1.70) and 10 cc. glacial AcOH refluxed 3.5 hrs. under N, evaporated in vacuo, the residue diluted with H2O extracted with Et2O, and the extract evaporated yielded an oil which was soluble in 10% aqueous NaOH, but insol. in 10% aqueous NaHCO3 and gave a pos. FeCl3 test. The conductometric titration of A and B gave the phenolic and carboxylic neutral equivs. 298, 144, and 295, 146, resp. The  $\lambda_{max}$  EtOH in m $\mu$  (log  $\epsilon$ ) were: compound A, 231 (4.54), 254 (4.49), 294 (3.81); compound B, 244 (4.54), 307 (3.87); III, 244 (4.56), 307 (3.85); 6,7,1-(MeO)2C10H5Ph, 238 (4.80), 290 (3.92). II (13.7 g.), 70 cc. EtOH, 100 cc. H2O, and 49 g. Ba(OH)2.8H2O refluxed 3 hrs. under N, the mixture partially distilled, the residue cooled, acidified with dilute HCl, extracted with Et2O, the extract evaporated, and the residue crystallized from EtOAc-ligroine (b. 97-120°) yielded 9 g. (72%) m-MeOC6H4CPH:C(CO2H)CH2CO2H, m. 148-53°, an alkaline solution of which, repeatedly fractionally acidified and the precipitate recrystd. from EtOAc-ligroine, gave clusters of needles, m. 166-7°; p-MeC6H4NH2 derivative, fine faintly pink needles, m. 155-6° (from EtOH) (no depression with V). Crude Stobbe diacid in 300 cc. 2.5% aqueous NaOH treated with 320 g. 4% Na-Hg during 12 hrs. in portions under N, the mixture allowed to stand several hrs.,

filtered, the filtrate acidified with dilute HCl, and the precipitate recrystd. from H<sub>2</sub>O yielded 11.9 g. (94%) m-MeC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH(CO<sub>2</sub>H)CH<sub>2</sub>CO<sub>2</sub>H, m. 79–80°, giving with p-MeC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> in the usual manner 1-(4-tolyl)-3-[phenyl(3-methoxyphenyl)methyl]-2,5-pyrrolidinedione, faintly pink prisms, m. 175–6° (from EtOH). The ultraviolet absorption spectra of III and compds. A and B are recorded.

IT 858225-41-9, 1-Indanacetic acid, 4,5-dimethoxy- $\alpha$ -methyl-  
(derivs.)  
RN 858225-41-9 CAPLUS  
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4,5-dimethoxy- $\alpha$ -methyl- (CA  
INDEX NAME)



L4 ANSWER 111 OF 111 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 1950:24898 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 44:24898

ORIGINAL REFERENCE NO.: 44:4883f-i,4884a-c

TITLE: Intramolecular acylation. I. The ring closure of some  $\beta$ -substituted glutaric acids

AUTHOR(S): Hey, D. H.; Kohn, D. H.

CORPORATE SOURCE: Univ. of London

SOURCE: Journal of the Chemical Society (1949)

3177-81

CODEN: JCSOA9; ISSN: 0368-1769


DOCUMENT TYPE: Journal

LANGUAGE: Unavailable


AB Intramol. acylation, as exemplified in the cyclization of aryl-substituted aliphatic acids or acid chlorides with elimination of H<sub>2</sub>O or HCl, resp., has frequently provided a useful route for the synthesis of polycyclic systems. The present work is concerned with the preparation and ring closure of a number of  $\beta$ -substituted glutaric acids by means of the reaction of AlCl<sub>3</sub> on the acid chloride or of HF and the free acid.  $\beta$ -Arylgutaric acids are best prepared by the alkaline hydrolysis of Et benzylidenebisacetoacetate (I) and its derivs. Details are given of the preparation of certain known glutaric acids. m-MeOC<sub>6</sub>H<sub>4</sub>CHO (64 g.) and 122 g. AcCH<sub>2</sub>CO<sub>2</sub>Et at 0°, treated dropwise with 5 g. piperidine, kept 2 hrs. at 0° and 3 days at room temperature, give 160 g. (crude) m-methoxybenzylidene analog (II) of I, m. 135–5.5° (monooxime, m. 181°); 160 g. II and 160 g. KOH in 108 cc. H<sub>2</sub>O, heated 30 min. at 90–100°, give 65 g.  $\beta$ -(m-methoxyphenyl)glutaric acid, m. 126–6.5°. 1-(p-Tolylsulfonyl)-2-(m-tolyl) hydrazine (III), m. 140°; 29.5 g. III in 100 cc. (CH<sub>2</sub>OH)<sub>2</sub> at 100°, treated with 29.5 g. Na<sub>2</sub>CO<sub>3</sub> and heated 3 min. at 160°, give 8.5 g. m-MeC<sub>6</sub>H<sub>4</sub>CHO (IV); 17 g. IV yields 33.5 g. Et (m-methylbenzylidene)bisacetoacetate, m. 123°, which gives 17 g.  $\beta$ -(m-tolyl)glutaric acid, m. 106–7°. AcCH<sub>2</sub>CO<sub>2</sub>Et (72 g.) and 37 g. 3,5-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CHO with 5 cc. piperidine, kept 2 days at room temperature, treated with 2 cc. piperidine, and allowed to stand an addnl. 2 days, give 79 g. (crude) Et (3,5-dimethylbenzylidene)bisacetoacetate, m. 151–2°; 74 g. ester yields 24.7 g.  $\beta$ -

(3,5-dimethylphenyl)glutaric acid, m. 160°. 1-C10H7CHO (6.3 g.) and 10.5 g. AcCH2CO2Et with 0.5 g. piperidine (6 days at room temperature) give 3.3 g. (crude) Et (1-naphthylidene)bisacetoacetate, m. 161.5° (monooxime, m. 195-6°); 1.8 g. ester yields 0.9 g. (crude)  $\beta$ -(1-naphthyl)glutaric acid, m. 181.5°. PhCH(CH2COC1)2 (V) (from 5.2 g. acid) and 3.5 g. AlCl3 in 6 cc. CS2, kept at room temperature 1 hr. and refluxed 2 hrs., give 3 g. 1-indanone-3-acetic acid (VI); in PhNO2 (0.5 hr. at 70-80° and overnight at room temperature) V yields 2 g. VI; 5.2 g. of the acid and HF give 0.5 g. VI. m- and p-O2NC6H4CH(CH2CO2H)2 could not be cyclized with AlCl3 or HF. p-MeOC6H4CH(CH2COC1)2 (from 5.95 g. acid) and 3.5 g. AlCl3 in 50 cc. PhNO2, heated 15 min. at 150°, give 1.8 g. of the 6-HO derivative of VI, m. 161-1.5°; ring closure does not occur in PhNO2 at 70-80° or in CS2 or with the acid and HF. m-MeOC6H4CH(CH2CO2H)2 (from 5.95 g. acid) and 3.5 g. AlCl3 in 50 ml. PhNO2, heated 10 min. at 150°, give 2.6 g. of the 5-MeO derivative (VII) of VI, m. 151°; ring closure did not occur in CS2; 5.95 g. of the acid and HF give 4.6 g. VII. 3,5-Me2C6H3CH(CH2CO2H)2 (8 g.) and HF give 6.8 g. of the 3,5-di-Me derivative of VI, m. 146°; the acid chloride is not cyclized by AlCl3. 1-C10H7CH(CH2CO2H)2 with HF gives 93% 4,5-benzindan-1-one-3-acetic acid, m. 206-8°; oxidation yields (1,2-C10H6CO)2O, m. 162-4°.

IT 24467-92-3P, 1-Indanacetic acid, 6-methoxy-3-oxo-  
 858225-37-3P, 1-Indanacetic acid, 5-hydroxy-3-oxo-  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 24467-92-3 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-methoxy-3-oxo- (CA INDEX NAME)



RN 858225-37-3 CAPLUS  
 CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-hydroxy-3-oxo- (CA INDEX NAME)



=> log off  
 ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF  
 LOGOFF? (Y)/N/HOLD:y  
 STN INTERNATIONAL LOGOFF AT 10:59:17 ON 08 DEC 2009